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Abstract 
 
Extracellular vesicles (EVs) is a collective name given to nanometer-sized 
membrane vesicles (30-200 nm) secreted by all cells and found in most body 
fluids. They originate either from endosomal multivesicular bodies, which by 
fusion with the plasma membrane are released into the extracellular environment 
as exosomes, or directly through the budding off the plasma membrane as 
microvesicles. They were first described to take part in the removal of unwanted 
plasma membrane proteins during the maturation of reticulocytes to erythrocytes, 
however, following the decades of research they are now recognized as being 
important mediators of cell-to-cell communication and vehicles to transfer active 
biological material. They contain lipids, proteins and different species of nucleic 
acids. Remarkably, their composition has been shown to be altered in 
pathological conditions, and although this feature has been widely explored to 
find low-invasive biomarkers, the physiological effects of such content alteration 
is greatly unknown. 
Obesity is reaching epidemic proportions worldwide mostly due to the growing 
incidence of metabolic syndrome (MetS), which is a cluster of metabolic 
abnormalities such as obesity, insulin resistance, dyslipidemia and hypertension 
that when occurring together increase the risk of cardiovascular complications 
and type 2 diabetes mellitus.  
In the current study, we focused on investigating the nature and the effect of 
different metabolic alterations observed in MetS development, such as the 
adipose hypertrophy, hepatic steatosis, inflammation and adipose tissue hypoxia, 
on the secretion and content of EVs. Furthermore, the work also addressed the 
effects of these EVs on the biology and metabolism of adipocytes. To achieve 
our aim, we established in vitro cellular models, that resemble the mentioned 
metabolic conditions and that are suitable for subsequent production and 
isolation of EVs. We performed detailed biochemical and structural 
characterization of EVs isolated from conditioned medium of hypertrophic 
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adipocytes, adipocytes cultured in hypoxia or macrophage- conditioned medium. 
In addition, we also analyse EVs from chemically-induced steatosis in hepatic 
cell lines and steatotic primary hepatocytes obtained from Zucker rat hepatocytes 
that represent a genetic model of obesity.  
We used cryo-EM technology to visualize the isolated EVs in their native state, 
and Nanoparticle Tracking Analysis to measure their concentration and size 
distribution. Furthermore, by Western blot analysis, we identified the abundance 
of EV-related and cell type-specific proteins, which could be affected by 
metabolic perturbation of the parental cell. In the case of Zucker hepatocyte-
derived EVs, we performed further analysis of their protein, RNA and lipid 
content. 
Our study demonstrates that the profile of EVs secreted by all our in vitro models 
of metabolic syndrome is highly affected in terms of the concentration and 
protein abundance. We found that steatotic hepatocytes secrete EVs with 
significantly reduced exosomal-markers such as Aip1/Alix, CD63, CD81, Tsg101 
and Flotillin1, and increased abundane in Hsp70 and 90. Furthermore, a 
proteomic analysis of EVs released by steatotic Zucker hepatocytes revealed a 
very specific protein signature, which reflected the metabolic state of the cell. 
The majority of proteins upregulated were related with the fat metabolism, fatty 
acid synthesis, glycolysis and pentose phosphate pathway, in turn, the 
downregulated ones were mainly mitochondrial. Interestingly, the abundance of 
diverse enzymes involved in xenobiotics metabolism was significantly 
downregulated in EVs from the steatotic model. Finally, we show that these EVs 
influence insulin sensitivity in recipient 3T3-L1 adipocytes.  
Moreover, we found the proinflammatory cytokine Tnf to be associated with EVs 
secreted by LPS-stimulated Raw264.7 macrophage-like cells. Interestingly, they 
were able to significantly reduce the mitochondrial functions in 3T3-L1 
adipocytes. In conclusion, our research supports the hypothesis that EVs play an 
important role in the development of pathologies associated with MetS. 
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General introduction  
 
1.1 Metabolic syndrome  
 
1.1.1 Overview 
 
The first description of metabolic syndrome (MetS) goes back to 1920 when 
Kylin, a Swedish physician demonstrated the association of high blood pressure 
(hypertension), high blood glucose (hyperglycaemia) and gout (Kylin 1923). Later 
in 1947, Vague described that visceral obesity was commonly associated with 
metabolic abnormalities found in cardiovascular disease (CVD) and Type 2 
Diabetes Mellitus (T2DM) (Emanuela et al. 2012) Finally, in 1988, the term 
Syndrome X was coined by Reaven describing it as the association of insulin 
resistance (IR), elevated blood glucose and very low density lipoprotein (VLDL) 
triglycerides, decreased blood high-density lipoproteins (HDLs) cholesterol, and 
hypertension (Reaven 1988). A crucial missing factor, not mentioned by Reaven 
was visceral obesity (Emanuela et al. 2012). It is well known now that the 
visceral obesity is one of the primary metabolic risk markers of MetS (Dragsbæk 
et al. 2016). Nowadays, visceral obesity is considered a multifactorial disease 
and a major risk factor for atherosclerotic cardiovascular disease (ASCVD) and 
T2DM (Grundy 2016). 
 
1.1.2 Prevalence and Risk Factors 
 
MetS represents one of the major public health challenges worldwide. In 2015, 
obesity was estimated to occur in 1.4 billion persons worldwide (O’Neill & 
O’Driscoll 2015). MetS is estimated that occurs in between 10 and 40% of the 
population around the world (Grundy 2016). It is expected to reach 365 million 
patients by the year 2030 (Schinner et al. 2005). The syndrome occurs most 
often in an population characterized by excessive nutrient intake and physical 
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inactivity with underlying metabolic or genetic susceptibilities (Emanuela et al. 
2012). The prevalence has been shown to increase with body mass index (BMI) 
and age (Ervin 2009).The main risk factors for the development of MetS include 
heredity, ethnicity, physical inactivity and tobacco exposure (Lee & Sanders 
2002).  
 
1.1.3 Clinical characteristics and diagnosis  
 
In 2009, a joint statement from the International Diabetes Federation Task Force 
on Epidemiology and Prevention, National Heart, Lung and Blood Institute, 
American Heart Association, World Heart Federation, International 
Atherosclerosis Society and the International Association for the Study of 
Obesity, was published regarding a consensus for clinical diagnosis for MetS 
(Alberti et al. 2009). The parameters include the following points:  
• Elevated waist circumference (population and country specific definitions) 
• Elevated triglycerides (≥ 150 mg/dL,1.7 mmol/L) 
• Reduced high-density lipoprotein-cholesterol (< 40 mg/dL, 1.0 mmol/L) in 
males; (< 50 mg/dL, 1.3 mmol/L) in females 
• Elevated blood pressure (systolic ≥ 130 and/or diastolic ≥ 85 mm Hg 
• Elevated fasting glucose (≥ 100 mg/dL) 
It was agreed that three abnormal parameters out of five, listed above would 
diagnose a person with MetS, with none of the parameters being obligatory to 
make a diagnosis, and waist measurement being a useful preliminary screening 
(Alberti et al. 2009). Essentially, the syndrome identifies individuals at an 
elevated risk for CVD and T2DM, according to the pathologies associated, 
together with other, non-metabolic syndrome risk factors (Grundy et al. 2005) 
(Figure 1).  
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Figure 1 Clinical manifestations of MetS. Hallmarks of MetS include central obesity, 
insulin resistance, increased blood pressure, and dyslipidemia. Adapted from: (O’Neill et al. 
2016). 
 
 
Most patients suffering from MetS are clinically obese, with a predominant upper 
body, visceral obesity. The underlying cause is the fat overload in obesity, which 
feeds free fatty acids to peripheral organs such as the liver and the muscle, 
which is linked with IR in these organs. Moreover, enlarging fat cells secrete 
adipose-factors known as adipokines, which additionally contribute to metabolic 
risk factors of MetS. Among many, adiponectin, interleukin 6 (IL-6), tumour 
necrosis factor (TNF), resistin, angiotensin, leptin, and the activator inhibitor-1 
(PAI1). Importantly, it has been well recognized that obesity is accompanied by 
macrophages infiltration and low-grade, local adipose tissue (AT) inflammation, 
triggering increased pro-inflammatory cytokine release leading up the 
development of low-grade systemic inflammation (Lumeng & Saltiel 2011; 
Johnson et al. 2012). Moreover, dyslipidemia, characterized by elevated low-
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density lipoproteins (LDL) and VLDLs, as well as, triglycerides and reduced HDL-
C seen in most MetS cases, is considered a major risk factor for, arterial 
atherosclerotic plaque formation leading to CV complications. Furthermore, 
enhanced renal reabsorption of sodium, activation of the sympathetic nervous 
system and renin-angiotensin-aldosterone system, the release of 
angiotensinogen from adipose tissue and insulin resistance have been proposed 
to contribute to the elevated blood pressure in MetS patients (Reaven 1991; Hall 
2000; Grundy 2016). Additionally, elevated fasting plasma glucose, known as 
hyperglycemia is another factor that is directly caused by IR in MetS patients. 
 
1.1.4 Treatment and management  
 
The primary treatment for MetS, which has been proven highly effective for all 
metabolic risk factors, including raised blood pressure, is a lifestyle change. 
Dietary modification to favour caloric restriction, increased physical activity and 
when applicable the cessation of smoking have been proved to be beneficial 
changes (Grundy 2015). The Dietary Approaches to Stop Hypertension (DASH) 
trial demonstrated that a diet that emphasizes fruits, vegetables, and low-fat 
dairy products, that includes whole grains, poultry, fish, and nuts, that contains 
only small amounts of red meat, sweets, and sugar-containing beverages, and 
that contains decreased amounts of total and saturated fat and cholesterol 
significantly lowers blood pressure in hypertensive patients (Sacks et al. 2001). 
Pharmacological treatment for those persons whose risk factors are not 
adequately reduced are considered as preventive measures (Kaur 2014). Thus, 
calcium channel blockers cause slight improvement of IR in MetS patients (Farah 
et al. 2013), as well as, antihypertensives, insulin sensitizers, thiazolidinediones 
(TZDs) and cholesterol-lowering agents (Fujioka 2006). Moreover, there are two 
main classes of agents for targeting obesity, such as appetite suppressants and 
inhibitors of nutrient absorption such as orlistat, an inhibitor of gastrointestinal 
lipase (Wilson & Grundy 2003). Apo B-containing lipoproteins (LDL and VLDL) 
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are a primary target of dyslipidemia therapy (Grundy 2016). Lipid-lowering 
medications in the form of statin therapy are the first choice for the treatment of 
dyslipidemia. Moreover, niacin and fibrates have been employed to target 
elevated triglycerides for primary, as well as, secondary prevention (Daniel 
2011). Patients with MetS are in a pre-diabetic state, which implicates increased 
fasting glucose levels and glucose intolerance, therefore the main goal is to 
prevent the progression to diabetes. In this case, weight loss and increased 
physical activity have been shown to be very effective, decreasing the rate of 
progression from pre-diabetes to diabetes by 50% (Grundy 2016). 
 
 
1.2 The Introduction to the insulin signalling pathway 
 
The hormone insulin acts on various target tissues, including the liver, skeletal 
muscle, and fat tissue, and regulates the blood glucose levels by promoting its 
uptake into target tissues. In the fasted state, glucose homeostasis depends 
upon the balance between hepatic glucose production and the glucose utilization 
by the major insulin-dependent tissues such as liver, adipose, and muscle, and 
by insulin-independent tissues such as brain and kidney. In normal conditions, 
glucose remains in a narrow range between 4-7 mM (Watson et al. 2004). Thus, 
in normal conditions, the response to increased plasma glucose is an increase in 
secretion of insulin from ß-cells of the pancreatic islets. Insulin is the most potent 
anabolic agent known, promoting the storage and synthesis of lipids, proteins, 
and carbohydrates and inhibiting their breakdown and release into the circulation 
(Watson et al. 2004). The increase in circulating insulin levels stimulates glucose 
transport into peripheral tissues and inhibits hepatic gluconeogenesis. Insulin 
also plays a role in ion and amino acid transport, lipid metabolism, glycogen 
synthesis, gene transcription and protein synthesis and degradation, and DNA 
synthesis.  
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The existence of the insulin receptor was discovered in 1971, followed by many 
subsequent studies on its structure and binding. However, a major contribution to 
understanding the insulin pathway was the observation that the ß-subunit of the 
insulin receptor possesses Tyr kinase activity, which autophosphorylates upon 
insulin binding (Kasuga, Masato, Karlsson F. Anders, Kahn 1982). 
The IR is expressed in almost all mammalian tissues with a varying number of 
receptor among different tissues. Two major targets of insulin, the adipose tissue 
and liver can contain as many as 300,000 receptors per cell (Cheatham & Kahn 
1995). The concentration of receptors is higher than the normal plasma insulin 
levels and ranges from 10-10–10-9 M providing rapid binding kinetics (Cheatham 
& Kahn 1995).  
The key action of insulin is to stimulate energy storage or utilization by regulating 
glucose transport into the cell, mediated by the facilitative glucose transporter 4 
(Glut4). This is achieved by increasing the functional units of Glut4 proteins at 
the plasma membrane, rather than increasing the activity of the transporter 
(Furtado et al. 2002). In the absence of insulin, Glut4 slowly recycles between 
the plasma membrane and the vesicular compartment within the cell. Insulin 
stimulates the translocation of a pool of Glut4 to the plasma membrane via 
exocytosis. The rate of glucose transport into fat and muscle cells is controlled by 
the concentration of Glut4 at the cell surface and the duration of which the 
protein is maintained at the site (Huang & Czech 2007).  
 
1.2.1 The Insulin signalling cascade  
 
The two main insulin transducer pathways starting at the insulin receptor are the 
phosphatidyl 3-kinase (PI3K)/Akt pathway and the Raf/Ras/MEK/MAPK. The 
PI3K pathway is responsible for most of the metabolic effects of insulin, whereas 
the mitogen-activated protein kinase (MAPK) pathway controls the cell growth 
(“mitogenesis”) and differentiation (De Meyts 2016).  
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The cascade of phosphorylation events is initiated upon insulin binding to the 
insulin receptor, which is a tetrameric protein composed of two extracellular α 
subunits and two transmembrane ß subunits joined together by disulfide bonds. 
As graphically explained on Figure 2, insulin binding to the α subunits causes a 
conformational change and activation of kinase activity in the ß subunits, 
resulting in their transphosphorylation, allowing the recruitment of the insulin 
receptor substrates (IRS) (Boucher et al. 2014). Moreover, receptor activation 
leads to the phosphorylation of the tyrosine residues on IRS proteins, which 
organize and mediate signalling.  
 
 
Figure 2 Insulin signalling pathway. Activation of the insulin receptor by their ligand 
initiates a cascade of phosphorylation events. Upon ligand binding conformational change 
and autophosphorylation of the receptors occurs, leading to the recruitment and 
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phosphorylation of receptor substrates such as IRS and Shc proteins Adapted from: 
(Boucher et al. 2014). 
 
 
They are recognized by the regulatory subunit of the PI3-kinase (PI3K) (Vadas et 
al. 2011; Boucher et al. 2014), whose activation depends on the binding of the 
two Src Homology 2 (SH2) domains in the regulatory subunit of tyrosine-
phosphorylated IRS proteins (Myers et al. 1992). This results in activation of the 
catalytic subunit, which rapidly phosphorylates phosphatidylinositol 4,5-
bisphosphate (PIP2) to generate the lipid second messenger phosphatidylinositol 
(3,4,5)-triphosphate (PIP3). PIP3 recruits Akt to the plasma membrane, where it 
is activated by phosphorylation and induces downstream signalling. Most of the 
physiological effects of PI3K-generated PIP3 are mediated by a subset of AGC 
protein kinase family members, which include isoforms of Akt/protein kinase B 
(PKB), p70 ribosomal S6 kinase (S6K), serum- and glucocorticoid – induced 
protein kinase (SGK), as well as several isoforms of protein kinase C (PKC). 
However, Akt phosphorylation at Ser-473 is required for full activation and is 
accomplished by the mechanistic target of rapamycin complex 2 (mTORC2) 
(Sarbassov et al. 2005). The Akt/PKB family of proteins is composed of three 
different isoforms of serine/threonine protein kinases. They all possess a 
pleckstrin homology (PH) domain, allowing interaction with PIP3 and recruitment 
to the plasma membrane. Akt2 is most abundant in insulin-sensitive tissues and 
seems to play a predominant role in mediating insulin action on metabolism. The 
PI3K-PKB/Akt pathway is highly conserved, and its activation is tightly controlled 
(Hemmings & Restuccia 2012). Activation of Akt by PDK-1 and mTORC2 allows 
the phosphorylation and activation of many downstream targets. Akt also 
phosphorylates and inactivates glycogen synthase kinase 3, resulting in 
glycogen synthase activation and glycogen accumulation in the liver (Boucher et 
al. 2014). mTORC1 substrates include the eukaryotic translation initiation factor 
4E binding protein 1 (4EBP1), and ribosomal protein S6 kinase, 70 kDa, 
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polypeptide 1 (S6K1), which, in turn, phosphorylates the ribosomal protein S6 
(S6/RPS6), promoting protein synthesis and cellular proliferation (Düvel et al. 
2010).  
The activation of the serine/threonine kinase Raf/MEK/ Erk1-2 cascade begins 
with the adapter protein grb2 binding to IRS and Shc. It exists in a complex with 
the son of sevenless (SOS), a guanyl nucleotide exchange factor that promotes 
GDP/GTP exchange on the small G protein p21ras (Skolnik et al. 1993). Under 
sufficient stimulation, phosphorylated Erk1-2 translocates to the nucleus and 
phosphorylates transcription factors and mitogen- and stress- activated protein 
kinases  
 
 
1.3 The energy producing pathways 
 
The metabolic activity of normal cells relies primarily on mitochondrial oxidative 
phosphorylation (OXPHOS), as it is more efficient than glycolysis in generating 
ATP for energy (Ramzan et al. 2013). However, glycolysis is an ancient and 
highly conserved energy producing pathway, and organs in the body still rely on 
it to function, such as brain, liver, and muscle. As the availability of free oxygen in 
the atmosphere increased, cells began relying more on OXPHOS for energy 
(Zheng 2012). 
 
1.3.1 Glycolysis  
 
Glycolysis is carried out in the cytoplasm and leads to the conversion of one 
molecule of glucose into two molecules of pyruvate with the consequent 
generation of two molecules of ATP. Pyruvate is a metabolic intermediate with 
several potential fates including entrance into the TCA cycle within mitochondria 
to produce nicotinamide adenine dinucleotide (NADH) and flavin adenine 
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dinucleotide, hydroquinone form (FADH2). The reducing agents subsequently 
donate electrons to the electron transport chain (ETC), which when fully coupled 
to complex V (ATP synthase) in the mitochondrial inner membrane generates an 
additional 34 molecules of ATP per molecule of glucose. Alternatively, pyruvate 
can be converted to lactate. The glycolytic pathway also supplies biosynthetic 
intermediates for cell growth and proliferation. The first product of glycolysis, 
glucose-6-phosphate, can drive the generation of NAPD+ from NADPH in the 
pentose phosphate pathway, which supplies metabolites for nucleotide 
biosynthesis that is required for DNA replication and ribonucleic acid (RNA) 
transcription (Teslaa & Teitell 2014).  
 
1.3.2 Oxidative Phosphorylation 
 
OXPHOS takes place in the mitochondria and consists of the ETC, which 
comprises NADH-dehydrogenase (complex I), succinate dehydrogenase 
(complex II), ubiquinone, bc1 complex (complex III), cytochrome c oxidase 
(complex IV). Most electrons transferred by the ETC are derived from NADH and 
enter the chain via complex I. Moreover, complex II pumps in electrons directly. 
While the electrons are transferred through the ECT, a mitochondrial membrane 
potential is generated by protons across the inner membrane, which is later used 
by complex V (ATP synthase) to produce ATP (Hüttemann et al. 2007). 
XF Extracellular Flux Analyzer is an instrument that allows studying physiological 
changes in bioenergetics and metabolic pathways of mitochondrial respiration 
and glycolysis of live cells. It is achieved by two sensors, one that measures 
oxygen consumption rate (OCR), as an indicator of mitochondrial respiration and 
another that measures extracellular acidification rate (ECAR) an indicator of 
lactic acid production of glycolysis.  
During the mitochondrial assay, cells are metabolically challenged by the 
addition of inhibitors of different complexes of the ETC that essentially shift the 
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bioenergetic profile of the cell (Figure 3A) (Agilent Technologies note 2017). 
Baseline rates are measured first, and the OCR reported in the unit of picomoles 
per minute (pmol/min). The first injection is done with a solution containing 
oligomycin, which is a compound that inhibits ATP synthase (Figure 3A). The 
response after injection of oligomycin can be used to establish the percentage of 
oxygen devoted to ATP synthesis and to naturally occurring proton leak. The 
second injection is a solution containing the ETC accelerator, Carbonyl cyanide-
p-trifluoromethoxyphenylhdrazone (FCCP) which disrupts ATP synthesis by 
transporting hydrogen ions across the mitochondrial membrane instead of the 
ATP synthase, causing energy usage without ATP production. The use of this 
compound allows the calculation of the maximal respiratory capacity of cells 
(Agilent Technologies note 2017).  
 
 
Figure 3 Mitochondrial respiratory and glycolytic profiles. Typical profile obtained with 
the XF Extracellular Flux Analyzer (Agilent Technologies). (A) Mitochondrial stress test 
graph showing the key parameters of mitochondrial function, following the sequential 
injection of specific compounds that Oligomycin, FCCP and Rotenone. (B) Glycolytic stress 
test graph with the parameters of cellular glycolysis. Adapted from (Pelletier et al. 2014). 
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Finally, the third injection is a solution containing rotenone, a complex I inhibitor 
(Figure 3A) that shuts down mitochondrial respiration by disrupting the 
membrane potential of the mitochondria. This compound allows for the 
calculation of the nonmitochondrial respiration (Figure 3A).  
During glycolysis stress test, as glucose is being converted to pyruvate and 
lactate, resulting in the production and excretion of protons, the acidification of 
the medium surrounding the cell is detected by the XF sensors as ECAR (Figure 
3B). The first injection is a saturating concentration of glucose, which is 
catabolized via the glycolytic pathway to pyruvate, producing ATP, NADH, water, 
and protons and allows the estimation of the rate of glycolysis under basal 
conditions. Second injection is done with a solution containing oligomycin, that, 
as described previously, inhibits mitochondrial ATP production, shifting the 
energy production towards glycolysis, revealing the maximal glycolytic capacity 
of the cell. The final injection is a solution containing 2-deoxy-glucose (2-DG), a 
glucose analog that inhibits glycolysis through competitive-binding to glucose 
hexokinase, confirming that the increase in ECAR is associated to glycolysis 
(Figure 3B).  
 
Oxidative phosphorylation and glycolysis are the two major energy-producing 
pathways in the cell and although seem separate pathways, they are tightly 
connected and intertwined (Zheng 2012). Most cells pose the ability to adapt to 
their environment by switching between those two pathways (Figure 4). 
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Figure 4. Schematic Representation of Cellular Bioenergetic Pathways. Cells generate 
energy in the form of ATP by a combination of two main metabolic pathways: glycolysis and 
oxidative phosphorylation. Glycolysis metabolizes glucose through a series of enzymatic 
reactions to pyruvate, which can be either reduced to lactate or oxidized via the TCA cycle 
and the mitochondrial ETC to generate energy. Adapted from (Pelletier et al. 2014).  
 
 
As already mentioned, adipose tissue is a very active, multifunctional organ 
maintaining energy homeostasis in check. Adipocytes, from white adipose tissue 
(WAT), contain a relatively low number of mitochondria compared to the overall 
size, but they either oxidize incoming fatty acids (FAs) and carbohydrate fuels 
through the TCA cycle and the ETC (Figure 4) or store them in the form of 
triglycerides until required for release. Glycerol-3-phosphate, a precursor 
substrate for FA-esterification is produced by mitochondria and is required for the 
packaging of lipids as triglycerides (TGs) in the lipid droplets (Kusminski & 
Scherer 2012). Mitochondria play a crucial role in de novo lipogenesis, lipolysis 
and FA-esterification.  
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1.4 Zucker rats as a genetic model of metabolic syndrome 
 
1.4.1 Discovery and development 
 
Zucker rats (ZRs) arose spontaneously by ‘fatty’ mutation during crosses 
between Sherman and Merc 13M rat stock (Zucker & Zucker 1961)(Kava et al. 
1990). It was discovered that the ‘fa’ mutation was inherited as a Mendelian 
recessive trait (Zucker & Zucker 1961; Kava et al. 1990) as about 25% incidence 
of obese pups were regularly found (Zucker & Zucker 1961). The picture 
presented in the original paper shows Brother and Fatty rats at the age of 10 
months with the respective weights of 447 and 1035 grams (Zucker & Zucker 
1961). Representative images of Zucker rats used in our experiments shown on 
Figure 5.  
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Figure 5. Appearance of heterozygous and homozygous Zucker rats. Clear differences were 
observed in the size of the animals already at 10 weeks of age. Left, heterozygous (+/fa; 
Zucker lean; ZL) and right, homozygous (fa/fa; Zucker fatty; ZF). 
 
 
They observed that morphological manifestations of the obese condition show up 
at 3 to 5 weeks of age due to overeating and even with a lifelong food restriction, 
fa/fa rats become obese with 50% body fat (Kava et al. 1990). The Zucker fatty 
rats are significantly hyperphagic compared to lean littermates as early as 17 
days of age (Kava et al. 1990). Homozygous animals develop hyperinsulinemia, 
hyperlipidemia, hypercholesterolemia, adipocyte hypertrophy and hyperplasia 
and hepatic insulin resistance (Kava et al. 1990)(Aiston et al. 2000). Liver 
hypertrophy is found as early as 6 weeks of age and persists until one year of 
age (Goldstein & Johnson 1980). A loss in glucose tolerance occurs in ZR by 10 
weeks of age and progressively worsens by 19 weeks of age (Augstein & 
Salzsieder 2009).  
The second important observation was related to the milky appearance of blood 
serum (lactescence). Biochemical analysis showed a ten-time increase in total 
fatty acids, raised cholesterol and phospholipids. Fasting lipid levels remained 
very high even after 18 hours (Zucker & Zucker 1961).  
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1.4.2 Molecular characteristics of the obese subjects 
 
The Zucker fatty rat (fa/fa), characterized by a mutation in the leptin receptor 
gene (Phillips et al. 1996), is considered a model for pre-diabetes. The 
consequences of this mutation result in hyperphagia, IR, hyperinsulinaemia, 
hyperlipoproteinaemia, and obesity. Additionally, these animals progressively 
develop glucose intolerance from 10 to 19 weeks of age, but do not develop 
T2DM (Apweiler & Freund 1993). Although they maintain their capability to 
control normoglycaemia, changes to pancreatic islets were also shown, as 
impaired islets histology, altered ß-cell mass. These abnormalities are related to 
the very early onset of insulin resistance and glucose intolerance (Augstein & 
Salzsieder 2009; Weir et al. 2001). In terms of the lean phenotype two 
genotypes, homozygous lean (+/+) and heterozygous lean (+/fa), exist. The 
heterozygous lean ZRs have been shown to be susceptible to diet-induced 
obesity (Morris et al. 2003). 
Throughout this thesis, Zucker rats were fed with regular diet and not obese 
phenotype was found in the heterozygote Zucker lean, and consequenty it was 
used as control of Zucker obese rats. Throughout the thesis the heterozygote 
Zucker lean subjects are denoted as ZL and the Zucker obese as ZF, also when 
referring to hepatocytes or their secreted EVs. 
 
1.4.3 Worldwide research use of Zucker rats 
 
To detect the early effects of the fa mutation and in search for the aetiology of 
obesity, Goldstain and Jahnson established for the first time a successful primary 
foetal hepatocyte culture from obese (ZF) and lean (ZL) Zucker rats, in the 
1980s. No difference was found in terms of growth or ornithine transcarbamylase 
activity between both strains. They also concluded that upon a change of media 
their lipogenic activity decreased in both types of cells (Goldstein & Johnson 
1980). A few years later, other groups confirmed this finding by studying the 
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incorporation of radioactively labelled U14C lactate as a source of carbon for fatty 
acid and glycerol synthesis. Enhancement in TG production was observed in ZF 
hepatocytes, reflecting their lipogenic state with augmented TG content as 
compared to their lean littermates. They concluded that metabolic activities in 
cells in vitro reflect well the phenomenon observed in vivo (Porquet et al. 1984). 
Yet another group found the increased activity of glucose-6-phosphate 
dehygrogenase together with the significantly higher rate of U14C glucose and 
U14C lactate incorporation into C14 lipid in ZF hepatocytes. They concluded that a 
very active phosphate pentose pathway (11-folds) could be responsible for 
enhanced glucose uptake in these hepatocytes, with no effect of insulin and no 
enhancement in glucose transport capacity (Carbó et al. 1991). 
Additional studies described other metabolic defects in hepatocytes from ZF rats. 
Aiston, Peak, and Agius discovered increased glucokinase activity and higher 
rates of glycolysis and lipogenesis in ZF hepatocytes which however had a 
decreased glycogen synthesis (Aiston et al. 2000).  
In summary, several metabolic pathways including insulin signalling and Glut4 
translocation with elevated hepatic glycolysis are altered in the Zucker rats.  
 
 
1.5 Pathology of Metabolic Syndrome 
 
1.5.1 Aetiology  
 
The aetiology of MetS is still matter of continuous debate. An early hypothesis 
states that insulin resistance is the primary cause of MetS (Reaven 1988). Then, 
at a closer look, obesity was viewed as the main cause. It is currently thought 
that the positive energy balance as the causative agent with obesity serving as a 
clinical indicator of over nutrition (Grundy 2015). Caloric restriction even in the 
47 
 
presence of obesity is able to reverse most metabolic risk factors for the 
development of MetS (Ikramuddin & Buchwald 2011). Factors that mediate the 
difference between metabolically healthy and metabolically unhealthy is not 
obesity per se, however fat storage in peripheral organs, which leads to the 
development of insulin resistance.  
As described in the previous section, adipocytes and their secreted components 
have a profound influence on neighbouring cells and distant organs. Most studies 
have focused on the adipocyte/macrophage axis in terms of the pathogenesis 
and progression of MetS. However, another major organ affected in those 
settings is the liver. As the main synthesizer of many factors in physiological 
conditions, the possibility cannot be discarded that factors secreted by 
hepatocytes also play a role in the pathology of MetS. Recently, a study was 
published, which identified fetuin B, secreted by steatotic hepatocytes, as being a 
link between steatosis and impaired glucose metabolism. The study concluded 
that steatosis changes protein secretion in hepatocytes and that they cause 
insulin resistance and inflammation (Meex et al. 2015). 
 
1.5.2 Adipogenesis 
 
Adipocytes are the major subset of cells in adipose tissue, which is areolar 
connective tissue forming an insulating layer under the skin and around the 
internal organs (Ali et al. 2013). Their primary function is insulation and the 
control of the energy homeostasis, which is storing fat in periods of energy 
excess and mobilizing it when needed (Cornelius et al. 1994). During long time it 
was thought that these were their only functions, however, this tissue is now 
recognized as a highly active metabolic and a very dynamic endocrine organ 
controlling many physiological processes via secreted factors, collectively called 
adipokines. One important function of the adipocyte is to deal with the daily influx 
of dietary fat (Goossens 2008). Importantly, they have a physiological, as well as, 
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a pathological impact on the metabolism of other tissues, insulin sensitivity, 
immunological responses and vascular disease.  
Adipocytes differentiate and mature from precursor cell to become functional in 
the process of adipogenesis. First, the undifferentiated mesenchymal stem cells 
become preadipocytes to later undergo a secondary differentiation featured by 
lipid accumulation into the cell cytoplasm.  
Most of what is known regarding adipogenesis have been studied in vitro using 
the 3T3-L1 pre-adipocyte cell line model, as studying this process in vivo is 
difficult. Differentiation is propagated chemically with an adipogenic cocktail 
containing a combination of insulin, which acts through the insulin-like growth 
factor 1 (IGF-1) receptor, a glucocorticoid, an agent that elevates intracellular 
cAMP levels, and foetal bovine serum. Dexamethasone (DEX), a synthetic 
glucocorticoid and the cAMP phosphodiesterase inhibitor 3-isobutyl-1-
methylxanthine (IBMX) are the most commonly used compounds to drive the 
differentiation process (Cornelius et al. 1994; Ntambi & Kim 2000). This multistep 
process is driven by the expression of numerous genes and transcription factors 
in a highly ordered and well characterized temporal sequence (Rosen et al. 
2000). After 48h of the induction of adipocyte differentiation, confluent 3T3-L1 
fibroblasts acquire a spherical, adipocyte-like morphology (Fan et al. 1983) due 
to a change in cytoskeletal components and extracellular matrix (ECM) (Gregoire 
et al. 1998). On a molecular level, adipogenesis involves the regulation of 
several genes that is orchestrated by different transcription factors. C/EBP1 and 
PPARγ transcription factor families are induced at early stages of differentiation, 
this period is characterized by a prominent period of growth arrest followed by 
expression of a fully differentiated phenotype (Rosen et al. 2000). Within the first 
hour after the addition of the of the adipogenic cocktail, a dramatic increases in 
the expression of CCAAT/enhancer binding proteins (C/EBP) ß and Δ are 
observed (Cornelius et al. 1994). During the first 24h C/EBP-ß and C/EBP-Δ 
accumulate. At this point, the cell enters in the cell cycle again and 
synchronously implements mitotic clonal expansion (MCE) (Tang et al. 2003). At 
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a G1 to S phase, C/EBP-ß is hyperphosphorylated and sequentially activated by 
glycogen synthase kinase-3ß and MAPK. Subsequently, both C/EBP-ß and 
C/EBP-Δ induce the expression of adipogenesis transcriptional regulators, 
PPAR-γ and C/EBP-α (Tong et al. 2005). They induce the cascade of gene 
expression that controls adipocyte differentiation. At 48h into the process, 
C/EBP-α protein accumulates and becomes phosphorylated by the cyclin D3, 
ceasing proliferation and allowing cells to enter into the terminal differentiation 
phase (Wang et al. 2006). After just 8 days of induction of differentiation nearly 
90% of cells are mature adipocytes (Moreno-Navarrete, Jose Maria and 
Fernandez-Real 2012). During the terminal differentiation phase, adipocyte de 
novo lipogenesis increases, and they become sensitive to the action of insulin 
with more insulin receptors as well as glucose transporters, seen as an increase 
in genes encoding for Glut4 and the insulin receptor. The activity of enzymes 
involved in triglyceride metabolism such as ATP citrate lyase, malic enzyme, 
acetyl Co-A carboxylase, fatty acid synthase, glycerol-3-phosphate 
acetyltransferase, and aP2 among others become up to 100-fold higher with 
extensive lipid accumulation. During this process, lipid-laden droplets begin to 
accumulate within the cytoplasm, and over time they become larger.  
 
1.5.3 Obesity  
 
Obesity results from an imbalance between energy intake and energy 
expenditure (Goossens 2008). Adipose tissue is the main lipid storage depot in 
the body, which has the capacity to rapidly respond to over nutrition. The excess 
energy is stored in lipid droplets of adipocytes that can be mobilized during the 
time of nutrient deprivation. However, if a state of over nutrition persists, to keep 
up with the nutrient influx adipose tissue expands, recruiting adipocyte progenitor 
cells to undergo adipocyte differentiation, entering a state of hypertrophy. In this 
condition, the size of the adipocyte can increase up to 140-180 µm in diameter, 
but the diffusion limit of oxygen is at most 100 µm resulting in local hypoxia 
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(Salans et al. 1973). The excess adiposity and adipocyte dysfunction in the state 
of obesity result in the deregulation of a wide range of adipose tissue-derived 
secretary factors that conducts to adipose tissue inflammation. Taken together, 
during the development of obesity, adipose tissue is characterized by adipocyte 
hypertrophy followed by hypoxia, immune cell infiltration, all leading to the 
development of insulin resistance, which effectively progresses into the systemic 
metabolic disease (Chan, Pei-chi and Hsieh 2017). Insulin resistance manifests 
as hyperinsulinemia in the presence of hyperglycemia and dyslipidemia 
(Rutkowski et al. 2015). Accumulating evidence suggests that dysfunctional 
adipose tissue plays a crucial role in the pathogenesis of obesity-related insulin 
resistance (Goossens 2008). 
 
1.5.4 Adipose tissue in metabolic syndrome 
 
As mentioned in the previous section, during obesity, expanding adipocytes are 
eventually unable to store excess lipids even with enhanced adipocyte 
proliferation (hyperplasia). This redirects fatty acids to the liver promoting 
dyslipidemia, characterized by elevated plasma free fatty acids (FFAs), 
triglycerides and LDL, and the reduction of high-density lipoproteins. In addition, 
enlarged adipocytes are characterized by enhanced lipolysis, the breakdown of 
stored triglycerides (TGs) by lipases releasing FFAs and glycerol, which further 
increases plasma FFA-level and up regulates TG synthesis in the liver.  
The view and understanding on adipose tissue physiology took a turn in 1994 
with the discovery of the product of the Ob gene that encodes for the hormone 
leptin (Zhang et al. 1994). With that, WAT was recognized as a major endocrine 
organ (Trayhurn et al. 2008) and a number of additional adipose products such 
as adipsin and later, the synthesis of pro-inflammatory TNF was demonstrated 
and directly linked to obesity-induced IR (Mcardle et al. 2013). Nowadays, it is 
clear that adipose tissue, through the secretion of adiponectin, resistin, adipsin, 
leptin, acylation stimulating protein (ASP), PAI-1, and lipoprotein lipase (LPL), 
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among many more, can signal locally as well as on a systemic level (Hosogai et 
al. 2007). Adipose tissue of obese insulin resistant subjects is characterized by 
increased expression and secretion of pro-inflammatory cytokines such as TNF, 
IL-6, PAI-1 and leptin and down regulation in the insulin-sensitizing adiponectin 
(Hosogai et al. 2007). The adipocyte ‘secretome’ also includes lipid moieties, 
including cholesterol, retinol, steroid hormones and prostaglandins (Trayhurn et 
al. 2008) that can influence the lipid metabolism. 
 
1.5.5 Hepatocytes  
 
The liver is a multifunctional organ and the metabolic centre of the body (Falcón-
Pérez et al. 2010). It plays an important role in many pathways involving nutrient 
homeostasis such as carbohydrates, lipids, and proteins (Bechmann et al. 2012). 
It regulates glucose homeostasis by storing excess glucose as glycogen and 
under hormonal stimulation releasing it into the bloodstream when needed 
(Klover & Mooney 2004). The liver is also the main detoxifying organ and the 
unique site for the synthesis of molecules such as bile, clotting factors, and other 
serum proteins (Medina-Santillán et al. 2013). Although they do constitute nearly 
80% of the liver parenchyma, hepatocytes are not the only cells of the liver. Liver 
macrophages (Kupffer cells), natural killer cells, as well as B and T cells, form a 
part of the hepatic immune system. Moreover, there are the hepatic stellate cells 
involved in angiogenesis and the main matrix-producing cells in the process of 
liver fibrosis (Moreira 2007).  
A central metabolic function of the liver is to maintain plasma glucose levels 
regardless of the nutritional state (Browning & Horton 2004). The liver produces 
glycogen in response to insulin to clear out and store glucose. However, when 
the liver is saturated with glycogen there is a shift towards fatty acid synthesis 
and their subsequent esterification to TG and export to AT as VLDLs (Postic & 
Girard 2008).  
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1.5.6 Development of hepatic steatosis 
 
In pathological conditions, hepatic lipid and carbohydrate metabolism is affected, 
being one of the reasons for the dysfunction of the insulin signalling. 
Consequently, the inability of metabolic tissues to respond to insulin leads to an 
increased amount of lipids and retention of TG in the liver causing fatty liver. If 
this state is maintained, simple steatosis can progress into steatohepatitis with 
inflammatory response and subsequently into cirrhosis, characterized by the scar 
tissue formation and leading to the development of hepatocellular carcinoma 
(HCC).  
The accepted hypothesis for the accumulation of triglycerides in the liver is an 
enhanced hepatic de novo lipid synthesis via the lipogenic pathway caused by 
obesity and insulin resistance of AT, which results in increased release of non-
esterified fatty acids (NEFA) from expanding adipose tissue to the liver. Lipid 
disposal via ß-oxidation and VLDL export are only very slightly affected (Postic & 
Girard 2008). Adipocyte hypertrophy leads to enhanced activity of hormone-
sensitive lipase and consequently an increased hydrolysis of triglycerides. This 
has a direct effect on hepatic FFA uptake, which are metabolized either to 
generate ATP via oxidative phosphorylation or esterified to triglycerides, which 
then can be incorporated into VLDL particles for excretion or stored within the 
hepatocyte (Browning & Horton 2004; Postic & Girard 2008).  
In the presence of excess nutrients, glucose gets converted to fatty acids via the 
conversion of glucose to pyruvate, which is then fed to the mitochondrial Krebs 
cycle. Citrate formed in the Krebs cycle is transferred to the cytosol where it is 
converted to acetyl-coA by ATP citrate lyase. Subsequently, acetyl-CoA is 
converted to malonyl-CoA by acelty-CoA carboxylase 1 (ACC1), which is used 
by fatty acid synthase to form fatty acids, such as palmitic, stearic or oleic acids, 
used for triglyceride synthesis. In steatotic livers, the rates of de novo fatty acid 
synthesis is elevated, as shown in humans and mouse models (Araya et al. 
2004). De novo fatty acid synthesis is regulated independently by insulin and 
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glucose (Koo et al. 2001). The insulin-triggered pathway is mediated by the sterol 
regulatory element-binding protein-1c (SREBP-1c) transcription factor. It 
activates lipogenesis-related genes in the nucleus and it has been shown to 
significantly influence the development of hepatic steatosis. Its inactivation in the 
liver of ob/ob mice results in significant reduction in hepatic triglycerides, with 
unchanged obesity and insulin resistance (Yahagi et al. 2002). On the other 
hand, over expression of SREBP-1c leads to increased lipogenesis and 
development of liver steatosis.  
The already mentioned, excess glucose also stimulates de novo lipid synthesis, 
via carbohydrate response element binding protein (ChREBP) that 
transcriptionally regulates the expression of lipogenic genes, such as fatty acid 
synthase (FAS), and acetyl CoA carboxylase (Medina-Santillán et al. 2013). It 
does that by binding to the promoter of the key enzyme in glycolysis, liver-type 
pyruvate kinase (L-PK), which catalyzes the generation of pyruvate used in 
Krebs cycle for citrate synthesis, the primary source of acetyl-CoA used for fatty 
acid synthesis. It is important to mention that PPAR-γ is also involved in the 
development of hepatic steatosis (Gavrilova et al. 2003). 
 
1.5.7 Deregulation of the insulin signalling pathway in metabolic syndrome 
 
Different mechanisms have been proposed to explain the molecular events 
behind the development of insulin resistance related with MetS. One hypothesis 
involves an increased serine phosphorylation of IRS-1, which leads to decrease 
in tyrosine phosphorylation and therefore a decrease in binding of the 
downstream enzyme PI3K, and essentially a decreased phosphorylation of the 
Akt kinase (Rask-Madsen & Kahn 2012) and inactivation of the downstream 
pathway. 
Mouse models with a loss of response to insulin have been critical to 
understanding the mechanism underlying insulin resistance. In particular, the 
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FIRKO model, with fat-specific deletion of the insulin receptor (Blüher et al. 
2002), the LIRKO model with liver-specific IR knockout (Escribano et al. 2009), 
MIRKO representing muscle-specific IR deletion (Brüning et al. 1998), ß cell-
specific an ß-IRKO model (Kulkarni et al. 1999) and mice models with adipose-
selective reduction of Glut4 (G4A-/-) (Abel et al. 2001). Studies on the FIRKO 
model, show that insulin resistance in adipocytes is crucial for the development 
of obesity and its metabolic abnormalities (Blüher et al. 2002). Moreover, the 
adipose-specific deletion of Glut4 in mice leads to impaired glucose tolerance 
and insulin resistance with no changes in adipose mass and causes the 
development of insulin resistance in muscle and liver (Abel et al. 2001). 
The major cause of fasting hyperglycemia in MetS is insulin resistance in the 
liver. The LIRKO mice exhibits pure hepatic insulin resistance (Biddinger et al. 
2005) with the complete loss of insulin suppressed hepatic glucose output due to 
increased expression of the gluconeogenic enzymes such as 
phosphoenolpyruvate carboxylase and glucose 6-phosphate and decreased 
expression of enzymes that regulate glycogen synthesis and glycolysis, including 
glucokinase and pyruvate kinase (Escribano et al. 2009; Rask-Madsen & Kahn 
2012). Moreover, insulin resistance affects the action of insulin on the regulation 
of circulating lipids in the liver, leading to hyperinsulinemia and causes increased 
circulating levels of FFAs and triglyceride as well as decreased clearance of 
LDLs due to downregulated LDL receptor. In LIRKO mice the secretion of 
triglycerides is decreased but the secretion of apoB and cholesterol is highly 
enhanced. LDL receptor expression, and therefore the clearance of apoB-
containing particles, is reduced creating pro-atherogenic lesions characterized by 
decreased HDL cholesterol and an increase in apoB containing particles. Hepatic 
insulin resistance can alone lead to dyslipidemia and increased risk of 
atherosclerosis associated with MetS (Biddinger et al. 2005).  
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1.6 Extracellular vesicles 
 
1.6.1 Overview and classification  
 
It is a commonly accepted fact that cells, both in vitro and in vivo secrete EVs to 
the extracellular environment (Simpson et al. 2008). EVs is a collective name 
suggested by the International Society for Extracellular Vesicles (ISEV) to refer a 
group of lipid membrane-enclosed vesicles released from prokaryotic and 
eukaryotic cells (van der Pol et al. 2016). EVs are released during basal 
conditions and under a stimulus or a cellular stress. Increased release of EVs 
has been reported to occur under many stress conditions such as hypoxia, 
oxidative stress, thermal change and many other factors (Iraci et al. 2016). 
Owing to the plasticity of cellular membranes, the organization of lipid 
membranes and the content of EVs may vary depending on the stimulus that 
generates them. Once released, EVs can act as mediators of intracellular 
communication (Yáñez-Mó et al. 2015). This communication may help to 
maintain homeostasis or may trigger destructive or degenerating process in a 
cell or organ. They serve not only as mediators but also effectors of cellular 
processes (H.-G. Zhang (ed.) n.d.).  
The extensive proteomic analysis of EVs in different cellular systems has found 
some common as well as cell-type-specific protein markers (Kalra et al. 2012; D. 
K. Kim et al. 2015). Currently, a broad classification of EV subpopulations, based 
on their size and biogenesis, separates them into exosomes, microvesicles 
(MVs) and apoptotic bodies (Figure 6). Exosomes are the smallest in this group, 
which is directly related to their endosomal origin, ranging in size from 30-150 
nm. Next are the more heterogeneous population of microvesicles that are 
formed by budding and shedding directly of the plasma membrane and can be as 
large as 1 μm in size (Lawson et al. 2016). 
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Figure 6 Schematic representation of the different types of EVs based on their 
intracellular origin. Major populations of EVs include exosomes, microvesicles and 
apoptotic bodies. Adapted from (György et al. 2011). 
 
Lastly, the apoptotic bodies that are products of cellular death, fall into a wider 
range of size from 1-5 μm. There are some small discrepancies as to the size 
range of different populations of EVs in the literature, as it seems to be 
dependent on cell type.  
Furthermore, independently of their biogenesis, EVs can carry proteins, lipids 
and nucleic acids: both coding and non-coding RNAs and DNA cargo (Abels & 
Breakefield 2016).  
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1.6.2 Discovery and brief history of the research in extracellular vesicles 
 
Initially, microparticles, not yet known as vesicles, were described to be the 
“dust” released by platelets (Wolf 1967). The existence of vesicles released by 
cells into the extracellular space was first mentioned in 1981 when the term 
exosomes was also coined (Trams et al. 1981). While studying the ecto-
ATPases and ecto-5’-nucleotidases, it was discovered that the culture medium of 
a variety of cells lines, both normal, as well as neoplastic, contained the ATPase 
and 5’-nucleotidase, which was shown to be associated with vesicles. The 
researchers concluded that the vesicle content reflected the ectoenzyme activity 
phenotype of the parent cells and for the first time the physiological function of 
those exfoliated membrane vesicles (exosomes) was proposed (Trams et al. 
1981). However, most reports attribute the discovery and initial characterization 
of EVs to the study of the transferrin receptor (TfR) shedding during the 
maturation of sheep reticulocytes (Pan & Johnstone 1983). The group led by 
Rose Johnstone followed the fate of the transferring receptor in vitro and 
discovered that it was removed from the plasma membrane and externalized 
(Figure 7A). Here the composition of the conditioned medium was concentrated 
by high-speed centrifugation at 100,000 x g and analyzed for the TfR-antibody 
complex. Its release was shown to be associated with released vesicles (Pan & 
Johnstone 1983). 
This system described, for the first time, specific sorting and externalization of a 
specific material in vesicles, since their protein composition was enriched in TfR 
which is not characteristic to plasma membranes (Pan & Johnstone 1983). In a 
later study, more evidence was presented on these vesicles containing 
enzymatic activity and characteristic components of the reticulocyte plasma 
membrane (Johnstone et al. 1987). This study has been followed up and 
validated by electron microscopy. TfR has been identified on the membrane 
surface of nano sized (50 nm) vesicles localized inside of a larger (1-1.5 μm) 
multivesicular structure (Pan et al. 1985) (Figure 7B and 7C).  
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Figure 7 The first report of exosomes existence and biogenesis. Electron micrographs 
showing (A) the evidence of vesicular material secreted from reticulocytes (Adapted from: 
(Pan & Johnstone 1983). (B) The Intracellular localization of multivesicular bodies (MVBs) 
and their (C) fusion with the plasma membrane following the release of gold labelled 
transferring receptor bearing nanovesicles (Adapted from: (Pan et al. 1985). 
 
 
These multivesicular structures were formed inside a cell, and upon fusion with 
the plasma membrane released their vesicular content together with the 
associated TfR. Authors hypothesized that the exocytosis of these vesicles could 
represent a mechanism of TfR shedding during reticulocyte maturation (Pan et 
al. 1985).  
Therefore, no major importance was attributed to them and their existence was 
forgotten for about 10 years until the pioneering studies by Raposo et al. which 
showed that B cells also secrete exosomes, as a result of fusion of multivesicular 
bodies (MVBs) with the plasma membrane. More importantly, these exosomes 
were carrying intact major histocompatibility complex class II (MHCII) molecule 
on their surface capable of triggering an immune response in a target cell 
(Raposo et al. 1996). A couple of years later, dendritic cells were also shown to 
release exosomes as a mechanism to modulate immunity (Zitvogel et al. 1998).  
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1.6.3 Biological Characteristics of EVs 
1.6.3.1 Biogenesis 
 
Exosome formation via the endocytic pathway begins with the invagination and 
endocytosis of the plasma membrane and formation of endocytic vesicles in the 
cytosol. The ubiquitination of some membrane proteins may serve as one 
possible internalization signal to trigger endocytosis (Raiborg & Stenmark 2009). 
These endocytic vesicles are then transported to and fused with early 
endosomes where they mature and transform to become late endosomes in a 
process involving changes in size, form, pH, and composition. Depending on 
their destination, molecules to be recycled are segregated into distinct 
subdomains of the endosomal membrane (Jovic et al. 2010; Trajkovic et al. 
2008). Subsequently, membranes of late endosomes, as they bud inwards and 
form numerous smaller (30-100nm) vesicles inside to become MVB or 
intraluminal vesicles (ILV) (Abels & Breakefield 2016). At this point, these 
vesicles can be addressed to lysosomal degradation or can be fused with the 
plasma membrane to release exosomes (Colombo et al. 2013).  
Microvesicles are formed through direct outward budding and fission of the 
plasma membrane as a result of dynamic interaction between phospholipid 
redistribution and cytoskeletal protein contraction (Akers et al. 2013). They are 
thought to arise from regions of the plasma membrane enriched in lipid rafts, and 
they expose phosphatidylserine on their membrane (Mittelbrunn & Sánchez-
Madrid 2012).  
 
1.6.3.2 Cargo 
 
EVs are formed by a lipid bilayer that encloses distinct biomolecules, such as 
proteins, lipids, and nucleic acids. Owing to high-throughput proteomic and 
transcriptomic studies, to date, thousands of vesicular proteins, lipids and RNAs, 
from many different cells types and body fluids, have been identified and a large 
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amount of work has been directed at creating databases of proteins and lipids 
associated to EVs. As a result, three different publically available databases 
have been created, the Vesiclepedia (Kalra et al. 2012), the EVpedia (D. K. Kim 
et al. 2015) and Exocarta (Maas et al. 2017). In general, EVs contain a common 
set of components but also cell specific molecules. They conserve a set of EV-
related proteins including ALIX, a member of the ESCRT machinery, and 
proteins related to membrane transport and fusion including annexins and Rab 
proteins. EVs also contain cytoskeleton-related proteins like tubulins, actins, 
moesin, cofilin-1 and profiling-1. Moreover, proteins involved in cell adhesion 
(integrins, ICAM-1, MFG-E8) that are probably involved in interaction with target 
cells, as well as, MHCs involved in antigen presentation. Signal trasducing 
proteins such as insulin growth factor receptor (IGFR) along with heat shock 
proteins and metabolic enzymes such as elongases, glyceraldehydes 3-
phosphate dehydrogenase and pyruvate kinase, that function in distinct cellular 
pathways. EVs are also known to be highly enriched in tetraspanin molecules 
such as CD9, CD63 and CD81 and other transmembrane proteins such as 
Lamp1. HSPs are induced under stress conditions and play many different roles 
such as directing protein folding, targeting of protein degradation, and binding of 
antigens for presentation (Tutar & Tutar 2010) and have been repeatedly 
documented in EVs. All the common proteins identified were found to originate 
from the cytoskeleton, cytosol, and the plasma membrane. Proteins associated 
with Golgi, ER or the nucleus were absent in EVs (Thery et al. 2001), however 
the presence of transcription factors such as Notch and Wnt has been recently 
reported (Abels & Breakefield 2016).  
Most reports regarding the biochemical composition of EVs concentrate on a 
heterogeneous population of exosomes and microvesicles. Thus, the actual 
composition of each subtype remains unknown. A group led by Clotilde Théry 
have characterized exosomal and nonexosomal subpopulations within small EVs 
and identified protein markers associated with larger EVs, secreted by human 
primary monocyte-derived dendritic cells (DCs) (Kowal et al. 2016). They 
confirmed that exosomes were enriched in known protein markers, such as 
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tetraspanins CD9, 63 and 81, although to a certain degree, they were present in 
all EV fractions. Moreover, HSPs and flotillin1 were more associated with 
medium size and larger EVs. Large EVs, in the 2,000 x g pellet were abundant in 
cell markers such as GRP94 and HSP90B1. They also identified proteins either 
unique or enriched protein markers of small and large EVs. TSG101, syntenin- 
Annexin XI and ADAM10 as being more specific to small EVs. Actinin-4 and 
mitofilin were more specific to large- and medium-sized EVs (Kowal et al. 2016). 
Lipids are the key components of EVs, with several of them been suggested to 
have a role in their formation and function. The smaller an EVs is, the larger the 
proportion of its total mass is contributed by the membrane lipids. ILVs 
accumulate cholesterol during their biogenesis from the MVB and they are 
subsequently enriched in cholesterol when compared to the parental cell. EVs 
are generally enriched in sphingomyelin, cholesterol, phospholipids and 
glycosphingolipids when compared to the cell of origin, which may be an 
important factor in their stability (Yáñez-Mó et al. 2015). EVs carry bioactive 
lipids such as eicosanoids but also transport active lipolytic enzymes such as 
different phospholipases (Record et al. 2014). They mediate intracellular lipid 
trafficking of sphingomyelin, leukotrienes, prostaglandins, cholesterol, 
lysophosphatidylcholine, arachidonic acid and other fatty acids. Moreover, the 
lipid composition of small EVs points towards sorting of lipidic molecules with 
enrichment in sphingomyelin, psosphatidylcholine, and 
phosphatidylethanolamine. On the contrary, the lipid composition of MVs reflects 
that of the plasma membrane of the secreting cell (Record et al. 2014).  
The exchange of RNA between cells by means of EVs was first observed by 
Valadi et al. (Valadi, H. Ekstrom, K. Bossios 2007). They have also 
demonstrated that vesicular mRNA and miRNA can be functionally transferred 
and can alter gene expression in neighbouring cells. This was a ground breaking 
discovery and since then more RNA species enriched in EVs have been 
identified such as small noncoding RNA species, including RNA transcripts 
overlapping with protein-coding regions, repeat sequences, structural RNAs, 
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tRNA fragments, vault RNA, Y RNA, and small interfering RNAs (Bellingham et 
al. 2012). Moreover, the RNA profile of EVs was found to be enriched relative to 
one of the originating cells (Valadi, H. Ekstrom, K. Bossios 2007; Ratajczak et al. 
2006; Raposo & Stoorvogel 2013).  
 
1.6.3.3 Uptake and Interaction with recipient cells  
 
A body of evidence exists on the physiological and pathological functions 
mediated by EVs. They are able not only to interact with the recipient cells but 
also transfer active material to execute the phenotypic change in the target cell. 
In order for this to be possible, EVs must interact with the cell plasma membrane, 
directly or indirectly. Different routes have been described such as endocytic 
pathways clathrin-dependent and independent endocytosis, caveolin-mediated 
endocytosis, macropinocytosis, phagocytosis, and lipid-rate mediated 
internalization [Summarized in Figure 8; adapted from (Mulcahy et al. 2014)].  
Valadi et al, have shown the transfer of functional mRNA and miRNA from 
mouse to human cells (Valadi, H. Ekstrom, K. Bossios 2007). It has also been 
demonstrated that EVs secreted by bone marrow BMDCs fused with target DCs, 
but released their content into the DCs cytosol and the functional miRNA 
repressed a target mRNA in the target cell (Montecalvo et al. 2012). 
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Figure 8 Different routes of EV uptake by the recipient cell. Uptake of EVs has been 
shown to be mediated through phagocytosis, clathrin- and caveolin-mediated endocytosis.  
[Image has been adapted from: (Mulcahy et al. 2014)].  
 
 
The experimental data suggests that endocytosis is the most frequently used 
process for EVs uptake. It was shown that it is a rapid, energy- and cytoskeleton 
–requiring process. At 40C the uptake was markedly reduced, as well as 
following actin depolarization with CytochalasinD. Moreover, EVs were not taken 
up by paraformaldehyde fixed cells (Mulcahy et al. 2014). Under the term of 
endocytosis there are other independent mechanisms, which have been 
implicated in EVs uptake such as clathrin-mediated and caveolin-dependent 
endocytosis and, macropinocytosis. Clathrin-mediated endocytosis, also known 
as receptor-mediated endocytosis involves internalization through an assembly 
of clathrin-coated vesicles containing receptors specific to molecules being 
absorbed and/or their ligand. The process involves membrane deformation and 
inward clathrin-pit formation. Once mature, it pinches off as a clathrin-coated 
vesicle. The uncoating and subsequent release of cargo take place at the 
endosome, where it is sorted and directed. Caveolin-mediated endocytosis, 
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involves the formation of caveolae-coated pits from domains of plasma 
membrane glycolipid rafts rich in caveolins, cholesterol, and sphingolipids. Lastly, 
macropinocytosis, also known as fluid endocytosis, is another endocytic 
pathway, which involves the formation of membrane invagination ruffles, which 
once pinched off give rise to macropinosomes absorbing extracellular fluids 
(Mulcahy et al. 2014). The role of lipid rafts has also been proposed for EVs 
uptake (Nabi & Le 2003). Clathrin-independent Endocytosis largely requires 
cholesterol, which is highly enriched in lipid rafts (Mulcahy et al. 2014). In 
melanoma cancer cells a direct fusion with the plasma membrane has also been 
shown (Parolini et al. 2009).  
 
1.6.3.4 New Mode of Cellular Communication  
 
Cells are required to communicate with each other for appropriate development 
and functioning of the whole organism. In addition to classical modes of cell 
communication, another mechanism, mediated by EVs has emerged. As 
explored in previous sections, EVs carry bioactive lipids, receptors, proteins, 
nucleic acids, such as mRNA and microRNA. Moreover, EVs can be taken up by 
the recipient cell and transfer their cargo to cause either transient or long term 
phenotypic changes in recipient cells (Tetta et al. 2013). EVs may directly 
activate the recipient cell by acting as signalling complexes through surface-
expressed ligands that directly stimulate the target cell (Camussi et al. 2010). For 
example, EVs derived from macrophages interact with platelets via the P-selectin 
glycoprotein ligand-1 expressed on their surface (Tetta et al. 2013). EVs may 
transfer receptors from LPS activated monocytes, as they were able to induce 
apoptosis of vascular smooth muscle cells via the caspase-1 contained in their 
secreted EVs (Sarkar et al. 2009). Moreover, tumour-derived EVs were identified 
promoting the formation of metastatic niche by priming bone marrow-derived 
cells towards a pro-angiogenic and pro-metastatic phenotype through 
upregulation of the tyrosine-protein kinase Met (Peinado et al. 2012). 
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Furthermore, active Wnt proteins secreted in exosomes activated the Wnt 
signalling pathway in target cells (Gross et al. 2012). These are just a few 
examples showing the importance of EVs in physiology and as mediators of 
pathology.  
 
1.6.3.5 Methods for Isolation and Characterization 
 
The technique chosen for the isolation of EVs has an impact on the amount, type 
and purity of EVs recovered (Van Deun et al. 2014; Gardiner et al. 2016). 
Differential-ultracentrifugation still remains the most commonly used technique 
(Gardiner et al. 2016) and the standard protocol for the isolation of exosomes, or 
enrichment in exosomes, often in a combination with sucrose density gradients 
or sucrose cushion (Théry et al. 2006). Differential-ultracentrifugation essentially 
consists of a series of centrifugation cycles of increasing centrifugal force and 
duration to isolate particles based on their density. The filtration step, through 0.2 
µm filter system, is added to enrich in small EVs. Additionally, as exosomes have 
been characterized to have densities between 1.1 and 1.19 g/ml, the differential 
ultracentrifugation is often coupled with the density gradient centrifugation to 
remove any aggregates and non-vesicular contaminants (Taylor & Shah 2015). 
However, EV isolation may be achieved by a variety of other methods including 
polymer-based precipitation, microfluidic separation, affinity capture with 
antibodies coated on latex beads or size-exclusion chromatography (SEC). 
Using SEC vesicles are separated based on their size and the interaction with 
the beads packed in the SEC column. Redistributed bead creates a ‘maze’, 
where vesicles, depending on their hydrodynamic diameter, can pass through 
(Taylor & Shah 2015).  
All the above-mentioned techniques are general approaches that isolate all 
circulating vesicle populations. Since EVs are membrane vesicles with an array 
of proteins and receptors on the surface, immunoaffinity capture-based 
techniques were developed to isolate them. Immobilized on different matrices, 
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beads, plates or filters, antibodies recognize specific antigens on EVs, isolating a 
very specific sub-population.  
Various optical and biochemical methods have been developed or adapted for 
the assessment of EV quantity, size, morphology and surface markers (Witwer et 
al. 2013). Single vesicle characterization is now commonly used such as electron 
microscopy (transmission-electron microscopy (TEM), atomic-force microscopy 
(AFM), or cryo-electron microscopy (Cryo-EM) for visualization. Size distribution 
measurements of EVs are done by nanoparticle-tracking analysis (NTA), 
dynamic light scattering, or resistive pulse scanning. Analytical techniques 
commonly used for the detection of proteins associated to EVs are WB, flow 
cytometry (FACS) and global proteomic analysis using mass spectrometry 
(Gardiner et al. 2016).  
 
1.6.3.6 Potential Application of EVs In the Clinic  
 
Since EVs are present in all body fluids, the emphasis has been placed on their 
use as non-invasive, early biomarkers for disease detection and assessment of 
prognosis (Simpson et al. 2009; Royo et al. 2016; Gonzalez & Falcon-Perez 
2015). MSCs, present in the stromal fraction of many adult tissues, have a self-
renewal potential and ability to differentiate into many tissue types (Di Rocco et 
al. 2016). MSC-EVs have been proven useful in regenerative medicine with their 
capacity to restore injured tissue (Quesenberry et al. 2015). MSC-EVs have been 
shown to suppress hypoxia-induced inflammation and hypertension in mice (Lee 
et al. 2014). Human umbilical cord-MSC exosomes transplanted into acutely 
injured and fibrotic livers could restore liver function and improved liver fibrosis 
(Li et al. 2012). Moreover, MSC-secreted EVs protect against acute kidney 
damage (Bruno et al. 2009). Furthermore, DC-derived EVs were able to induce 
antigen-specific naïve T cell activation in vivo (Théry, Duban, et al. 2002). EVs 
from cancer cells carry tumoral antigens and present them to T cells, priming 
them to induce an anti-tumour response and eventually tumour cell death (Cho et 
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al. 2005). Using EVs as a cell-free vaccine was proposed by Viaud et al., (Viaud 
et al. 2010). Cancer-EVs were shown not only to be very promising diagnostic 
biomarkers but also markers for identification of cancer aggressiveness (Verma 
et al. 2015). Furthermore, plants also secrete exosome-like nanoparticles, which 
have been proposed to have potential to influence cell biology through ingested 
foods as they are highly resistant to gastric juices (Quesenberry et al. 2015).  
In terms of the drug delivery, currently preferred systems include liposomes and 
polymeric nanoparticles, which have been used to deliver anti-cancer drugs, anti-
fungal drugs and analgesics (Ha et al. 2016). Recently, accumulating evidence 
indicate that EVs would be more suitable drug delivery system due to their longer 
half-life, tissue specificity and minimal toxicity. One study involved the use of EVs 
to deliver curcumin for treatment of inflammatory disease (Sun et al. 2009). 
Besides the delivery of small molecules such as drugs, they are used to deliver 
large molecules such as protens. It has been explored for the delivery of 
antioxidant catalase for the treatment of Parkinson’s desease (Haney et al. 
2015). Lastly, there is an increasing interest in using EVs for delivery of 
therapeutic genetic material for strategy involving gentic therapy (Ha et al. 2016). 
These are only a few examples of applications of EVs (Quesenberry et al. 2015).  
 
1.6.4 Extracellular Vesicles in Metabolic Syndrome  
 
As already explored, during obesity progression there is an accumulation of 
immune cells within AT. In that context, the role of adipose-EVs in a crosstalk 
between adipocytes and macrophages has also been studied and they have 
been shown to significantly contribute to AT inflammation and insulin resistance 
development (Zhang et al. 2015). In 2009, a study concluded that EVs released 
by adipose tissue, cultured ex vivo from a genetically obese mouse model 
(ob/ob), were able to activate blood monocytes into M1 pro-inflammatory 
macrophages (30 μg/mice). Additionally, they enhanced the migration of 
macrophages into adipose tissue and the liver, where they caused an insulin 
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resistance (Deng et al. 2009). The presence of immunomodulating factors has 
been shown in EVs isolated from an in vitro model of differentiated human 
adipocytes and ex vivo AT-explants, which were also capable of macrophage 
activation (Mariette E G Kranendonk et al. 2014).  
Another study showed that THP-1 macrophage-derived EVs decreased insulin-
stimulated Akt phosphorylation, through nuclear factor kappa-light-chain-
enhancer of activated B cells (NFκB) activation, and decreased glucose uptake 
in human primary adipocytes. Additionally, the amount of insulin-stimulated 
GLUT4 translocation was reduced in adipocytes pre-treated with M1 
macrophages, as compared to M2, anti-inflammatory macrophages (Zhang et al. 
2015). Another study showed that MetS patients have increased levels of blood-
circulating EVs as compared to healthy patients (O’Neill et al. 2016). Moreover, 
quantitative differences in microRNA content have been found in exosomes from 
obese visceral adipose tissue (Ferrante et al. 2015). Together these findings 
indicate that metabolic stress alters the nature and amount of EVs secreted and 
that EVs have a potential to alter cellular metabolism.  
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1.8 Thesis objectives  
 
Extracellular vesicles have been linked with the development of different 
diseases including MetS. Most studies linking extracellular vesicles to MetS have 
focused their attention on expanding adipose tissue and associated 
abnormalities, such as hypoxia and macrophage infiltration.  
 
The aim of this thesis was to perform comparative characterization of 
extracellular vesicles in the pathophysiology of metabolic syndrome. To address 
this issue, we first aimed to establish and characterize several in vitro models, 
including hypertrophic (lipid overloaded) adipocytes, adipocytes cultured in 
hypoxia or in the presence of macrophage conditioned medium and activated M1 
macrophages as a model of inflammation. Moreover, two models of 
hepatoculluler steatosis were used, the chemically-induced in hepatic cells lines 
and primary hepatocytes from Zucker rats, which represent a genetic model of 
obesity that accumulates of lipids in hepatocytes.  
The goal was to isolate and characterize extracellular vesicles from the 
conditioned medium of all these cellular models. Lastly, we aimed to shed light 
on a possible role of hepatic and proinflammatory extracellular vesicles on 
adipocytes in the context of metabolic syndrome. The experimental design is 
schematically represented on Figure 9. 
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Figure 9 Schematic view of the experimental models and objectives of the thesis. EVs 
were isolated from the conditioned medium of different cellular models including 
Hepatocytes, Macrophages, and Adipocytes, and incubated under conditions that resemble 
some manifestations of metabolic syndrome. Once establishes the models were used to 
produce and characterized EVs. Next, the objectives were to investigate whether these EVs 
influenced the insulin sensitivity, adipokine secretion, the progression of adipogenesis and 
finally bioenergetic balance in 3T3-L1 adipocytes, in the context of MetS. 
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MATERIALS and METHODS 
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2. Materials and Methods 
 
2.1 Animal models  
 
Male Zucker rats, Fatty (ZF) and its Lean (ZL) counterpart, (ZUC(Orl)-Leprfa 
strain) were purchased at 10-12 weeks of age from Charles River Laboratories 
(France). In CICbioGUNE animal facility, Zucker rats were maintained in an 
environmentally controlled room at 220C on 12 h light/dark cycle and provided 
with standard, 14% protein diet, (Rodent Maintenance Diet, Harlan Teklad Global 
Diet 2014) and water ad libitum. All experiments were performed following the 
two weeks adaptation period and in accordance with the guidelines of the 
CICbioGUNE institutional review committee on animal use. 
 
2.2 Cell culture  
 
2.2.1 Primary cell culture  
 
2.2.1.1 Generation of the primary rat hepatocytes 
 
2.2.1.1.1 Perfusion of the liver to obtain primary hepatocytes 
 
The surgery was performed under anesthetic gas Isoflurane (IsoFLO, Abbott 
Laboratories), and all efforts were made to minimize the suffering of the animals. 
Rat hepatocytes were obtained by liver perfusion of Zucker lean (ZL) and Zucker 
fatty (ZF) rats. Briefly, after the rat was anesthetized with isoflurane, according to 
our institutions approved animal protocol, a laparotomy was performed to expose 
the liver and portal vein. The portal vein was cannulated for continuous perfusion 
with 150 ml Leffert’s buffer containing (Leffert’s buffer: 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) 10 mM, KCl 3 mM, NaCl 130 mM, 
NaH2PO4-H2O mM,glucose 10 mM) with 1 mM ethylene glycol-bis(β-aminoethyl 
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ether)-N,N,N',N'-tetraacetic acid (EGTA). The infrahepatic inferior vena cava was 
open to allow the flow through. Then, 150 ml of Leffert buffer was perfused and 
finally 150 ml of Leffert’s buffer containing 30,000 units of collagenase Type I 
(Worthington Biochemical Corp, Lakewood, NJ). After removing the catheters 
from the portal vein, the liver was explanted into a Petri dish to be gently minced 
with tweezers, and finally filtered through a cell strainer into a 50 ml Falcon tube.  
 
2.2.1.1.2 Percoll Density Gradient 
 
Rat hepatocytes suspension was centrifuged at low speed (400 rpm) for 4 min at 
40C to pellet cells and remove perfusion debris. Resulting cell pellet were 
resuspensed in 30 ml of cold Dulbecco’s modified eagle medium (DMEM) and 15 
ml of the 90% Percoll (GE Healthcare, 17-0891-01) in ice cold, sterile 10X 
Dulbecco’s Phosphate-buffered Saline (D-PBS) buffer. The tube was gently 
inverted and centrifuged at 500 rpm for 10 min for the density separation. 
Resulting cell pellet was washed with 30 ml of cold DMEM and centrifuged at 
500 rpm for 5 min. This step was repeated twice, and the final pellet was 
resuspended in 50 ml of DMEM for counting and subsequent seeding.  
 
2.2.1.1.3 Cell Counting and Viability 
 
Cell viability was evaluated with a benchtop automated cell counter (CountessTM, 
Life technologies) that performs cell count and viability (live, dead, and total cells) 
measurements using Trypan blue exclusion method. Briefly, small sample of the 
hepatocyte cell suspension was diluted 1:10 in DMEM and then mixed 1:1 with 
Trypan blue. A fraction of 10 μl of the sample/Trypan blue mixture was then 
loaded onto a Countess™ cell counting chamber slide. The camera of the 
equipment acquires cell images from the sample on the slide and the image 
analysis software automatically analyzes acquired cell images, and measures 
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cell count and viability based on Trypan blue extrusion method. The 
measurement provides live and dead cell concentration (per ml), total cell 
concentration (per ml) and viability (% of live cells). 
 
2.2.1.1.4 Collagen coating of cell culture plates 
 
A day prior the perfusion, plates were coated with collagen for the culture of 
primary hepatocytes. Plates were well covered with 0.05 mg/ml of Collagen type 
I from Rat Tail (354236, Corning) solution diluted in ultrapure water and 600 
μl/500 ml of acetic acid. The solution was left for 1h at room temperature and 
then washed twice in D-PBS Cl2+Mg2+, and left to dry, wrapped tightly in 
aluminium foil and stored at 40C until needed. 
 
2.2.1.1.5 Cell seeding and cells culture conditions 
 
Primary rat hepatocytes were seeded onto 150 mm collagen-coated dishes at 
25-30 million cells per dish. Cells were cultured in complete DMEM [(Gibco, Life 
technologies, Heidelberg, Germany) containing L-Glutamine and 25 mM (4500 
mg/l) glucose and supplemented with 10% (v/v) fetal bovine serum (FBS) 
(Gibco), penicillin (100 u/ml, Lonza), streptomycin (0.1 mg/L, Lonza, Walkersville, 
MD, USA), and amphotericin-B (0.25 µg/ml, Lonza) (PSA)] at 37°C and 5% CO2. 
Cells were allowed 4 h to attach and were then washed twice with 1X D-PBS and 
incubated for 36 h in complete DMEM containing 25 mM HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid) that previously have been 
depleted from contaminating vesicles by 16 h ultracentrifugation at 100,000 × g, 
4°C. The importance of FBS pre-cleaning of contaminating EVs cannot be 
underestimated as it is known to contain significant quantities of native vesicles. 
In addition, it has been shown that FBS-EVs overlap in the size and density with 
exosomes also carrying typical vesilcular protein markers such as TSG101, 
CD81 and CD63 (Shelke., GV et al, 2014). Moreover, when RNA profiles of 
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cellular and FBS EVs were compared, it was discovered that they were very 
similar, enriched in small RNAs and undetectable 18S and 28S ribosomal RNA 
peaks (Shelke., GV et al, 2014). Most cells cultured with EV-depleted FBS 
showed a reduced growth rate, which is enhanced when supplying cells with 
FBS-EVs (Eitan., E et al, 2015). In terms of functionality of the FBS derived EVs, 
they were shown to be internalized by recipient cells, which could point towards 
their role as signal carriers (Shelke., GV et al, 2014). More importantly, FBS-EVs 
were able to induce the migratory phenotype in recipient cells and their removal 
affected proliferation and differentistion of myoblasts in vitro (Shelke., GV et al, 
2014; Aswad., H et al, 2016). EV research, the preferred method used for 
depletion of EVs from FBS is the over night ultracentrifugation based on the 
knowledge that 95% of RNA containing FBS-EVs were removed by 18h 
centrifugation at 120,000 x g as compared to short time centrifugation (Shelke., 
GV et al). It is important to come to consensus as to the speed and duration of 
the EV-FBS depletion, to obtain comparable experimental results. In addition, 
when studying effect of EVs on recipient cells, it is vital to carry a control 
incubated with EV-depleted medium only.  
 
2.2.1.1.6 Insulin sensitivity in primary Zucker rat hepatocytes  
 
Primary Zucker rat hepatocytes were cultured on collagen-coated plates for 4 h 
before being washed with warm 1XD-PBS and stimulated with insulin (100 nM) 
for 5 min at 370C. Primary rat hepatocytes were seeded at a density of 5 x 106 
cells on collagen-coated cell culture dishes (100 x 20 mm). After 4 h, once 
attached, hepatocytes were stimulated with insulin (100 nM) for 30 min at 370C. 
After that, cells were immediately lysed on ice with ice-cold lysis buffer (0.5% 
Triton X-100, 300 mM NaCl, 50 mM Tris-HCl, pH 7.4) in the presence of 
protease and phosphatase inhibitors cocktail. The untreated controls were 
carried in parallel. Densitometry analysis was performed on WB bands using 
ImageJ software. The increase in phosphorylation upon incubation with insulin 
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was calculated by dividing the value of insulin-stimulated sample by the value of 
the unstimulated control to obtain a fold increase in phosphorylation upon insulin 
stimulation. 
2.2.1.2 Generation of the bone marrow-derived macrophages  
 
Bone marrow macrophages were differentiated from mice femur bone marrow 
cells. Mice were euthanized by cervical dislocation with all efforts made to 
minimize the suffering of the animals, following the guidelines of the Home 
Office, UK. Bone marrow cells were harvested by gently flushing the bone with 
pre-warmed DMEM (D5648, Sigma) using a 23-gauge needle attached to a 
syringe into a sterile Petri dish. The suspension containing bone barrow cells 
was transferred into 15 ml Falcon tube and centrifuged at 1500 rpm for 4 min. 
Resulting pellet was re-suspended in 2 ml of 0.83% ammonium chloride (A9434, 
Sigma) and left for 3min for the erythrocyte lysis. The suspension was 
centrifuged again at 1500 rpm for 4 min. Cells were plated onto a 6-well cell 
culture dish (1.5x106/well) and cultured at 37oC, 5% C02 in DMEM supplemented 
with penicillin and streptomycin (100 U/ml and 100 µg/ml respectively, P4333, 
Sigma), 5% FBS (F7524, Sigma) and 10% (v/v) of media containing macrophage 
colony stimulating factor 1 (MCSF-1). The fresh media was replaced 24h after 
seeding to remove debris and unattached cells. After 5 days in culture, 
macrophage conditioned media was collected, filtered (0.2 μm) and stored at 40C 
if not used immediately.  
 
2.2.2 Cell culture of commercial cell lines  
 
2.2.2.1 Thawing cell stocks  
 
To defrost the cell stocks, the cryo-tube was immediately immersed into the 
water-bath at 370C for 1-2 min. The cell suspension was then gently transferred 
onto a 100 x 20 mm cell culture plate (83.3902, Sarstedt) with 8 ml of pre-
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warmed and pre-calibrated complete culture media at 370C incubator, 5% CO2 
and 95% 02. Following the cell attachment, media was then replaced with fresh 
media solution. 
 
2.2.2.2 Culture of AML12, MLP29, HepG2 and Raw264.7 cell lines  
 
All cell lines mentioned in this section were cultured in DMEM containing L-
Glutamine and 25 mM (4500 mg/L) glucose supplemented with 10% (v/v) FBS 
and 1% PSA and incubated at 37°C in humidified atmosphere of 5% CO2-95% 
02. 
The alpha mouse liver 12 (AML12), purchased from American type culture 
collection [(ATCC (Cat number: CRL-2254)], cell line was established from CD1 
mouse strain (line MT42) hepatocytes transgenic for human transforming growth 
factor alpha (TGFα). Like normal hepatocytes, AML12 cells express high levels 
of messenger RNA (mRNA) for serum albumin, α1-antitrypsin and transferrin as 
well as gap junction proteins, connexins 26 and 32. (Wu et al. 1994). 
Morphologically, these cells exhibit typical hepatocyte features such as 
peroxisomes and bile canalicular like structures.  
Mouse Liver Progenitor 29 (MLP29) were a kind gift of Dr. E. Medico (University 
of Totino, Italy).  
HepG2 cells, purchased from ATCC (Cat number: HB-8065) is a human liver 
cancer cell line, derived from the liver tissue of a 15-year-old Caucasian 
American male with well-differentiated hepatocellular carcinoma. These cells are 
epithelial in morphology and tend to grow in multilayer clumps (Costantini et al. 
2013). HepG2 cells are highly differentiated and display many of the genotype 
features of normal liver cells. They exhibit lower metabolic capacity, reduced 
levels of cytochromes (CYPs) but normal levels of phase II enzymes with the 
exception of UDP-glucuronosyl transferases (Gerets et al. 2012). 
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Raw264.7 is a murine macrophage cell line that was established from a tumour 
induced by Abelson murine leukemia virus (Raschke et al. 1978). For 
maintenance, cells were kept in suspension in bacterial, non-cell culture treated 
plates to avoid frequent trypsinization and cell activation. For the experiments, 
cells were seeded on cell culture treated plates. These cells were a kind gift of Dr 
Nicolas Navassa (CICbioGune, Spain).  
 
2.2.2.3 Maintenance and differentiation of the 3T3-L1 cells  
 
Table 1 Compounds used for the differentiation of the 3T3-L1 cells. 
Compound [Stock] [Final] Vehicle Supplier 
Dexamethasone  
(DEX) 
1mg/mL 0.25µM 100% EtOH Sigma 
D4902 
Insulin 1mg/mL 1µg/mL 0.1N HCl Sigma 
I6634 
Isobutylmethylxanthane 
(IBMX) 
55.6mg/mL 500µM 0.35M KOH Sigma 
I5879 
Rosiglitazone 10mM 1µM DMSO Sigma 
R2408 
 
3T3-L1 cells were purchased from ATCC (CL-173) as a murine embryonic cell 
line that under a right stimulus can undergo a pre-adipocyte to adipocyte 
conversion. As fibroblasts cells were cultured in high glucose (4500 mg/L 
glucose; 25mM) DMEM supplemented with 10% calf serum and 1% penicillin 
(100 u/ml, Lonza), streptomycin (0.1 mg/L, Lonza, Walkersville, MD, USA) as a 
monolayer in 100 x 20 mm cell culture plates and were maintained at maximum 
confluence of 70%. For adipocyte differentiation, cells were used at no more than 
10 passages. 
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For the differentiation to adipocytes, 3T3-L1 fibroblasts were grown to confluence 
in DMEM supplemented with 10% Calf serum and 1% PS. At 100% of 
confluence, fresh complete medium was added and incubated for additional 48 
h. At 2 days post-confluence, cells were switched to differentiation media 
containing DMEM supplemented with, 10% FBS, 1 μg/ml insulin, 0.25 μM DEX, 
500 μM IBMX and 1 μM Rosiglitazone for 48 h. After 2 days, DEX, IBMX and 
Rosiglitazone were withdrawn, and cells are maintained in complete medium and 
1 μg/ml insulin for another 48 h. At day 4, already differentiated adipocytes were 
maintained in DMEM with 10% FBS, and 1% PS. The medium was replenished 
every 2 days until day 12 when adipocytes become fully mature. For 
experimentation, adipocytes at day 13 were used.  
 
2.2.3 Generation of cellular models  
 
2.2.3.1 Induction of hepatocellular steatosis  
 
Steatosis was induced in the following hepatic cell lines, AML12, MLP29 and 
HepG2 with a mixture of long-chain free fatty acids (FFA), oleic acid (OA, O1008, 
Sigma) and palmitic acid (PA, P0500, Sigma), at a ratio of 2:1 (1 mM final) for 24 
h. For conjugation of FFAs, stock solution of 100 mM was prepared in culture 
medium containing 1% FFA-free bovine serum albumin (BSA Fraction V, Fatty 
Acid free, 10775835001, Roche). BSA-conjugated FFA-containing media were 
used to challenge cells, as previously described (Gómez-Lechón et al. 2007). 
  
2.2.3.2 Induction of adipocyte hypertrophy  
 
The protocol used for induction of heptic steatosis was followed to induce 
adipocyte hypertrophy in 3T3-L1 cells. Briefly, 3T3-L1 were differentiated to 
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adipocytes and afterward treated with BSA-conjugated FFA-containing media for 
24 h.  
 
2.2.3.3. Activation of Raw264.7 macrophage-like cells 
 
To induce the pro-inflammatory phenotype, Raw264.7 macrophages were 
treated with 100 nM of lipopolysaccharide [(LPS), from Salmonella typhimurium, 
L 6511, Sigma)] in complete growth medium for 6h at 370C. Cells were then 
washed three times with pre-warmed 1XD-PBS and incubated, in the absence of 
LPS, with the EV-depleted medium to produce EVs (48-72 h).  
 
2.2.3.4 Hypoxia 
 
For hypoxia experiments, cells were incubated in an Invivo2 400 hypoxia 
Workstation (Baker Ruskinn, USA) at 1% O2 for 24 h and lysed/fixed in the 
hypoxia chamber unless otherwise stated.  
Importantly, to avoid contamination by EVs from other sources such as FFAs or 
the LPS, in the case of all our models, the treatment was removed for the 
subsequent production of EVs.  
 
2.2.3.5 Generation of the macrophage conditioned medium  
 
The macrophage-conditioned medium was collected from bone marrow 
differentiated macrophages stimulated with the MCSF-1, as detaled in the 
section 2.2.1.2. The 5-day conditioned medium was collected and centrifuged at 
1500 rpm to remove cells and debris to generate the macrophage-conditioned 
media. After, 3T3-L1 adipocytes were incubated for 24 h with EV-depleted 
complete media containing 15% of the macrophage-conditioned media.  
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2.2.4 Experiments to evaluate the effect of EVs on 3T3-L1 adipocytes 
 
2.2.4.1 Adipogenesis 
 
3T3-L1 cells were differentiated as described in section 2.2.2.3 in a multiwall 
plate of 12-wells. Alongside the adipogenic agents, cells were treated with 30 µl 
of ZL or ZF-EVs, in EV-depleted medium, or left untreated. The treatment was 
repeated every 48 h at each point of medium replenishment and samples 
collected for subsequent analysis (Figure 50). 
 
2.2.4.2 Insulin sensitivity 
 
3T3-L1 cells were differentiated as described in section 2.2.2.3 in a multiwall 
plate of 12-wells. On a 13th day of differentiation, cells were treated with 10 µg of 
ZL or ZF-EVs per well in EV-depleted medium for 24 h in the case of acute 
experimental group. For chronic experiments, cells were repeatedly treated 
(three times) with 10 µg of ZL or ZF-EVs or left untreated in EV-depleted medium 
for 24 h period each treatment. 
Subsequently, cells were incubated with 100 nM insulin for 5 min at 370C or left 
untreated, and then directly lysed on ice with ice cold lysis buffer (1% Triton X-
100, 300 mM NaCl, 50 mM Tris-HCl, pH 7.4) in the presence of protease and 
phosphatase inhibitors. Cellular lysates were prepared (section 2.6.1) and WB 
analysis performed (section 2.6.2). Protein bands were quantified by 
densitometry analysis using ImageJ software. The percentage of phosphorylation 
was calculated by dividing the density of the phosphorylated protein by the 
density of the total protein and multiplied by 100. Moreover, the increase in 
phosphorylation upon incubation with insulin was calculated by dividing the value 
of insulin-stimulated sample by the value of the unstimulated control to obtain a 
fold increase in phosphorylation upon insulin stimulation. 
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2.3 Production and isolation of extracellular vesicles 
 
2.3.1 Preparation of the EV-depleted medium  
 
50 ml of FBS was redistributed into five-70 ml centrifuge polycarbonate tubes 
(Beckman Coulter Inc, Brea, California) and each diluted with 40 ml of DMEM 
containing 25 mM HEPES to make up a final volume of 50 ml and subsequently 
subjected to 16 h ultracentrifugation at 100 000 x g at 40C. The remaining of the 
medium was supplemented with L-Glutamine and PSA if needed, for 3T3-L1 
cells PS only, and stored at 40C. Following the centrifugation, the supernatant 
was collected to the bottle of media previously supplemented. EVs-depleted 
medium was filtrated through a 0.22 μm pore size filter system (Corning, NY 
USA) and stored at 40C until needed.  
2.3.2 Isolation of extracellular vesicles by differential ultracentrifugation  
 
The isolation protocol is common to all cell types used in the study and slightly 
modified from Théry, Amigorena, Raposo, & Clayton, 2006 (Théry et al. 2006). 
Briefly, to produce EVs, cells were incubated for 36 h in case of Zucker primary 
hepatocytes and for 48 h for cell lines, at 370C and 5% CO2. The conditioned 
medium was collected to 50 ml Falcon tube and centrifuged at 2000 × g during 
10 min at 40C and the resultant supernatant was filtrated through a 0.22 μm pore 
size filter system (Corning, NY USA) to remove large debris while keeping small 
membranes (under 0.22 μm) for further purification by ultracentrifugation. 
Filtrated supernatant was transferred to 50 ml centrifuge polycarbonate tubes 
(Beckman Coulter Inc, Brea, California) and ultracentrifuged 30 min at 14 000 × g 
4°C to remove large vesicles. The resultant supernatant was transferred to a 
fresh tube and centrifuged at 100 000 × g 40C during 75 min to pellet EVs. To 
reduce contaminating proteins not associated to the vesicles, the supernatant 
was completely removed, pellets resuspended in 1 ml of sterile, pre-chilled 1XD-
PBS and same samples were pooled in a single centrifuge tube. Tubes were 
filled up to 50 ml with 1XD-PBS and ultracentrifuged again at 100,000 × g 4°C 
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during 75 min. Supernatants were removed and final pellet resuspended in 150 
µl 1XD-PBS. This method favours the enrichment of the preparation in small EVs 
(mostly exosomes, small microvesicles and small apoptotic blebs). Finally, the 
sample was split in aliquots of 50 µl to avoid repeated cycles of freezing and 
thawing. If not used immediately aliquots were frozen at -80ºC. Centrifuge tubes 
were always pre-chilled on ice for the subsequent centrifugation step and all 
sample manipulations, such as pellets re-suspension were done on ice to reduce 
clumping and content degradation.  
 
 
2.4 Structural and molecular characterization of extracellular 
vesicles 
 
2.4.1 Protein concentration determination  
 
The concentration of protein present on EVs was quantified by the Bradford 
protein assay (Bio-Rad Laboratories, Inc) using bovine serum albumin (BSA) as 
standard and spectrophotometrically determined using a Spectramax M3 
spectrophotometer (Molecular Devices, USA). To assure accuracy, the 
comparison with the bicinchoninic acid (BCA) protein assay (Pierce, USA) was 
made and as minimal differences were found, the Bradford assay was used in 
the study.  
 
2.4.2 Cryo Electron Microscopy (Cryo-EM)  
 
The sample of EVs, usually 5 µl, was directly adsorbed onto glow-discharged 
holey carbon grids (QUANTIFOIL, Germany). Grids were blotted at 95% humidity 
and rapidly plunged into liquid ethane with the aid of VITROBOT (Maastricht 
Instruments BV, The Netherlands). Vitrified samples were imaged at liquid 
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nitrogen temperature using a JEM-2200FS/CR transmission cryo-electron 
microscope (JEOL, Japan) equipped with a field emission gun and operated at 
an acceleration voltage of 200 kV. In cryo-EM sessions, digital images were 
taken using low-dose technique by means of an ULTRASCAN 4000SP (4096 × 
4096) cooled slow-scan CCD camera (GATAN). An in-column energy filter 
(Omega Filter) was used to improve the signal-to-noise ratio of these images by 
zero-loss filtering.  
 
2.4.3 Nanoparticle Tracking Analysis (NTA) 
 
Particle size distribution and concentration of EVs were analyzed using a 
NanoSight LM10 system (NanoSight, Amesbury, U.K.), which is equipped with a 
fast video capture and particle-tracking software. In this system vesicles are 
visualized by light scattering using a light microscope. NTA software tracks the 
Brownian motion of individual vesicles and calculates their size and total 
concentration. NTA post acquisition settings were kept constant for all samples, 
and each video was analyzed to give the median vesicle size, and the 
concentration of vesicles in each sample. 
 
2.4.4 OptiPrepTM Density Gradient 
 
5% and 40% OptiPrepTM Density Gradient Medium (D1556, Sigma) was 
prepared by diluting the 60% original solution in ice-cold 20 mM HEPES pH 7.4 
solution. Next, 5.5 ml of the 40% solution was carefully dropped to the bottom of 
the tube (Beckman centrifuge tube Cat. No. 344059, SW40 Ti rotor) and 5.5 ml 
of the 5% solution on top. Continuous gradient was made in a Gradient Master 
(Biocomp) by running the following program: Long Opti 5-40% WV 4 St: Once 
the gradient was pre-formed, 250 μg of EVs was diluted in 20 mM Hepes pH 7.4 
up to 100 μl and it was carefully loaded on top of the gradient. The tube was 
centrifuged at 100 000 x g for 4 h in no break mode for stopping speed. Using 
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Autodensity-flow 230 V (Cat No 4517200, Labconco), twelve fractions of 1 ml 
each were collected and mixed by vortex. The refractory index (RI) was 
measured by means of refractometer (Abbe 2WAJ). RI was translated to density 
following the correlation built from the data provided by OptiPrepTM. The 1 ml 
fractions were transferred into apolycarbonate thick wall tubes (Cat No 3623.5, 
Beckman) and diluted with 2 ml of 20 mM Hepes pH 7.4, before being 
centrifuged at 100 000 x g at 40C for 1h in a TLA 110 rotor. Supernatant was 
carefully removed, and pellet resuspended in 30 μl of sterile 1XD-PBS and 
stored at -800C until needed.  
 
2.4.5 Targeted-profiling of EVs-associated RNA  
 
The RNA was isolated from EVs using Rneasy Mini Kit (74104, QIAGEN) 
according to the manufacturer’s instructions. Detection, quality, yield and size of 
the vesiclular RNA was analyzed using capillary electrophoresis (Qagilent on an 
Agilent 2100 Bioanalyzer, Agilent Technologies, Santa Clara, CA, USA). 2 µl of 
the RNA solution was analyzed in the Bioanalyzer.  
 
 
2.5 Analysis of total RNA in cells  
 
2.5.1 RNA isolation 
 
The isolation of total RNA was carried out using TriReagent (Sigma-Aldrich, 
USA) or the Rneasy Mini Kit (74104, QIAGEN) according to manufacturer´s 
instructions. RNA concentration and purity were determined 
spectrophotometrically in the Nanodrop ND-100 spectrophotometer 
(ThermoFisher Scientific, USA). 
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2.5.2 Retrotranscription and Real Time quantitative PCR (RT-qPCR) 
 
1µg of isolated RNA were treated with Dnase I (Invitrogen) according to 
manufacturer’s instructions. Subsequently, complementary DNA (cDNA) was 
synthesized from 1 µg of eluted RNA using the Quanta cDNA SuperMix (Quanta 
bioscience, Inc). Resulting cDNA was diluted 1/10 in Nuclease-free water 
(ThermoFisher Scientific, USA). RT-qPCR was performed using the BioRad 
iCycler iQ5 Thermalcycler, with 2X SYBR Green Select Master Mix 
(ThermoFisher Scientific, USA). For the iCycler, 5 µl of cDNA were used and 
including the specific primers the total reaction volume was 15 µl in a 96-well 
plate (BioRad). All reactions were performed in duplicate. PCR conditions were 
as follows, the initial denaturation for 180 secs at 950C, 40 cycles of denaturation 
step for 20 sec each at 950C, 20 secs at 600C, and 20 secs at 720C, annealing 
and extension.  
Primers were designed using the Primer 3 software via the national centre for 
biotechnology information (NCB)-Nucleotide webpage (Ye et al. 2012) and 
synthesized by Sigma Aldrich. Primer sequences are detailed in Table 2 and 3. 
After checking the specificity of the PCR products with the melting curve, data 
was normalized to the expression of a corresponding housekeeping gene.  
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Table 2 List of mouse primer sequences. 
 
ID 
 
Target  
 
Forward Sequence (5’-3’) 
 
Reverse Sequence (5’-3’) 
11461 Actb CCTGTGCTGCTCACCGAGGC GACCCCGTCTCTCCGGAGTCCATC 
11450 Adipoq AGAATGTGGACCAGGCCTCT AGTCCATTGTGGTCCCCATC 
11770 Ap2 GGGAACCTGGAAGCTTGTCT ACTCTCTGACCGGATGGTGA 
11947 Atp5b TGGCTCAGAGGTGTCTGC TCAGTCAGGTCATCAGCAGG 
20296 Ccl2 CCACAACCACCTCAAGCACT AGGCATCACAGTCCGAGTCA 
20304 Ccl5 TAGTCCTAGCCAGCTTGGGG GAGCAGCTGAGATGCCCATT 
12606 Cebp1 GTTAGCCATGTGGTAGGAGACA CCCAGCCGTTAGTGAAGAGT 
59122 COXIII CGTGAAGGAACCTACCAAGG ATTCCTGTTGGAGGTCAGCA 
14104 Fasn GCCACCTCAGTCCTGCTATC GGTATAGACGACGGGCACAG 
14433 Gapdh TGCACCACCAACTGCTTAGC GGATGCAGGGATGATGTTCT 
15452 Hprt1 ACATTGTGGCCCTCTGTGTG TTATGTCCCCCGTTGACTGA 
16193 Il6 ACCCCAATTTCCAATGCTCTC AACGCACTAGGTTTGCCGAG 
16337 Insr GAGAGGATGTGAGACGACG CAGGTTGTTCCGGATGTCC 
16819 Lcn2 GGCCAGTTCACTCTGGGAAA TGGCGAACTGGTTGTAGTCC 
16846 Lep TGACACCAAAACCCTCATCA AGCCCAGGAATGAAGTCCA 
53610 Nono TGCTCCTGTGCCACCTGGTACTC CCGGAGCTGGACGGTTGAATGC 
18126 Nos2 CAGCGGGATGACTTTCCAA AGGCAAGATTTGGACCTGCA 
11520 Plin2 AAACGTCTGTCTGGACCGAAT ACACGCCTTGAGAGAAACAGA 
66905 Plin3 CGCCTATGAACACTCCCTCG CGAGCACACTTGTTAGCTGC 
19016 Pparg ATCATCTACACGATGCTGGCC CTCCCTGGTCATGAATCCTTG 
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19288 Ptx3 GTGGGGGCTTTGACGAATCA ATTTCCCCGGATGTGACAGG 
57264 Rent CTGCCAGTGTGCAAGGATAG AGACCCTCAGCTTAGACCTGC 
56235 Rpl GGCTGCCGAAGATGGCGGAG GCCTTCACAGCGTACGACCACC 
20525 Slc2a1 GCTGTGCTTATGGGCTTCTC CACATACATGGGCACAAAGC 
20528 Slc2a4 CTTGGCTCCCTTCAGTTTG TGCCTTGTGGGATGGAAT 
21926 Tnfa CTGTAGCCCACGTCGTAGC TTGAGATCCATGCCGTTG 
21780 Tfam TAGGCACCGTATTGCGTGAG GTGCTTTTAGCACGCTCCAC 
22631 Ywhaz AAAAACAGCTTTCGATGAAGCC GCCGGTTAATTTTCCCCTCC 
 
 
Table 3 List of rat primer sequences. 
 
ID 
 
Target 
 
Forward Sequence (5’-3’) 
 
Reverse Sequence (5’-3’) 
24172 Adh1 AAGCGGCCGTGCTATGGGAG CGCGTGATCATCTGAGCGGCA 
24177 Afp ACCATCGAGCTCGGCTATTG CGTTTCAGACTGGGAGCACT 
24186 Alb AGCAGCCTGCCTGACACCGA CAGGTCGCCGTGACAGCACT 
24297 Cyp1a2 CCCAGGAAGAGCGAGGAGATG GGGTTGGGCAGGTAGCGCAG 
24360 Fabp1 CGGCAAGTACCAAGTGCAGAGCC CTCCAGTTCGCACTCCTCCCCC 
50671 Fasn GCCTAACACCTCTGTGCAGT GGCAATACCCGTTCCCTGAA 
25735 Hnf4a TGGACAGATGTGTGAGTGGC TCTCTGAGGGTGTGAGCCAG 
24482 Igf1 TTTGCGGGGCTGAGCTGGTG ATGTCAGTGTGGCGCTGGGC 
25664 Pparg GAGATCCTCCTGTTGACCCAG CCACAGAGCTGATTCCGAAGT 
113992 Ugt1a6 ACTCGGGGAGCTGGGGTGAC GCGCCCCCTTGTGCCTCATC 
89 
 
83474 Tfam CCAAAAAGACCTCGGTCAGC GTGACTCATCCTTAGCCCCC 
59086 Tgfb1 CTGCTGACCCCCACTGATAC AGCCCTGTATTCCGTCTCCT 
 
 
2.6 Protein 
 
2.6.1 Preparation of the whole cell lysates  
 
Extraction of total protein was performed as follows, cell pellets (̴1x106) were 
lysed on ice with 150 μl of the lysis buffer (1% Triton X-100, 300 mM NaCl, 50 
mM Tris-HCl, pH 7.4) supplemented with protease and phosphatase inhibitor 
cocktails during 15 min, with 3 cycles of vortex every 5 min. Subsequently, the 
lysates were centrifuged at 10,000 x g and the supernatant transferred to a fresh 
Eppendorf tube. The protein extract was quantified as already described 
(Section.2.4.1). 
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2.6.2 Western blotting 
 
Table 4 List of commercial antibodies used for Western blot analysis 
 
Antibody 
against 
 
Spe
cies 
 
Species 
Reactivity* 
 
Clone 
 
ID 
 
Supplier* 
 
Working 
Dilution 
4E-BP1 Rb R, M, H, Mk 53H11 9644 CS 1:1000 
Actin M M, R, Rb, H, C, 
GP, Hm, Co, Ca, 
Dg 
AC-15 ab6276 Abcam 1:1000 
Adiponectin M R, M, H, Rb, Ba 19F1 ab22554 Abcam 1:1000 
Adipophilin Rb H, M, R - 251533 Abbiotec 1:1000 
AIP1 M R 49/AIP1 611621 BD 1:1000 
Akt Rb H, M, R, Mk, Pg, 
C, Hm, B, GP, 
Dm, Dg 
- 9272 CS 1:1000 
AnnexinV Rb M, R, H - ab14196 Abcam 1:1000 
Alix M M, H, X 3A9 sc:53538 Santa Cruz 1:1000 
ApoB Rb M, R, H H-300 sc: 25542 Santa Cruz 1:1000 
ApoE Gt M, R R-20 sc: 6385 Santa Cruz 1:1000 
Catalase Rb M, R, Sh, C, Dg, 
Cow, H 
- ab1877 Abcam 1:1000 
CD63 M R AD1 ab108950 Abcam 1:1000 
CD81 Hm 
(Ar) 
M, R Eat2 MCA1846G
A 
Serotec 1:1000 
COMT Gt H, R, M, Hr, Pg, 
Dg 
- ab51984 Abcam 1:1000 
COXIV M H, M, R, Mk 4D11-B3-E8 11967 CS 1:1000 
CytC M M, R, H, aquine 
and avian 
7H8 sc: 13560 Santa Cruz 1:1000 
Fas Rb M, R, H - ab: 2759 Abcam 1:1000 
Ferritin LC Rb H, M, R H-53 sc: 25617 SC 1:1000 
Flotillin-1 M H, M, C (R) 18 610821 BD 1:1000 
GAPDH M M, R, Rb, C, Cow, 
Dg, H, Pg, X, Mk 
(Cynomolgus), Hm 
- 9484 Abcam 1:1000 
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(Chinese) 
Glut4 Rb H, M, R 1F8 2299 CS 1:1000 
GRP78 M D, R, M 40/BiP 610978 BD 1:1000 
HSP70 M R, Rb, M, B, H, 
Hm, GP, M, Dm 
BRM-22 Ab6535 Abcam 1:1000 
HSP90 M M, R, C, Dg 68/Hsp90 610418 BD 1:1000 
IR ß Rb H, M, R 4B8 3025 CS 1:1000 
IRS-1 Rb H, M, R, Mk D23G12 3407 CS 1:1000 
Lamp1 M R, H, Mk H4A3 25630 HB 1:1000 
LIMPII Rb H, M - ab16522 Abcam 1:1000 
LIPC Rb R, H, M - PA5-36962 Invitrogen 1:500 
P450 2D1 Rb R - ab22590 Abcam 1:1000 
p4E-BP1 Rb H, M, R, Mk, Dm 236B4 2855 CS 1:1000 
p44/42 
(Erk1/2) 
Rb H, M, R, Hm, Mk, 
Mi, Z, B, Pg, Sc 
- 9102 CS 1:1000 
p-AKT Rb H, M, R, Hm, Dm, 
B, Dg, Pg 
Ser473 9271 CS 1:1000 
PARP Rb H, M, R, Mk - 9542 CS 1:1000 
PGD M M, R, H G-2 sc:398977 SC 1:500 
p44/42 
(Erk1/2) 
Rb H, M, R, Hm, Mk, 
Mi, Dm, Z, B, Pg, 
Ce 
Thr202/ 
Tyr204 
9101 CS 1:1000 
Prohibitin Rb M, R, H, avian H-80 sc: 28259 SC 1:1000 
PTEN Rb H, M, R, Mk 138G6 9559 CS 1:1000 
p-S6 Rb H, M, R, Mk, Z (C, 
X) 
Ser240/244 2215 CS 1:1000 
Rab8 M Dg, M, R, Dm 4/Rab4 610844 BD 1:1000 
Rab10 Rb H, M, Mk D36C4 8127 CS 1:1000 
Rab11 M M, H, R, C 47/Rab11 610656 BD 1:1000 
S6 Rb H, M, R, Mk, Dm 54D2 2317 CS 1:1000 
Syndecan4 Rb M, R, H - ab24511 Abcam 1:1000 
Syntenin1 Rb H, M, R C2C3 GTX108470 GeneTex 1:1000 
TSG101 M M, R, H, Dm 4A10 Ab83 Abcam 1:1000 
TGFα M M, R, H 134A sc:36 SC 1:1000 
αTubulin M M, R, C, GP, Hm, 
Cow, Dg, H, Pg, 
DM1A ab7291 Abcam 1:1000 
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X, Mk (African 
Green), Gerbil 
VEGF M M, R, H, canine VG-1 sc:53462 SC 1:1000 
*Reactivity: H-human, M-mouse, Mk-monkey, R-rat, Rb-rabbit, Ba-baboon, X-Xenopus laevis, Dg-dog, C-chicken, Dm- 
Drosophila melanogaster, B-bovine, Pg-pig, Z-zebrafish, Mi-mink, Ce-C. elegans, GP-guinea pig, Hm-hamster, Hr-horse, 
Sc-S. cerevisiae, Gt-goat, Sh-sheep 
*Supplier: CS-cell signalling, SC- Santa Cruz, HB- Hybridoma Bank 
All primary antibodies were diluted in sterile, filtered 5% bovine serum albumin 
(BSA) in 0.1% sodium azide in Tween PBS (0.1%) solution, kept at 40C.  
 
Table 5 List of secondary antibodies used for Western blot analysis. 
Antibody 
against 
 ID Supplier Working 
Dilution 
Mouse DαMo-HRP Ab205724 Abcam 1:6000 
Rabbit RbαMo-HRP 315-035-045 Jackson 
ImmunoResearch 
1:6000 
Goat RbαGt-HRP A5420 Sigma 1:6000 
Hamster 
Armenian 
GtαHmAr-
HRP 
127-035-160 Jackson 
ImmunoResearch 
1:6000 
Rat DαRt-HRP Ab205723 Abcam 1:6000 
 
All secondary antibody incubations were done in blocking solution of 5% blotting-
grade blocker in 1XPBS containing 0.1% Tween-20.  
Protein extracts or the sample of EVs were sequentially heated at 370C for 5 min, 
at 650C for 10 min and boiled at 95ºC for 15 min in NuPAGE® LDS Sample 
Buffer [(4X) NP0008, Life Technologies, Inc] to prepare protein samples for 
denaturing gel electrophoresis. Following the heating cycle, sample was briefly 
cooled on ice and clarified by centrifugation at 10 000 x g for 15 min. An 
appropriate amount of protein, depending on protein abundance and antibody 
sensitivity, was separated on 4-12% pre-casted polyacrylamide gel (NuPAGE® 
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Bis-Tris gel, Life Technologies, Inc) by sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis (SDS-PAGE) using a Xcell SureLockTM Mini-Cell 
Electrophoresis System (ThermoFisher Scientific, USA). Gels were transferred 
onto a Polyvinylidene difluoride (PVDF) membrane using Life Technologies 
iBlot® 2 Dry Blotting System (program 0: 20V for 1min, 23V for 4 min and 25V for 
2 min, default run time being 7 min) or onto nitrocellulose membranes by 
electroblotting using a Mini Trans-Blot cell (Bio-Rad). Membranes were blocked 
with 5% blotting-grade blocker (BioRad) in 1XPBS containing 0.1% Tween-20 
(Sigma) for 1h at room temperature (RT), washed three times with T-PBS-0.1% 
and incubated overnight 40C with commercial primary antibodies. Primary 
antibodies and their optimal incubation conditions are detailed in Table 4. 
Membranes were then washed three times with TPBS-0.1% and incubated for 1 
hour at RT in blocking solution-containing secondary antibodies conjugated to 
horseradish-peroxidase (HRP). Chemioluminiscence detection of bands was 
performed using enhanced chemiluminescence (ECL) Plus chemiluminiscent 
substrate (GE Healthcare, Buckinghamshire, UK) in a Curix 60 Developer 
(AGFA, Belgium) under dark room conditions. All proteins were detected under 
non-reducing conditions, unless otherwise stated. In reducing conditions, 20 mM 
dithiothreitol (DTT) was added to the sample buffer.  
 
2.7 Proteomics 
 
2.7.1 SDS-PAGE and Sypro Ruby staining 
Protein samples were boiled for 5 min and resolved in 12.5% acrylamide gels, 
using a Mini-Protean II electrophoresis cell (Bio-Rad). A constant voltage of 150 
V was applied for 45 min. Gels were fixed in a solution containing 10% acetic 
acid, 40% ethanol for 30 min, and stained overnight in SYPRO Ruby (Bio-Rad). 
Gels were then washed in a solution containing 10% ethanol and 7% acetic acid 
for 30 min, and the image was acquired using a Typhoon Trio scanner (GE 
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Healthcare). Each lane subjected to tryptic digestion, followed by LC–MS/MS 
analysis. 
2.7.2 Tryptic digestion of gel bands 
 
Gel bands were cut and washed in milli-Q water. Reduction and alkylation were 
performed using ditiothreitol (10 mM DTT in 50 mM ammonium bicarbonate) at 
56 ºC for 20 min, followed by iodoacetamide (50 mM iodoacetamide in 50 mM 
ammonium bicarbonate) for another 20 min in the dark. Gel pieces were dried 
and incubated with trypsin (12.5 µg/ml in 50 mM ammonium bicarbonate) for 20 
min on ice. After rehydration, the trypsin supernatant was discarded; Gel pieces 
were hydrated with 50 mM ammonium bicarbonate, and incubated overnight at 
37ºC. After digestion, acidic peptides were cleaned with TFA 0.1% and dried out 
in a RVC2 25 speedvac concentrator (Christ). Peptides were resuspended in 10 
µl 0.1% FA and sonicated for 5 min prior to analysis. 
 
2.7.3 Protein extraction 
 
An equivalent volume of a solution containing 7 M Urea, 2 M Thiourea, 4% 
CHAPS 100 mM DTT was added to the samples for protein extraction, and 
incubated under agitation for 30 min. The sample was vortexed for 30 secs every 
10 min of incubation. 
 
2.7.4 FASP in solution digestion and sample preparation 
 
In solution digestion was carried out following FASP protocol with minor 
variations (Wisniewski et al. 2009). This protocol relies in the use of standard 
filtration devices, allowing buffer exchange and acting as a reactor for the 
digestion. 20 min centrifugations at 13000 rpm are carried out between each 
digestion step to remove buffer from the filter. Samples were loaded onto Amicon 
Ultra 0.5 ml 30K centrifugal units (Millipore), washed twice in UA solution (8 M 
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Urea, 100 mM Tris-HCl pH 8.5) and alkylated by a 20-min incubation in 50mM 
Chloroacetamide prepared in UA solution. 3 more washes in UA were carried 
out, followed by additional 3 washes in 50 mM AMBIC. Protein was quantified 
using Bio-Rad protein assay (Bio-Rad), and trypsin was added to a trypsin: 
protein ratio of 1:10. The mixture was incubated overnight at 37oC. 
Peptides were recovered from the filter units and subjected to ethyl acetate 
extraction following the protocol described by Yeung and Stanley (Yeung & 
Stanley 2010). Briefly, 1ml of water-saturated ethyl acetate was added to the 
peptide solution and vortexed for 1 min. Then, tubes were centrifuged 15 s at 
13000 rpm and the upper ethyl acetate layer was depleted. These steps were 
repeated 5 times. After the careful removal of the last upper ethyl acetate layer, 
samples were speed-vacuumed in a RVC2 25 speedvac concentrator (Christ). 
Samples were further desalted using stage-tip C18 microcolumns (Zip-tip, 
Millipore) and peptides were resuspended in 0.1% FA prior to MS analysis. 
 
2.7.5 Mass spectrometry analysis 
 
Peptide separation was performed on a nanoACQUITY UPLC System (Waters) 
connected to an LTQ Orbitrap XL mass spectrometer (Thermo Electron) or a 
Synapt G2 Si (Waters). An aliquot of each sample was loaded onto a Symmetry 
300 C18 UPLC Trap column (180 µm x 20 mm, 5 µm (Waters). The precolumn 
was connected to a BEH130 C18 column, 75 μm x 200 mm, 1.7 μm (Waters), 
and equilibrated in 3% acetonitrile and 0.1% FA. Peptides were eluted directly 
into the nanoelectrospray capillary (Proxeon Biosystems) at 300 nl/min, using a 
60-min linear gradient of 3–50% acetonitrile. 
 
The LTQ Orbitrap XL ETD automatically switched between MS and MS/MS 
acquisition in DDA mode. Full MS scan survey spectra (m/z 400–2000) were 
acquired in the orbitrap with mass resolution of 30000 at m/z 400. After each 
survey scan, the six most intense ions above 1000 counts were sequentially 
subjected to collision-induced dissociation (CID) in the linear ion trap. Precursors 
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with charge states of 2 and 3 were specifically selected for CID. Peptides were 
excluded from further analysis during 60 s using the dynamic exclusion feature. 
 
2.7.6 Database searches 
 
Searches were performed using Mascot search engine v2.1 (Matrix Science) 
through Proteome Discoverer 1.4. (Thermo Electron). Carbamidomethylation of 
cysteines was set as fixed modification, and oxidation of methionines as variable 
modification, and 2 missed cleavages were allowed. 10 ppm of peptide mass 
tolerance and 0.5 Da fragment mass tolerance was used for Orbi acquisitions, 
whereas 15 ppm peptide mass tolerance and 0.2 Da fragment mass tolerance 
were used for Synapt G2Si runs. Spectra were searched against Rattus 
norvegicus databases obtained from Uniprot/Swissprot (database version 
2016_03). A decoy search was carried out to estimate the false discovery rate 
(FDR). Only peptides with a false discovery rate of <1% were selected.  
 
2.7.7 Progenesis LC-MS software analysis 
 
Progenesis LC-MS (version 4.0.4265.42984, Nonlinear Dynamics) was used for 
the label-free differential protein expression analysis. After importing of the Raw 
files, one of the runs was used as the reference to which the precursor masses in 
all other samples were aligned to. Only features comprising charges of 2+ and 
3+ were selected. The raw abundances of each feature were automatically 
normalized and logarithmized against the reference run. Samples were grouped 
in accordance to the comparisons being performed, and an ANOVA analysis was 
performed. A peak list containing the information of the features was generated 
and exported to the Mascot search engine (Matrix Science Ltd.) and searched 
against the database. The list of identified peptides was imported in Progenesis 
LC-MS and the previously and the three most intense non-conflicting peptides 
(peptides occurring in only one protein) of each protein were specifically chosen 
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for quantitative purposes. Proteins with at least two different non-conflicting 
peptides and a p value<0.05 were selected for further analyses. 
 
2.7.8 Functional analysis 
 
GO enrichment analysis was carried out using the DAVID online tool 
(http://david.abcc.ncifcrf.gov/summary.jsp) (Huang et al. 2009). DAVID is a GO 
Term annotation and enrichment analysis tool used to highlight the most relevant 
GO terms associated with a given gene list. A Fisher Exact test is used to 
determine whether the proportion of genes considered into certain GO term or 
categories differ significantly between the dataset and the background. FDR-
corrected version of the Fisher’s test p-value can be obtained and used for more 
conservative result selection. Biological Process (BP), Molecular Function (MF) 
and Cellular Component (CC) categories were assessed, and only GO Terms 
enriched with a FDR<5% were considered for comparison and discussion. 
Additionally, KEGG Pathways were also analyzed, considering terms with an 
enrichment p-value<0.01. In addition, DAVID provides a Functional Annotation 
Clustering report, where similar annotations are displayed together, making the 
interpretation of the result biology clearer and more focused in interesting 
enriched processes. The Group Enrichment Score gives the geometric mean (in 
–log scale) of the cluster member’s p-values, and is used to rank their biological 
significance. 
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2.8 Immunostaining assays 
 
2.8.1 Immunofluorescence analysis 
 
Table 6 List of commercial antibodies used for Immunofluorescence analysis. 
Antibody ID Supplier Working 
Dilution 
DαRb Alexa488 A-21206 Molecular Probes 1:600 
DαMo Alexa488 A-21202 Molecular Probes 1:600 
DαMo Cy3 715-165-150 Jackson 
ImmunoResearch 
1:600 
 
 
Cells were seeded at 50–80% confluence over 12 mm glass coverslips and fixed 
with 2% paraformaldehyde (Santa Cruz Biotechnology) for 10 min then washed 
with PBS. Coverslips were then blocked and permeabilized with PBS solution 
containing 0.1% BSA and 0.1% saponin (Sigma) for 30 min at RT. After blocking, 
the coverslips were washed in PBS and incubated overnight in a humidified 
chamber with primary antibody in blocking solution. Coverslips were washed to 
remove unbound antibodies and then incubated with secondary antibody in 
blocking solution for 30 min at RT protected from light. Following the last PBS 
wash, the coverslips were mounted onto glass slides in Fluoromont G (Southern 
Biotechnology Associates, Birmingham, AL) containing 0.7 g/ml 4’,6-diamidino-2-
phenylindole (DAPI) to stain DNA. The solutions of primary and secondary 
antibody were clarified by 15 min centrifugation. Images were taken using an 
Axioimager D1 microscope (Zeiss).  
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2.8.2 Bodipy Staining  
 
BODIPYR493/503 (4,4-Difluoro-1,3,5,7,8-Pentamethyl-4-Bora-3a,4a-Diaza-s-
Indacene) was purchased from Molecular Probes (D-3922, Invitrogen). The 
original stock (10 mg/ml) was diluted in absolute ethanol (EtOH) and stored 
protected from light at -200C. The original stock was diluted 100X in sterile 1X D-
PBS and clarified by 15 min centrifugation before being used. Cells were fixed as 
described above (Section 2.8.1) and directly stained with Bodipy (10 µg/ml) for 
45 min at RT protected from light. Coverslips were then washed twice with D-
PBS, 10 min each time and mounted as described above. Protocol modified from 
(Gocze & Freeman 1994). 
 
 
2.9 Sandwich Enzyme-Linked Immunosorbent Assay (ELISA) 
 
Table 7 Reagents used for ELISA. 
Buffer Components 
Coating buffer 0.2M Na Carbonate, pH= 9.6 
Blocking buffer 10% FBS in PBS 
Wash buffer PBS 1X 0.05% Tween 
Stop solution 2M Sulfuric acid 
 
The capture antibody was diluted in a coating buffer (Goat Anti-mouse TNFα Cat. 
No AF-410-NA) at a final concentration of 1:500 and 100 μl of the solution was 
added to each well of the ELISA microplate before being covered and incubated 
overnight at 40C. The following day, the antibody/coating buffer solution was 
removed, and plate was washed 4 times with 200 μl of the wash buffer using the 
automated plate washer. Subsequently, 200 μl of the blocking buffer was added 
per well and incubated for 1 h at RT. In the mean time, samples and standards 
(KMTNFA, Thermo Scientific) were prepared in a volume of 50 μl per well. 
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Standard, 100 ng/ml stock solution, was diluted 8 times ½ in blocking buffer 
starting from 5000 pg/ml. Supernatant samples were centrifuged at 2000 rpm for 
5 min to remove cell debris and 50 μl was directly added on a plate, in triplicate. 
At this point, the blocking buffer was removed and both, standards as well as the 
samples were added to a plate and incubated for 2 h at 370C. Then, the solution 
was removed, and the wash step repeated 6 times. While the plate was being 
washed, the Biotinylated detection antibody (Agoat Anti-mouse TNFα, BAF410) 
was diluted at a final concentration of 1:500. 100 μl of the diluted detection 
antibody was added to a plate and incubated for 1 hour at RT. The solution was 
removed, and the plate washed 8 times with 200 μl and dried by tapping the 
plate on a paper towel. At this point, the enzyme conjugate, streptoavidine HRP 
(434323, Invitrogen) was diluted 1:1000 in blocking buffer. The volume per well 
was adjusted to the volume of capture antibody used before. 100 μl of a SA-HRP 
was added to a plate and incubated for 45 min at RT. The plate was then 
washed 9 times, as described earlier and towel dried. Additional PBS wash was 
performed to remove any remaining Tween that could increase the background. 
The TMB substrate solution (34021, Pierce) was added in a same volume of the 
capture antibody and incubated for 30 min at RT. The reaction was ceased by 
adding equal amount of the stop solution and the absorbance was read at 450 
nm within 30 min of stopping the reaction.  
 
2.10 Flow cytometry 
 
Flow cytometry analysis was performed using the BD FACSCantoTM II system 
(BD Biosciences). Data was analyzed using the BD FACSDivaTM software (BD 
Biosciences) and later processed using FlowJo 7.6 software.  
FITC-AnnexinV (556419, BD Biosciences) was used as a sensitive probe to 
reveal exposure of phosphatidyl serine (PS) on the cell membrane, as an early 
stages of apoptosis (Gómez-Lechón et al. 2007). AnnexinV-FITC binding was 
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determined by flow cytometry following manufacturer’s instructions. Propidium 
iodide (PI) was added to detect late apoptotic and necrotic cells.  
Flow cytometry analysis of Bodipy staining, cells were lifted with TrypLE TM 
(12563, Gibco) and fixed in suspension with 2% formaldehyde solution for 10 min 
and subsequently washed three times, 10 min each, with D-PBS. Then cells 
were stained with Bodipy (2 µg/ml) for 30 min at RT, protected from light. Then, 
cells were washed twice with PBS and finally resuspended with D-PBS (400 µl) 
for flow cytometry analysis. 
 
2.11 XF Seahorse Extracellualar eflux Analyser  
 
Cellular metabolic profile was determined using a Seahorse XF24 Extracellular 
Flux Analyzer (Seahorse Biosciences, Billerica, MA), providing real-time 
measurements of OCR, as a measure of the OXPHOS, and ECAR, as a 
measure of glycolysis. Primary Zucker rat hepatocytes were seeded at a density 
of 50 × 104 cells per well in collagen-coated (Section 2.2.1.1.4; 3h at RT) V7 
microplates in complete growth medium (DMEM, 1% L-Glutamine, 1%PSA and 
10% FBS). Cells were allowed 4 h to adhere and the culture medium was 
changed 1 h prior to the assay unbuffered DMEM [D 5030, Sigma, (8.3g/l)], for 
the mitochondrial stress test supplemented with L-glutamax, glucose and sodium 
pyruvate, all at the final concentration of 10mM and sodium chloride (NaCl, at 
0.18 g/ml) and for glycolysis stress test with NaCl and 0.5 % phenol red (60 
µl/100ml) only. The pH was adjusted to 7.4 with sodium hydroxide (NaOH), 
filtered through 0.22 µm filter system and placed in 370C water-bath until needed. 
Meanwhile, the XF24 Sensor Cartridge, hydrated overnight prior the assay in XF 
Calibrant pH 7.4 at 370C without CO2 [Seahorse Biosciences, #100840-000 (1 
ml/well)], was injected with drugs corresponding to each assay. Mitochondrial 
stress test requires the sequential injection (per well) of 55 µl assay medium for 
basal respiration measurement, 60 µl oligomycin (1 µL/ml of 10 mg/ml), 65 µl 
carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone [(FCCP), 0.3 µl/ml of 10 
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mM stock] and 70 µl rotenone (20 µl/ml of 1.0 mM stock). The glycolysis stress 
test requires the sequential injection of glucose (40 µl/ml of 100X), oligomycin (1 
µl/ml of 10 mg/ml) and finally 2-Deoxy-D-glucose [(2-DG) 0.18 g/ml, pH 7.4]. 
 
For the experiments with the 3T3-L1 adipocytes, 3T3-L1 fibroblasts were 
differentiated on V7 microplates, according to previously described protocol 
(Section 2.2.2.3). Slight modification to the concentration of drugs used were 
made for experiments with 3T3-L1 adipocytes, double dose of oligomycin, triple 
does of FCCP and double dose of rotenone for the mitochondrial stress test. 
Single dose of glucose, double dose of oligomycin and single dose of 2-DG for 
the glycolysis stress test. The 3T3-L1 cells were differentiated on V7 microplates 
coated with 0.1% gelatin solution. Briefly, 2% gelatin (Sigma) solution was 
prepared in ultrapure H20 (Sigma) and completely liquefies at 370C water-bath. 
0.1% working solution was made and 400 µl added/well and incubated for 15 min 
at 370C, allowing gelatin to polymerize. The excess gelatin solution was 
discarded and plate allowed drying for 2 h under ultraviolet (UV) light.  
 
Following the assay, cells were fixed and stained with 0.1% crystal violet stain in 
20% methanol solution for minimum of 1h at RT. Next, the cells were washed 
twice with distilled H20 (dH20) to eliminate the excess crystal violet. The residual 
H20 was gently removed by tipping the plate on a paper towel and the plate was 
left to air dry overnight. Once the wells were completely dry, a 10% acetic acid 
solution was added to resuspend the crystals (50 µl/well). The absorbance at 595 
nm wavelength was determined spectrophotometrically using a Spectramax M3 
spectrophotometer, and the data used for normalization (duplicate measurement 
per well). Normalized data were expressed as pMole of O2 per minute or milli-pH 
units (mpH) per minute. The Seahorse XF Analyzer was turned on a day before 
the assay to allow the instrument to warm to 370C before an assay. 
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2.12 Enzymatic assay to measure lipase activity 
 
Triglyceride content of Zucker rat hepatocytes and secreted EVs was measured 
using lipase digestion assay. Lipoprotein Lipase (62335 10MG, Sigma) was 
dissolved in 500 µl of dH20 (10 mg/ml). Cell pellets were lysed with ice-cold lysis 
buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-100, 1X protease inhibitor) 
for 15min on ice following 10min centrifugation at 10 000 x g. Resulting cellular 
extract was transferred to a fresh tube and protein determined by Bradford 
(Section.2.4.1). In case of EVs the same protocol was as follow, and the lysis 
buffer was 2X concentrated to avoid high sample dilution. All samples in the 
assay were run in duplicate and taken to the same volume of 30 µl and to equal 
protein concentration. Samples were incubated at 700C for 5 min. Subsequently, 
7.5 µl of the Lipoprotein Lipase (10 mg) was added to each tube following the 
overnight incubation at 370C. The next day assay was developed with 200 
µl/sample of the Free Glycerol Reagent (FGR). The absorbance was read on 96-
well plates at 540 nm wavelength with Spectramax M3 spectrophotometer.  
 
 
2.13 Glycerol estimation assay  
 
In order to evaluate if the EVs were able to mobilize intracellular TG, cells were 
exposed to EVs and the amout of glycerol released into the media was estimated 
by a method modified from (Sagar et al. 2015). Briefly, 3T3-L1 fibroblasts were 
grown and differentiated into adipocytes (Section 2.2.2.3) in the 24-well plate. 
For the glycerol assay 3T3-L1 adipocytes were serum starved overnight in 
DMEM supplemented with 2 % FA-free BSA and 1% PS for 24 h. Next, cells 
were treated with ZL- or ZF-EVs (10 µg), in EV-depleted medium containing 
0.5% BSA, for 24 h. Supernatants were assayed for glycerol present with FGR 
(Sigma) as described in above section. 
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2.14 P450 activity assay 
 
Luminescent assay that measures the activity of cytochrome P450 2D6 were 
used to determine the activity of their corresponding rat orthologs P450 2D1 
(V8891, Promega), according to manufacturer’s instructions. Briefly, luciferin-
attached substrate specific of cytochrome P450 2D1 was added to each sample 
in 1M potassium phosphate (KPO4) buffer. Samples were incubated for 10min at 
370C. Next, the nicotinamide adenine dinucleotide phosphate (NADPH) 
regeneration system was added to each sample following the 30min incubation 
at 370C. NADPH is required for the measurement of oxidase activity catalyzed by 
P450 cytochromes. After incubation, luciferin detection reagent (LDR) was added 
to each sample and the luminescence was read in a luminometer. 
 
 
2.15 Insulin-stimulated glucose uptake  
 
For the glucose uptake experiment, the 3T3-L1 adipocytes were cultured and 
differentiated in 24-well cell culture plates (Section 2.2.2.3). The cells were 
serum starved for 12 h before the 24 h treatment with EVs (from 5-10 µg/ml per 
well). Next, cells were washed with sterile, ice-cold uptake solution (137 mM 
NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM of KH2PO4, 2.5 mM CaCl2, 20 mM of 
HEPES and 2 mM of Pyruvate, pH=7.4) and then incubated at 370C with the 
uptake solution for 45 min (255 µl/well). Then, the insulin (100 nM) was directly 
added to the uptake solution and the plate further incubated for 30 min. The 
subsequent steps were done over the radioactive work area. Here 3H2-
deoxyglucose (MP Biomedicals) at 1µCi/ml was added to the uptake solution to a 
final 0.1 mM concentration and was added in staggered 10 sec intervals to each 
well. After the solution was added to all the wells the plate was incubated at 370C 
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for a total of 10 min. Subsequently, the reaction was stopped with ice cold stop 
solution (50 mM glucose in 1XD-PBS) followed by couple of washes. Cells were 
then lysed with 300 µl of 0.5 N NaOH and suspension transferred to 1.5 ml 
eppendorf. The protein concentration was measured by Bradford (Section 2.4.1) 
and 150 µl was used for the reading in the scintillation counter. The 5 ml of the 
scintillation fluid was added to the scintillation vial together with the sample and 
incubated overnight.  
 
 
 
2.16 Adipokine array  
 
Proteome ProfilerTM Mouse Adipokine Array Kit (ARY013, R&D) was used for the 
parallel determination of the relative levels of the 38-selected mouse Adipokines. 
The assay was performed according to the manufacturer’s instructions. Capture 
and control antibodies spotted in a duplicate, for each adipokine, on 
nitrocellulose membranes were probed in cell culture supernatant of the 3T3-L1 
adipocytes previously treated with ZL- and ZF-EVs. In more detail, 3T3-L1 
adipocytes were grown in 12-multiwell plate and differentiated as previously 
described (Section 2.4.1). Mature adipocyts were either left untreated or treated 
with 30 µg of ZL- or ZF-EVs for 12 h. Subsequently, the EV-depleted medium 
was replenished and incubated for additional 12 h. The conditioned medium was 
collected and centrifuged at 1500 rpm to remove cells and large cellular debris. 
The adipokine assay was performed on the day of the collection to avoid freezing 
and thawing. Briefly, assay membranes were blocked with the Array Buffer 6 for 
1h at RT on a rocking platform. Meanwhile, samples (1 ml) were incubated with 
Array buffer 4 (0.5 ml) and 15 µl of the Mouse Adipokine Detection Antibody for 
1h at RT. After the membranes were blocked, each was incubated with the 
corresponding sample/antibody cocktail overnight at 40C on a rocking platform 
shaker. Then, membranes were washed three times with the 1X wash buffer (20 
ml/membrane each time) to remove any unbound material. Subsequently, 
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membranes were incubated with Streptavidin-HRP for 30 min at RT, following 
the three washes. Finally, the chemiluminescence detection reagents were 
applied, and a signal was produced at each capture spot corresponding to the 
amount of protein bound. The signal was detected by exposure to X-ray film. 
Signal was quantified on scanned filmed, using the same exposure time, using 
ImageJ software. 
 
 
 
2.17 Statistical analysis  
 
GraphPad Prism 6 software and Excel were used for all statistical analyses. 
Unpaired student t-test or ANOVA analyses were carried out with a confidence 
interval of 95% and statistical significance was considered if p<0.05.  
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RESULTS CHAPTER 1 
 
3. Cells and EVs characterization of the in vitro MetS 
models developed using 3T3-L1 adipocytes 
 
3.1 Chapter 1 Aims: 
 
• Establish a viable working model of in vitro adipocytes with high 
differentiation status.  
• Establish and characterize suitable models of lipid overloaded/ 
hypertrophic adipocytes, adipocytes cultured in hypoxia (1 % 02) and 
cultured in the presence of the macrophage-conditioned medium, for the 
subsequent isolation of EVs. 
• Detailed biochemical characterization of EVs secreted by models 
established in 3T3-L1 adipocytes.  
 
3.2 Introduction  
 
The exact aetiology for the development of obesity-related complications has not 
yet been elucidated. However, central obesity, insulin resistance, dyslipidemia 
and high blood pressure are common characteristics. Obesity causes an 
expansion of adipose tissue with proinflammatory phenotype and local hypoxia 
with increased secretion of FFAs. In addition, cells release soluble factors, as 
well as, membrane vesicles into the extracellular environment. These factors can 
mediate responses in neighbouring cells or can act at distant locations. There is 
accumulating evidence supporting the hypothesis that the concentration of EVs 
are elevated in above mentioned conditions of adipose hypertrophy and may 
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contribute to some pathophysiology of metabolic syndrome (Lawson et al. 2016; 
Jayachandran et al. 2011).  
With this knowledge, in our study, we used the 3T3-L1 cells as in vitro model of 
adipocytes to find out whether these pathological conditions affect the release 
and the phenotype of adipocyte-secreted EVs. The work presented in this 
chapter represents the comprehensive analysis of in vitro models established in 
3T3-L1 adipocytes and evidence that metabolic syndrome-resembling conditions 
affect the endocytic pathways that control exosomes secretion, and may activate 
alternative secretory routes.  
 
 
3.3 Results 
 
3.3.1 Morphological characterization of the 3T3-L1 adipocytes  
 
The study of adipocyte biology and differentiation has become an area of intense 
research due to the growing worldwide obesity epidemic. 3T3-L1 cells are a 
widely used and very well characterized adipocyte model (Ntambi & Kim 2000; 
Reichert & Eick 1999). 3T3-L1 cells have the capacity to be differentiated into the 
adipocyte phenotype in vitro upon exposure to an adipogenic cocktail of insulin, 
glucocorticoid agent DEX and IBMX (Green & Kehinde 1975; Green & Kehinde 
1974; Mehra et al. 2007). Recently, in more and more studies, a PPARγ agonist, 
Rosiglitazone, along with above mentioned adipogenic agents, was used for the 
differentiation of the 3T3-L1 adipocytes and it has been shown to significantly 
improve the adipocyte phenotype and increase adipose tissue mass (Kallen & 
Lazar 1996). This compound belongs to the family of thiazolidinediones (TZDs) 
that are a group of clinically used anti-diabetic drugs, which improve insulin 
sensitivity (Crossno et al. 2006). They work by stimulating the formation of new 
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adipocytes from preadipocytes and progenitor cells, by binding to PPAR 
receptors in fat cells making them more sensitive to the action of insulin.  
High level of differentiation of the 3T3-L1 adipocytes depends on many factors 
such as for example the cell culture dish (Mehra et al. 2007) and the media 
height above the cell layer (Sheng et al. 2014), maintenance of 3T3-L1 
fibroblasts and the passage number. Having that in mind, to assure a high level 
of differentiation of our cells and to examine to what extent rosiglitazone was 
improving 3T3-L1 adipocyte differentiation, we tested rosiglitazone, alongside 
other adipogenic agents. As a readout, we compared the expression of adipocyte 
differentiation markers, which all play their respective roles in the transcriptional 
cascade during adipocyte differentiation.  
We compared the level of mRNA expression of the Fatty acid-binding protein 4 
(Fabp4), Adiponectin (Adipoq), Glut4 (Slc2a4) and CCAAT/enhancer-binding 
protein alpha (Cebpa) in pre-adipocytes and in adipocytes, using confluent 
fibroblasts stage as a control, differentiated without and with rosiglitazone 
(Figure 10). Results of qPCR indicate that in rosiglitazone-differentiated 
adipocytes, the expression of all differentiation-related markers is significantly 
improved at both, the pre-adipocyte and adipocyte stage together with the 20-
time increase in C/EBP alpha (Figure 10D), a master regulator of adipocyte 
differentiation (Reichert & Eick 1999). In consequence, to have the highest rate 
of adipocyte differentiation we used rosiglitazone for the rest of the study.  
The morphological characterization of 3T3-L1 cells was evaluated thought the 
different stages of differentiation (Figure 11). Using light microscopy images 
(Figure 11A) we could appreciate the morphological changes that 3T3-L1 
fibroblasts undergo to become mature adipocytes. The first and most notable 
alteration is seen in the gain of spherical shape as fibroblasts cells convert to 
preadipocytes (Figure 11A, middle panel). 
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Figure 10 Rosiglitazone improves 3T3-L1 adipocyte differentiation. Differentiation 
efficiency was compared with and without Rosiglitazone. Quantitative PCR analysis of genes 
expressed during differentiation, encoding for the (A) Fabp4/Ap2 (B) Adiponectin, (C) 
Glut4, and (D) Cebpα proteins. Expression in fibroblasts was used as a control. Biological 
replicate = 1, technical replicate = 3  
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This occurs due to a change in an extracellular matrix (ECM) and cytoskeletal 
components (Symonds 2012). Moreover, the lipid droplets begin to accumulate 
as seen by Bodipy staining in Figure 11B. The localization of proteins associated 
with lipid droplets such as adipophilin and adiponectin was assessed by 
immunostaining (Figure 11C and 11D) and their expression confirmed by WB in 
cellular lysates from 3T3-L1 adipocytes (Figure 11E).  
In conclusion, molecular and morphological results confirmed that our method of 
differentiation is adequate, and consequently, it was used for the rest of the 
study. 
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Figure 11 Morphological and molecular changes through 3T3-L1 adipocyte 
differentiation. (A) Light microscopy images of 3T3-L1 cells throughout the differentiation 
stages. Live cells were imaged using inverted microscope at 40X magnification. 3T3-L1 
fibroblasts were imaged at sub-confluent state, pre-adipocytes at day 6 of the differentiation 
process and adipocytes at day 13, the final day of differentiation; bar = 50µm. (B) 3T3-L1 
fibroblasts, pre-adipocytes and adipocytes stained with Bodipy (10 µg/ml) confirming lipid 
accumulation; bar=20µm. Immunofluorescent staining of 3T3-L1 adipocytes with antibodies 
against (C) adipophilin and (D) adiponectin proteins. (E) Expression of both markers was 
confirmed by Western-blotting in 3T3-L1 adipocyte cell lysates (10 µg).  
 
 
3.3.2 Energetic demands of 3T3-L1 cells during the differentiation process 
 
As cell differentiation progresses, the energetic demand increases significantly to 
maintain cellular processes. In the terminal differentiation stage, there is an 
increase in the activity of enzymes responsible for triglyceride synthesis, glucose 
transport, and synthesis of adipocyte-related products. (Gregoire et al. 1998). 
Previous studies have also demonstrated an increase in expression levels of 
essential components of the mitochondrial respiratory chain such as peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) and 
Cytochrome c, concluding that cells increase their mitochondrial content during 
adipogenesis (Keuper et al. 2014).  
Therefore, we decided to monitor the mitochondrial respiratory function 
throughout the 3T3-L1 differentiation, in fibroblasts, pre-adipocytes, and 
adipocytes, using a Seahorse XF24 extracellular flux analyzer. During the 
experiment, by sequential addition of oligomycin, FCCP, and rotenone, 
mitochondrial ETC can be inhibited at very specific sites, allowing the cellular 
response to be detected as a change in the rate of oxygen consumed by cells. 
Figure 12A shows the time-lapse measurements of the OCR in values 
normalized by the number of cells per well. Preadipocytes exhibit higher basal 
respiration, as compared to fibroblasts and even adipocytes. However, the 
respiratory capacity increases notably in mature adipocytes (Figure 12A).  
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Figure 12 The profile of mitochondrial stress test in 3T3-L1 cells throughout the 
adipocyte differentiation process. (A) OCR was measured under basal conditions and 
following the sequential addition of oligomycin (1 mM) FCCP (300 nM) and rotenone (1 
µM) to obtain the response profile of mitochondrial function in 3T3-L1 fibroblasts, 
preadipocytes and adipocytes. Individual parameters of (B) non-mitochondrial respiration, 
(C) proton leak, (D) basal respiration, (E) ATP production, (F) maximal respiration and 
(G) spare capacity were established. 3T3-L1 cells were differentiated directly on specific 
microplates from the XF24 flux analyzer. Replicate/condition = 6, error bars=SD. The p 
values were denoted as follows: 0.01- 0.05 = *, 0.01-0.001=**, 0.001-0.0001=***. Unpaired 
student t-test was performed to determine significant differences.  
 
 
Using XF24 flux analyzer, specific mitochondrial parameters can be studied, 
such as non-mitochondrial respiration, basal respiration, proton leak, ATP 
production, maximal respiration and spare capacity, (Figure 12B-12G). Besides 
the decrease in spare capacity (Figure 12G), all other parameters increase in 
preadipocytes, upon differentiation. This could be associated with higher energy 
demand due to preadipocytes conversion. The addition of rotenone, an inhibitor 
of ETC complex I hindered mitochondrial respiration and therefore allowed us to 
make a distinction between mitochondrial and non-mitochondrial respiration. In 
fibroblasts, the non-mitochondrial respiration is barely detectable, indicating that 
all energy seems to be associated with mitochondria (Figure 12B). There was a 
significant increase in basal respiration (Figure 12D) and the production of ATP 
by preadipocytes (Figure 12E). Yet surprisingly, the increase in proton leak was 
also observed upon differentiation (Figure 12C). Maximal respiration (Figure 
12F) and spare capacity (Figure 12G) are the parameters which are significantly 
higher in mature adipocytes. These processes are related to the maximal ATP 
output controlled by the cells substrate oxidation capacity (Keuper et al. 2014). 
They can be measured by the addition of the ion carrier, FCCP, which disrupts 
ATP synthesis by transporting hydrogen ions across the mitochondrial 
membrane and dissipating/uncoupling the membrane potential gradient. The 
energy is rapidly consumed without generation of ATP which allows the 
estimation of maximal respiration rate that the cell could perform. Spare capacity 
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is determined by subtracting basal respiration value from the maximal induced by 
FCCP.  
Together these results indicate that adipogenesis is highly energy producing and 
consuming process as judged by an increase in the main mitochondrial 
parameters. In addition, the spare capacity was decreased in preadipocytes as 
compared to fibroblasts which could take place to allow the adipogenic 
procession, which is later recovered when adipocytes become mature (Figure 
12G). 
 
3.3.3 Induction of hypertrophy in 3T3-L1 adipocytes 
 
3.3.3.1 Model characterization 
 
We established an in vitro model of hypertrophic adipocytes in differentiated 3T3-
L1 adipocytes by challenging them with a mix of oleic and palmitic acids at a ratio 
of 2:1 and at a final concentration of 1 mM (section 2.2.3.2). Bodipy staining of 
these cells revealed the presence of significantly enlarged fat droplets within 
adipocytes (Figure 13A), as also confirmed by flow cytometry analysis of Bodipy 
stained FFA-treated adipocytes (Figure 13B and 13C). 
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Figure 13 Treatment with FFAs induces fat-overload in 3T3-L1 adipocytes. Mature 
3T3-L1 adipocytes were cultured with a combination of oleic and palmitic acid (2:1 ratio), at 
a final concentration of 1 mM for 24h. (A) Images of the Bodipy stained, control and lipid-
overloaded 3T3-L1 adipocytes, inserts were magnified 2.5X, bar=20 µm. (B) Representative 
flow cytometry histogram of Bodipy stained control and FFA-treated cells. (C) 
Quantification of FITC-A fluorescence in control and hypertrophic 3T3-L1 adipocytes. 
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3.3.3.2 Characterization of isolated EVs 
 
Adipose tissue inflammation is a hallmarks of obesity, characterized by 
hypertrophic adipocytes, increased influx of immune cells and AT inflammasome 
activation (Mariëtte E G Kranendonk et al. 2014; Weisberg et al. 2003; Zhang et 
al. 2015). Soluble factors and adipokines, secreted by adipose tissue are 
involved in the recruitment and activation of macrophages (Keophiphath et al. 
2010). Through secreted adipokines, adipose tissue actively communicates with 
other organs such as liver, skeletal muscle and the brain (Ailhaud 2006; Zhang et 
al. 2016). EVs from in vitro differentiated adipocytes were previously 
characterized (Mariëtte E G Kranendonk et al. 2014). They were visualized by 
TEM and on a density gradient, they were detected at known exosomal density 
range, between 1.12-1.14 g/ml. Subjected to the WB analysis, they were found to 
contain EV specific markers such as CD9 and CD63 and adipocyte specific 
proteins like adiponectin and fatty acid binding protein. The increase in EVs 
secreted by omental adipose tissue in obese patients, has also been reported 
(Mariëtte E G Kranendonk et al. 2014).  
We performed the characterization of EVs derived from chemically-induced 
hypertrophic 3T3-L1 adipocytes. Importantly, to avoid the contamination coming 
from FFAs, medium was removed after 24 h and cells were cultured for an 
additional 48 h for the isolation of EVs (section.2.3.2). Detailed characterization, 
including visualization by cryo-EM, size distribution profile and particle 
concentration by NTA and protein expression profile of common EV markers by 
WB was performed (Figure 14). 
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Figure 14 Characterization of EVs secreted by hypertrophic 3T3-L1 adipocytes. 
Ultrastructural and biochemical characterization of EVs isolated from conditioned medium 
of hypertrophic 3T3-L1 adipocytes. (A) Cryo-EM analysis; bar=100 nm, inserts are 
magnified 2.5X (B) Particle size range distribution profile measured by NTA. (C) Particle 
concentration (1010) (D) Particle mean size was measured by NTA, n=4 (E) Protein extracts 
from two independent preparations of EVs (5 µg) together with their corresponding cell 
lysates (10 µg) were analyzed by WB with antibodies for EV specific as well as cellular 
markers. Error bars = SD 
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Cryo-EM analysis revealed the presence of a heterogeneous population of 
membrane vesicles limited by a lipid bilayer. Representative electron 
micrographs are shown in Figure 14A. Concerning the size of secreted vesicles, 
previous studies have shown that, the peak size distribution of EVs secreted by 
human adipose tissue derived mesenchymal stem cells was found to be between 
150 and 200 nm (Katsuda et al. 2013; Zhang et al. 2016). Our analysis of four 
independent preparation of EVs from control and hypertrophic adipocytes 
reinforced this result, as the peak size of our EV preparations ranged between 
150-200 nm for both groups, with no difference in the overall size distribution of 
vesicle population (Figure 14B). On the other hand, there was a slight increase 
in the concentration of particles released by hypertrophic adipocytes (Figure 
14C) with no change in the mean particle size between both groups (Figure 
14D).  
Protein analysis of EV-related markers was performed by WB in control and 
hypertrophic adipocytes, two independent preparations are shown on Figure 
14E.  
Importantly, organelle marker proteins, such as, Grp78 and CoxIV, endoplasmic 
reticulum and mitochondrial markers, respectively, were absent in the EV 
preparations (Figure 14E). These results indicate that under our lipid overload 
conditions no significant cell toxicity was produced and consequently no 
contamination by intracellular material. Interestingly, Hsp70 is a protein 
frequently found in EVs preparation obtained from different cell-types (Kalra et al. 
2012). However, although we could detect this protein in the cell extracts, it was 
not present in the adipocyte-EV preparations (Figure 14E). Comparison of the 
abundance of Cd81 and Aip1 proteins, in 3T3-L1 adipocytes and their 
corresponding EVs, reveals that these EVs were highly enriched in these two 
exosomal markers (Figure 14E). No significant changes were observed in the 
abundance of these proteins depending on the FFA treatment (Figure 14E). 
Moreover, significantly increased expression of the lysosomal protein, LimpII, as 
well as, Flotillin1 were observed in EVs isolated from hypertrophic adipocytes. 
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Interestingly, while the higher expression of Flotillin1 was also observed in 
hypertrophic adipocyte-cell lysates, the intracellular expression of LimpII was not 
altered by the treatment. This result could indicate that there are different 
mechanisms for sorting these proteins into EVs.  
Therefore, these results indicate that lipid-overload of adipocytes increases EV 
secretion and alter their composition.  
 
3.3.4 3T3-L1 Adipocytes cultured under hypoxia and in the presence of the 
macrophage conditioned medium  
 
3.3.4.1 Model characterization 
 
Adipocyte hypertrophy that occurs during obesity is associated with macrophage 
infiltration and local hypoxia due to limiting blood supply resulting from lipid 
overload in adipocytes. To mimic these conditions in vitro, 3T3-L1 adipocytes 
were incubated in a hypoxic chamber with 1%02 or were cultured in the presence 
of macrophage conditioned medium (MØ) (v/v) (15%), previously obtained from 
differentiated primary mouse bone marrow cells, for 24 h (Section.2.2.1.2). 
Induction of a cellular response to counter the lack of oxygen was confirmed in 
lysates of 3T3-L1 adipocytes (Figure 15A). Elevated expression levels of various 
oxygen sensitive proteins such as Catalase, Ferritin-LC, Vegf and Rab11 were 
observed by WB (Figure 15A). Rab11 is important in vesicular transport in the 
cell and it has been described to be implicated in hypoxia-induced invasion of 
breast cancer cells (Yoon et al. 2005) Cellular hypoxia has been reported to 
correlate with increased glucose uptake, and accordingly, we have also observed 
elevated expression of the Slc2a1 gene encoding for the glucose transporter 1 
(Glut1) in hypoxic adipocytes (Figure 15B).  
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Figure 15 Characterization of 3T3-L1 adipocytes cultured in hypoxia and in 
macrophage-conditioned medium. Differentiated 3T3-L1 adipocytes were exposed to 
hypoxia (1%02) and to the macrophage-conditioned medium (MØ) for 24h. (A) 3T3-L1 cell 
lysates (10µg) from normoxic and hypoxic adipocytes were characterized by WB for the 
induction of hypoxia, n=2 (B) Hypoxia induced Glut1 (slc2a1) mRNA expression in 
normoxic and hypoxic adipocytes, n=2 (C) Representative WB of insulin stimulated Akt on 
Ser473 and Erk1/2 phosphorylation in 3T3-L1 adipocytes exposed to hypoxia and the 
macrophage-conditioned medium. Quantification of phosphorylation, represented as the 
fold increase in phosphorylation with insulin (D) Akt(Ser473) (E) Erk1/2. Quantification 
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was done using ImageJ software. Representative figure and quantification of 4 independent 
experiments. Error bars = SD. 
 
We then sought to investigate the insulin sensitivity in our cellular models by 
evaluating the phosphorylation of the serine/threonine-protein kinase akt-1 (Akt) 
and extracellular signal-regulated kinase (Erk1/2) following insulin stimulation. 
We studied the insulin response in two models: the 3T3-L1 adipocytes under 
hypoxic conditions, and the 3T3-adypocytes exposed to medium conditioned by 
macrophages to resemble inflammatory conditions (Figure 15C). Results of WB 
analysis, although not statistically significant, indicate that insulin sensitivity is 
slightly inhibited in 3T3-L1 adipocytes cultured in proinflammatory conditions 
(Figure 15D) with no the change in hypoxic adipocytes. Although a higher level 
of Erk1/2 total and phosphorylated was found in inflammatory conditions, no 
differences in the response to insulin were observed (Figure 15E).  
 
3.3.4.2 Characterization of isolated EVs 
 
It has been demonstrated that cellular stress such as hypoxia induces increased 
release of EVs (Belting & Christianson 2015). It is also true for adipocytes 
cultured in hypoxic conditions (Syn et al. 2016). Interestingly, the hypoxia-
inducible factor-1α (HIF-1α) was found to be excreted in hypoxic adipocytes-
derived EVs (Syn et al. 2016). Moreover, results of quantitative proteomic 
analysis showed that hypoxic EVs contain increased amount of lipogenic 
enzymes such as fatty acid synthase (FASN), glucose-6-phosphate 
dehydrogenase (G6PD), and acetyl-CoA carboxylase (ACC). These in vitro 
results have been validated in serum of obese mice (ob/ob) (Sano et al. 2014). 
Furthermore, hypoxic EVs were able to transfer their proteomic phenotype on 
neighbouring cells as seen by elevated expression of Fasn and higher lipid 
accumulation in normoxic 3T3-L1 adipocytes exposed to hypoxic-EVs (Sano et 
al. 2014) 
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In our model we characterized EVs secreted by 3T3-L1 adipocytes exposed to 
hypoxia (Figure 16) and to the macrophage conditioned medium (MØ) (Figure 
17) for 24h, as two independent models.  
Cryo-EM analysis confirmed the presence of a heterogeneous size population of 
lipid membrane-enclosed vesicles, as can be appreciated on the electron 
micrographs in Figure 16A. Fused vesicles can also be found as well as vesicles 
slightly larger than defined exosomes. NTA analysis of the size distribution 
confirms the presence of larger particles (Figure 16B). However, it also verifies 
that taking the whole population into account, most vesicles present were found 
to be within the size range of 100-150 nm and that more vesicles were secreted 
in hypoxic conditions in that size range (Figure 16B). It can also be seen that the 
concentration of EVs secreted in hypoxia was increased as compared to control 
3T3-L1 (Figure 16C). Together with the increased release of EVs by adipocytes 
in hypoxia the mean particle size decreases (Figure 16D). 
Western blot analysis revealed that the tetraspanin Cd81 was present in the EV 
fractions as well as in the parent whole cell lysates (Figure 16E) with an 
enrichement in EVs. Moreover, the expression of Cd81 in donor cells correlated 
negatively with the expression in corresponding EVs, as more Cd81 was 
secreted with control EVs (Figure 16E). Reverse situation was observed in 
hypoxia (Figure 16E). Interestingly, as compared to the control EVs, the 
expression decreased in EVs secreted by hypoxic adipocytes. The organelle 
markers, prohibitin (mitochondria) and Grp78 (endoplasmic reticulum) were 
detected exclusively in the whole cell lysates, indicating the presence of very low 
or none contamination in our preparations by cellular lysis.  
To address the hypothesis of whether possible changes in insulin stimulated 
glucose uptake in adipocytes could be related with the amount of glucose 
transporter, we evaluated the protein level of Glut4, one of the prominent glucose 
transporter isoforms expressed in adipocytes. Although we could not detect the 
protein in the cell extracts, Glut4 was in fact present in EV fractions secreted by 
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adipocytes, and remarkably, the transporter was more abundant in EVs from 
hypoxic adipocytes (Figure 16E).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16 Characterization of EVs released by hypoxic 3T3-L1 adipocytes. 
Ultrastructural and biochemical characterization of EVs, isolated from conditioned medium 
of 3T3-L1 adipocytes in normoxia and hypoxia (1%02). (A) Cryo-EM analysis, size 
bar=100nm, inserts magnified 2.5X (B) Size range distribution (C) Particle concentration 
(1010) (D) Particle mean size was measure by NTA, n=3 (E) Protein extracts from two 
126 
 
independent preparations of EVs (5 µg) together with their corresponding cell lysate (10 µg) 
controls were analyzed by WB, with antibodies against protein markers of EVs as well as 
protein markers of intracellular compartments. Representative figure. Error bars = SD. 
 
EVs obtained from control as well as from 3T3-L1 adipocytes cultured in the 
presence of the MØ. Isolated EVs were visualized in their native state by cryo-
EM, again revealing some important structural details such as the presence and 
thickness of phospholipid bilayer or the electron density of vesicles. Figure 17A 
shows representative electron micrographs where it can be noted the presence 
of mostly electron lucent vesicles can be appreciated. It also seems that smaller 
vesicles have a more densely packed lipid bilayer (Figure 17A, Control, 2.5X 
insert) than larger vesicles. NTA confirmed this heterogeneity of isolated vesicle 
populations (Figure 17B). A filtration step in the isolation protocol to some 
degree discards the presence of larger particles, however due to clumping or 
formation of fused vesicles, frequently observed by cryo-EM, they are present in 
the sample and detected by NTA. Their presence was abundant in the control EV 
sample, as can be observed on the size distribution curve (Figure 17B). 
Furthermore, the MØ EV sample shows a 10 % increase in the amount of 100-
150 nm EVs with a significant decrease in the overall mean particle size (Figure 
17C). The total concentration remains unchanged (Figure 17C) between both 
groups. Western blotting confirmed the presence and enrichment of Cd81 in the 
EV preparations, with a slight reduction in the expression in EVs produced by 
adipocytes exposed to the macrophage-conditioned medium (Figure 17D). 
Mitochondrial (prohibitin) and ER (Grp78) markers were solely associated to 
whole cell lysates, discarding contamination by cell lysis. Moreover, as already 
observed, Glut4 was found to be secreted into the extracellular space by means 
of EVs, and importantly, slightly more in EVs from adipocytes exposed to the 
macrophage-conditioned medium than the control ones. 
The results obtained from these experiments indicate that the secretion of EVs 
by adipocytes is sensitive to stress conditions such as hypoxia and presence of 
proinflammatory cytokines.  
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Figure 17 Characterization of EVs released by 3T3-L1 adipocytes cultured with 
macrophage-conditioned medium. Ultrastructural and biochemical characterization of 
EVs, isolated from the conditioned medium of the 3T3-L1 adipocytes cultured in the 
presence of the macrophage-conditioned medium. (A) Cryo-EM analysis; bar=100nm; 
inserts magnified 2.5X. (B) Size range distribution (C) Particle concentration (1010). (D) 
Particle mean size, n=2. (E) Protein extracts from two independent preparations of EVs (5 
µg) together with their corresponding cell lysate (10 µg) controls were analyzed by WB, with 
antibodies for EV as well as cellular markers. Replicate/condition = 3, error bars=SD. The p 
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value = 0.001-0.05=*. Unpaired student t-test was performed to determine significant 
differences.  
 
 
3.3.4.3 Investigating the insulin sensitivity in 3T3-L1 adipocytes upon exposure to 
hypoxic- and MØ-EVs 
 
As previously mentioned, in obesity, adipose tissue expansion results in local 
tissue hypoxia and macrophage infiltration causing local inflammation. We have 
demonstrated that our in vitro models of 3T3-L1 adipocytes cultured in hypoxia or 
co-cultured with macrophage-conditioned medium exhibit altered insulin 
sensitivity (Figure 15C) reflecting the metabolic state adipose tissue in obesity 
and MetS.  
These two mechanisms cause cellular stress and as shown by our results, 
contribute to the increased generation of EVs with altered expression of EV-
related markers (Figure 16 and Figure 17). With that knowledge we next aimed 
to determine whether these EVs could have en influence the metabolic 
phenotype of the 3T3-L1 adipocytes. We determine the activation of the insulin 
signalling pathway by monitoring phosphorylation of Ser473 of Akt and of 
Thr201/Tyr204 on Erk1/2 in response to insulin stimulation upon treatment with 
EVs. For these experiments, differentiated 3T3-L1 adipocytes were either left 
untreated or treated with EVs isolated from either control adipocytes, adipocytes 
cultured in hypoxia or adipocytes cultured in the presence of the macrophage-
conditioned medium for 24 h. In dose dependant manner, we detected a small 
but significant decline in Ser473 Akt phosphorylation in cells treated with EVs 
secreted by 3T3-L1 adipocytes cultured in hypoxia as compared to untreated 
cells or control 3T3-L1 adipocytes (Figure 18A and 18B). On the contrary, we 
did not detect any difference in the activation of Erk1/2 proteins in any of the 
experimental groups (Figure 18C).  
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Figure 18 EVs from hypoxic 3T3-L1 adipocytes inhibit insulin signalling in recipient 
3T3-L1 adipocytes. (A) Cellular lysates from 3T3-L1 adipocytes treated for 24 h with EVs 
from CTRL 3T3-L1 adipocytes (EVs CTRL), cultured in 1% oxygen (EVs hypoxia) and 
cultured in macrophage conditioned medium (EVs MØ), at concentration between 5-10 µg. 
Cells were then stimulated with 100 nm insulin for 30 min. Equal amounts of lysates were 
immunoblotted with antibodies as indicated. (B) Quantification of Akt phosphorylation (%) 
compared to the phosphorylation in cells treated with EVs CTRL. (C) Quantification of 
Erk1/2 phosphorylation (%) compared to the phosphorylation in cells treated with EVs 
CTRL. Graphs show ± STDEV; n=4 for Akt and n=2 for Erk1/2. p value *** <0.01. One 
Way ANOVA.  
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3.3.4.4 Investigating the insulin stimulated glucose uptake in 3T3-L1 adipocytes 
upon exposure to hypoxic- and MØ-EVs 
 
To confirm our results, we performed the insulin stimulated glucose uptake in 
3T3-L1 adipocytes upon exposure to EVs. Following 24 h treatment with EVs, 
the insulin-stimulated glucose uptake was measured.  
 
In untreated control cells insulin increased 2-DG uptake levels by 3-fold over 
basal uptake (Figure 19A and 19B). Cells treated with EVs from control 
adipocytes exhibited a similar response to untreated cells and no statistical 
significance were detected in basal or insulin-stimulate uptake values compared 
to untreated cells (Figure 19A). However, cells treated with EVs from hypoxic 
adipocytes displayed a 25% decrease in the insulin-stimulated response, while 
no statistical significances were observed in the basal glucose transport rates 
(Figure 19A). Moreover, the insulin-stimulated glucose uptake achieved treated 
with EVs obtained from hypoxic cells was restored upon heating hypoxic EVs at 
400C for 30 min prior treatment of cells (Figure 19C). This result suggests that 
heat-mediated denaturation of proteins associated to EVs either has an effect 
over the uptake of EVs by recipient 3T3-L1 adipocytes or other mediator of the 
action over the insulin sensitivity. Furthermore, cells treated with EVs released by 
adipocytes cultured with macrophage conditioned medium did not display any 
significant differences in either basal or insulin-stimulated glucose uptake 
compared to cells untreated or cells treated with EVs derived from control cells 
(Figure 19B).  
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Figure 19 EVs from hypoxic 3T3-L1 adipocytes inhibit insulin-stimulated glucose 
uptake in recipient 3T3-L1 adipocytes. (A)(B)(C) Differentiated 3T3-L1 adipocytes were 
left untreated or treated for 24 h with EVs from CTRL 3T3-L1 adipocytes (EVs CTRL), 
cultured in 1% oxygen (EVs hypoxia), cultured in macrophage conditioned medium (EVs 
MØ) or with heat inactivated EVs hypoxia (400C for 30 min). In all three independent 
experiments, basal or stimulated with insulin (100 nM) 2-DG uptake was measured. Uptake 
was normalized to protein content in cellular lysates. The (A)(B)(C) represent three 
independant experiments. The graph show mean ± SEM; biological replicates n=3; p value * 
indicates <0.05; One Way ANOVA.  
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3.4 Summary  
 
In summary, adipocytes under cellular stress conditions such as hypertrophy, 
hypoxia or cultured in the presence of the macrophage-conditioned medium alter 
the number and the composition of secreted EVs. Hypertrophic adipocytes have 
shown to secrete more EVs and displayed higher expression of Flotillin1 and 
Cd81 in cells and secreted EVs. 
We identified the presence of Glut4 protein and increased expression level of it in 
EVs coming from adipocytes cultured in hypoxia and with macrophage-
conditioned medium. Moreover, in both cases, the expression of Cd81 protein in 
EVs was downregulated. 
Finally, we have also shown that EVs released by 3T3-L1 adipocytes cultured in 
hypoxia caused a significant reduction in insulin-stimulated phosphorylation of 
Akt on Ser473 and in addition, these EVs significantly affected the insulin-
stimulated glucose uptake in 3T3-L1 adipocytes (Graphically represented in 
Figure 20). 
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3.5 Discussion  
 
For studies in biomedical research different methods are employed, from 
experimental animals, to tissues, primary cell culture and immortalized cell lines 
(Kanuri & Bergheim 2013). Establishing a valid cellular in vitro model for 
subsequent isolation of EVs from the conditioned medium is very challenging, 
with many factors to consider, such as the contamination with EVs from other 
sources, minimal toxicity to avoid the contamination by cellular debris or the 
release of apoptotic bodies.  
The characteristic of obesity is an enlargement of adipose tissue due to increase 
storage of the excess energy. There are two possible growth mechanisms, a 
pathological enlargement of adipocytes known as hypertrophy and hyperplasia, 
an increase in adipocyte cell number (Jo et al. 2009). Currently, there is not any 
well-established in vitro model of hypertrophic transition of adipocytes. In a 
recent study, researchers maintained already mature 3T3-L1 adipocytes in 
culture supplemented with 10% FBS and 0.1% insulin. The hypertrophic 
phenotype was already seen on day 24, approximately two weeks post-
differentiation, manifested as en enlargement of lipid droplets, accompanied by 
elevated levels of pro-inflammatory factors, with conditioned medium displaying 
macrophage-attracting activity in cell migration assays. Additionally, they showed 
that the activity of cytochrome c oxidase was reduced in hypertrophy (Xinxu et al. 
2016). Yet another group, challenged the 3T3-L1 adipocytes with saturated 
(palmitic and stearic) and monosaturated (oleic) FFAs, which resulted in 
adipocyte hypertrophy in time and dose dependant manner. Moreover, they 
found that oleic acid did not cause the induction of the inflammatory responses in 
adipocytes as the saturated palmitic acid. Regardless the treatment, hypertrophic 
adipocytes exhibit attenuation in insulin-dependent glucose uptake, with Akt and 
Irs-1 phosphorylation being unchanged between the treatment and the control 
groups. Insulin dependent Glut4 translocation to the plasma membrane was 
decreased in hypertrophic adipocytes (J. I. Kim et al. 2015).  
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In addition, a study from 2012 provided evidence that adipose hypertrophy 
results in lysosomal destabilization and the activation of the lysosomal cysteine 
protease, cathepsin B (Ctsb) in the cytosol (Gornicka et al. 2012). Similarly, to a 
previous group, they used the 3T3-L1 adipocyte model and only saturated FAs 
(palmitic and stearic) for up to 18 h for the induction of hypertrophy. It has been 
reported that individual FFAs have a distinct toxic potential, with palmitate alone 
being highly toxic to hepatocytes, when compared to oleic and that the 
combination of both FFAs, with a low proportion of palmitic acid, result in 
maximal fat accumulation and minimal cytotoxic effect (Gómez-Lechón et al. 
2007). Having that in mind, we tested different concentration of oleic and palmitic 
acids alone, as well as the combination of both, and we found that the ratio of 2:1 
of oleic and palmitic acid at a final concentration of 1 mM was most appropriate 
for our study (data not shown). To avoid contamination from FFAs in our EV 
preparations, mature 3T3-L1 adipocytes were exposed to FFA mix for 24 h for 
the induction of hypertrophy, following the replenishment of fresh, EV-depleted 
medium for the production of EVs.  
The visualization of EVs by EM-techniques and the size and concentration 
analysis are often the first steps into a more detailed characterization of isolated 
EVs from different sources. We found that under hypertrophic conditions, 
adipocytes released more particles as compared to basal conditions. This 
phenomenon is widely accepted in EVs research field that under stressed 
conditions, cells secrete overall more EVs. It is clear, from the WB analysis, that 
hypertrophy in adipocytes induce the release of a distinct population of EVs, 
exhibiting striking differences in protein abundance of EV-specific markers. One 
possible explanation of this result could be obtained from the existence of a 
heterogeneous population of MVBs (Simons & Raposo 2009). The authors 
reasoned that there must be at least two classes of MVBs, one that fuses with 
the lysosome and another, which fuses with the plasma membrane to release 
exosomes (Simons & Raposo 2009). Moreover, it seems obvious to think that 
that there is a transfer or exchange of material between the different cellular 
compartments involved in vesicular transport, which would explain the presence 
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of late endosomal/lysosomal markers in our preparations. Our results could 
suggest alteration of the composition of MVBs and in the intracellular vesicular 
trafficking. 
Unexpectedly, minor changes were observed in NTA distribution analysis and 
clear difference in abundance of EV markers by WB, such as an increase in 
Cd81 in EVs secreted by hypertrophic cells. It is important to highlight that we 
focused on the characterization of small vesicles, thus under our conditions we 
cannot study the possible difference caused in larger vesicles. In addition, it is 
important to have into account that NTA has some limitations in terms of 
determining purity of the samples, considering, for example, protein aggregates 
and lipoproteins (Boing et al. 2014) which may contribute to the final EV 
concentration.  
Regulation by EVs has been widely implicated in adipose tissue development 
and homeostasis (Lakhter & Sims 2015). Adipocyte-EVs have been well studied, 
during pre- and post-adipogenesis (Connolly et al. 2015), in hypoxia (Sano et al. 
2014), identified as mediators of macrophage-induced insulin resistance (Deng 
et al. 2009). Moreover, exosomes from visceral adipose tissue of obese 
individuals induced deregulation of the transforming growth factor ß (TGF-ß) 
pathway in HepG2 and hepatic stellate cell line (Koeck et al. 2014). 
Flotillins are highly conserved proteins involved in many cellular processed such 
as signal transduction, cell adhesion, and cellular trafficking. They are post-
translationally modified by fatty acid acylation (a single palmitate in flotillin-1) and 
form hetero-oligomers constitutively associated with cholesterol- and 
sphingolipids-enriched microdomains (Meister & Tikkanen 2014). Reversible 
palmitoylation on Cys residues was suggested as a means of recruitment or 
exclusion of proteins from lipid microdomains, with a single palmitoylation not 
being sufficient for protein recruitment to rafts (Levental et al. 2010). Upon 
differentiation of 3T3-L1 adipocytes, flotillin-1 from a cytoplasmic compartment to 
the plasma membrane (Liu et al. 2005). It is important to mention this fact, as we 
detected Flotillin1 protein, as a double band in our adipocytes and one in their 
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corresponding EVs. Interestingly, Flotillin-1 was more abundant in hypertrophic 
adipocytes and their secreted EVs, as compared to control adipocytes. Lipid rafts 
have been strongly implicated in the endocytic process, endosomal trafficking 
and cargo sorting (Meister & Tikkanen 2014). Glebov et al. found increased 
amounts of flotillin-1 in early endocytic vesicles with no co- localization with 
clathrin, and proposed the existence of the flotillin-1 mediated clathrin-
independent endocytic pathway (Glebov et al. 2006). We observed not only 
higher Flotillin-1 accumulation in hypertrophic adipocytes but also in their 
secreted-EVs, which could indicate the possible enrichment of vesicles, which 
production is mediated by Flotillin1-mediated endocytic pathway. 
Interestingly, increased abundance of lysosomal protein, LimpII in hypertrophic-
EVs is very clear, however, in cells, LimpII does not seem to be affected. The 
enrichment in LimpII in secreted-EVs could be related with lysosomal 
permeability was seen in adipose hypertrophy, which could contribute to the 
lysosomal-marker enrichment in hypertrophic-EVs.  
Genes involved in all aspects of lysosome biogenesis and function are 
upregulated with insulin resistance and obesity (Xu et al. 2013) translated as 
increased expression of lysosomal proteins. Excess lipid supply largely impair 
lysosomal function as observed in diet-induced obesity and metabolic disorders 
(Jaishy & Abel 2016).  
The absence of Hsp70 in EVs secreted by adipocytes was somewhat a surprise, 
as it is considered one of the principal makers of EVs. One possibility for not 
detecting its expression is that as the 24 h media containing FFAs for the 
induction of hypertrophy is removed, a population of EVs could be lost there and 
not replenished in the following 48 h. In one study it has been concluded that 
Hsp70 release from peripheral blood mononuclear cells (PBMCs) does not occur 
via raft-dependant pathway (Lancaster & Febbraio 2005), which could be the 
predominant secretory pathway in hypertrophic adipocytes. 
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The understanding of molecular events occurring in hypertrophic adipocytes is 
important to understand changes seen in their secreted-EVs. The use of primary 
adipocytes would be ideal, however, there are various technical drawbacks such 
as their fragility, purity, due to possible contamination from stromal vascular cells 
and macrophages, and therefore separating pure population would not be 
feasible (J. I. Kim et al. 2015).  
Whole-animal studies have been very useful in deciphering the metabolic 
abnormalities associated with insulin resistance, however when studying 
molecular mechanisms, cell culture conditions have been extensively used, 
mostly in assessing insulin-receptor-coupled processes (Knutson & Balba 2012). 
Insulin resistance can be induced in cultured adipocytes by a variety of 
treatments, however, it remains unknown what aspects of the in vivo responses 
are covered by these models and how closely they resemble the situation in vivo 
(Lo et al. 2014). The 3T3-L1 cell line has been widely used to study insulin 
resistance in adipocytes, following an induction with Tnf, IL-6, IL-1, FFAs, high 
insulin, hypoxia, DEX, among others. It was found that different in vitro models 
capture distinct features of adipose insulin resistance. Researchers concluded 
that the combination treatment with Tnf and hypoxia caused the downregulation 
of many glucose, lipid and amino acid metabolic pathways observed in vivo, 
more than any individual treatment (Lo et al. 2014). The existence of hypoxic 
areas within adipose tissue was assessed in ob/ob obese mice and in dietary- 
induced obese mice, by immunihistochemistry, use of 02 sensors and lactate 
detection (Regazzetti et al. 2009). 
In our study, we also used the 3T3-L1 adipocytes and cultured them in hypoxia 
(1% 02) or with macrophage conditioned medium (MØ) for the induction of insulin 
resistance phenotype. We observed marked decrease in insulin stimulated-Akt 
phosphorylation in MØ-adipocytes with no change in Erk1/2 phosphorylation, and 
surprisingly a slight increase in adipocytes cultured in hypoxia. One study has 
investigated the impact of transient (2-4 h) hypoxia on differentiated 3T3-L1 
adipocytes and they found an increase in insulin-dependant and independent 
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glucose uptake and on differentiating adipocytes what caused the enhanced 
insulin sensitivity (Brown et al. 2016).  
Our findings do not agree completely with published data. In 2009 it was reported 
that hypoxia creates a state of insulin resistance in adipocytes by inhibiting 
phosphorylation of the insulin receptor tyrosine, leading to a decrease in glucose 
transport. Moreover, it was found to be dependent upon hypoxia-inducible factor 
1 and 2 (HIF) transcription factor expression (Regazzetti et al. 2009). Studies on 
hypoxic cancer cells have shown enhanced exosome secretion accompanied by 
an increase in typical protein markers associated with exosomes, CD81 and 
CD63 (L. Li et al. 2016; Rong et al. 2016). Our results indicate that the 
pathological state of hypoxia or co-culture with macrophage-conditioned medium 
inhibit the secretion of certain subpopulations of EVs or other secretory pathways 
are activated. A recent paper demonstrated the existence at least two distinct 
populations of EVs secreted by 3T3-L1 adipocytes, termed the small and the 
large EVs. They carry a very distinct protein and lipid profile (Durcin et al. 
2017a). They found that the typical proteins associated with exosomes such as 
ALIX, TSG101, and tetraspanins CD9, CD63 and CD81, were significantly less 
abundant in larger EVs, with CD9 and CD81 being barely detectable (Durcin et 
al. 2017a). This could mean that in our experimental conditions of adipocytes 
cultured in hypoxia as well as in the presence of macrophage-conditioned 
medium, we are enriching in larger EVs as opposed to exosomes, indicated by a 
decrease in expression of Cd81 protein. Interestingly, by means of proteomic 
analysis, they were able to identify proteins specifically associated to larger EVs 
such as aP2/Fabp4, AnnexinA2, and Endoplasmin, and with smaller EVs 
Adiponectin and Fas (Durcin et al. 2017b). Moreover, they saw an enhanced 
secretion of both populations induced by stimuli related to the chronic low-grade 
inflammation state of obesity such as FFAs and TNF. The difference in results is 
most probably related to modifications in experimental settings such as the 
purification of EVs, which might have profound effect on the population of EVs 
isolated.  
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Lastly, in this part we investigated the biological impact of EVs secreted by 
stressed adipocytes on the insulin sensitivity and specifically tested the 
hypothesis that these EVs could contribute to the development of the insulin 
resistance, a hallmark of adipose dysfunction seen in pathological states such as 
obesity and T2DM. We found that hypoxic-EVs negatively impact on insulin-
stimulated glucose uptake in 3T3-L1 adipocytes and our results indicate that it 
could be in part by inhibiting their Ser473 Akt phosphorylation. The uptake was 
restored upon heating up the hypoxic-EVs before treatment, with the intact EV 
structure. This could be an indication that the effect on glucose uptake is 
mediated by membrane associated proteins that are denatured by heat, or by 
heating we inhibited the actual EV upake in recipient cell and thus suppressing 
the negative effect over insulin signalling in 3T3-L1 adipocytes. In addition, 
several other molecular mechanisms could contribute to the inhibition of insulin 
signalling in recipient adipocytes such as the altered secretion of adipokines, 
which act in both autocrine and paracrine fashion. Thus, it cannot be discarded 
that adipose-EVs affect insulin signalling indirectly through an adipokine 
mediated mechanism. Moreover, a tumour suppressor protein, normally localized 
in the cytoplasm and nucleus is also a natural inhibitor of the PI3K/Akt pathway 
was described to be associated with exosomes (Putz et al. 2012). In addition, it 
was shown that PTEN was internalised by recipient cells and exerted functional 
activity over the Akt phosphorylation. We have seen that our EVs secreted by 
3T3-L1 adipocytes carry associated PTEN and interestingly more PTEN was 
secreted in hypoxic-EVs as compared to the control, with the simultaneous 
reduction in protein abundance in parental cells (data not shown). Thus, it is 
plausible that PTEN may be in an active form in our EVs and as significantly 
more is being excreted by hypoxic cells, those EVs will exert more profound 
inhibitory effects on the Akt(Ser473) phosphorylation in recipient 3T3-L1 
adipocytes. However, further studies are needed to reveal the exact mechanism 
behind the inhibition in our system. 
Most of studies, which used the macrophage-conditioned medium co-culture with 
adipocytes, focused on its antiadipogenic effect. Medium conditioned by 
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macrophages inhibits adipogenesis of murine 3T3-L1 cells and primary human 
preadipocytes in dose-dependent fashion (Constant et al. 2006) and that the 
anti-adipogenic effect was associated with inhibition of cyclin-dependant kinase 2 
activation, one of the key upstream kinases that phosphorylates retinoblastoma 
protein (Rb) binding transcription factors driving adipogenesis (Ide et al. 2011). 
Moreover, yet another study concluded that macrophage-secreted factors 
induced a major inflammatory response in human adipocytes with strong 
upregulation of inflammation-related genes, matrix metalloproteinase (MPP) 
family members. Additionally, they showed that the effect was mediated by the 
proinflammatory cytokine TNFα (O’Hara et al. 2009) 
Likely, there are other subgroups of EVs based on the mechanism of secretion 
and on their content, as it has already been shown that cellular activation can 
alter the dynamics of exosomes release by increasing the release of specific 
populations of vesicles (Willms et al. 2016). Still, a generally accepted fact is that 
three distinct populations of EVs exist such as, exosomes, microvesicles and 
apoptotic bodies. However, it has recently been identified that as thought 
homogenous population of exosomes, there are at least two distinct 
subpopulations based on the difference in densities (Willms et al. 2016). 
Interestingly, typical exosomal markers were identified in both, low (fractions 3-5) 
and high (fractions 8-9) -density exosomes such as ALIX and TSG101, but with 
significantly lower relative abundance in low-density exosomes. Both populations 
were formed through a ceramide-dependant pathway, as assessed by nSMase 
inhibition. The mean size difference is probably responsible for the difference in 
density with HD-Exo (66 nm) and LD-Exo (117 nm). Our results indicate that 
hypoxia has an influence on the secretion of EVs by 3T3-L1 adipocytes as 
observed by the expression of Cd81 marker in EVs but also in parent cells.  
It has been shown that cargo of EVs is actively sorted, as the level of a given 
molecule can be very different in EVs and in the parent cell, which indicates their 
specific physiological roles (Yáñez-Mó et al. 2015). EVs can serve to remove 
unwanted material from a parent cell such as missfolded soluble proteins, which 
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were found to be released in EVs (Bellingham et al. 2015). The first example 
being the process of maturation of the transferrin receptor (Johnstone et al. 
1991). 
Evidence are beginning to accumulate in support of the hypothesis that the 
release of EVs often serves as an alternative disposal pathway, with an active 
role of the lysosome in the secretion of EVs and sorting of their cargo. The exact 
mechanism remains unknown as to how MVBs are directed to the plasma 
membrane or to the lysosome, however, it has been shown that the inhibition of 
the lysosome increases EV secretion (Eitan et al. 2016).  
Theories that could be explored as to the differences in EV-related proteins in 
stress conditions could be the activation of an alternative disposal pathway under 
conditions of oxidative stress when endosomal machinery is overloaded. On the 
other hand, the unspecific expulsion of EVs in increased concentration, which is 
specifically modified under these stress-inducing conditions. The evidence of 
alternative usage of endosomal-lysosomal pathway came from studies of 
neurodegenerative diseases where researches have shown that causative 
agents such as self-aggregated proteins are secreted in EVs (Bellingham et al. 
2015). 
Interestingly, we found Glut4 to be associated with adipocyte-EVs, secreted by 
adipocytes not previously stimulated with insulin. Moreover, the protein 
abundance was slightly higher in EVs secreted by adipocytes cultured in hypoxia 
as well as when cultured with the macrophage conditioned medium. Glut4 is an 
insulin-regulated glucose transporter in fat and muscle cells. In the absence of 
insulin, the majority of Glut4 is stored in small (50-70 nm) intracellular vesicles, 
Glut4 storage vesicles (GSVs) as well as in larger structures derived from 
endosomes or sub-compartments of the trans-Golgi network (TGN) (Stöckli et al. 
2011). The possible existence of the separate Glut4 storage compartment was 
proposed previously (Hashiramoto & James 2000). The group has proposed that 
in the insulin-sensitive cells, there may be a unique Glut4-containing vesicular 
population derived of the endosomes which exhibit little insulin responsiveness 
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(Hashiramoto & James 2000). Our results would indicate that in the population of 
EVs isolated from conditioned medium of adipocytes, there is an enrichment of 
Glut4 containing-EVs and their secretion increases in pathological conditions. 
 
 
 
 
 
 
 
 
A. 
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Figure 20 Summary diagram of results described in chapter 1. Graphical representation 
of results regarding (A) the characterization of EVs obtained from in vitro models induced in 
3T3-L1 adipocytes and (B) the effect of hypoxic adipose-EVs on recipient 3T3-L1 
adipocytes in terms of insulin sensitivity.  
 
 
 
 
 
 
 
 
B. 
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RESULTS CHAPTER 2 
 
4. Characterization of the In Vitro model of inflammation 
in Raw264.7 macrophage-like cells and the EVs secreted 
by them. 
 
4.1 Chapter 2 Aims: 
 
• Characterize the Raw264.7 macrophage-like cells following LPS 
activation. 
• Morphological and biochemical characterization of EVs secreted by 
Raw264.7 macrophage-like cell under basal (EVs CTRL) and 
proinflammatory conditions (EVs LPS). 
• Investigate a possible influence of the macrophage-EVs on bioenergetics 
and insulin sensitivity of the 3T3-L1 adipocytes. 
 
4.2 Introduction  
 
Inflammation is a feature of many pathologies, including MetS, which is 
manifested as an infiltration of AT by macrophages that causes an enhancement 
in the secretion of proinflammatory cytokines from AT. In addition, EVs from 
adipose tissue have been shown to contribute to the development of 
inflammation and insulin resistance associated with obesity and MetS via 
interaction with healthy adipocytes and peripheral organs (Lakhter & Sims 2015).  
Our aim was to isolate EVs secreted by proinflammatory macrophages activated 
with LPS, as an in vitro model of AT-infiltrating macrophages. That could allow 
the distinction between the population of EVs secreted by affected adipocytes 
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from the population of EVs secreted by infiltrating macrophages and their 
contribution to the effect that AT-EVs produce peripherally in the context of MetS. 
The results presented in this chapter include a characterization of Raw264.7 
macrophage-like cells following the activation with LPS followed by detailed 
biochemical characterization of EVs secreted by macrophages in basal state as 
well as following LPS activation, and lastly effects of macrophage-EVs on 
mitochondrial functions and insulin sensitivity of 3T3-L1 adipocytes.  
 
 
4.3 Results 
 
4.3.1 Induction of the Proinflammatory Phenotype in Raw264.7 
Macrophages 
 
Bacterial lipopolysaccharide (LPS), the major structural component of the outer 
wall of Gram-negative bacteria (Fujihara et al. 2003) was used for the induction 
of the proinflammatory phenotype in Raw264.7 macrophage-like cells. Upon 
stimulation with LPS, macrophages secrete cytokines, including TNF, IL-6 and 
IL-1ß, among others, that activate the inflammatory responses (Rutledge et al. 
2012; Soromou et al. 2012). 
The ultimate objective was to isolate EVs from the conditioned medium of 
macrophages at a basal state as well as upon LPS activation. Therefore, when 
setting up the experimental conditions the contamination with LPS-derived EVs 
as well as secondary effects for downstream experiments had to be considered. 
Briefly, the proinflammatory phenotype in Raw264.7 cells were induced with LPS 
(100 nM) in complete DMEM for 6 h, followed by three washes with 1X D-PBS, 
and the addition of fresh, EV-depleted medium to produce EVs, for another 48-
72h.  
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First, the activation in Raw264.7 macrophage-like cells was confirmed by 
morphological analysis using Phalloidin that selectively binds to F-actin filaments 
and allows observing actin cytoskeleton remodeling. Reorganization of the actin 
cytoskeleton can be appreciated in Raw264.7 cells stimulated with LPS (Figure 
21A). On a biochemical level, the secretion of Tnf, following LPS stimulation, was 
measured by ELISA that reveals a significant increase in the concentration of Tnf 
secreted by LPS-stimulated macrophages at 6 h (Figure 21B). Although, slightly 
decreased, the levels of secreted Tnf stays elevated at 72 h, meaning that the 
pro-inflammatory phenotype is maintained even without constant LPS stimulation 
(Figure 21B). 
 
 
 
Figure 21 LPS induces proinflammatory phenotype in Raw264.7 macrophages. 6h of 
exposure to LPS induces a proinflammatory phenotype in Raw264.7 macrophages (A) 
Phalloidin immunostained Raw264.7 macrophages with and without LPS, bar=20µm (B) 
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LPS stimulated cells had increased Tnf secretion as measured by ELISA; biological 
replicates=3, technical replicates=3. (C) LPS induced Nos2 mRNA expression in Raw264.7 
macrophages; n=3; error bars=SD p values were denoted as follows: 0.01- 0.05=*, 0.01-
0.001=**, 0.001-0.0001=*** and p value< 0.0001=**** (D) Western immunoblot for Tnf 
expression in Raw264.7 macrophages at 6 and 72h. Unpaired student t-test was performed 
to determine significant differences. 
 
Similar results can be observed by WB analysis (Figure 21D). Together with the 
induction of Tnf, macrophages also secrete nitric oxide (NO) (Reis et al. 2011). 
Inducible nitric oxide synthase encoded by Nos2 gene is one of the main 
enzymes catalyzing the generation of NO (Lirk et al. 2002). We therefore 
measured the mRNA expression level of Nos2 in stimulated macrophages and 
found a 200-fold increase in expression at 6 h as compared to untreated cells 
(Figure 21C). The results indicate that the proinflammatory phenotype is 
maintained even without the constant exposure to LPS. Thus, this culture and 
activation conditions are valid for producing EVs of activated macrophages 
without being contaminating with LPS. 
 
4.3.2 Characterization of isolated EVs 
 
First, in order to justify our experimental design, we isolated EVs from the cell 
culture medium (EV depleted) containing LPS (100 nM) only, that we incubated 
for 48h at 370C in the absence of cells. The isolated EVs were analysed by Cryo-
EM (Figure 22A) and size distribution profile was established by NTA (Figure 
22B). The analysis has revealed the presence of membrane-bound vesicles of a 
mean particle size of 208nm (SD=17.0) and concentration 3.5x108/mL 
(SD=0.16). It can be observed that structurally LPS isolated EVs resemble EVs 
secreted by cells, therefore we concluded that in fact, LPS could greatly 
influence the accuracy of EVs characterization if not removed. 
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Figure 22 Vesicles isolated from EV-depleted LPS-containing medium. Analysis of 
the material isolated by using the conventional EV isolation produce from EV-depleted 
LPS-containing medium incubated in the absence of cells during 48h at 370C. Note the 
presence of vesicles resembling EVs. (A) Cryo-EM analysis, bar = 100nm, inset magnified 
2.5X. (B) Size range distribution by NTA; n=3. Error bar s= SD. 
 
 
Cryo-EM analysis of EVs isolated from Raw264.7 macrophages at basal 
conditions (EVs CTRL) and following the stimulated with LPS (EVs LPS), 
revealed the presence of a heterogeneous population of membrane-bound 
vesicles of different sizes. Representative electron micrographs are shown in 
Figure 23A. Raw264.7 macrophage-like cells were found to release a significant 
amount of EVs in both conditions. The size distribution of the distinct population 
of vesicles did not change significantly with the LPS treatment as revealed by 
NTA (Figure 23B). In the LPS treated group, there was an enrichment in larger 
vesicles as judged by the tiny shift of the curve towards the right. Moreover, a 5% 
decrease was observed in concentration size of the sub-population between 50-
100 nm (Figure 23B).  
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However, considering the total concentration of particles there was a significant 
decrease in the amount secreted by LPS-treated cells (Figure 23C) with no 
change in mean particle size (Figure 23D). WB was performed to compare the 
abundance of some well-known EV markers as well as cell specific proteins 
selectively packaged in EVs and excreted into the extracellular space. Figure 
23E shows results from two independent preparations of EVs isolated from LPS 
stimulated Raw264.7 macrophages with their corresponding untreated controls. 
We found that potent proinflammatory cytokine, Tnf was shuttled out in EVs 
secreted by LPS-activated macrophages. In terms of specific EV-related 
markers, the endosomal machinery specific, Aip1/Alix and Tsg101 was barely 
detectable in EVs LPS as opposed to EVs CTRL. In cells, on the other hand, 
Aip1/Alix was equally abundant in both conditions as well as the tetraspanin 
Cd63. The decrease in Tsg101 expression in proimflammatory macrophages, 
with respect to the control macrophages, was mirrored in their corresponding 
EVs. Along the same line, expression of the adapter protein Syntenin1, which 
forms a complex with Syntaxin and Alix, necessary for exosome secretion, was 
abundant in EVs CTRL and has not been detected in EVs isolated from LPS-
treated cells (Figure 23E). 
On the contrary, macrophage-EVs were found to be rich in lysosomal 
glycoprotein, LimpII, which is naturally located in both, late endosomes (often 
restricted to the limiting membranes) and lysosomes. The expression profile of 
the LimpII protein in cells (Figure 23E) indicates that the proinflammatory 
macrophages contain slightly more LimpII, which is not reflected in their 
secreted-EVs, as EVs LPS contain reduced LimpII protein. In the support of this 
result, the expression of another late endosome and lysosomal marker, Lamp1 
protein was also significantly decreased in EVs LPS. Moreover, cellular 
abundance of one of the major cytosolic chaperons, Hsp70 was variable in 
cellular lysates, whereas in their corresponding EVs there was a clear reduction 
in EVs LPS. In addition, Hsp70 associated to EVs LPS, was post-translationally 
modified, as seen by the appearance of the double band (Figure 23E).  
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Figure 23 Characterization of EVs released by proinflammatory Raw264.7 
macrophages. Ultrastructural and biochemical characterization of EVs isolated from 
conditioned medium of Raw264.7 macrophages at a basal state and following the exposure 
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to LPS. (A) Cryo-EM analysis, bar=100nm, inserts magnified 2.5X (B) Size range 
distribution. (C) Particle concentration (1010). (D) Particle mean size; n=3. (E) Protein 
extracts from two independent preparations of EVs (5 µg) together with their corresponding 
cell lysate (10 µg) were analyzed by WB, with antibodies for EV as well as cellular markers; 
n=4; representative figure. Unpaired student t-test was performed to determine significant 
differences. Error bars = SD. 
 
Furthermore, EVs LPS exhibit reduction in amount of Flotillin1 protein. Flotillin1 
appears at a different molecular weight as compared to their corresponding 
cellular lysates, as it was the case of the Aip1, Cd63 and Tsg101 proteins. Lastly, 
immunoblotting of mitochondrial and ER proteins, CoxIV and Grp78 respectively 
was performed for quality control. As can be observed, both, CoxIV and Grp78 
were readily detectable in the whole cell lysates and were completely absent in 
the EV samples indicating that the EV preparations were not contaminated with 
cellular compartments.  
Moreover, the mitochondrial functions in proinflammatory macrophage cells 
could have been affected, as seen by decreased expression of CoxIV. 
Additionally, ER was affected by LPS polarization, reflected in the decrease in 
Grp78 expression in proinflammatory macrophages. Our results indicate that 
under our conditions, activated, proinflammatory macrophages release not only 
significantly fewer vesicles when compared to the control, but also with the 
abundance of protein markers specific to EVs being significantly affected.  
Once having done the characterization of the macrophage derived-EVs, we 
progressed to the subsequent aim, which was to shed a light onto a possible 
effect of these EVs on the 3T3-L1 adipocytes. For that purpose, we isolated and 
characterized the protein content of another set of macrophages derived-EVs 
(Figure 24). The association of Tnf protein was confirmed in EVs LPS. 
Moreover, a significant decrease in markers of exosome biogenesis such as 
Tsg101 and Syntenin1 was confirmed in EVs LPS. Interestingly, we found a 
member of a family of small GTPases, Rab8, one of the key regulators of 
membrane trafficking, to be highly associated to macrophage-EVs. Interestingly, 
the abundance of Rab8 in LPS-activated Raw264.7 macrophages was reduced. 
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On the contrary, no difference in EVs was found in the abundance of Rab8 
protein when comparing both groups. Finally, the lack of organelle contamination 
can be deduced from the association of Grp78 solely to macrophage lysates and 
not to their secreted-EVs. 
 
 
 
 
 
 
 
 
 
 
 
Figure 24 Raw264.7 macrophage-like cells activated with LPS secrete EVs with the 
proinflammatory phenotype. Protein extracts from two independent preparation of EVs 
(5 µg) together with their corresponding cell lysates (5 µg) were analyzed by WB, with 
antibodies for EV as well as cellular markers; n=2. 
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4.3.3 The effect of the macrophage-secreted EVs on mitochondrial and 
glycolytic function of the 3T3-L1 adipocytes 
 
The inflammatory effect of macrophage-secreted EVs on adipose tissue has 
already been shown (Zhang et al. 2015). The reciprocal relationship of adipose-
tissue EVs on the activation of blood monocytes has also been reported (Deng et 
al. 2009). However, we sought to find out whether EVs LPS had any effect on the 
bioenergetics of the 3T3-L1 adipocytes. A Seahorse FX analyzer was employed 
to analyze the mitochondrial and glycolysis function on 3T3-L1 adipocytes upon 
exposure to EVs LPS (Section.2.2.3.3). For that, cells were treated with 10 µg of 
EVs per well, in EV-depleted medium, for 24 h. The general scheme of 
mitochondrial stress test is shown in Figure 25A. For this experiment, 3T3-L1 
fibroblast cells were differentiated into mature adipocytes on Seahorse V7 
microplates and were treated on the day 13 of the differentiation. As previously 
mentioned, during the experiment, serial injection of oligomycin, FCCP and 
rotenone allow establishing the profile of mitochondrial function of assayed cells. 
For the mitochondrial stress test, various parameters were measured such as 
non-mitochondrial respiration, proton leak, basal respiration, ATP production, 
maximal respiration and spare capacity in receiving adipocytes (Figure 25B-
25G).  
Our results indicate that upon exposure to macrophage-secreted EVs, at the 
basal level there was no difference in mitochondrial respiration between the 
treated cells and the control group (Figure 25C). A slight increase in non-
mitochondrial respiration was observed in adipocytes treated with macrophage-
derived EVs (Figure 25B). Moreover, a significant reduction was seen in ATP 
production, maximal respiration and spare capacity in cells treated with EVs LPS 
(Figure 25E-25G). This difference was specific to the subset of EVs secreted by 
proinflammatory macrophages, as the EVs CTRL did not have any effect on 
mitochondrial functions of the 3T3-L1 adipocytes.These results could indicate 
that the limited OXPHOS capacity reported in white adipocytes of the high fat 
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diet murine obesity models (Schöttl et al. 2015), might be mediated via pro-
inflammatory EVs.  
In terms of glycolysis, a figure representative of three independent experiments 
and normalized to the untreated sample is shown in Figure 25H. Individual 
parameters, non-glycolytic acidification, glycolysis, glycolytic capacity and 
glycolytic reserve are plotted. Slight increasing trend can be seen in glycolysis 
and glycolytic capacity in adipocytes treated with EVs secreted by the pro-
inflammatory adipocytes. No changes were observed in other glycolytic 
parameters (Figure 25H). Our results indicate that adipocytes exposed to EVs 
LPS reduce the capacity to maximal respiratory response, additionally reflected 
in the decrease in spare capacity. Moreover, it could be that due to slightly 
increased proton leak, there is a significant decrease in ATP production of the 
cell exposed to EVs LPS, possibly due to uncoupling of the membrane gradient 
potential.  
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Figure 25 Bioenergetic changes in 3T3-L1 adipocytes treated with Raw264.7 
macrophage-derived EVs. A Seahorse XF analyzer was used to measure mitochondrial 
and glycolytic functions in 3T3-L1 adipocytes treated with 10 µg of EVs CTRL and EVs 
LPS (A) A representative figure of the mitochondrial stress test with the experimental 
groups indicated on the graph by arrows. Individual parameters of the mitochondrial 
functions such as (B) non-mitochondrial respiration (C) basal respiration (D) proton leak 
(E) ATP production (F) maximal respiration (G) spare capacity, were plotted; biological 
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replicates=3, technical replicates=9 (H) Parameters of glycolysis function; biological 
replicates= 3; technical replicates=18 (per experimental group); error bars=SD p values were 
denoted as follows: 0.01- 0.05=*, 0.01-0.001=**, 0.001-0.0001=*** and p value< 
0.0001=****. Unpaired student t-test was performed to determine significant differences. 
 
 
4.3.4 Investigating the insulin sensitivity in 3T3-L1 adipocytes upon 
exposure to proinflammatory-EVs 
 
Disturbance in insulin signalling is a hallmark of MetS and diabetes. The 
involvement of adipose tissue macrophages (ATMs) in altering adipocyte 
function, including firing inflammatory responses and decreasing insulin 
sensitivity has long been described as a factor sufficient for the development of 
adipose tissue inflammation. Recently, however, the notion that EVs could 
mediate the phenotypic tranfer is being explored. It has been shown that 
treatment with M1 macrophage-derived EVs significantly reduce insulin-
stimulated Akt phosphorylation in human primary mature adipocytes and in 3T3-
L1 adipocytes as compared to the M2 macrophages. This result was coupled 
with decreased GLUT4 translocation (Zhang et al. 2015).  
To study insulin sensitivity in 3T3-L1 adipocytes upon exposure to macrophage-
derived EVs two experimental groups were created: acute and chronic. In the 
acute group, cells were treated with 10 µg of EVs for 24 h and the chronic group 
that was expose to three doses of 10 µg separating each dose by 24 h. Following 
the treatment, adipocytes were stimulated with insulin (100 nM) and directly 
lysed. Figure 26A and Figure 26D show representative WB figures of acutely 
and chronically treated cells, respectively. We showed the phosphorylation of 
Akt(Ser473) and Erk1/2, with and without insulin stimulation. The percentage of 
phosphorylated Ser473 on Akt was quantified with relation to the total protein 
present, in basal and insulin-treated cells (Figure 26B). Then, the fold increase 
157 
 
following the insulin treatment was plotted (Figure 26C). The same was done for 
Erk1/2 phosphorylation in chronic group (Figure 26G and Figure 26H). 
Our results show that 3T3-L1 adipocytes, following acute exposure to EVs CTRL, 
exhibit an increase in Akt(Ser473) phosphorylation when compared to untreated 
cells (Figure 26B). Moreover, EVs LPS did not cause the same effect, they only 
induce a very slight increase in the percentage of Akt(Ser473) phosphorylation 
with the decrease in the basal level of phosphorylation. The increase in the 
percentage of the Akt(Ser473) phosphorylation was maintained when EVs were 
administered chronically (Figure 26E). A small decrease in Akt phosphorylation 
after insulin was seen in adipocytes treated with both EVs CTRL and EVs LPS 
when compared to untreated (Figure 26F).  
Currently, research is being conducted on targeting the ERK signalling pathway 
as a potential treatment for insulin resistance, as it has been implicated in the 
development of IR associated with obesity and type 2 diabetes mellitus. Erk1/2 
activity increases during the development of 3T3-L1 adipocyte hypertrophy and 
is elevated in adipose tissue of leptin receptor-deficient (db/db) mice. We 
therefore investigated whether Erk1/2 phosphorylation in 3T3-L1 adipocytes was 
affected by chronic exposure to the proinflammatory EVs. Quantification of WB 
bands indicates the increase in basal Erk1/2 phosphorylation in EV-treated 
adipocytes (Figure 26G). After stimulation with insulin, Erk1/2 activity was seen 
and was higher in treated cells (Figure 26H). Furthermore, when analyzing the 
fold change in Erk1/2 phosphorylation after insulin, there is a decline in Erk1/2 
phosphorylation in EVs from LPS-treated adipocytes. 
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Figure 26 Insulin Sensitivity Studies in 3T3-L1 Adipocytes Upon Exposure to 
Raw264.7 macrophage-derived EVs (A) Representative WB for of 3T3-L1 adipocytes 
acutely exposed to macrophage-EVs (30 µg) for 24 h (B) Quantification of the Akt(Ser473) 
phosphorylation (%). (C) Fold increase in Akt(Ser473) phosphorylation upon insulin 
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stimulation. (D) Representative WB figure of 3T3-L1 adipocytes chronically exposed to 
macrophage EVs (10µgx3) 24h each dose; UNT n=1, EVs CTRL n=2, EVs LPS n=3. (E) 
Quantification of the Akt(Ser473) phosphorylation (%). (F) Fold increase in Akt(Ser473) 
phosphorylation upon insulin stimulation. (G) Quantification of the Erk1/2 
phosphorylation (%). (H) Fold increase in Erk1/2 phosphorylation upon insulin 
stimulation; n=3. ImageJ was used for densitometry. Error bars = SD. 
 
 
To summarize, EVs secreted by macrophages, both at basal and following LPS 
stimulation caused changes in Akt(Ser473) and Erk1/2 phosphorylation in 3T3-
L1 adipocytes. It seems that acute exposure to EVs cause increase in Akt 
phosphorylation (higher effect is caused by CTRL-EVs). Moreover, following a 
chronic exposure to EVs, insulin stimulated Akt phosphorylation was decreased 
in 3T3-L1 adipocytes by both, CTRL and LPS-EVs. Moreover, CTRL-EVs caused 
marked decrease in insulin-stimulated Erk1/2 phosphorylation. 
 
 
4.4 Summary 
 
We conclude that Raw264.7 macrophage-like cells stimulated with LPS are a 
viable model to study cellular inflammation, as seen by the secretion of the Tnf 
and the expression of Nos2. Moreover, our protocol is appropriate for the 
subsequent isolation of EVs from the conditioned medium of macrophages, with 
minimal contamination of cellular organelles and LPS. 
The overall concentration of EVs secreted by activated Raw264.7 macrophages 
is significantly reduced. In addition, Raw264.7 macrophage-like cells at a basal 
state and previously activated with LPS, secrete a very distinct population of 
EVs, as seen by the abundance of EV-related proteins. All of them, including 
Aip1/Alia and Syntenin1, related with exosome biogenesis, as well as lysosomal 
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protein LimpII, are significantly downregulated in EVs LPS. Hsp70 protein was 
found to be post-translationally modified in EVs LPS as compared to EVs CTRL.  
Interestingly, macrophages previously activated with LPS, were found to have 
markers of mitochondrial and ER decreased.  
In terms of the functional effects mediated by macrophage derived-EVs, we 
observed that they cause a significant reduction in mitochondrial functions as 
well as modification of insulin sensitivity in 3T3-L1 adipocytes.  
Finally, we identified the presence of the proinflammatory, Tnf protein, in EVs 
LPS, which was absent in EVs CTRL. The association of the potent mediator of 
pro-inflammatory responses could be a possible mediator of the effects observed 
in 3T3-L1 adipocytes Graphically represented in Figure 27. 
 
 
4.5 Discussion 
 
Raw264.7 cell line has been widely used in the study of macrophage cellular 
physiology due to its resemblance to primary macrophages (Maurya et al. 2013). 
Considering that FFAs are elevated in obesity and activate macrophages via 
Toll-like receptor-4 (TLR4), in our model we used LPS, the TLR4 ligand to obtain 
M1, proinflammatory phenotype in Raw264.7 macrophages.  
Macrophage derived-exosomes were previously described in the context of the 
complex regional pain syndrome (CRPS) (McDonald et al. 2014). Mouse 
macrophage cells stimulated with LPS secreted EVs that contained elevated 
levels of cytokines and miRNAs, and were able to mediate inflammation by 
activating the NF-κB pathway in naïve macrophages. Furthermore, their results 
suggested that activated macrophages secrete exosomes that are primed to 
signal an immune response to recipient cells (McDonald et al. 2014). Another 
study using EVs secreted by THP-1 as an in vitro polarized M1 proinflammatory 
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macrophages, show reduced abundance of the exosomal marker TSG101, as 
compared to their M2 counterpart (Zhang et al. 2015), which is in agreement with 
our results, that exosomal markers are all markedly decreased in EVs LPS.  
We isolated and characterized EVs from the conditioned medium of the 
Raw264.7 cells at basal, naive state and activated with LPS. A difference with 
most of the published work, in our study, LPS was removed after 6 h to avoid 
contamination during the production of EVs, thus, reducing the carryover of LPS-
derived particles in our EV preparations. In these conditions, we observed a 
significant decrease in the concentration of EVs secreted by the proinflammatory 
cells in the 48 h production time, which goes against the generally accepted 
notion that LPS exposure enhances the secretion of EVs (Kalra et al. 2016). Our 
unexpected results as to the concentration of EVs secreted by proinflammatory 
macrophages, could be an indication that stressed cells release higher 
concentration of EVs in an initial response to cellular stress such as LPS the 
population of EVs we are removing. The initial phase may follow by a decline in 
secretion of EVs by stressed cells, on a contrary to a cell at a basal state, which 
might be releasing EVs at steady constant rate. The contamination with particles 
from other sources are especially important to consider when EVs are used for 
downstream experiments, as they may carry active components, other than EVs. 
This hypothesis is supported by evidence, as we isolated particles, overlapping 
in size with EVs, as estimated by NTA, from the medium containing LPS only 
that has not been incubated with the cells (Figure 22). 
In addition to the significant decrease in the overall concentration of EVs 
secreted by proinflammatory macrophages, the abundance of protein markers 
related with EVs were also markedly decreased. To explain our findings, we 
hypothesize that either we are dealing with an enrichment in completely distinct 
population of EVs or in part, the subset of EVs carrying these markers was 
removed together with LPS after the 6 h, with low level of replenishment in the 
next 48 h. Another possible explanation is that the endosomal pathway may be 
inhibited or affected in these cells. Additionally, the mechanisms that control 
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exosome composition and content are not very well understood yet (Villarroya-
Beltri et al. 2016). Lastly, it cannot be discarded that because of cellular stress, 
the cell uses EVs to discards the unwanted or damaged cellular components.  
Interesting finding regards the possible post-translational modifications of 
proteins associated to EVs secreted by Raw264.7 macrophage-like cells, 
regardless the condition. We observed that some proteins, associated to EVs, 
such as Tsg101, Cd63, Aip1/Alix, and Flotillin1 seem to be modified in EVs 
secreted by macrophages. Aip1, Cd63, Tsg101, and Hsp70 proteins are of a 
higher molecular weight as compared to their corresponding cellular lysates from 
their parent cells. Flotillin1 on the other hand was found to be of a lower 
molecular weight and additionally as a single band as opposed to a double band 
in cell lysate controls. Interestingly, the modification of the Hsp70 protein was 
found to be solely associated to EVs LPS, which may be triggered by the 
conditions of cellular stress.  
A protein can undergo many posttranslational modifications (PTMs), changing its 
properties and broadening its capacity to adapt to cellular needs. Specific pattern 
of PTMs is seen in EVs (Moreno-Gonzalo et al. 2014) which are involved in the 
sorting of specific proteins into exosomes (Villarroya-Beltri et al. 2016). Several 
examples have already been described such as the CD63 was previously 
described to be post-translationally modified by poly N-acetyl lactosamine 
addition during dendritic cell maduration (Engering et al. 2003). Interesting, the 
HSP70 was found to be sorted into exosomes independently of its ubiquitination, 
meaning that the knockdown of the deubiquitin domain increases the 
enrichement of both, modified and non-modified HSP70 in EVs (Moreno-Gonzalo 
et al. 2014). It could be that depending on a state that the cell, distinct subset of 
the Hsp70 protein is being selectively secreted, as we observe in our 
macrophage derived-EVs.  
The markers of ER (Grp78) and mitochondria (CoxIV) were markedly decreased 
in our M1 macrophages. ER stress is often associated with inflammation, it 
modulates inflammatory responses during chemical stress or microbial infection 
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(Bronner et al. 2015). They have discovered that ER stress factors mediate the 
activation of mitochondrial damage pathway, which in turn activate the 
inflammasome and IL-1ß production (Bronner et al. 2015). Subsequently, 
mitochondrial ROS leads to lysosomal membrane permeabilization (Heid et al. 
2013). Under these conditions the cell might be switching to the survival mode, 
which may have a profound influence on the secretion of EVs as well as on their 
content. EVs released by inflamed macrophages have been proposed to 
represent a class of inflammatory factors involved in inflammatory processes 
associated with metabolic diseases by their ability to upregulate proinflammatory 
mediators such as NFkB. 
One of the first, most striking findings on EVs biology, was the fact that they 
harbour molecules involved in the function of the cell from which they are 
derived. In our study, we found the Tnf protein, potent proinflammatory mediator, 
to be associated with EVs isolated from the conditioned medium of LPS 
activated, M1 Raw264.7 macrophages. TNF naturally occurs in two forms: a 26-
kDa type II membrane protein (mTNF) and a soluble form (sTNF) that is derived 
from the membrane form by proteolytic cleavage (Zhang et al. 2006). The 
association of the membrane form of TNF with EVs secreted by immune cells, 
such as DCs has been demonstrated (Zhang et al. 2006; Munich et al. 2012; 
Gao et al. 2016). Employing protein array and ELISA and using intact as well as 
lysed EVs, it was demonstrated, that the TNF was associated to the membrane 
of EVs as opposed to being carried in their lumen. In addition to that, they were 
shown to contribute to the inflammation of endothelial cells, through an activation 
of the NF-κB pathway in a manner similar to that of LPS, and induce 
atherosclerotic lesions in vivo (Gao et al. 2016). Furthermore, another study has 
revealed that DC-EVs activated natural killer cells and mediated apoptosis in 
tumour cells, via associated TNF superfamily ligands, such as TNF, FasL and 
TRAIL (Munich et al. 2012).  
In the context of obesity accompanying MetS, expanding adipose tissue and the 
infiltration of macrophages, generate inflammatory responses in adipose tissue. 
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Underlying insulin resistance has lead to many studies on the 
adipocyte/macrophage axis and the involvement of EVs as mediators and 
possible causative agent for the development of MetS associated metabolic 
perturbations. Mitochondrial dysfunction, which has been implicated in the 
development of insulin resistance, seen as a decrease in the mitochondrial 
OXPHOS (Montgomery & Turner 2014).  
Having that in mind, we have investigated the possible role of EVs LPS on 
bioenergetics of the 3T3-L1 adipocytes. We observed a significant reduction in 
mitochondrial functions, as measured using Seahorse XF extracellular flux 
analyzer. Mitochondrial dysfunction can result from a number of factors such as 
decrease in mitochondrial biogenesis, reduced mitochondrial protein content and 
the oxidative activity of the ETC (Montgomery & Turner 2014). The Tnf, 
associated to the membrane of EVs LPS, could be a possible mediator, however 
additional experiments would have to be performed to reveal the exact 
mechanism involved in producing these effects.  
On the other hand, we also were interested to study the influence of EVs LPS, 
secreted by proinflammatory Raw264.7 macrophages, on insulin sensitivity in 
3T3-L1 adipocytes. 
One study has examined the effect of M1 THP-1 macrophages on insulin 
sensitivity in adipocytes by measuring the phosphorylation of the Akt kinase 
(Zhang et al. 2015). Treatment of primary adipocytes with 100 µg of M1 THP-1 
derived-EVs caused a significant reduction in the abundance of phosphorylated 
Akt protein and decreased translocation of Glut4, effectively reduce glucose 
uptake activity and enhanced activation of the NF-kB. In contrast, the anti-
inflammatory M2-derived EVs significantly increased the insulin sensitivity in 
adipocytes and mibilize Glut4 protein toward at the plasma membrane (Zhang et 
al. 2015). In our experiments we treated the 3T3-L1 adipocytes with one dose of 
10 µg of macrophage derived-EVs, at a basal as well as the pro-inflammatory 
state. In agreement with previous results, but with 10-times less EVs 
concentration they caused increased phosphorylation of Akt and Erk1/2 protein. 
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The pro-inflammatory EVs were not able to cause the same effect over the 
insulin stimulated Akt phosphorylation with only a slight decrease in basal Akt 
phosphorylation upon exposure with Raw-EVs. These differences could be an 
indication that a higher dose of EVs would have to be needed to produce similar 
results. Three consecutive doses of macrophage-EVs (10 µg/each for 24h), the 
Akt phosphorylation was slightly reduced as seen in Akt protein abundance. It is 
important to consider that the induction of insulin resistance is not an instant 
process, therefore additional experiments would be needed to establish the dose 
curve response.  
Interestingly, it has been demonstrated that macrophage-secreted factors block 
the insulin action in adipocytes via downregulation of Glut4 and IRS-1, leading to 
a decrease in Akt phosphorylation and impaired insulin-stimulated Glut4 
translocation to the plasma membrane (Lumeng, Deyoung, et al. 2007). It was 
discovered by culturing adipocytes with conditioned medium of activated M1 
macrophages, as well as co-culture of both cell types. Moreover, TNF-
neutralizing antibodies partially reversed the insulin resistance produced by 
macrophage-conditioned media. This is another supporting evidence for the 
involvement of TNF in the development of insulin resistance in context of MetS, 
that may be mediated in association with M1 macrophage-EVs.  
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Figure 27 Summary diagram of results described in chapter 2. Graphical representation 
of results regarding (A) the characterization og EVs obtained from LPS induced Raw264.7 
cells and (B) their effect on mitochondrial respiration of the 3T3-L1 adipocytes. 
 
A. 
B. 
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RESULTS CHAPTER 3 
 
5. Characterization of the in vitro models of 
hepatocellular steatosis and their secreted-EVs 
 
Chapter 3 Aims: 
 
• Establish and characterize the in vitro models of hepatocellular steatosis 
in hepatic cell lines.  
• Characterize the genetic model of steatotic Zucker rat hepatocytes in a 
primary in vitro culture.  
• Characterize EVs secreted by models of hepatocellular steatosis  
• Comprehensive characterization of EVs secreted by the primary Zucker 
rat hepatocytes, in terms of morphology, concentration, protein, lipid and 
nucleic acid content.  
 
5.2 Introduction  
 
The liver is a complex environment comprised of several different cell types 
(Imani Fooladi & Hosseini 2014) (Figure 28). Hepatocytes and cholangiocytes, 
both types of liver epithelia, natural killer T cells, hepatic stellate cells, adult liver 
stem cell, and hepatic sinusoidal endothelial cells, were all shown not only to 
release EVs but also be the direct target of EVs (Masyuk et al. 2013; Conde-
Vancells et al. 2008; Witek et al. 2009; Fonsato et al. 2012; Royo & Falcon-Perez 
2012).  
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Figure 28 Cells of the liver. Healthy liver lobules are formed from hepatocytes on a loose 
basal membrane (space of Disse) surrounding sinusoid. The space of Disse is alsowhere 
quiescent hepatic stellate cells are found, while Kupffer cells can be found in the hepatic 
sinusoid.  
 
 
In addition, EVs have been implicated in a spectrum of liver diseases such as 
NAFDL, NASH, cirrhosis, fibrosis, and HCC (Shen et al. 2016; Borges et al. 
2013; Guo & Guo 2015; Ban et al. 2016). The level of circulating vesicles has 
been shown to be increased in liver disease, particularly associated with the 
alcohol consumption (Momen-Heravi et al. 2015), viral infection and features of 
MetS including diabetes, obesity, and dyslipidemia, as a result of increased 
secretion and/or decreased clearance of EVs. Moreover, EVs released by injured 
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hepatocytes include certain antigens, specific hepatic enzymes, miRNAs, and 
mRNAs (Imani Fooladi & Hosseini 2014).  
Simple steatosis, known as the fatty liver is a common, and reversible condition 
when employing behavioural changes. However, little attention has been 
attributed to EVs secreted by hepatocytes in conditions of simple steatosis. 
In our study, we used two different models of hepatic steatosis to isolate and 
characterize EVs from their conditioned medium. On one hand, we used three 
different hepatic cell lines and induced hepatocellular steatosis with the mix of 
FFAs, oleic and palmitic (2:1, 1 mM for 24 h). Then, we isolated hepatocytes 
from Zucker lean and fatty livers, as a genetic model of obesity induced liver 
steatosis.  
In this part of the thesis, in vitro models were characterized in terms of lipid 
accumulation profile and in the case of primary rat hepatocytes, their 
bioenergetic profile, the expression of markers related to hepatic functions and 
insulin sensitivity. Subsequently, we performed the comprehensive 
characterization of their secreted EVs in terms of morphology, overall 
concentration, specific cargo and association of active compounds.  
 
 
5.3 Results 
 
5.3.1 Induction of steatosis in hepatic cell lines 
 
As already mentioned, we used three different hepatic cell lines for the induction 
of hepatocellular steatosis. The AML12 cell line was created in 1994 as a 
differentiated, nontransformed hepatic cell line derived from mice transgenic for 
transforming growth factor α (TGFα) (Wu et al. 1994), the human HepG2 cells, 
derived from differentiated hepatocellular carcinoma of the liver tissue of a 
fifteen-year-old Caucasian American male (Costantini et al. 2013) and MLP29 a 
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liver progenitor cell line. All three cell lines were widely used in a variety of in 
vitro studies (Conde-Vancells et al. 2008; Cui et al. 2010; Kohli et al. 2007).  
We tested different conditions of steatosis induction, to achieve a fat 
accumulation profile with a minimal cytotoxic and apoptotic effect. In our work 
and as previous studies have revealed, individual fatty acids have a distinct toxic 
potential (Gómez-Lechón et al. 2007) with saturated, palmitic acid being the most 
toxic one. Having that in mind, several concentrations of the oleic and palmitic 
acid were tested ranging from 0.1 to 1 mM (data not shown). However, the most 
effective approach, with optimal cytosolic fat accumulation and minimal toxicity, 
as measured by AnnexinV/PI assay, resulted to be the combination of both 
FFAs. After testing the different combination of concentrations, a 2:1 ratio of oleic 
to palmitic acid at a final concentration of 1 mM (BSA-conjugated) was selected 
for further experiments.  
AML12, MLP29 and HepG2 cell viability, following 24 h treatment with the FFA 
mixture was determined with AnnexinV-FITC/PI assay. Representative FACS 
plots, for the three tested cell lines, are shown in Figure 29A-29C. A slight 
displacement of the treated population can be seen with respect to the untreated 
control. AML12 cells seem to be more sensitive exhibiting overall lower viability 
(>75%), as compared to the MLP29 (<80%) and HepG2 cells (>80%). However, 
considering that the same drop in viable cell count can be seen in the control 
sample, it could be the result of the handling and the assay sensitivity. 
Importantly, in all three experimental groups, the treatment did not seem to 
significantly affect cell viability as compared to their respective controls (Figure 
29). 
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Figure 29 Treatment with FFAs does not affect viability of hepatocyte-like cells. Flow 
cytometry analysis of AnnexinV-FITC/Propidium iodide staining in (A) AML12 (B) 
MLP29 and (C) HepG2 hepatocyte-like cells, following the treatment with FFA mix 
(OA/PA; 2:1; 1 mM). Graphs represent: (D) viable cells, (E) cells entering in early 
apoptosis and (F) late apoptotic cells, for all three cell lines; n=1. 
 
5.3.1.1 AML12  
 
FFA (OA/PA; 2:1;1 mM;24 h) challenged AML12 cells were stained with Bodipy 
(10 μg/ml) for the estimation of fat accumulation. Upon exposure to OA/PA 
mixture, AML12 cells accumulated large number of fat droplets, when compared 
to untreated control (Figure 30A). This result was confirmed and quantified by 
flow cytometry. Representative histogram is shown on Figure 30B with the 
quantification of the fluorescent signal (Figure 30C). 
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Figure 30 Treatment with FFAs causes triglyceride accumulation in AML12 
hepatocyte-like cells. Steatosis was induced in AML12 hepatic cell line with FFA mixture: 
OA/PA, at 2:1 ratio, final concentration at 1 mM for 24 h. (A) Representative images of 
Bodipy staining showing accumulation of lipids in AML12 cells. Following the treatment, 
cells were fixed with 2% paraformaldehyde and stained. Lipid content was additionally 
quantified by flow cytometry. (B) Flow cytometry histogram of control and steatotic 
population of cells stained with Bopdipy. (C) FITC-A median fluorescent intensity 
quantification of Bodipy (30,000 events/P1); bar = 20 µm; n=1. 
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5.3.1.1.1 Characterization of EVs secreted by steatotic AML12 cells 
 
We characterized AML12-EVs, following the same schema as in previous 
sections. Evaluation of the purity of EV preparations as well as their initial 
structural characterization was done using cryo-EM without fixation or staining. In 
the case of AML12 hepatocyte secreted EVs, control as well as steatotic, cryo-
EM demonstrated the presence of membrane-enclosed vesicles of different sizes 
(Figure 31A). The majority however, fell into the exosomal size range, around 
100 nm. Among them smaller electron dense round structures could be 
identified. Larger vesicles were also present, as well as fusions of two or more 
vesicles (Figure 31A, right panel, 2.5X).  
NTA was carried out to measure the range size distribution of particles (Figure 
31B) and their concentration (Figure 31C) in the AML12-derived EV samples. 
The results show two peaks that represent the largest size groups in terms of the 
amount of EVs, at 100-150 nm and at 150-200 nm in both samples, constituting 
25 and 28% for the control and steatotic within 100-150 nm size range 
respectively and 27 and 29% in 150-200 nm range. 80% of the whole population 
is confined to 50-250 nm. Moreover, there was a slight increase in the overall 
concentration of vesicles released from AML12 cells (Figure 31C). No change 
was observed in terms of mean size distribution between the samples (Figure 
31D). 
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Figure 31 Characterization of EVs secreted by steatotic AML12 hepatocyte-like cells. 
Ultrastructural and biochemical characterization of EVs isolated from conditioned medium 
of steatotic AML12 cells. (A) Cryo-EM analysis; bar=100 nm, inserts are magnified 2.5X. 
(B) Size range distribution. (C) Particle concentration (1010). (D) Particle mean size; 
parameters measured by NTA; n=4 (E) Protein extracts from two independent preparations 
of EVs (5 µg) together with their corresponding cell lysates (10 µg) were analyzed by WB 
with antibodies for EV specific as well as cellular markers. Error bars =SD 
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AML12-derived EVs were shown to be highly enriched in markers such as 
membrane tetraspanin Cd81, endocytic marker proteins such as Aip1/Alix, and 
Tsg101 as compared to the cellular extracts of their parent cells. Interestingly, 
their expression was notably decreased in steatotic EVs. Flotillin1 was detected 
in both cells and EVs. However, there was no enrichment of this marker in EVs. 
Flotillin1 expression seems to be post-translationally regulated at the level of EVs 
as in cells it is expressed as a double band, with the upper band being more 
pronounced compared to the single band in EVs. Moreover, glycoprotein, LimpII 
was found to be abundant in AML12 cells. Comparing the control cells of 
steatotic hepatocytes, there is an enhancement in LimpII expression in steatotic 
hepatocytes with the expression mirrored in EVs. Similar expression pattern was 
observed for the Ras-related protein, Rab8. Hsp70 is a chaperon protein 
involved in maintaining cellular protein homeostasis and cell survival in response 
to stressful cellular conditions (Lancaster & Febbraio 2005). Exosomes were 
shown to contribute to the release of Hsp70 in both basal and stress induced 
conditions (Lancaster & Febbraio 2005). AML12 cells secreted Hsp70 into the 
extracellular environment in association with EVs. However, the amount secreted 
in EVs did not correlate with that remaining in cells. Its level of expression remain 
unchanged in the parent cell regardless the condition, however, there was a 
clear decrease in Hsp70 shuttled in steatotic EVs as compared to the control 
ones. In addition, to discard the presence of contamination from cellular 
compartments in our preparations, the expression of protein markers of 
endoplasmic reticulum (Grp78) and mitochondria (CoxIV and Prohibitin), was 
assessed. They were readily detectable in whole cellular lysates and absent in 
our EV preparations, ruling out possible contamination by these intracellular 
organelles. Importantly, expression of the apoptosis related protein Parp, 
although detected in all samples there was no significant difference between 
them. Together, the lack of intracellular organelles in EVs and the lack of the 
alteration in the cellular Parp pattern indicate that under our culture conditions 
there was not cell death induction by the FFA treatment. 
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Overall, the AML12 cells with fat accumulation phenotype secreted increased 
number of vesicles when compared to the control cells. Moreover, the expression 
of exosomal markers was markedly decreased in these EVs.  
5.3.1.2 MLP29 
 
Lipid accumulation was evaluated in MLP29 cells treated with FFAs mixture for 
the induction of hepatocellular steatosis, using the same scheme as for the 
AML12 cells. Bodipy staining confirmed lipid accumulation in the MLP29 cells 
(Figure 32A). Moreover, the signal of Bodipy, lipid staining was quantified by 
flow cytometry (Figure 32B and Figure 32C). 
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Figure 32 Treatment with FFAs causes triglyceride accumulation in MLP29 
hepatocyte-like cells. Steatosis was induced in MLP29 hepatic cell line with FFA mixture: 
OA/PA, at 2:1 ratio, final concentration at 1 mM for 24 h. (A) Representative images of 
Bodipy staining showing accumulation of lipids in AML12 cells. Following the treatment, 
cells were fixed with 2% paraformaldehyde and stained. lipid content was additionally 
quantified by flow cytometry. (B) Flow cytometry histogram of control and steatotic 
population of cells stained with Bopdipy. (C) FITC-A median fluorescent intensity 
quantification of Bodipy (30,000 events); bar = 20µm; n=1. 
 
 
5.3.1.2.1 Characterization of EVs secreted by steatotic MLP29 cells 
 
We characterized the EVs secreted by MLP29 cells, at basal state and during 
hepatocellular steatosis (Figure 33). Ultrastructurally, MLP29 EVs present a 
heterogeneous population of typical, bilayered-membrane vesicles (Figure 33A). 
The NTA profile of MLP29-derived EVs is slightly different than the AML12 cells, 
a peak at the 100-150nm size (Figure 33B) and with a slight shift in the size 
distribution curve towards larger vesicles. Moreover, there is a slight increase in 
the total concentration of particles in EVs isolated from steatotic MLP29 cells 
(Figure 33C). There was no difference observed in mean size distribution 
(Figure 33D). Furthermore, results obtained from WB (Figure 33E) show that 
MLP29 cells secrete a slightly different population of EVs than AML12 cells. The 
expression pattern for many proteins was different when comparing EVs coming 
from control and treated cells. It should be considered that both cell lines, 
although both of hepatic origin, they are very distinct. MLP29 cells are a hepatic 
progenitor cell line and AML12 overexpress a potent hepatocyte mitogen, TGFα, 
of human origin (Wu et al. 1994).  
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Figure 33 Characterization of EVs secreted by steatotic MLP29 hepatocyte-like cells. 
Ultrastructural and biochemical characterization of EVs isolated from conditioned medium 
of steatotic MLP29 cells. (A) Cryo-EM analysis; bar=100 nm, inserts are magnified 2.5X. 
(B) Size range distribution. (C) Particle concentration (1010). (D) Particle mean size was 
measured by NTA; n=4. (E) Protein extracts from two independent preparations of EVs (5 
µg) together with their corresponding cell lysates (10 µg) were analyzed by WB with 
antibodies for EV specific as well as cellular markers. Error bars = SD. 
 
 
There was a clear enrichment in protein markers of EVs in our MLP29 
preparations, Cd81, Aip1/Alix and Tsg101 are highly expressed in EVs compared 
to whole cellular lysates of parent cells. Interestingly, Cd81 and Aip1/Alix were 
detected in cells. The abundance of Cd81 was decreased significantly in 
steatotic hepatocytes, which was mirrored in their secreted EVs. Positive 
correlation can be observed in the expression of Hsp70 and Rab8 between the 
amount of protein retained in the cell and the amount excreted in EVs. There was 
a decrease in Hsp70 in steatotic cells with more protein being shuttled out of the 
cell in association with steatotic EVs. Also, in this model, Flotillin1 was modified 
for secretion of EVs and significantly more was packaged into steatotic EVs as 
compared to control EVs. Interestingly, as opposed to AML12 cells, in the MLP29 
model, the bottom band was more highly expressed. MLP29-EVs exhibit 
significant enrichment in LimpII protein with no major differences between the 
control and steatotic vesicles. Interestingly, as seen by the expression in cellular 
lysates, fat overload in cells affected its abundance. Syntenin1, an important 
adaptor protein for the formation of exosomes was found to be more associated 
to steatotic EVs, as compared to the control. Steatosis also caused a decrease in 
the expression of mitochondrial CoxIV. Importantly, CoxIV as well as Grp78 
expression was absent in EV preparations, discarding the presence of 
contamination. Finally, although more amout of Parp protein was found in one of 
the preparation, as judged by the abundance of the unprocessed 100 kDa Parp 
band, it could be concluded that cells were not significantly affected by the 
treatment with FFAs (Figure 33E). This result together with the already 
180 
 
mentioned lack of traces of intracellular organelles in EVs indicate that under our 
culture conditions there was not cell death induction by the FFA treatment. 
 
5.3.1.3 HepG2  
 
Finally, we assessed the lipid accumulation profile upon treatment with the FFAs 
mixture in the human HepG2 cell line. Bodipy staining confirmed the presence of 
lipid droplets in the cytoplasm of the HepG2 cells (Figure 34A). Flow cytometry 
quantification of Bodipy confirmed significant lipid accumulation, as seen by 
immunostaining of fixed cells (Figure 34B). Moreover, as can be deducted from 
the FITC-A channel of the FACS analysis, HepG2 cells, under similar conditions, 
accumulated significantly more lipids than the previously characterized AML12 
and MLP29 cells (Figure 34C).  
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Figure 34 Treatment with FFAs causes triglyceride accumulation in HepG2 
hepatocyte-like cells. Steatosis was induced in HepG2 hepatic cell line with FFA mixture: 
OA/PA, at 2:1 ratio, final concentration at 1 mM for 24 h. (A) Representative images of 
Bodipy staining showing accumulation of lipids in HepG2 cells; bar = 20µm. Following the 
treatment, cells were fixed with 2% paraformaldehyde and stained. Lipid content was 
additionally quantified by flow cytometry. (B) Flow cytometry histogram of control and 
steatotic population of cells stained with Bopdipy. (C) FITC-A median fluorescent intensity 
quantification of Bodipy (30,000 events); n =1. 
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5.3.1.3.1 Characterization of EVs secreted by steatotic HepG2 cells  
 
EVs isolated from HepG2 cells at basal state and in steatosis, were observed in 
their native state by Cryo-EM analysis revealing some important structural details 
such as the presence of a phospholipid bilayer or electron density. Figure 35A 
shows representative electron micrographs of EVs obtained from control, as well 
as, steatotic HepG2 cells. Vesicles of a varying sizes and electron density can be 
appreciated. The size of the EV population, as determined by NTA, peaked 
around 150-200 nm for both, control and steatotic hepatocytes (Figure 35B). An 
8% decrease in the number of smaller vesicles, 50-100 nm secreted by steatotic 
hepatocytes was observed. On the contrary, the number of vesicles between 
100-200nm increased by 10%, with the total concentration (1010) remaining 
unchanged (Figure 35C). There seem to be a drop in the mean particle size of 
the overall population of steatotic EVs (Figure 35D). Figure 35E shows a 
representative immunoblotting of two HepG2-EV preparations together with their 
corresponding whole cell lysates. WB analysis revealed that EV fractions were 
highly enriched in tetraspanin Cd63, which was undetectable in whole cell 
lysates (Figure 35E). The amount of Cd63 was unchanged between control and 
steatotic EVs. Tsg101, the ESCRT machinery protein was found abundant in 
HepG2-EVs, and was increased in steatotic-EVs, mirroring the expression in 
cells.  
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Figure 35 Characterization of EVs secreted by steatotic HepG2 hepatocyte-like cells. 
Ultrastructural and biochemical characterization of EVs isolated from conditioned medium 
of steatotic HepG2 cells. (A) Cryo-EM analysis; bar=100 nm, inserts are magnified 2.5X. 
(B) Size range distribution. (C) Particle concentration (1010). (D) Particle mean size was 
measured by NTA, n=4. (E) Protein extracts from two independent preparations of EVs (5 
µg) together with their corresponding cell lysates (10 µg) were analyzed by WB with 
antibodies for EV specific as well as cellular markers. Error bars = SD. 
 
 
HepG2 cells were found to highly express the lysosomal protein LimpII as well as 
the chaperone Hsp70. The amount of Hsp70 protein was reduced in steatotic 
HepG2 cells. In comparison, the quantity in EVs was significantly less with no 
clear differences seen between the control and steatosis. Flotillin1 expression in 
EVs was variable between the two independent preparations, although in cells it 
seems that there was a slight increase in steatotic HepG2 cells. Syntenin1 was 
barely detected in EV fractions. Cellular markers, CoxIV and Grp78 were 
exclusively present in cells with decreasing amount of CoxIV in steatotic EVs. 
The expression of apoptosis marker Parp, was unaffected by the treatment. 
Important to remark at this point is that when comparing the abundance of 
proteins in EVs isolated from AML12, MLP29 and HepG2 cell lines, we 
discovered some remarkable differences. The one that called most attention was 
the expression of the lysosomal LimpII protein. It was highly enriched in MLP29-
derived EVs as compared to the secreting cells. Moreover, its expression was 
affected upon induction of steatosis (Figure 33E). The opposite effect was seen 
in AML12 and HepG2 cells were LIMPII was mostly associated to cells (Figure 
31E and Figure 35E). Moreover, the expression of Hsp70, Rab8 and Flotillin1 
were clearly augmented in steatotic MLP29-derived EVs, which cannot be 
observed for the AML12 and HepG2-derived EVs. There was a very little of 
Hsp70 in HepG2-derived EVs. Furthermore, Flotillin1 in cellular lysates was 
detected as a double band, which was modified in EVs and expressed as a 
single band. Interestingly in MLP29 lysates there was an enrichment in the lower 
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band of flotillin1 and in AML12 cell lysates in the upper band. Syntenin1 was 
readily detected in MLP29-derived EVs and barely in HepG2. Lastly, Cd81 
protein was detected in cell lysates from MLP29 and it was undetectable in 
AML12 or HepG2. The MLP29 cells release EVs with distinct protein profile and 
most probably it is related with the fact that the MLP29 is a liver progenitor cell 
line (Figure 33E).  
 
 
5.4 Primary Zucker rat hepatocytes as a genetic model of obesity 
 
5.4.1 Characterization of primary hepatocytes from Zucker rats  
 
5.4.1.1 Morphological characterization of steatotic primary hepatocytes isolated 
from Zucker lean and fatty livers  
 
Zucker fatty (fa/fa) rats (strain Crl: ZUC-Leprfa) are widely used as a research 
model in the study of obesity and its metabolic complications such as 
hyperinsulinaemia and insulin resistance. They have a homozygous mutation in 
the leptin receptor gene resulting in severe obesity due to hyperphagia. Although 
the phenotype of these genetically obese rats is well characterized in vivo, little 
research has been conducted on isolated hepatocytes from Zucker rat livers. We 
aimed to culture these hepatocytes in vitro and isolate secreted EVs from their 
conditioned medium.  
Zucker rat hepatocytes were obtained by two-step collagenase perfusion and 
subject to Percoll density gradient centrifugation (Section 2.2.1.1.1 and 
2.2.1.1.1.2) before seeding. Cell viability after perfusion was determined by 
trypan blue exclusion method and the results from 12 independent isolations 
were presented (Figure 36A). Overall viability ranged from 86-98%. ZF- 
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hepatocytes were found to be slightly more sensitive, as noted in the drop of 
viability when compared to their lean control hepatocytes. The cultured cells 
were then examined for the lipid content by immunostaining with Bodipy at 4 h 
and 36 h of culture (Figure 36B). Representative images, with quantitative data 
obtained by flow cytometry analysis of Bodipy stained hepatocytes are presented 
on Figure 36C-36D. 
 
 
Figure 36 Characterization of Primary Zucker Rat Hepatocytes In Culture. Zucker rat 
hepatocytes, from ZL (Fa/+) and ZF (fa/fa) livers were isolated by two step collagenase 
perfusion technique. (A) Cell viability was assessed by trypan-blue exclusion method; n=12. 
(B) Bodipy lipid staining of ZL- and ZF- hepatocytes, previously fixed with 
paraformaldehyde (2%), at 4 h and 36 h in culture; size bar=20 µm. (C) Flow cytometry 
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histogram of Bopdipy stained ZL- and ZF-hepatocytes at T0 and after 36 h in culture. (D) 
Flow cytometric quantification of lipids in ZL- and ZF-hepatocytes at T0 and after 36h in 
culture; (30,000 events); n=4. Error bars represent SD. The p values were denoted as 
follows: 0.01-0.05=*, 0.01-0.001=**, 0.001-0.0001=***. 
 
As expected, ZF-hepatocytes were found to have higher lipid content before 
plating (T0) as compared to their lean counterpart. This difference can be well 
appreciated on the flow cytometry histograms (Figure 36C). The fat content of 
ZF-hepatocytes did not seem to be affected by the culture conditions, between 
T0 and 36h. Moreover, ZL-hepatocytes in culture seem to accumulate lipids in 
the cytoplasm, as seen by the shift in the stained population, reflected in flow 
cytometry histograms (Figure 36C). 
 
 
5.4.1.2 Gene Expression changes in cultured Zucker rat hepatocytes 
 
To further characterize the phenotype of Zucker rat hepatocytes in cell culture 
conditions, we analyzed the expression of a panel of genes related to hepatic 
functions, lipid management and metabolism (Figure 37). The analysis was done 
by normalizing the level of expression in ZF hepatocytes to their lean control 
hepatocytes (value=1) at T0 (just after perfusion of the liver, before seeding the 
primary culture) and after 36h in culture. The expression of key genes involved in 
lipid metabolism including fatty acid synthase (Fasn), the enzyme catalyzing the 
formation of long-chain fatty acids and the fatty acid binding protein (Fabp1) 
mRNAs were 1.5 and 1-fold increased with respect to the control hepatocytes at 
T0 (Figure 37B and Figure 37A respectively). Insulin growth factor 1(Igf1), 
primarily produced by the hepatocytes in the liver (Mallea-Gil et al. 2012), was 
significantly augmented in ZF hepatocytes at T0 and this difference was reduced 
after 36h of culture (Figure 37C). Albumin (Alb), hepatocyte nuclear factor 4 α 
(Hnf4α), and transforming growth factor ß (Tgfß), are important markers of 
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hepatic function, and were found to be over 1-fold increased in ZF over ZL 
hepatocytes at T0 and the differences were reduced after 36h in culture (Figure 
37D, Figure 37E and Figure 37F respectively). UDP-glucuronosyltransferase 1-
6, encoded by the Ugt1a6 gene, important for the conjugation and elimination of 
toxic compounds, was nearly 2-fold increased in ZF hepatocytes at T0 and 
significantly decreased after 36h, as compared to the lean, control hepatocytes 
(Figure 37I).  
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Figure 307 Gene expression changes in Zucker hepatocytes. qPCR analysis of RNA 
transcripts in ZL- and ZF-hepatocytes, encoding for: (A) fatty acid binding protein 4, (B) 
fatty acid synthase, (C) insulin-like growth factor 1, (D) albumin, (E) hepatocyte nuclear 
factor 4 α, (F) transforming growth factor ß, (G) cytochrome 1a2, (H) alcohol 
dehydrogenase 1, and (I) glucuronosyltransferase 1a6, at T0 and following 36h in culture. 
Represented are changes in ZF- hepatocytes, normalized to the control, ZL hepatocytes (set 
as a value of 1). Biological replicate = 1, technical replicate=3. Unpaired student t-test was 
performed to determine significant differences. Error bars = SD.  
 
The expression of nearly all genes analyzed, except for cytochrome P450 1a2 
(Figure 37G) and aldehyde dehydrogenase 1 (Figure 37H), was upregulated in 
ZF-hepatocytes at T0 as compared to their control cells. Interestingly, the 
expression of Cyp1a2, encoding for an important enzyme involved in an NADPH-
dependant electron transport pathway, increased over time, between T0 and 36 
h when compared to ZL hepatocytes (Figure 37G). 
 
5.4.1.3 Insulin Sensitivity of Cultured Zucker Rat Hepatocytes  
 
Insulin regulates the transcription of genes for hepatic glucose and lipid 
metabolism (Zhang et al. 2011). The insulin sensitivity of ZL- and ZF- 
hepatocytes in culture upon stimulation with insulin was tested by WB analysis 
for the expression of the Akt(Ser473), and its major negative inhibitor, the 
phosphatase and tensin homologue deleted on chromosome 10 (PTEN), both 
components of the insulin signalling pathway (Figure 38A).  
In the case of ZF-hepatocytes, the fold increase in phosphorylation of Akt, 
although not significant, is higher when compared to the ZL hepatocytes (Figure 
38B). It is worth noting however that the total amount of Akt protein in ZF 
hepatocytes was notably decreased when compared to ZL-hepatocytes (Figure 
38A). The increase in the Pten phosphorylation upon insulin was unchanged 
between ZL- and ZF- hepatocytes (Figure 38C).  
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Figure 38 Insulin sensitivity in ZL and ZF hepatocytes. (A) Protein extracts (30 µg) 
from untreated and insulin treated ZL- and ZF-hepatocytes, were analyzed by WB for the 
abundance of phosphorylated Akt(Ser473) and phosphorylated Pten, together with their 
corresponding total proteins, and other control proteins. The percentage of phosphorylation 
was quantified with respect to the total protein for the (B) Akt(Ser473) and (C) Pten 
protein.  
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Moreover, WB analysis also showed an increase in CoxIV levels in ZF-
hepatocytes. Interestingly, upon stimulation with insulin, the expression of 
Rab10, an important regulator of insulin that controls Glut4 trafficking to the 
plasma membrane (Karunanithi et al. 2014) was significantly decreased in ZF-
hepatocytes after insulin induction. 
 
5.4.1.4 Metabolic differences between Zucker lean and fatty hepatocytes in 
culture 
 
To further characterize the Zucker primary culture hepatocytes in culture, we 
sought to measure cellular metabolism and gain insights into the possible 
metabolic alternations in ZF-hepatocytes. For that, a Seahorse XF analyzer was 
used to measure the mitochondrial and glycolytic functions of ZL-and ZF-
hepatocytes, at 4 h and 24 h of cell culture. 
Representative figures of the general scheme for the mitochondrial stress test at 
4 h and at 24 h are shown on Figure 39A and Figure 39C respectively. As 
indicated by arrows, during the experiment, cells were metabolically challenged 
with sequential injections of ETC inhibitors, oligomycin, FCCP, and rotenone. We 
obtained several respiratory parameters including basal respiration, ATP 
production, proton leak, maximal respiration and spare respiratory capacity of the 
cell (Figure 39B). It can be clearly seen that ZF- hepatocytes have significantly 
decreased mitochondrial function as compared to ZL-hepatocytes (Figure 39A). 
Beyond the basal level changes, ZF-hepatocytes did not respond in the same 
way when subjected to the mitochondrial stress test. Following the injection of 
inhibitors, the response of ZF- hepatocytes was reduced, however, the action 
was delayed as compared with the ZL- hepatocytes, indicating perhaps that cells 
were more resistant to the action of inhibitors. Highly significant differences were 
found in most parameters measured (Figure 39B).  
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Figure 39 Zucker fatty hepatocytes show decreased mitochondrial functions. ZL and 
ZF-hepatocytes were metabolically profiled using Seahorse XF 24 Analyzer at 4 h and 24 h 
in culture. (A) Representative response curve of the mitochondrial stress test at 4 h. (B) 
Individual parameters of the mitochondrial functions at 4 h. (C) Representative response 
curve of the mitochondrial stress test at 24 h. (D) Individual parameters of the 
mitochondrial stress test at 24 h. Values of individual parameters are represented as OCR 
following additions of ETC inhibitors such as oligomycin (1 mM), FCCP (300 nM) and 
rottenone (1 µM). Replicate/condition=11; error bars=SD. The p values were denoted as 
follows: 0.01-0.05=*, 0.01-0.001=**, 0.001-0.0001=***. Unpaired student t-test was 
performed to determine significant differences.  
 
 
Maximal respiratory rate, that occurs under conditions of uncoupled respiration 
following the FCCP injection, and spare capacity were significantly decreased in 
ZF-hepatocytes (Figure 39B). The ATP production was not significantly different 
between ZF- and ZL-hepatocytes (Figure 39B). Following 24 h in culture, the 
mitochondrial response of the ZF-hepatocytes shifts slightly towards the lean 
counterpart, exhibiting higher response as compared to the 4 h time point 
(Figure 39C). Most notably there was a slight recovery in mitochondrial 
respiration and spare capacity in ZF-hepatocytes (Figure 39D). The differences 
however remained pronounced and ZF-hepatocytes maintain decreased 
mitochondrial function as compared to ZL-hepatocytes. The ATP production 
dropped slightly in ZF hepatocytes over the time in culture (Figure 39D).  
Cells also generate energy in the form of ATP through the conversion of glucose 
to lactate via glycolytic pathway (Nicholls et al. 2010). Using the Seahorse XF 
analyzer was used to alongside the mitochondrial functions, also to perform the 
glycolysis stress test. During the experiment, the first injection of saturating 
glucose concentration (10 mM) causes the switch towards glycolysis as the main 
energy-producing pathway (Figure 40A and Figure 40C). Released protons 
cause acidification of the surrounding medium detected as ECAR and reflects 
the glycolytic response of our Zucker rat hepatocytes.  
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Figure 40 Zucker Fatty hepatocytes show increased glycolytic capacity. ZL- and ZF- 
hepatocytes were metabolically profiled using Seahorse XF 24 Analyzer at 4 h and 24 h in 
culture. (A) Representative response curve of the glycolytic stress test at 4 h. (B) Individual 
parameters of the glycolytic functions at 4 h. (C) Representative response curve of the 
mitochondrial stress test at 24 h. (D) Individual parameters of the mitochondrial stress test 
at 24 h. Values of individual parameters are represented as ECAR following additions of 
ETC inhibitors such as glucose (10mM), oligomycin (1µM) and 2-DG (100mM). 
Replicate/condition=11; error bars=SD. The p values were denoted as follows: 0.01-0.05=*, 
0.01-0.001=**, 0.001-0.0001=***. Unpaired student t-test was performed to determine 
significant differences. 
 
 
Briefly, following the injection of oligomycin, by shutting down the ATP synthase 
of the ETC, and with it the ATP production, the cell is forced to generate energy 
entirely via a less efficient route of glycolysis. Finally, the glucose analog, 2-DG, 
which competitively occupies the binding sites of the first enzyme in the glycolytic 
pathway, glucose hexokinase is added. This causes the inhibition of glycolysis 
and confirms that the ECAR previously measured was in fact due to glycolysis. 
We found that ZF-hepatocytes had an increased glycolytic reserve and an 
increasing trend was seen in their glycolytic capacity, when compared to the ZL 
control cells (Figure 40B).  
The general scheme of glycolysis stress test at 4h is shown in Figure 40A and at 
24h in Figure 40C, with sequential injections indicated by arrows. At a basal 
level, the non-glycolytic acidification was not significantly different between ZL 
and ZF hepatocytes (Figure 40B). Although, for both cell types, the addition of 
assay medium cause a slight decrease in ECAR. From the graph in Figure 40A 
glycolysis is also highly increased in ZF-hepatocytes. However, after the injection 
of glucose, the response of ZL is higher, resulting in an increased glycolysis 
value following oligomycin injection. Moreover, it is worth noting that, after the 
first measurement, following the injection of oligomycin, although the response of 
the ZL-hepatocytes is higher, it plateaus immediately. ZF hepatocytes, did not 
only not reach the plateau but after two measurements the trend was still 
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ascending. This is reflected in a higher glycolytic reserve and glycolytic capacity 
values (Figure 40B). At 24h the graph slightly changed (Figure 40A) Non-
glycolytic acidification levels out and the decrease in glycolysis in ZF-
hepatocytes is greater (Figure 40B). The augmented glycolytic reserve remains. 
Lastly, to sum up all independent experiments, comparing ZL and ZF-hepatocyte 
mitochondrial function and glycolysis, the fold change difference observed in ZF-
hepatocytes with respect to its control in the time between 4 and 24 h was 
plotted (Figure 41). In terms of mitochondrial functions, besides ATP production, 
which remains unchanged, there is a recovery tendency in all other parameters 
measured in ZF-hepatocytes between 4 and 24 h in culture (Figure 41A). 
Substantial recovery of the maximal respiratory and spare capacity by ZF-
hepatocytes is observed. The opposite effect can be seen for the measure of 
glycolytic functions.  
 
Figure 41 Fold change in OCR and ECAR in ZF hepatocytes. Fold change difference 
in ZF-hepatocytes compared to the ZL control hepatocytes in individual parameters of the 
(A) Mitochondrial stress test (OCR), and the (B) Glycolysis stress test (ECAR). Error bars 
represented as SD; n=4. 
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There was a decrease in fold change difference in all parameters related to 
cellular glycolytic functions at 24 h (Figure 41B). Our results indicate that 
metabolically, ZL and ZF-hepatocytes are significantly different. ZF-hepatocytes 
exhibited a significant decrease in all mitochondrial functions, most notably in 
maximal respiration and spare capacity. Interestingly, following 20 h of additional 
cell culture, there was some recovery in these parameters, mostly in spare 
capacity. Moreover, at 20 h there was a significant decrease in ATP production 
by ZF-hepatocytes.  
 
5.4.2 Characterization of Zucker Rat Hepatocyte-derived EVs  
 
5.4.2.1 Zucker fatty hepatocytes secrete distinct population of EVs in terms of 
protein concentration as well as composition 
 
Having performed the initial characterization of the primary Zucker rat 
hepatocytes, we proceeded into the isolation and analysis of their secreted-EVs. 
The first report on hepatocyte-derived EVs was published in 2008 by Conde-
Vancells et al. (Conde-Vancells et al. 2008) with detailed ultrastructural and 
proteomic characterization of EVs isolated from the conditioned medium of the 
cultured primary rat hepatocytes as well as hepatic cell lines. In the current 
study, for the first time, Zucker rat hepatocytes, obtained by hepatic perfusion of 
fatty (fa/fa) and lean (Fa/+) matched Zucker rat livers, were cultured for 
subsequent isolation of EVs from the conditioned medium.  
 
A plethora of different methods is currently available for the quantification of EVs 
in a liquid sample, based on diverse structural parameters, or the presence of a 
specific protein marker. Choosing the appropriate quantification technique is vital 
for further downstream applications. Here, the protein concentration of the EV-
samples was determined by Bradford assay and the result of the quantification 
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from 12 independent preparations is shown in Figure 42A. Values obtained 
(μg/μl) were normalized by the total number of cells plated in each preparation. 
Results indicate that the mean concentration (μg/μl) was 3.9 (SD=1.4) and 6.8 
(SD=3.3) in ZL and ZF respectively, across 12 independent EV preparations. 
Nearly a two-fold increase in total protein concentration in ZF-EV sample was 
observed as compared to their lean counterparts. Following normalization, this 
result was maintained with 8.3 x 10-09 (SD=3.4-09) and 1.90 x 10-08 (SD=1.2-08) 
protein (µg/number of cells) in ZL and ZF-EV samples respectively per number of 
cells plated. A statistically significant increase in total protein concentration was 
found in the ZF-EVs sample, despite a degree of variability (Figure 42A).  
To assure the accuracy of the Bradford measurements, the total protein 
concentration in 6 independent preparations was determined simultaneously by 
Bradford and BCA protein assay (Figure 42B). Results obtained by Bradford and 
BCA were comparable between the 6 independent samples assayed. Slight 
differences were seen in highly concentrated samples, however remained within 
the same range (Figure 42A). Relying on this result, Bradford assay was used to 
determine protein-loading amounts for the rest of the study.  
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Figure 42 Determination of protein concentration in Zucker rat hepatocyte-derived 
EVs. (A) The protein concentration in the EV samples was measured by Bradford. 
Represented are normalized values to the total amount of cells plated/preparation; n=12. 
(B) Comparison of protein concentration measurement by Bradford and BCA; n=6. (C) 
Sypro Rubi staining of the gel loaded with 2 µl of Zucker rat hepatocyte-secreted EVs; n=4. 
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Differentially expressed bands are indicated. (D) Identity of differentially expressed bands; 
n=3. Error bars = SD. Unpaired student t-test was performed to determine significant 
differences. 
 
Additionally, in order to validate the accuracy of Bradford protein quantification, 2 
μg of ZL and ZF-EVs were subjected to SDS-PAGE, followed by a SYPRO Ruby 
protein gel staining of separated proteins (Figure 42C). EV samples, from 4 
independent preparations, two of which were isolated from hepatocytes treated 
with Percoll density gradient centrifugation, as indicated on Figure 42C were 
assayed. The analysis revealed no significant differences in protein loading 
between samples as judged by the intensity of the staining. Interestingly, some 
differentially expressed band pattern between ZL- and ZF-EVs could be 
identified, notably in the low size range. Indicated bands were cut and analyzed 
by MALDI-MS with the pool of three selected samples for each band was used 
for proteomic analysis. Resulting proteins were identified according to the highest 
protein score, which is the sum of the ion scores of all peptides identified, and 
the highest number of peptide spectrum matches (PSM) for that protein. 
Selected proteins, were identified as Catechol-O-methyltransferase (COMT), 
Ferritin light chain (Ferritin-LC) and Cytochrome b5 (Figure 42D).  
Interestingly, Comt was more abundant in ZF-EVs. COMT is an enzyme involved 
in the degradation of catecholamine transmitters such as dopamine, epinephrine 
and norepinephrine as well as the metabolism of endogenous substances and 
catechol drugs with the liver being the main metabolic site. The expression of the 
other two proteins, Ferritin-LC and cytochrome b5, was decreased in ZF EVs. 
Interestingly, very early studies have associated cytochrome b5 to liver 
microsomes and that it acts as an intermediary electron carrier, and takes part in 
hepatic microsomal fatty acid desaturation (Oshino et al. 1971).  
Our results show that ZF-EVs have higher protein content when compared to ZL-
EVs. Moreover, we identified some important differences in the protein 
composion between ZL- and ZF-EVs. 
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5.4.2.2 Ultrastructural comparison of ZL and ZF secreted EVs 
 
Isolated EVs were identified and purity verified by cryo-EM analysis. 
Representative electron micrographs show that in general, most particles 
visualized in culture supernatant of Zucker rat hepatocytes were round, typically 
translucent and enclosed in a visible, electron dense lipid bilayer (Figure 43A). 
Most vesicles isolated by differential ultracentrifugation were consistent with 
exosomal size vesicles. However, cryo-EM also revealed more structural details 
and considerable morphological heterogeneity. Apart from round vesicles, 
complex triple vesicles with smaller vesicles inside a larger one, all translucent 
and carrying a lipid membrane as well as incompletely closed vesicle were 
observed. Varying thickness of the lipid bilayer was also noted, with smaller 
vesicles having a slightly thicker membrane. Moreover, some vesicles were 
electron dense indicative of a lumen filled with cargo.  
Electron dense round structures lacking the membrane were not considered true 
EVs. The presence of some impurities in the EV samples that could correspond 
to protein aggregates, were also observed. The majority (>90%) of particles were 
below 300 nm in diameter, with the main population at around 100-200 nm 
(Figure 43B). The vesicle count was 166 × 1010 per millilitre in ZL sample and 
630× 1010 in ZF-EV sample. These significant differences in concentration of 
vesicles were seen across specific size groups with 50% increase in the number 
of smaller vesicles up to 50nm. 11% of the total population in both samples 
occupy a size between 50-100 nm. Moreover, a 4% decrease, from 28%-24% 
was seen in 100-150 nm population. Statistically significant decrease was seen 
in the subsequent 150-200 size range. On the other hand, a statistically 
significant increase in larger vesicles between 300-350 nm was seen in ZF-EV 
samples. Furthermore, only about 1% of the total population was composed of 
larger vesicles up to 500 nm. NTA indicates a very slight decrease in the total 
mean size, however the size difference was not significant (Figure 43D). In 
terms of particle concentration there was a significant 3.5-time increase in ZF 
derived EVs (Figure 43C).  
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Figure 43 Ultrastructural characterization of EVs secreted by Zucker rat hepatocytes. 
Ultrastructural and biochemical characterization of EVs isolated from conditioned medium 
of ZL and ZF hepatocytes. (A) Cryo-EM analysis, two electron micrographs are 
shown/condition, size bar=100nm, inserts magnified 2.5X. (B) Size range distribution. (C) 
Particle concentration (1010). (D) Particle mean size; n=4. Error bars=SD. The p values were 
denoted as follows: 0.01-0.05=*, 0.01-0.001=**, 0.001-0.0001=***. Unpaired student t-test 
was performed to determine significant differences. 
 
 
5.4.2.3 Protein composition analysis 
 
Protein expression analysis of ZL and ZF-derived EVs was carried out to 
determine whether vesicles identified by cryo-EM and NTA, carried exosome-
associated markers. Three independent preparations of EVs along with their 
corresponding cell extracts was separated by SDS-PAGE and immunoblotted 
with antibodies for specific EV markers (Figure 44). Results show that vesicles 
isolated from conditioned medium of Zucker rat hepatocytes highly resembled 
exosomes in their protein composition since they were enriched in several 
exosomal markers such as Cd81, Cd63, Tsg101, and Aip1/Alix. However, the 
amount of protein expressed varied significantly between the ZL and ZF 
samples. The tetraspanins Cd63 and Cd81 were very abundant in ZL-EVs and 
barely detectable in ZF-EVs. The same trend of expression was seen in whole 
cell lysates, however with detectable expression of both markers in ZF whole cell 
lysates. ESCRT machinery associated proteins, Tsg101 and Alix were both 
found in Zucker rat hepatocyte derived- EVs. A comparable amount of AIP1 was 
found in whole cell lysates as in EVs. The expression of both markers was down 
regulated in ZF whole cell lysates as well as in EVs. Moreover, Flotillin1, a 
common lipid raft marker widely considered to be an exosomal marker was again 
highly decreased in ZF-EVs. 
204 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44 Protein profiling of EVs secreted by primary hepatocytes from Zucker rats. 
Whole cell lysates (10 µg) of Zucker rat hepatocytes, ZL and ZF, with their corresponding 
EVs (5 µg) were analyzed by WB, using antibodies against several markers of exosomes 
(Cd81, Tsg101, Aip1, Cd63, Hsp70, Hsp90, Flotillin1) microvesicles (AnnexinV), and 
markers of other cellular components such as ER (Grp78), mitochondria (CoxIV), 
lysosomes (LimpII) and G-proteins (Rab8, 10 and 11) and adiponectin. Representative 
figure; n=4. 
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Along with the typical exosome-related markers, we detected few members of 
small GTPases proteins. Rab8 was highly expressed in cells and clearly less 
protein was found in ZF hepatocytes as compared to the lean control, across all 
three preparations. The same situation was found for Rab11. 
The only proteins in the above panel, which were found to be more abundant in 
ZF-EVs as compared to ZL-EVs, were heat shock family member proteins, 
Hsp70 and Hsp90. Interestingly, when comparing their expression in cell lysates 
and in secreted EVs, the pattern was reversed. As more protein was being 
secreted out via EVs, the cellular abundance was effectively decreasing, which 
could be an indication of the regulated cargo sorting. Moreover, LimpII was found 
abundant in Zucker rat hepatocytes, with decrease expression in ZF-
hepatocytes. In addition, LimpII was associated to vesicles secreted by Zucker 
hepatocytes, with a significant reduction in ZF-EVs.  
Protein expression analysis has revealed very significant differences in the 
composition of EVs secreted by ZL- and ZF-hepatocytes. While investigating the 
lipid content of Zucker hepatocyte-EVs, we were also interested in the 
expression of adipocyte-related proteins, more importantly, adiponectin, a 
hormone affected by obesity. The adipocyte complement-related protein of 30 
kDa (Acrp30) was discovered to be produced by adipocytes during identification 
of adipocyte differentiation genes (Combs & Marliss 2014). The expression of 
adiponectin was reported to be decreased in adipose tissue of obese (ob/ob) 
mice as well as in fat samples from obese human individuals, with no other 
adipose-specific genes being unaffected by obesity (Hu et al. 1996). In the liver, 
adiponectin acts through the activation of 5-AMP-activated protein kinase and 
peroxisome proliferator-activated receptor-α pathways (Polyzos et al. 2010). 
Adiponectin has been shown to suppress hepatic glucose production, therefore 
the reduction in circulating adiponectin in T2DM contributes to the increased 
glucose production leading to fed and fasted hyperglycemia (Combs & Marliss 
2014). The effect of high insulin and low adiponectin signalling in humans is 
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characteristic of fatty livers (Combs & Marliss 2014). Furthermore, adiponectin 
levels can serve as a guide in predicting grade of hepatic steatosis (Polyzos et 
al. 2010).  
Adiponectin was highly abundant in Zucker hepatocytes as shown by WB 
analysis (Figure 44), with no clear differences between ZL- and ZF- hepatocytes. 
However, surprisingly adiponectin was also found to be associated to Zucker-
EVs with significantly reduced expression in ZF-EVs. Representing the metabolic 
phenotype of fatty liver and adiponectin reduction described in obesity  
Annexins are a family of cytosolic proteins that have phospholipid-binding 
domains, and associate with intracellular membranes in a calcium dependant 
manner. Several annexins were found to be involved in membrane-fusion events 
between intracellular compartments (Théry, Zitvogel, et al. 2002), and have been 
recognized markers of microvesicles due to their membrane origin. The 
expression of AnnexinV was confirmed in Zucker rat hepatocyte secreted EVs. 
The abundance in whole cell lysates was clearly increased in ZF-hepatocytes as 
compared to the control (Figure 44). Reverse expression pattern was seen in 
EVs, with decreased amount of AnnexinV being secreted in EVs. Finally, the 
protein markers for other subcellular compartments such as mitochondrial CoxIV 
and ER-associated Grp78 were absent in EV preparations discarding the 
possibility of contamination with cellular organelles in our preparations. 
Interestingly, both proteins were differentially expressed in ZL and ZF-
hepatocytes. The amount of CoxIV was higher in ZF hepatocytes however Grp78 
was decreased as well as Parp protein when compared to lean. Lastly, some 
degree of cleaved Parp was detected, more in ZL hepatocytes, however it was 
not significant. This result indicates a low degree of apoptosis and that existing 
apoptosis was not significantly different between both groups.  
Our results show that ZF-EVs have significantly higher concentration of proteins. 
Moreover, there is a significant increase in the concentration of particles in ZF-
EV samples together with a decrease in all exosomal markers, except Hsp’s. 
These changes could be the reflection of the metabolic state of the cell.  
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5.4.2.4 Distribution of protein markers on a density gradient 
 
The differential expression of most markers as seen in the previous section 
suggest that ZF-hepatocytes could secrete a different population of EVs or the 
secretion of a specific type of EVs is enriched in ZF- in comparison to ZL- 
samples.  
To shed some light on this idea, we explored one of the hallmarks of exosomes 
as vesicular carriers, which is, their floatation in a sucrose gradient. Specifically, 
exosomes have been determined to float at a density that ranges from 1.13 to 
1.21 g/ml. A study by Conde-Vancells and co-workers determined that purified 
exosomes released by primary hepatocyte float at a density of approximately 
1.21 g/mL in a continuous sucrose gradient, which remain in the exosome 
density range as described for other cell types (Conde-Vancells et al. 2008). We 
analysed the buoyant density of vesicles to verify whether EVs purified from 
primary Zucker rat hepatocytes also float at similar density, using iodoxanol, 
OptiPrepTM in the velocity gradient. 250 μg of EVs were separated on a 5-40% 
density gradient into 12, 1 ml fractions. Subsequent WB analysis indicated that 
Zucker rat hepatocyte secreted EVs, ZL and ZF, were enriched at a buoyant 
density of 1.16 g/ml, based on the presence of markers such as Cd63, Rab8 and 
ApoE (Figure 45). The presence of Cd63 and Rab8 was detected in two distinct 
fractions at a density of 1.16 and 1.19 g/ml. In ZF-EVs, Rab8 enriched fractions 
were at 1.19 g/ml, however for ZL EVs it was at 1.16 g/mL indicating the 
existence of a distinct population of EVs between ZL and ZF secreted EVs.  
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Figure 45 Zucker rat hepatocytes-derived EVs float at a density characteristic of 
exosomes.  The density of EVs secreted by Zucker rat hepatocytes, ZL and ZF, was 
determined by floatation on an OptiPrepTM density gradient. Samples were collected from 
12, 1 ml, fractions following 16 h ultracentrifugation at 32,000 rpm. Fractions were analyzed 
by WB using antibodies against the indicated proteins, Cd63, Rab8 and ApoE. Starting 
material of 250 µg of EVs.  
 
 
The same enrichment pattern was seen for the ApoE protein; however, it was 
associated with a single fraction. In terms of the expression of the tetraspanin 
Cd63, the abundance in ZF-EVs was markedly decreased, as previously shown 
(Figure 45). Moreover, the pattern of separation across the different fractions 
was different for both samples. In ZF-EVs, Cd63 and Rab8 were present in two 
fractions the 1.16 and 1.19 g/ml, while Cd63 was enriched in the lower density 
fraction, Rab8 was enriched in the higher density fraction. In addition, the 
presence of Cd63-positive vesicles, floating at lower densities, between 1.07 and 
1.12 g/ml was detected in ZL-EVs.  
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5.4.2.5 LC-MS/MS analysis 
 
We wanted to obtain further insight into the nature of EVs secreted by steatotic 
Zucker hepatocytes and for that we performed a mass spectrometry proteomic 
analysis. Mass spectrometry is a powerful technique for the identification, 
quantitation, and characterization of proteins. The sample to be analyzed is 
subjected to enzymatic digestion with a protease such as trypsin to generate a 
heterogenous mixture of peptides. The peptides obtained are subsequently 
separated by liquid chromatography coupled to mass spectrometry (LC-MS) 
(Schmidt et al. 2014). Tandem MS/MS provide information about the sequence 
of the peptide, which is key to their identification. 
Proteomic analysis of EVs from many different sources had shown the presence 
of vesicle-specific as well as cell-type specific proteins. As already mentioned, 
the very first report with a comprehensive proteomic analysis of EVs secreted by 
primary hepatocytes as well as hepatic cell lines, was published in 2008 by 
Conde-Vancells and co-workers (Conde-Vancells et al. 2008). The analysis 
resulted in the identification of 251 proteins including EV-specific markers such 
as tetraspanins, Cd81 and Cd63, endosomal pathway related proteins, annexin 
and GTPases. Moreover, hepatocyte specific proteins were also detected, 
asialoglycoprotein receptor and members of P450 family of enzymes.  
The aim of the current study was to profile EVs isolated from conditioned 
medium of Zucker rat hepatocytes. The method chosen for our analysis was 
shotgun approach where no prior knowledge of the peptides present in the 
sample is required to define peptide selection criteria during the LC-MS analysis. 
Liquid Chromatography-MS/MS of protein quantification analysis of four 
replicates for each group (ZF vs ZL) yielded a total of 438 proteins, 137 being 
upregulated in ZF-EVs and 301 were downregulated in ZF-EVs (Figure 46A).  
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Figure 46 Proteomic analysis of Zucker rat hepatocyte-secreted EVs. (A) Comparison 
of proteins identified in LC-MS/MS analysis. A total of 438 proteins were identified, among 
which 144 were differentially expressed proteins (DEPs), between ZL- and ZF-EVs. (B) 
Up- and down-regulated DEPs in ZF-EVs. Analysis was carried out on 4 independent 
biological replicates. 
 
Among these 438 proteins, 144 (33% of the total) were categorized as 
statistically significant (p < 0.05), differentially expressed proteins (DEPs) (Figure 
46B). In turn, among DEPs, 35 proteins (24.3%) occupy the category of 
significantly up-regulated in ZF EVs and the remaining 109 were down-regulated. 
A full list of DEPs identified for ZL- and ZF-EVs are available in the 
supplementary information (Table 16 and 17).  
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Table 8 Gene ontology cellular component classification of all proteins detected in Zucker 
rat hepatocyte derived-EVs  
 
PANTHER GO-Slim Cellular Component  
 
Rattus norvegicus-REFLIST 
 
Analysis Type: 
Analysed List: 
Bonferroni correction: 
Bonferroni count: 
PANTHER Overexpression Test 
Upload_1 (Rattus norvigcus) 
True 
61 
 
Fold change 
 
p value 
Cytosol (GO:0005829)   4.59 5.67E-21 
Cytoplasm (GO:0005737)   2.4 8.81E-19 
Intracellular (GO:0005622)   1.83 6.65E-15 
Ribosome (GO:0005840)   4.76 2.62E-14 
Ribonucleoprotein complex 
(GO:0030529) 
  3.23 5.93E-10 
Integral to membrane 
(GO:0016021) 
  <0.2 1.27E-09 
Membrane (GO:0016020)   0.22 2.45E-08 
Macromolecular complex 
(GO:0032991) 
  2.04 5.76E-08 
Organelle (GO:0043226)   1.72 9.84E-07 
Cell part (GO:0044464)   1.44 2.25E-06 
Plasma membrane (GO:0005886)   0.31 4.42E-05 
Tubulin complex (GO:0045298)   16.65 1.32E-04 
Actin cytoskeleton (GO:0015629)   3.41 1.73E-02 
Microtubule (GO:0005874)   4.05 2.93E-02 
Vesicle coat (GO:0030120)   6.4 7.62E-02 
Nucleoplasm (GO:0005654)   <0.2 5.61E-01 
Extracellular space (GO:0005615)   0.35 5.90E-0.1 
Cytoskeleton (GO:0005856)   1.87 8.30E-0.1 
Endosome (GO:0005768)   0.55 1.00E+00 
Extracellular region (GO:0005576)   0.65 1.00E+00 
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We were then interested whether there was a specific enrichement in proteins 
related with extracellular environment, considering all proteins identified in 
Zucker rat hepatocyte-derived EVs. We therefore performed the PANTHER 
Gene Ontology (GO) Cellular component analysis. The identified cell 
components are listed in Table 8. The analysis revealed that most of the proteins 
identified have cytoplasmic and plasma membrane localization.  
Further, we began interpreting the differentially expressed proteins, again using 
GO classification. The total 137 up-regulated proteins and 301 down-regulated 
proteins in ZF-EVs were categorized according to the molecular function (Figure 
47A), the biological processes (Figure 47B) and the cellular compartment 
(Figure 47C).  
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Figure 47 Gene ontology classification of up- and down-regulated proteins identidied 
in ZF-EVs. Up (137) and down-regulated (301) proteins found ZF-EVs were classified 
according to the (A) molecular function, (B) biological process, and (C) cellular 
compartment categories. Data is expressed in percentages. 
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Results were presented as pie diagrams and percentage distribution was 
annotated for each individual process. Although, twice as many proteins were 
found to be down-regulated, as much as 10% of up-regulated proteins were 
categorized as having catalytic activity. Moreover, in terms of biological 
processes, an increase in proteins associated with metabolic processes was 
seen (Figure 47B). More importantly, the analysis revealed, that the major 
differences between the content of up and down-regulated proteins identified in 
ZF-EVs lies in enrichment of DEPs related to metabolic processes. Nearly 60% 
of all DEPs up-regulated in ZF-EVs were implicated in general metabolic 
processes, which was a very significant difference in biological processes, when 
considering that 2.5-times less total DEPs were detected (Figure 48). 
 
 
 
 
Figure 48 Proteins related with metabolic processes are enriched in ZF-EVs. GO 
gene ontology classification of up (35) and down regulated (109) DEPs in ZF EVs in 
category of biological processes.  
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5.2.2.5.1 Classification of proteins up-regulated in ZF-EVs  
 
Functional annotation of identified proteins was done with GO enrichment 
analyses using the Database for Annotation, Visualization and Integrated 
Discovery (DAVID) online tool to highlight the most relevant GO terms 
associated with up- and down-regulated DEPs in ZF-EVs.  
In terms of ZF-EVs, a specific set of proteins was identified. The majority, 75% of 
all upregulated DEPs in ZF-EVs were found to be enzymes involved in variety of 
metabolic processes (Table 9). Moreover, our results indicate that the most 
significant active pathways enriched in ZF-EVs were the energy producing 
pathways, namely pentose phosphate pathway and glycolysis (Table 10). The 
two most differentially expressed proteins in ZF-EVs were 6-phosphogluconate 
dehydrogenase (6PGD) and glucose-6-phosphate 1-dehydrogenase (G6PD), 
both enzymes having their role in oxidative phase of the pentose phosphate 
pathway (PPP). G6PD is responsible for the first step in the conversion of 
glucose to ribose-5-phosphate, a nucleotide component, making NADPH. 
However, 6PGD, an oxidative carboxylase that catalyses the decarboxylating 
reduction of 6-phosphogluconate into ribulose 5-phosphate in the presence of 
NADP. The second most highly represented pathways were glycolysis with 
NADP-dependant malic enzyme (MAOX) and ATP-citrate synthase (ACLY) being 
highly represented in ZF-EVs. MAOX generates NADPH for fatty acid and 
cholesterol biosynthesis (Al-Dwairi et al. 2014). Moreover, rat liver malic enzyme 
plays an important role in lipogenesis (Morioka et al. 1988). It is a major lipogenic 
enzyme that catalyzes the oxidative decarboxylation of malate to pyruvate and 
reduces NADP+ to NADPH, which is used in fatty acid and cholesterol 
biosynthesis, especially in the rate limiting steps catalyzed by fatty acid synthase 
(Al-Dwairi et al. 2014). ATP-citrate synthase is the primary enzyme responsible 
for the synthesis of cytosolic acetyl-CoA. A central role in several important 
biosynthetic pathways of de novo lipid synthesis and cholesterogenesis. Lastly, 
phosphoglycerate kinase 1 (Pgk1), the first ATP-generating enzyme in the 
glycolytic pathway that catalyzes the transfer of the high-energy phosphate from 
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the 1 position of 1,3-diphosphogly- cerate (1,3-BPG) to ADP, which leads to the 
generation of 3-phosphoglycerate (3-PG) and ATP of 1,3 diphosphoglycerate to 
3-phosphoglycerate (X. Li et al. 2016). In tumours it has been shown 
mitochondria-translocated PGK1 functions as a protein kinase to coordinate 
glycolysis. 
Hepatocytes play an essential role in carbohydrate and lipid metabolism. Most 
processes of lipid metabolism are predominantly performed in the liver, including 
synthesis of lipoproteins, fatty acids, and triglycerides. As identified by proteomic 
analysis, the second most enriched group of up-regulated proteins found in ZF 
EVs were associated with lipid metabolism (Table 11). In that group, the most 
highly enriched protein was the proinflammatory cytokine, the microphage 
migration inhibitory factor (MIF), which has been implicated in obesity, insulin 
resistance, T2DM and associated hepatic pathologies. Its role in the 
development of hepatic steatosis was indicated (Morrison & Kleemann 2015). 
Moreover, hepatic lipogenic gene expression was significantly lower in the 
absence of microphage migration inhibitory factor (Finucane et al. 2014). 
Furthermore, enzymes crucial for the catalysis of long-chain fatty acid formation 
such as fatty acid synthase (Fas) and acetyl-CoA carboxylase 1 (Acaca) were 
also highly up-regulated in ZF-EVs. Moreover, the acyl-CoA synthase 5 (Acsl5), 
which activates long-chain fatty acids for the synthesis of cellular lipids as well as 
degradation via beta-oxidation and retinaldehyde dehydrogenase 1 has been 
shown to coordinate hepatic gluconeogenesis and lipid metabolism (Kiefer et al. 
2012). 
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Table 9 Majority of up-regulated proteins in ZF-EVs are enzymes. 
Mapped ID Catalytic activity Fold 
change 
ANOVA 
(pvalue) 
6PGD_RAT 6-phosphogluconate dehydrogenase, 
decarboxylating 
3.5 0.00000356 
MIF_RAT Macrophage migration inhibitory factor 1.9 0.000123 
MAOX_RAT NADP-dependent malic enzyme 7.2 0.000209 
G6PD_RAT Glucose-6-phosphate 1- dehydrogenase 15.5 0.000605 
ACYL_RAT ATP-citrate synthase 3.9 0.000618 
AL1A1_RAT Retinal dehydrogenase 1 3.6 0.001163 
FAS_RAT Fatty acid synthase 2.5 0.002199 
ST2A2_RAT Alcohol sulfotransferase A 5.1 0.003782 
EF1A1_RAT Elongation factor 1-alpha 1 1.7 0.006062 
AL1L1_RAT Cytosolic 10-formyltetrahydrofolate 
dehydrogenase 
3.6 0.006914 
VAT1_RAT Synaptic vesicle membrane protein VAT-1 
homolog 
2.3 0.008198 
ACSL5_RAT Long chain fatty acid CoA ligase 5 2.5 0.00896 
PGK1_RAT Phosphoglycerate kinase 1 1.7 0.009191 
TBA1C_RAT Tubulin alpha-1C chain 2.3 0.009453 
CMBL_RAT Carboxymethylenebutenolidase homolog 2.4 0.011306 
PUR9_RAT Bifunctional purine biosynthetic protein 
PURH 
1.9 0.011392 
GSTK1_RAT Glutathione S-transferase kappa 1 3.0 0.012802 
SYDC_RAT Aspartate-tRNA ligase, cytoplasmic 1.8 0.013114 
CP2A1_RAT Cytochrome P450 2A1 2.5 0.013636 
AL1A7_RAT Aldehyde dehydrogenase, cytosolic 1 3.4 0.018937 
TERA_RAT Transitional endoplasmic reticulum ATPase 1.9 0.019298 
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ACACA_RAT Acetyl-CoA carboxylase 1 1.5 0.021909 
GSTT1_RAT Glutathione S-transferase theta 1 1.6 0.038933 
DHPR_RAT Dihydropteridine reductase 1.9 0.040027 
LPP60_RAT 60 kDa lysophospholipase 1.7 0.045716 
PH4H_RAT Phenylalanine-4-hydroxylase 1.5 0.049157 
 
 
 
Table 10 Pathways significantly enriched in ZF-EVs. 
Mapped ID Pentose biosynthetic process Fold 
change 
ANOVA  
((pvalue)  
6PGD_RAT 6-phosphogluconate dehydrogenase, 
decarboxylating 3.5 
0.000003 
G6PD_RAT Glucose-6-phosphate 1-dehydrogenase 15.5 
 
0.000605 
 Pyruvate Metabolism   
MAOX_RAT NADP-dependent malic enzyme 7.2 
 
0.000209 
ACLY_RAT ATP-citrate synthase 
 
3.9 0.000618 
PGK1_RAT Phosphoglycerate kinase 1 
 
1.7 0.009191 
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Table 11 Group I: proteins overexpressed in ZF-EVs. 
Mapped ID Fat Metabolism Fold 
change 
ANOVA 
(pvalue) 
MIF_RAT Macrophage migration inhibitory factor 1.9 
 
0.000123 
MAOX_RAT NADP-dependant malic enzyme 7.2 
 
0.000209 
G6PD_RAT Glucose-6-phosphate 1-dehydrogenase 15.5 
 
0.000605 
ACLY_RAT ATP-citrate synthase 3.9 
 
0.000618 
AL1A1_RAT Retinal dehydrogenase 1 3.6 
 
0.001163 
FAS_RAT Fatty acid synthase 2.5 
 
0.002199 
ACSL5_RAT Long Chain Fatty Acid  
CoA Ligase 5 
2.5 
 
0.00896 
CP2A1_RAT Cytochrome P450 2A1 2.5 
 
0.013636 
ACACA_RAT Acetyl-CoA carboxylase 1 1.5 
 
0.021909 
LPP60_RAT 60 kDA Lysophospholipase 1.7 
 
0.045716 
 
The remaining proteins were manually grouped into ones involved in the 
synthesis and post-translational modifications of proteins and cytoskeleton 
related proteins (Table 12).  
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Table 12 Group II: proteins overexpressed in ZF-EVs. 
Mapped ID Protein synthesis and post translation 
modifications 
Fold change ANOVA 
(pvalue) 
RS4X_RAT 40S ribosomal protein S4 1.5 
 
0.003988 
EF1A1_RAT Elongation factor 1-alpha 1.7 
 
0.006062 
RL9_RAT 60S ribosomal protein L9 2.0 
 
0.037221 
EF1D_RAT Elongation factor 1-delta 1.6 
 
0.040249 
 Cytoskeleton-related proteins   
TBA1C_RAT Tubulin alpha-1C chain 2.3 
 
0.009453 
MARE2_RA
T 
Microtubule-associated protein RP/EB 
family member 2 
3.0 
 
0.018809 
 
 
5.2.2.5.2 Classification of proteins down-regulated in ZF-EVs  
 
In the category of proteins identified as down-regulated in ZF-EVs, 40% were of 
mitochondrial origin (Table 13). Surprisingly in that group, one of the proteins 
identified was the molecular ER chaperone, Grp78, which is generally localized 
in the ER (Sun et al. 2006) and assist in folding of cytoplasmic proteins (Prasad 
et al. 2017). We have already shown the expression of Grp78 by WB in Zucker 
rat hepatocytes (Figure 44). Its abundance was reduced in lysates from ZF-
hepatocytes, as compared to the control, and by WB it was not detected in EVs. 
The presence of Grp78 protein among the mitochondrial proteins associated to 
hepatocyte-EVs coud be due to the fact that GRP78 was shown to be present at 
the mitochondria-associated ER membrane (MAM), which physiologically 
connects the ER to mitochondria (Prasad et al. 2017) and this apposition of the 
outer mitochondrial membrane and the ER was first shown in rat liver and 
cultured rat hepatocytes (Lebiedzinska et al. 2009). Another protein in this 
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category, which presence was previously validated by MALDI-MS from SYPRO 
Ruby protein gel staining was the Cytochrome b5 (Figure 42). Here we confirm 
that the reduction of the Cytochrome b5 protein was statistically significantly (p 
value = 0.003195) in ZF-EVs.  
 
Table 13 Group III: proteins down-regulated in ZF-EVs. 
Mapped ID Mitochondria Fold 
change 
ANOVA 
(pvalue) 
PDIA3_RAT Protein disulfide isomerase family A, 
member 3 
2.5 5.38E-05 
BSG_RAT Basigin 4.5 0.000395 
DHE3_RAT Glutamate dehydrogenase 1 6.1 0.000455308 
CATA_RAT Catalase 2.7 0.000515 
RHOA_RAT Ras homolog family member A 2.0 0.000621 
CYP2D4_RAT Cytochrome P450, family 2, subfamily 
d, polypeptide 4 
4.0 0.000995789 
HMGCL_RAT 3-hydroxymethyl-3-methylglutaryl-
CoA lyase 
3.4 0.001006814 
HSD17B4_RAT hydroxysteroid (17-beta) 
dehydrogenase 4(Hsd17b4) 
3.1 0.001532433 
PYC_RAT Pyruvate carboxylase 3.5 0.001833 
PCCA_RAT Propionyl-CoA carboxylase alpha 
subunit 
3.4 0.001952956 
CYP2D1_RAT Cytochrome P450, family 2, subfamily 
d, polypeptide 1 
3.2 0.001968706 
ACOX3_RAT Peroxisomal acyl-coenzyme A oxidase 
3 
1.9 0.002165 
IVD_RAT Isovaleryl-CoA dehydrogenase 2.9 0.002316491 
CYB5A_RAT Cytochrome b5 type A 3.9 0.003195191 
MGST1_RAT Microsomal glutathione S-transferase 
1 
2.5 0.003286481 
CH60_RAT 60 kDa heat shock protein, 
mitochondrial 
1.9 0.005119052 
ALDH2_RAT Aldehyde dehydrogenase, 
mitochondrial 
4.1 0.006310028 
GRP78_RAT 78 kDa glucose-regulated protein 2.0 0.007384784 
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IDHP_RAT Isocitrate dehydrogenase [NADP], 
mitochondrial 
3.7 0.009461225 
AGT2_RAT Alanine-glyoxylate aminotransferase 
2, mitochondrial 
2.9 0.009529205 
PCCB_RAT Propionyl-CoA carboxylase beta 
subunit 
4.5 0.010487016 
PECR_RAT Peroxisomal trans-2-enoyl-CoA 
reductase 
2.1 0.011373881 
MDHM_RAT Malate dehydrogenase, mitochondrial 2.2 0.012192884 
S22A7_RAT Solute carrier family 16 member 1 2.6 0.012442 
MCCA_RAT Methylcrotonoyl-CoA carboxylase 1 3.2 0.012851807 
ACADM_RAT Medium-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
3.0 0.013927 
SDHA_RAT Succinate dehydrogenase complex 
flavoprotein subunit A 
2.3 0.017234 
AL3A2_RAT Fatty aldehyde dehydrogenase 1.9 0.018048282 
ETFDH_RAT Electron transfer flavoprotein 
dehydrogenase 
2.2 0.020696775 
THIM_RAT 3-ketoacyl-CoA thiolase, 
mitochondrial 
2.6 0.021379907 
MMSA_RAT Methylmalonate-semialdehyde 
dehydrogenase, mitochondrial 
2.2 0.02176398 
CPS1_RAT Carbamoyl-phosphate synthase 1 2.7 0.022820558 
CLU_RAT Clusterin 2.3 0.023728152 
HMCS2_RAT Hydroxymethylglutaryl-CoA synthase, 
mitochondrial 
3.4 0.026934354 
BDH_RAT D-beta-hydroxybutyrate 
dehydrogenase, mitochondrial 
2.5 0.029277 
SARDH_RAT Sarcosine dehydrogenase 2.7 0.029758 
AL4A1_RAT Delta-1-pyrroline-5-carboxylate 
dehydrogenase, mitochondrial 
2.8 0.03048617 
ACOX2_RAT Peroxisomal acyl-coenzyme A oxidase 
2 
3.6 0.03222387 
HSPA1A_RAT Heat shock 70 kDa protein 1A 1.6 0.033711025 
ACON_RAT Aconitate hydratase, mitochondrial 2.8 0.036747316 
ANXA6_RAT Annexin A6 1.8 0.037249 
CHDH_RAT Choline dehydrogenase  0.038216395 
NADK2_RAT NAD kinase 2, mitochondrial 1.7 0.040638811 
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Table 14 Group IV: proteins down-regulated in ZF-EVs. 
Mapped ID The citric acid (TCA) cycle 
and electron transport 
Fold 
change 
ANOVA 
(pvalue) 
BASI_RAT Basigin 4.5 0.000395 
MOT1_RAT Monocarboxylate transporter 1 3.9 0.000853 
IDHP_RAT Isocitrate dehydrogenase [NADP], 
mitochondrial 
3.7 0.009461 
MDHM_RA
T 
Malate dehydrogenase, mitochondrial 2.2 0.012193 
SDHA_RAT Succinate dehydrogenase flavoprotein 
subunit, mitochondrial 
2.3 0.017234 
ETFD_RAT Electron transfer flavoprotein-ubiquinone-
oxidoreductase, mitochondrial 
2.2 0.020697 
ACON_RAT Aconitate hydratase, mitochondrial 2.8 0.036747 
NDUAA_RA
T 
NADH dehydrogenase 1 alpha subcomplex 
subunit 10, mitochondrial 
2.2 0.045338 
 
 
Only a few exosomal markers were identified in the proteomic analysis of Zucker 
rat hepatocyte-derived EVs, namely Cd81 (p value = 0.010499), Aip1/Alix (p 
value = 0.002796), Ras-related protein Rab1A (p value = 0.014829) and Rab11A 
(p value = 0.04518) They were all down-regulated in ZF-EVs, which was 
previously shown by WB analysis carried out to characterize the content of 
Zucker rat hepatocyte-secreted EVs (Figure 44). AnnexinVI, a member of a 
group of calcium dependant membrane and phospholipid binding proteins, which 
have been implicated in endocytic pathways, specifically in membrane 
organization and cell surface receptor activity through interactions with the actin 
cytoskeleton (Cornely et al. 2011). Another annexin, AnnexinV was validated by 
WB, confirming its down-regulation in ZF-EVs (Figure 44). Another differentially 
expressed protein was PDC6I which is involved in sorting cargo proteins of the 
MVB for incorporation into ILVs. Proteomic analysis has also revealed the 
presence of the tetraspanin Cd81 was also identified in EVs secreted by Zucker 
rat hepatocytes and, as previously shown, significantly less abundant in ZF-EVs. 
In agreement with the proteomic analysis there were also increased shuttling of 
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Hsp70 in ZF-EVs. Various GTPases, the key regulators in intracellular 
membrane trafficking were also found in ZL DEPs, such as Rab1A and Rab1B. 
On the other hand, GTP-binding protein SAR1b is a curvature-sensing 
component of the COPII coat complex and has been showing to be crucial in 
membrane bending, recruitment of coat components and vesicle formation. 
Additionally, the intrinsic GTPase activity of Sar1 is necessary for remodelling 
lipid bilayers (Hanna et al. 2016). The lysosomal protein, Lamp1 was also 
associated to ZF-EVs (p value = 0.00216).  
The list of proteins rendered by the proteomic analysis was also searched for 
proteins which were characteristic to hepatocytes. Thus, we found that the 
facilitated glucose transprter 2 (Glut2) was significantly down-regulated in ZF-
EVs (p value=0.000316). This transporter is specific to the liver and it is 
responsible for the transfer of glucose across the plasma membrane of 
hepatocytes. On the other hand, classification according to functions revealed 
the presence of proteins involved in detoxification processes and xenobiotic 
metabolism (Table 15). Several members of the P450 superfamily were 
included, with specific enrichment of those belonging to the 2D family. However, 
other proteins functioning in metabolism of endogenous and exogenous 
compounds such as UDP, UGTs and glutathione S-transferases were detected 
as well. UGTs are, after P450s, the major contributors to drug metabolism. At 
least three distinct members of the 2B family of UGT proteins were present in 
Zucker rat hepatocyte secreted EVs and their expression reduced in ZF-EVs. 
UGT enzymes are membrane bound and are found primarily in ER (Conde-
Vancells et al. 2010).  
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Table 15 Group V: proteins down-regulated in ZF-EVs. 
Mapped ID Xenobiotic metabolism Fold 
change 
ANOVA 
(pvalue) 
MGST1_RAT Microsomal glutathione S-transferase 1 2.5 0.003286481 
CP2C7_RAT Cytochrome P450 2C38 2.3  0.03454715 
CP2DQ_RAT Cytochrome P450 2D26 3.5 0.001033149 
CP2D1_RAT Cytochrome P450 2D1 3.3 0.000933666 
CP2D4_RAT Cytochrome P450 2D6 4.0 0.001033149 
UGDH_RAT UDP-glucose 6-dehydrogenase, 
mitochondrial 
1.7 0.024328271 
ALDH2_RAT Aldehyde dehydrogenase, mitochondrial 4.1 0.006310028 
CP2DA_RAT Cytochrome P450 2D10 3.7 0.001968706 
HYEP_RAT Epoxide hydrolase 1 3.7 0.005862539 
 
Some of the proteins specifically produced by the liver such as serum albumin, 
fibrinogen, angiopoietin, plasminogen, serotransferrin, alpha-1-macroglobulin 
and, prothrombin, were all identified in EVs isolated from conditioned medium of 
Zucker primary rat hepatocytes and were all reduced in ZF-EVs, which again 
may reflect the condition of steatotic hepatocytes. 
 
5.2.2.5.3 Validation by Western blot 
 
To confirm the quantitative proteomics data, the differential abundance of a set of 
proteins was investigated using WB analysis (Figure 49). In agreement with the 
proteomics data, an increased expression in Fas, Comt and Pgd6 proteins was 
seen in ZF-EVs. Moreover, Catalase, Cyp2d1, Syndecan4 as well as FerritinLC, 
among others were found to be highly down-regulated in ZF-EVs. WB has 
revealed that Fas and Ferritin LC were solely detected in EVs. ZF-EVs were 
highly enriched in Comt protein, interestingly, we detected a lower mobility, 
protein band for Comt in association with Zucker rat hepatocyte-derived EVs, 
probably corresponding to post-translationally modified forms of the protein. 
Modified Catalase protein was also secreted in EVs, and visualized as a double 
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band. Pgd6 protein expression in cells was mirrored in their secreted EVs, and 
confirmed our previous proteomics results of its increased abundance in ZF-EVs. 
Syndecan4, one of four members of transmembrane proteoglycan family of 
proteins that functions as a receptor in intracellular signalling (Ju et al. 2014). 
Additionally, together with Syntenin and Alix regulate exosomes formation 
(Baietti et al. 2012) was not detected in neither ZF-hepatocytes nor in their 
secreted EVs. Additionally, as already mentioned, other proteins, previously 
validated by WB (Figure 44) were identified in our proteomic analysis.  
 
 
 
 
 
 
 
 
 
 
 
Figure 49 Western-blot analysis of DEPs identified by quantitative label free 
proteomic analysis, by WB. Representative WB of three independent preparations of EVs. 
Whole cell lysates of Zucker rat hepatocytes (10 µg) and their corresponding EVs (10 µg) 
were immunoblotted using antibodies against proteins such as fatty acid synthase (Fas), 6-
phosphogluconate dehydrogenase, decarboxylating (Pgd6) and Catechol O-
methyltransferase (Comt), which were up-regulated in ZF-EVs and Catalase, Cyp2d1, 
Syndecan4 and FerritinLC, which were found down-regulated in ZF-EVs. 
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5.4.2.6 Nucleic acid content 
 
Afterwards, we have analyzed the nucleic acid material that was contained in 
250 μg of ZL- and ZF-EVs. Briefly, following EV lysis and nucleic acid 
purification, a small amount of the exosomal RNA (exoRNA) fraction was stored 
for analysis and the remaining part was treated with DNaseI. The RNA 
concentration before and after the treatment with DNaseI was measured by 
NanoDrop (Figure 50A). Most of the nucleic acid disappeared with the DNaseI 
treatment, indicating that these EVs contained a significant amout of DNA 
(Figure 50C). Our results show that although the overall amount of isolated RNA 
was low in both, ZF-EVs contained nearly 3-times more RNA as compared to the 
ZL-EVs (Figure 50A, bottom table). However, the nucleic acid concentration 
before DNA treatment was 12 times lower in ZF-EVs (Figure 50A, top table). 
Together these results could indicate that different proportion of DNA and RNA 
are found in ZL versus ZF, with ZF containing more RNA and less DNA than ZL. 
It seems that, before the treatment with DNaseI, the measurement of RNA 
concentration was inaccurate (Figure 50A). 
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Figure 50 Nucleic acid content of Zucker rat hepatocyte-derived EVs. RNA was 
isolated from 250 µg of ZL-EVs and ZF-EVs using RNeasy Mini Kit. (A) Quantification of 
isolated RNA with NanoDrop, before (top) and after (bottom) the DNase treatment. (B) 2 
µl of each RNA sample was resolved by SDS-PAGE electrophoresis. (C) The 
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electropherograms showing the size distribution in nucleotides (nt) and fluorescent intensity 
of the total RNA in EVs before the DNase treatment (D) The electropherograms showing 
the size distribution in nucleotides (nt) and fluorescent intensity of the total RNA in EVs 
after the DNase treatment (E) RNA quantification (pg/µl), as analyzed by Bioanalyzer. n=1. 
 
 
Subsequently, the RNA profiles of both fractions were analyzed using Agilent 
2100 Bioanalyzer (Figure 50). Individual electropherograms corresponding to 
untreated samples (Figure 50C) and DNaseI-treated samples (Figure 50D) are 
shown. We did not observe significant amount of ribosomal RNAs, and the major 
peak detected indicated the presence of nucleic acids of small size. Furthermore, 
this major peak was significantly reduced after the DNaseI treatment what was 
indicative as already mentioned that these EVs contains DNA (Figure 50E).  
In summary, our results show that EVs secreted by Zucker hepatocytes contain 
DNA and RNA, and the proportion of these two nucleic acids are different in EVs 
secreted by lean (ZL) and fatty (ZF) hepatocytes.  
 
 
5.4.2.7 Lipid content 
 
Once having explored proteins and nucleic acids that are present in Zucker 
hepatocyte secreted-EVs, we studied their lipid content. The presence of 
sphingomyelin, cholesterol, lysophosphatidylcholine, arachidonic acid and other 
fatty acids, prostaglandins and leukotrienes among other, has been shown in 
EVs (Record et al. 2014). As a starting point in this section, we decided to 
evaluate the possible contamination of our preparations with lipoproteins, giving 
that they are major carriers of lipids. 
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To address this issue, we analysed the presence of some Apolipoproteins by 
WB, in particular ApoB, a protein forming part of the core of lipoproteins, and 
ApoE, a protein involved in the renewal of lipoproteins (Getz & Reardon 2009). 
We performed WB analysis of three independent preparations of lysates 
obtained from Zucker rat hepatocytes and their secreted EVs and confirmed the 
presence of both, ApoB and ApoE (Figure 51A). As can be observed, ApoB was 
highly enriched in cells, as compared to ApoE, with no differences between the 
two sample groups (ZL vs. ZF). However, ApoE clearly was more abundant in 
ZF-hepatocytes as compared to the control (ZL). Moreover, Zucker-EVs were 
enriched in ApoE protein, with no obvious difference between the two sample 
groups. Importantly, although we could detect some ApoB in the EVs 
preparations that could indicate certain degree of contamination by lipoproteins, 
there was no difference in enrichment between ZL- and ZF-EVs. The elevated 
levels of ApoE associated to hepatic EVs, rise the possibility of EVs having a role 
in lipoprotein metabolism or serving to transport out recycled lipoprotein-
associated proteins has already been proposed (Conde-Vancells et al. 2008). In 
agreement with this possible role of ApoE-associated to EVs in metabolism of 
lipoproteins, although in other cellular systems came from a recent article 
published by van Niel and co-workers (van Niel et al. 2015). This work highlight 
the role of ApoE in sorting molecules to ILV in MVB (van Niel et al. 2015). In 
summary, the low presence of ApoB and taking also into account, the cryo-EM 
analysis that has been performed for a significant number of independant 
preparatios of Zucker-EVs (Figure 51A) in which was not observed the presence 
of lipoproteins, it is possible to conclude that the lipoprotein contamination of the 
hepatic-EV preparation was low.  
 
 
 
 
231 
 
 
 
Figure 51 Triglyceride content in Zucker rat hepatocyte-derived EVs. Triglyceride 
content of primary Zucker rat hepatocytes and their secreted-EVs was measured using lipase 
activity assay. (A) Lipid-related proteins were analyzed by WB in lysates from Zucker rat 
hepatocytes (10 µg) and their secreted-EVs (5 µg). (B) Lipase assay of lysates from the 3T3-
L1 adipocytes and hypertrophic 3T3-L1 adipocytes with their secreted-EVs, to establish the 
sensitivity of the assay. 50 µg of the whole cell lysates of Zucker rat hepatocytes and 2µg of 
lysed EVs were used in the assay (C) Lysed samples; n=4. (D) Intact EV samples; n=4. 
Error bars=SD. The p values were denoted as follows: 0.01-0.05=*,0.01-0.001=**, 0.001-
0.0001=***. Unpaired student t-test was performed to determine significant differences.  
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Adipophilin, another adipocyte-associated protein was also secreted in Zucker 
hepatocyte EVs as seen by WB (Figure 51A). We found adipophilin/perilipin2 
associated with our vesicles and, although it varied between preparations, it was 
slightly reduced in ZF-EVs, as compared to the lean control. The trend was 
mirrored in the parent cells, although it was also variable. These results could 
indicate the presence of some lipid droplets in our preparations although 
alternatively, it could be as ApoE, in which the protein plays a role in their 
metabolism.  
Subsequently, using the lipase activity assay (section 2.12), we investigated the 
triglyceride content in Zucker hepatocytes and their secreted EVs. In order to 
determine the triglyceride concentration, the amount of free glycerol, 
enzymatically hydrolyzed from triglycerides by lipoprotein lipase, can be 
accurately measured (Demel & Jackson 1985). The optimization of the assay 
was performed first, with negative controls of PBS, lysis buffer and the FGR, 
producing minimal background (Figure 51B), and VLDLs as positive controls 
confirming the functionality of the assay. Biological samples of lysates obtained 
from 3T3-L1 adipocytes as well as as hypertrophic 3T3-L1 adipocytes and their 
corresponding, secreted-EVs were also assayed in parallel as positive controls 
(Figure 51B). Hypertrophic adipocytes were found to have significantly higher 
triglyceride content as expected. Interestingly, their secreted EVs present exactly 
the opposite trend, with more triglycerides being retained in the cell as to what is 
being secreted in EVs (Figure 51B). Subsequently, Zucker rat hepatocytes at T0 
and after 36 h in culture, and their secreted EV were lysed and subjected to the 
lipase activity assay to measure their triglyceride content. OD values were 
normalized by the protein concentration and presented in Figure 51C. As 
expected, significantly increased levels of triglyceride content were observed in 
ZF-hepatocytes at T0 as well as at 36 h, with a slight increase at 36 hours, 
indicating possible accumulation of TG in culture. Moreover, no differences were 
found between the triglyceride content of ZL- and ZF-EVs. 
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Figure 52 Validation of the lipid content in intact Zucker rat hepatocyte-derived EVs. 
The content of lipids in EV samples was evaluated directly by flow cytometry of Bodipy-
stained EV samples. A representative SSC vs. FSC density plots of Bodipy stained samples: 
(A) PBS control (B) ZL-EVs (C) ZF-EVs. (D) Flow cytometry histograms of P1 gated 
unstained (green line) and Bodipy-stained (orange line) EVs in 4 independent preparations 
of ZL- and ZF-EVs. (E) Median FITC-A fluorescent intensity, in 30,000 events; n=4. Error 
bars = SD. 
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However, when intact EV samples were subjected to the lipase activity assay, 
under the same conditions, an increase in the triglyceride content was seen in 
the sample of ZF-EVs (Figure 51D).  
To further validate these results, Bopidy staining of intact EVs was performed 
and analyzed by flow cytometry (Figure 52). The population of EVs was selected 
based on their forward and side scatter properties, not considering the 
background of PBS, in which the EVs are resuspended (Figure 52A). The 
selected gate (P1) was specific to the population of ZL- (Figure 52B) and ZF-
EVs (Figure 52C). Four independent pairs of EVs were assayed. Figure 52D 
shows the histograms of the FITC-A intensity peaks in ZL- and ZF-stained EVs in 
matched preparations. Quantification of the median FITC-A fluorescent intensity, 
although not significant, it showed an increase in Bodipy-stained lipids in ZF-
EVs, in agreement with previous results of lipase activity assay in intact EVs 
(Figure 52B).  
 
 
5.4.2.8 Testing the Presence of Active Compounds in Zucker Hepatocyte-derived 
EVs 
 
Hepatic triacylglycerol lipase (LIPC) was identified by proteomic analysis to be 
present in EVs, and although not significant, a trend to be higher in ZF-EVs was 
observed. This was a trigger to investigate whether the enzyme was active and 
could catalyze the hydrolysis of TG. We modified the lipase assay and used our 
EVs as a possible external source of lipase. Briefly, for this experiment, 20 μg of 
ZL- and ZF-EVs were lysed and each sample assayed in duplicate (10 µg each). 
VLDLs were selected as a substrate for the assay and used in a concentration of 
1μg per sample. Intact EV samples were also included in the assay. Results are 
represented in Figure 53A.  
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Figure 53 Active molecules in Zucker rat hepatocyte-derived EVs. (A) Lipase activity 
assay in Zucker rat hepatocyte secreted-EVs, using VLDL as a substrate; n=4 (B) Lipase 
activity assay in Zucker rat hepatocyte secreted EVs, using Triglyceride Mix as a substrate; 
n=4. (C) Representative WB figure immunoblotted for Cyp2d1 in Zucker rat hepatocytes 
and their corresponding EVs; n=3 (D) Quantification of the fold change in the Cyp2d1 
protein secreted in ZL- and ZF-EVs. (E) Average fold change Cyp2d1 of the three 
independent preparations. (F) Activity assay in Zucker rat hepatocyte secreted EVs in three 
independent preparations; n=3 (G) The average activity of Cyp2d1; n=3. (H) The activity in 
Zucker rat hepatocyte alone. (I) The activity in Zucker rat hepatocyte-derived EVs alone. 
Error bars=SD. The p values were denoted as follows: 0.01-0.05=*, 0.01-0.001=**, 0.001-
0.0001=***. Unpaired student t-test was performed to determine significant differences. 
 
 
Lipase activity was detected in all samples; however, it was higher in lysed-EVs 
as compared to intact ones, which indicates that the lipase was not only 
associated to the surface of the EV, and some enzymatic activity was enclosed 
in EVs. In agreement with the proteomics data, a statistically significant increase 
in activity was seen in lysed ZF-EVs compared to ZL-EVs (Figure 51C). 
In addition, we also compared the activity in lysates from Zucker rat hepatocyte 
at T0 and 36h (Figure 53B). 10 μl of each sample was assayed and the resultant 
OD values were normalized by predetermined protein concentration. Using a 
triglyceride mix as a substrate, lipase activity was detected in hepatocyte 
extracts, both at T0 and at 36h, although significant reduction in activity was 
observed in that time frame. Moreover, the level of activity detected in EVs was 
significantly lower as compared to their parent cells (Figure 53B). Compared 
with the previous experiment, very low activity was seen in EVs with no 
differences between the sample of ZL- and ZF-EVs (Figure 53B). This could be 
due to the different substrates used in both assays.  
In our proteomic analysis of EVs, coming from Zucker rat hepatocytes, we also 
observed the presence of various subfamilies, C, D, and B of the P450 enzymes. 
In particular, cytochrome P450 2D1, an enzyme found in liver microsomes, 
involved in the NADPH-dependant electron transport and a oxidizes variety of 
compounds, fatty acids, steroids, and xenobiotics, was found to be significantly 
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down-regulated in ZF-EVs as compared to the control. This result was validated 
by WB, not only in EVs but also in parent cell whole lysates, which as missing in 
our proteomic analysis, and was associated with very interesting finding (Figure 
53C). First, significantly more Cyp2d1 was associated with hepatic-EVs as 
compared to their secreting cells. The densitometry of the Cyp2d1 excreted in 
EVs into the extracellular space as compared to the remaining in the secreting 
cell, although highly variable between the three independant preparations 
(Figure 53D), revealed that more Cyp2d1 was associated to ZF-EVs (Figure 
53E). To study in more detail, the presence of Cyp2d1 in Zucker rat hepatocyte-
derived EVs, we decided to explore the possibility that the enzyme contained 
within EVs, could, in fact, be in an active form. A luminescent assay, specific for 
the measurement of P450 2D1 was used. The activity of P450 2d1 was 
measured in 20 μl of EVs purified from primary Zucker rat hepatocytes after 36 h 
of in vitro culture and their corresponding hepatocyte lysates, from three 
independent sets of samples (Figure 53F). The activity of Cyp2d1 was readily 
detectable in EVs, confirming that the enzyme, which is carried in Zucker-EVs 
was active. Moreover, the activity of P450 2d1 in EVs was significantly higher 
than in parent cell lysates (Figure 53G). In addition, as mentioned above, we 
observed a significant variability in the level of activity, between independent 
preparations (Figure 53F). The average of three sample sets is presented in 
Figure 53G. In terms of the difference in activity between the ZL- and ZF-
hepatocytes and their corresponding EVs, our results indicate that slightly more 
active Cyp2d1 was associated to ZF-hepatocytes and the opposite trend was 
seen in EVs. 
In summary, we have detected the lipase activity as well as Cyp2d1 activity in 
our ZL- and ZF-EVs. More active lipase was associated to ZF-EVs when the 
VLDLs were used as a substrate. When using the triglyceride MIX as substrate, 
we detected higher level of lipase activity in cells than their secreted EVs, with 
more lipase being present in ZF-hepatocytes. The levels of activity have dropped 
between T0 and 36 h. On the other hand, we showed that the Cyp2d1 enzyme 
associated with hepatic-EVs was active. In terms of the protein expression we 
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confirmed that less Cyp2d1 protein was found in ZF-EVs as compared to the 
control EVs. Interestingly, however, when the difference the expression in cells 
and in secreted EVs was compared, which was missing in our proteomic 
analysis, we found that more Cyp2d1 was associated to ZF-EVs.  
 
5.5 Summary 
 
In summary, we conclude that our model of hepatocellular steatosis is valid and 
reflects the state of lipid overload in hepatocytes during simple steatosis. 
Moreover, with the experimental approach taken for the isolation of EVs, our 
preparations were free of contamination and exhibit significant enrichment in 
proteins related with EVs. 
The conditions of steatosis did affect the secretion and protein markers 
associated to EVs, isolated from all three hepatocyte-like cells. The result was 
confirmed in our primary hepatocyte model, which represents genetically induced 
obesity-related steatosis. Overall, the secretion of EVs increased in these 
steatotic conditions. The majority of exosomal proteins were significantly 
downregulated with an increase in heat shock proteins. 
We discovered that Zucker rat hepatocytes, lean and fatty show significant 
metabolic differences. It seems that during steatosis, mitochondrial functions are 
affected and accompanied by an increase in glycolysis. Interestingly, these 
conditions were reflected their secreted-EVs. The proteomic analysis of ZL- and 
ZF-EVs has revealed that the differentially expressed proteins up-regulated in 
ZF-EVs are related with PPP, pyruvate and fat metabolism, in contrary 
mitochondrial proteins were significantly down-regulated as well as proteins 
related to hepatic functions such as xenobiotic metabolism. We showed that the 
lipase enzyme and Cyp2d1 enzyme were active in hepatic-EVs. 
In addition, we identified that the abundance of adiponectin in ZF-EVs reflected 
the state of obesity, as judged by the reduction in adiponectin in ZF-EVs. Finally, 
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we identified nucleic acids in Zucker hepatocyte-derived EVs and slightly more 
contained in ZF-EVs. Graphically represented on Figure 54. 
 
5.6 Discussion 
 
Many studies have shown that hepatocytes can uptake the long-chain fatty acids, 
with C12-C18, and esterify them into neutral fat droplets that are then stored in 
their cytoplasm (Yan et al. 2015). The first case of an in vitro hepatic steatosis 
model was induced by the addition of 50% rat serum in a co-culture of adult and 
neonatal rat hepatocytes (Vajta et al. 1986). The use of FFAs was first 
established in HepG2 hepatoma cell line (Cui et al. 2010). In this study, 
researchers have induced the triglyceride accumulation with OA (1 mM), which 
resulted in lipid accumulation into the cytoplasm accompanied by the increase in 
ApoB protein. In addition, the Glut2 gene expression was upregulated in steatotic 
cells, which has been previously correlated with an increased glucose output 
from the liver and gluconeogenesis (Okamoto et al. 2002; Cui et al. 2010). 
Moreover, an OA-induced steatosis in HepG2 cells was associated with 
increased production and secretion of TNF and decreased expression of PPARα 
(Cui et al. 2010). It cannot be ignored however, that HepG2 is a cancer cell line 
that can exhibit abnormal function and altered metabolism. Chang liver cells 
were also used to induce lipid accumulation with OA and characterized as being 
viable model (Yan et al. 2015). A very elegant in vitro model was developed to 
study hepatic steatosis in the Reuber H35 rat hepatoma carrying the GFP 
reporter cells cultured in oleic or linoleic acid (Amol et al. 2009). The cells have 
been shown to recapitulate the main features of the actual disease such as 
increased fatty acid intake, intracellular triglyceride accumulation, increased 
reactive oxygen species accumulation, and decreased mitochondrial membrane 
potential. Moreover, it allows the study of the role of transcriptional regulation of 
nuclear factor κB (NFκB), heat shock response elements (HSE), and 
glucocorticoid response element (GRE) (Amol et al. 2009). While steatosis 
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represents a reversible state of excess intra-hepatic lipids, it is known to lead to 
generation of intracellular reactive oxygen species (ROS), via the oxidation of 
FAs, that in turn reduces the induction of oxidative stress and a reduction in the 
mitochondrial membrane potential. Moreover it has been shown that steatosis 
partially attenuated the NFκB reporter response to TNF in a dose dependant 
manner of free fatty acids (Amol et al. 2009).  
Fatty acid metabolism can be cell type specific and the different doses of FFAs 
and exposure time might be required, therefore, for our study, we selected three 
different hepatocyte-like cell lines, AML12, MLP29 and hepatoma HepG2 cells. 
We chose them to determine whether these differences would influence the 
amount of secreted EVs and in their marker composition. In order to achieve 
maximal lipid accumulation with minimal cytotoxic effect for subsequent isolation 
of EVs, we used oleic and palmitic acids, in a ratio of 2:1 at a final concentration 
of 1mM (Gómez-Lechón et al. 2007).  
One of the first reports on hepatic-EVs was by Conde-Vancells and co-workers 
where they successfully isolated EVs from the conditioned medium of the MLP29 
cells as well as primary rat hepatocytes, and pinpointed specific hepatic protein 
associated to EVs, asialoglycoprotein receptor (Asgr) (Conde-Vancells et al. 
2008). In this thesis for the first time we demonstrate the characterization of EVs 
secreted by hepatocytes in conditions of simple steatosis. Surprisingly, most the 
research conducted on liver-EVs, related with metabolic diseases, is related with 
non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) 
(Povero et al. 2008; Povero et al. 2015; Povero et al. 2014; Hirsova et al. 2016; 
Kakazu et al. 2015; Ban et al. 2016). It is unexpected, because simple steatosis 
is asymptomatic and reversible, with appropriate measures, therefore, we 
considered studying EVs at this stage of liver disease as vital for discovery of 
diagnostic measures. 
In our cellular models of steatosis, induced in the AML12 and MLP29 cells, we 
observed that the overall concentration of EVs was increased, which was not the 
case HepG2 cells, which could be due to its origin and better handling of cellular 
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stress or already increased rate of metabolism. As already mentioned, it is well 
described that cells under pathological conditions release higher concentration of 
EVs. Depending on the nature of EVs, it could be either a mechanism of disposal 
as a defence measure to cellular stress or release of mediators of protective 
immune response or signalling a proinflammatory response.  
In addition to increase in the amount of secreting EVs, we found significant 
difference in the abundance of EV-related proteins in steatotic conditions. 
Furthermore, we discovered variability in the expression of EV-related proteins 
between our three models, which could arise from their different origin, as the 
conditions of the purification process were kept constant throughout. It has been 
described that exosomal content vary depending on the source and the 
pathological conditions of the cell and can provide insight into how cells cope 
with the pathology (McDonald et al. 2014). Lipid overloaded-AML12 cells 
secreted EVs with downregulated markers of exosomes, such as Cd81, Aip1/Alix 
and Tsg101. Our results are in agreement with a recent research on EVs isolated 
from palmitic acid induced lipotoxicity in hepatoma cell line, Huh7 (Hirsova et al. 
2016). EVs in these conditions were shown to exhibit decreased expression of 
Alix, Tsg101 and Cd63 proteins, and were, as in accordance with our study, 
small vesicles of a maximum size of 200 nm. More importantly, they have shown, 
by targeting ROCK1, a kinase required for membrane blebbing, as well as 
Rab27b important for exosome biogenesis, that the main site of origin of this 
population of EVs was the plasma membrane (Hirsova et al. 2016). This could 
suggest, that the population, at least in part, of EVs secreted by our steatotic 
AML12 cells is composed by microvesicles, originating from the plasma 
membrane.  
On the other hand, MLP29 cells, responded completely different to the lipid 
overload. Their secreted-EVs did carry exosomal marker proteins with an 
enrichment of Rab8, Hsp70 and Flotillin-1 in steatotic-EVs. Interestingly, there 
was a significant amount of lysosomal marker LimpII in these EVs and lysosome 
function has been implicated in the regulation of EV content and secretion (Eitan 
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et al. 2016). The increase in Hsp70 could indicate a stress response, which 
might be induced due to accumulation of misfolded or aggregated protein in the 
cells, because of oxidative stress, and EVs reflect metabolic state of the cell and 
serve as a cargo disposal. Enhanced expression of Flotillin-1 in steatotic MLP29-
EVs, could indicate an involvement of lipid-rafts in EVs secretion as it has been 
described as one of the ESCRT-independent secretory pathways. In this system 
the Cd81 protein was detected in cells and affected by steatosis, however this 
result is not reflected in their secreted EVs. To sum up, these data suggest that 
these cells secrete more than one population of EVs, and depending on the 
condition the amount of each of them is altered.  
Despite the still limited knowledge on liver-EVs, as compared to other origins, 
initial observations suggest that these vesicles are important in liver physiology 
and pathophysiology (Masyuk et al. 2013). It has been shown that EVs isolated 
from an in vitro cell culture model of saturated fatty acid-induced lipotoxicity 
exhibit proangiogenic effect mediated by the protein vanin-1 associated to EVs 
(Povero et al. 2013). Utilizing the choline-deficient L-amino acid (CDAA) dietary 
murine NASH model, the same group have demonstrated the increased 
secretion of EVs in NASH (Povero et al. 2014). In addition, an involvement of 
hepatocyte-derived EVs on liver repair and regeneration via increasing the 
synthesis of sphingosine-1-phosphate (S1P) has recently been discovered 
(Nojima et al. 2016)  
Our research contributes to the knowledge on hepatocyte-EVs in physiology and 
pathology of hepatic steatosis. We have shown that steatotic hepatocytes 
secrete higher amount of EVs and that their content is significantly affected by 
these conditions, as seen by the change in protein marker expression, which 
could be further explored for disease biomarker discovery. Further experiments 
would be needed to confirm whether serum-EVs reflect the nature of EVs from 
steatotic hepatocytes.  
Although cell lines are suitable in vitro models to study EVs secreted by 
hepatocytes, primary hepatocytes are meant to provide more relevant data since 
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it is the in vitro model that more closely mimics the in vivo state of these cells. In 
this study, we use hepatocytes from the livers of Zucker rats (Lean and Fatty), 
and for the isolation of EVs we culture them in standard cell culture conditions 
with EV-depleted medium for the period of 36h. The animals used for the study 
were all males, age-matched between 12-14 weeks that already have the 
manifestations of MetS, including the obesity accompanied by hyperinsulinemia, 
hyperlipidemia, adipose hypertrophy, insulin resistance, and hepatic steatosis. 
Livers were dispersed using a collagenase and cell suspension subjected to a 
Percoll density centrifugation to eliminate contamination from other cells of the 
liver. As observed during the hepatic perfusion, the livers of ZF animals were 
larger and were paler due to a very high fat content. Although only a few studies 
have been conducted on primary Zucker hepatocytes, it has been concluded that 
the Zucker fa/fa rat’s obesity is expressed at the organismal as well as cellular 
levels (Kava et al. 1990). In addition to that, another study demonstrated that 
hepatocytes derived from Zucker rats can be successfully grown in primary 
culture and can be used to study the effects of the Fa gene (Goldstein & Johnson 
1980) which makes it suitable in vitro model for short time culture.  
Study on mitochondria from ZF rats showed that due to hepatic accumulation of 
fat, there was an impairment of mitochondrial function, reflecting the loss of 
oxidative phosphorylation capacity (Teodoro et al. 2006). The excessive build up 
of FFAs most probably causes a shift in metabolism of hepatocytes. To get more 
insights into the energy metabolism of our primary hepatocytes, we used an 
extracellular flux analyzer to measure their mitochondrial and glycolytic functions 
at 4 hours and following 24 hours in culture. ZF-hepatocytes exhibit a significant 
loss in all mitochondrial functions, which are slightly recovered after the 24 hours, 
and enhanced glycolytic parameters. Under normal conditions, the liver has a 
tremendous capacity for regeneration after injury, however this compensatory 
proliferation is compromised in steatotic livers (Vetelainen et al. 2007). 
Furthermore, as already mentioned, steatosis is a reversible process. Therefore, 
one possible explanation for the slightly recovery which we observe at 24h, could 
be the fact that the cells are trying to improve their metabolic phenotype which is 
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reflected as an increase in maximal respiration in ZF-hepatocytes. This 
improvement could also be attributed to the lack of stimulus from the expanding 
adipose tissue, which feeds FFAs to the liver due to uninhibited lipolysis (Qureshi 
& Abrams 2007). Moreover, it could also be associated with the increase in 
expression of genes encoding for hepatic functions.  
In terms of lipid accumulation assessment by Bodipy staining we discovered that 
hepatocytes isolated from the Lean (Fa/?) rat liver, accumulated some 
intracellular lipid droplets. It could be due to the high glucose media, as the 
animals heterozygous for the fa allele are prone to diet induced metabolic 
disturbances (Morris et al. 2003). For future studies, we could used a Sprague 
Dawley rat, which is a match genetic background control to ZL rat (fa/+) to 
exclude any effects of the heterozygosity of the fa allele.  
A theory has been put forward, that following the necessary change of media, 
after the cell attachment, some essential factors important for their own 
maintenance and conditioning are removed with arginine being proposed as an 
important conditioning factor (Goldstein & Johnson 1980). Moreover, lack of 
other cells of the liver also contribute to the effect of cell culture conditions. 
Interestingly, we found that the expression of Rab10 upon stimulation with insulin 
was significantly reduced in ZF-hepatocytes. Rab proteins are important 
regulators of insulin-stimulated Glut4 translocation to the plasma membrane 
(Chen et al. 2012), which has been described in cultured 3T3-L1 adipocytes 
(Vazirani et al. 2016). Moreover, it has been shown that the adipose-specific 
Rab10 knockout mice exhibit significantly reduced insulin-stimulated glucose 
uptake and Glut4 translocation and severely inhibited glucose production 
(Vazirani et al. 2016). As it is a partial inhibition, full effect of insulin on adipose 
tissue is the combined effect of Rab10-dependant and Rab10-independant 
pathways, which as indicated by our results may also cause the hepatic insulin 
resistance. 
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The first study on the nature and composition of EVs isolated from the 
conditioned medium of Zucker rat hepatocytes (Lean and Fatty) is presented in 
this thesis. We have performed a comprehensive analysis of their biochemical 
nature, protein cargo and showed that they carry active molecules. 
ZF-EV samples were significantly more concentrated when compared to their 
control ZL-EVs, both by protein amount (determined by Bradford and BCA 
assays) and by particle number (determined by NTA). In agreement with this 
result, increased number of circulating vesicles has been linked with obesity, 
inflammation and insulin resistance (M.-J. Lee et al. 2016). However, we 
observed that this alteration in amount accompanied by important differences in 
the presence of EV-related protein between ZL and ZF-EVs. Initially, we 
suspected that the abundance of lipids (expected to be hgher in ZF-EVs) could 
be interfering with the determination and then our interpretation that steatosis 
affects exosomal secretion in hepatocytes could be wrong. As we are working 
with primary culture of hepatocytes, we considered the possibility of lipoprotein 
co-isolation with our EVs, which would also influence the final quantification of 
the preparaions. Some ApoB signal was detected in EVs, indicating some extent 
of lipoprotein presence in EV preparations, however no significant differences 
were observed between ZL- and ZF-EVs, discarding that the observed 
differences in EV secretion were due to a higher lipoprotein contamination in ZF-
EV preparations. We also loaded a SDS-PAGE gel with equal amount of protein, 
according to the estimation done by Bradford, and again based on Comassie and 
Ponceu, no difference was found between ZL- and ZF-EVs. Together, these data 
indicate that different population of EVs were secreted by steatotic hepatocytes. 
This was also supported by the change in the size distribution and in the 
idioxanol density gradient that showed the presence of vesicles with different 
densities when comparing ZL- and ZF-EV preparations.  
There was one main population of vesicles associated with fraction 8 at density 
of 1.16g/ml, as seen by the distribution of Cd63, Rab8 and Apoe markers. 
However, in the sample of ZF-EVs, additionally the markers were also enriched 
246 
 
in fraction 9 at density of 1.19g/mL, corresponding to heavier vesicles. 
Interestingly, in ZF-EVs ApoE was solely present in vesicles of higher-density 
Moreover, the protein very highly enriched in the fraction 9 was Rab8 -a member 
of the Rab family of small GTPases- which plays an important role in membrane 
trafficking from the trans-Golgi network and recycling endosomes to the plasma 
membrane (Wang et al. 2015). The possibility that different routes, such as 
regulated by specific Rab GTPases, might be implicated in the production and 
secretion of EVs, with different biological functions has been proposed (Blanc & 
Vidal 2017). Each transport step requires that the activated Rab proteins bind to 
soluble factors that act as ‘effectors’ to transduce the signal of the Rab GTPase 
in the transport mechanism (Zerial & McBride 2001). Interestingly, the effector 
function of Rab8 is the stress activated protein kinase, which would be the 
second evidence that vesicles isolated from conditioned medium of ZF-
hepatocytes reflect the state of the cell and carry cell-specific markers. This 
would suggest a mechanism of specific cargo sorting or a specialized way that 
cell uses for the management of cellular stress. 
In connection with that, the composition of EVs is not a mere copy of cytosolic 
content; rather, specific molecules are selectively sorted into EVs to be secreted 
and amount and content of EVs can change in response to different stimuli 
(Villarroya-Beltri et al. 2016). In the case of ZF-EVs, their production must be 
governed by different mechanisms when compared with ZL-EVs, as seen by 
changes in all markers assessed, the Rab8, Cd81, Cd63, Tsg101, Aip1/Alix, 
Flotillin-1 and LimpII, and the overall increase in the secretion of EVs as 
measured by Bradford and NTA. We are possibly dealing with the enrichment in 
cell type-specific population of EVs. It must be considered that vesicular 
trafficking in the cells is a very complex process and involved endosomes, 
lysosomes, TGN and even the mitochondria. Therefore, more targeted 
experiments would be needed to unravel the exact origin of steatotic-EVs. 
Along these lines, increased levels of microvesicles have been observed in 
plasma, urine and other body fluids in patients suffering from a wide range of 
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complex diseases, which has been directly related with cell activation and 
pathogenesis (Müller 2012). Their release is often modulated by specific 
extracellular signals, which in the case of ZF-EVs could be caused by lipotoxicity, 
increased fatty acid synthesis or the ROS production in steatosis, supported by 
the controlled and regulated secretion of Hsp’s in ZF-EVs, accompanied by a 
clear reduction in the secreting cell.  
To gain further insight into the nature of Zucker hepatocyte derived-EVs we 
performed their proteomic, LC-MS/MS analysis. The obtained results have 
confirmed a very clear functional distinction between down- and up-regulated 
proteins enriched in ZF-EVs. In agreement with our results on mitochondrial and 
glycolytic functions in Zucker hepatocytes, which revealed that mitochondrial 
functions in ZF-hepatocytes were significantly downregulated when compared to 
the control with a respective increase in glycolytic capacity. The proteomic 
analysis of EVs secreted by these cells has shown that they seem to reflect the 
metabolic state of the cell. Most of proteins identified were down-regulated 
(>75%) in ZF-EVs and interestingly most of the down-regulated proteins were 
mitochondrial proteins. Furthermore, as shown by LC-MS/MS analysis, ZF-EVs 
concentrate proteins involved in glycolysis, de novo lipogenesis and PPP, which 
again goes in agreement with our previous results showing augmented glycolytic 
functions in ZF-hepatocytes. Our results indicate that cellular stress conditions 
are reflected in the content of cell derived-EVs. According to the proteomic 
analysis of EVs secreted by hypoxic 3T3-L1 adipocytes there was an enrichment 
in enzymes related to de novo lipogenesis such as acetyl-CoA carboxylase, 
glucose-6-phosphate dehydrogenase, and fatty acid synthase, which was 
confirmed in serum exosomes from ob/ob mice (Sano et al. 2014). We could 
hypothesize that the phenotype could be related with excessive lipid 
accumulation in tissues such as adipose hypertrophy, which in fact results in 
hypoxia and could also be related with hepatic steatosis, as reflected in our 
results. It is reasonable to hypothesize that steatotic-EVs could mediate 
phenotypic transfer in healthy cells, propagating the pathology.  
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Hepatocytes are the main functional constituents of the liver (<80%) which is 
involved in many vital functions of an organism, such as glycogen storage, 
hormone production, plasma protein synthesis, detoxification and production of 
bile necessary for digestion. In relation with the liver functions, it was previously 
shown by Conde-Vancells et al. that exosomes secreted by primary rat 
hepatocytes contain proteins involved in the detoxification processes as well as 
proteins synthesized in the liver (Conde-Vancells et al. 2008). The detoxifying 
enzymes are sorted in two different classes: those that induce chemical changes 
in the compound such as P450s (phase I metabolism), and those that are 
capable of forming adducts with the metabolite to facilitate its clearance from 
circulation such as UGTs and GSTs (Phase II metabolism) (Iyanagi 2007). In 
accordance with previously published results, we have identified members of 
P450 superfamily of enzymes, mainly of the class 2D, as well as uridine 5'-
diphospho-glucuronosyltransferase’s (UGTs) and Glutathione S-transferases 
(GSTs). Interestingly, most of these proteins primarily residue in the ER near 
each other and their extracellular existence is not a common phenomenon, 
neither their association with EVs. Moreover, it seems to be specific to certain 
members of the distinct families of drug metabolizing enzymes. The reason for 
this segregation is still unknown. 
Interestingly, LC-MS/MS analysis has revealed a consistent decrease in the 
abundance of all proteins necessary for drug metabolism in ZF-EVs as validated 
by WB and activity assay of Cyp2d1. In addition, as to the protein abundance, it 
was also consistently decreased in ZF-hepatocytes and interestingly the Cyp2d1 
activity was associated to EVs and in lesser extent to hepatocytes. The decrease 
in the number of drug-metabolizing enzymes may lead to inappropriate drug 
metabolism or have adverse effects on the liver. Significant alterations in the 
activity of drug-metabolizing enzymes may affect the clearance of therapeutic 
drugs, with the potential to result in harmful drug reactions. These results would 
indicate that steatotic liver could be more susceptible to liver damage due to 
lower expression of enzymes responsible for detoxification. Our results in EVs, 
are in agreement with previous findings that decreased P450 activities and 
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protein levels were observed with steatosis, and moreover, significant correlation 
between P450 activities and liver fat content have been found (Donato et al. 
2006).  
Interestingly, the proteomic analysis has also revealed the presence of the 
Catechol-O-methyltransferase (COMT) in Zucker hepatocyte-derived EVs. 
COMT is an enzyme predominantly expressed in the liver and is found in soluble 
(S-COMT) or membrane bound (MB-COMT) form (Doyle et al. 2004). Its main 
function includes degrading catecholamines such as dopamine, epinephrine, and 
norepinephrine and various other drugs and substances having catechol 
structure. It is involved in the inactivation of the catecholamine neurotransmitters 
by introducing a methyl group to the catecholamine donated by S-adenosyl 
methionine (SAM) (Raxworthy et al. 1982; Doyle et al. 2004; Casal et al. 2016). 
The association of COMT protein and activity with hepatic-EVs has been shown 
before (Conde-Vancells et al. 2008; Casal et al. 2016). However, in this doctoral 
thesis we show for the first time the significantly enhanced secretion of the 
soluble, short form Comt (S-Comt) of 24kDa, associated to steatotic-EVs, when 
compared to the control. COMT is predominantly expressed in the liver and a 
study has found elevated level of the protein in both liver tissue and plasma 
during liver injury to be a blood-marker of acetaminophen (APAP)-induced 
hepatotoxicity (Hu et al. 2014). Furthermore, our findings would also support the 
involvement of COMT in the response to liver injury. Methylation of catechols by 
COMT limits their oxidation and conjugation to glutathione therefore if this 
process is downregulated due to increased secretion of Comt, extracellularly, it 
would ultimately give rise to increased accumulation of toxic metabolites.  
There are some evidence of abnormalities in catecholamine metabolism in 
obesity (Levin et al. 1981). The ob/ob mice were shown to have less COMT 
activity in their liver than a normal mice (Feldman & Henderson 1978), which is in 
complete agreement with our results. According to the proteomic analysis and 
WB validation, we detected less Comt protein in hepatocyte lysates, however the 
phenotype of increase in secretion of Comt in EVs was evident. This would 
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support the hypothesis that decreased activity in the liver of the ob/ob mice could 
mean that more Comt protein is being secreted in association with EVs. Our 
results support that elevated levels of Comt in EVs could permit early detection 
of simple steatosis which will avoid that metabolic syndrome evolve to a more 
advanced state. 
In relation with MetS conditions, our proteomic analysis has also identified the 
presence of two lipases, the 60kDa lysophospholipase (LPP60) and the hepatic 
triacylglycerol lipase (LIPC). Both were increased in ZF-EVs, 1.68 and 2.6 folds 
respectively. The first studies on the function of hepatic lipase, performed in 
whole animals revealed that the enzyme was involved in the metabolism of 
remnant lipoproteins (Galan et al. 2000). Hepatic triacylglycerol lipase (H-TGL) is 
a lipolytic enzyme synthesized by hepatocytes and present in liver sinusoid 
capillaries bound to heparin sulphate proteoglycans (Miksztowicz et al. 2012). Its 
catalytic activity contributes to the hepatic uptake of HDL cholesterol by reducing 
particle size (Marques-Vidal et al. 1994). The activity of hepatic lipase was 
detected in plasma of both fed and fasted rats and was correlated with that in the 
liver (Galan et al. 2000). Our preliminary results show that the lipase associated 
to ZF-EVs could be active as we showed that they might be able to catalyze the 
hydrolysis of VLDL.  
The early studies on secretion of hepatic lipase were conducted on isolated rat 
liver parenchymal cells and in primary cultures of rat hepatocytes, and concluded 
that the continuous secretion requires protein syntheses (Galan et al. 2000). In 
that regard, results of our proteomic analysis indicate that one of the groups of 
up-regulated proteins in ZF-EVs, were related with protein synthesis and post-
translational modifications such as 40S ribosomal protein S4, elongation factor 1-
alpha, 60S ribosomal protein L9, and elongation factor 1-delta.  
The increase in hepatic lipase activity affects the remodelling of remnants 
lipoproteins and of HDL and subsequently increases the formation of small, 
dense LDL and smaller HDL particles (Carr et al. 2002). Its action leads to 
increase in FFA pool, which is available for uptake into hepatocytes (Miksztowicz 
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et al. 2012). Hepatic lipase activity is increased in insulin resistance states. In 
addition, patients with hepatic steatosis had higher lipase activity, which 
positively correlated with the severity of hepatic steatosis, even after controlling 
the insulin resistance (Miksztowicz et al. 2012). Interestingly it has correlated 
with the reduction in circulating adiponectin, which agrees with our results. 
Adiponectin has a hepato-protective role suppressing the in situ pro-inflammatory 
adipokines expression (Lucero et al. 2011).  
Our results indicate that the cargo of EVs released by steatotic hepatocytes do 
reflect the molecular state of the parent cell. Moreover, the fact that the lipase 
carried in ZF-EVs was active could negatively contribute to the atherogenic 
profile seen in MetS.  
We performed detailed proteomic analysis of EVs secreted by steatotic 
hepatocytes. Moreover, we gained some insight into their lipidic nature and 
lastly, we have shown that Zucker hepatocyte-derived EVs also contain nucleic 
acids. The Bioanalyzer RNA analysis has revealed, that no ribosomal RNA was 
detected and according to the nt count, that the predominant population of 
nucleic acids were of small size. ExoRNA was isolated using commercial 
columns from 250 µg of starting material, and samples were analysed before and 
following the DNaseI treatment. In the untreated experimental group, a 
predominant peak was identified at low nt count, which disappeared following the 
DNaseI treatment. These results indicate that along with the RNA we co-purifying 
small DNA species. Taking that into account, the RNA quantification of the 
DNase treated samples were indicative that the overall overall amount of RNA 
isolated was limited. We also observed that, ZF-EVs contained higher amout of 
RNA that their lean counterpart. The open question remains whether the RNA 
isolated is functional and how could it influence the physiology of a target cell. 
Our results are in agreement with the previous report of the existence of mRNA 
in EVs isolated from the conditioned medium of hepatic cell lines as well as 
primary hepatocytes, which was incorporated by recipient hepatic stellate cells 
(Royo et al. 2013). In addition, they identified that a significant subset of RNAs 
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was associated with hepatic functions, which points towards an existence of a 
regulated sorting mechanism and that the RNA content greatly depended on the 
cellular model (Royo et al. 2013). As to the potential DNA contamination, the 
possibility of apoptotic DNA contribution cannot be discarded, however our WB 
results did not indicate significant enrichement in cleaved Parp, neither the 
trypan blue viability assessment. Moreover, the intensity of the peak, in the 
DNase untreated samples, in both ZL- and ZF-EV samples was comparable. 
These results argue against the DNA present in EVs mostly come from 
undergoing apoptosis, and open the question about the possible role of the DNA 
associated to Zucker-EVs. The presence of single-stranded exosomal DNA 
(exoDNA) was found in microvesicles from tumour cells (Balaj et al. 2011). 
Genomic DNA fragments were discovered in prostate cancer secreted EVs. 
Moreover, the p53 and PTEN genes in the EV subpopulations had the same 
mutation as the parental tumour cells (Lazaro-Ibanez et al. 2014).  
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Figure 54 Summary diagram of results describen in chapter 3. Graphical representation 
of results regarding the characterization of EVs isolated from steatotic hepatocytes.  
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RESULTS CHAPTER 4 
 
6. The effect of Zucker rat hepatocyte-derived EVs on 
3T3-L1 adipocytes 
 
6.1 Chapter 4 Aims: 
 
• Study the possible influence of hepatic-EVs on 3T3-L1 adipogenesis.  
• Investigate the changes in adipokine secretion by 3T3-L1 adipocytes upon 
exposure to hepatic-EVs. 
• Study whether Zucker-EVs can transfer their glycolytic phenotype on 
recipient 3T3-L1 adipocytes.  
• Investigate insulin sensitivity in 3T3-L1 adipocytes following the treatment 
with hepatic-EVs. 
 
6.2 Introduction  
 
As it has been emphasized along this thesis that the adipose tissue in the 
context of obesity is highly affected in terms of physiology and metabolism. In 
addition, adipose tissue greatly influences the physiology of peripheral tissues 
involved in the development of MetS. Besides, it has been shown that, at least in 
part, these effects are mediated by adipose-derived EVs. They have been shown 
to cause activation in peripheral blood monocytes and acquisition of the 
proinflammatory phenotype with increased secretion of TNF and IL-6 (Deng et al. 
2009). Moreover, human AT-EVs are able to modulate insulin signalling in 
hepatocytes and thereby contribute to systemic insulin resistance (Mariëtte E G 
Kranendonk et al. 2014). More recently it was concluded that AT is a very 
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important source of circulating exosomal miRNAs, which can regulate gene 
expression in target tissues such as liver and muscle (Thomou et al. 2017). 
These are just few examples, but overall, most of research on the involvement of 
EVs in the development of MetS addresses the effect produced by adipose-
derived EVs. Conversely, based on data presented in this thesis, other cell types 
metabolically affected, such as hepatic steatosis not only secrete EVs, but of a 
significantly distinct phenotype, which in physiological conditions contribute to the 
pool of circulating EVs.  
Having that in mind, in the last part of this thesis, we focused on the possible 
effects that EVs, isolated from steatotic hepatocytes, may have on adipocytes. 
Our preliminary analysis covers processes such as adipogenesis progression, 
gene expression, adipokine secretion, energy metabolism and finally insulin 
sensitivity.  
 
6.3 Results 
 
6.3.1 Effect of Zucker Rat Hepatocyte-derived EVs on 3T3-L1 Adipocyte 
Differentiation 
 
The 3T3-L1 cell line is derived from 17-19-day-old Swiss 3T3 mouse embryos 
(Sarjeant & Stephens 2012) and can be propagated indefinitely in culture. For 
differentiation into adipocytes, once the confluent monolayer is reached, the 3T3 
cells stop growing and remain viable in resting state for a long period of time 
when the accumulation of lipid droplets is observed (Green & Kehinde 1974) 
which has been shown to be significantly enhanced by insulin (Green & Kehinde 
1975; Efthimios 1978). Furthermore, apart from insulin other hormones are 
involved in the differentiation process of the 3T3-L1 pre-adipocyte cell line such 
as prostaglandins, which increase cyclic AMP levels in fibroblasts and lower 
them in adipocytes. Indomethacin, an inhibitor of prostaglandin biosynthesis, has 
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been found to shorten the differentiation time significantly in the presence of 
insulin and increase the expression of lipogenic enzyme activity (Williams & 
Polakis 1977).  
In the presence of an adipogenic cocktail, confluent 3T3-L1 cells differentiate to 
mature adipocytes. The basic adipogenic cocktail contains insulin, DEX, and 
IBMX and in some studies, rosiglitazone. The usage of rosiglitazone additive was 
based on the earlier observation that human liposarcoma cells can be induced to 
undergo adipose differentiation in the presence of thiazolidinedione (Zebisch et 
al. 2012). In recent years several microarray studies on the gene expression in 
the 3T3-L1 cell differentiation have been published, which came with the 
discovery of several differentiation markers.  
AT in obesity is characterized by dysfunctional hypertrophic adipocytes, an 
increase in proportion of adipose progenitors and infiltration of immune cells. The 
limitation in AT expansion, in part due to inhibition of adipocyte progenitor 
differentiation in an inflammatory microenvironment, which in turn leads to 
ectopic accumulation of lipids in peripheral tissues (Dani 2013). 
Having all that in mind, we first sought to study the effect of Zucker rat 
hepatocyte secreted EVs on the progression of the 3T3-L1 cells differentiation. 
The workflow of the experimental design is shown in Figure 55. Briefly, standard 
protocol for the differentiation of 3T3-L1 cells was followed with the minor 
modification of EV-depleted medium being used throughout the differentiation 
process instead of the ordinary DMEM, to avoid confusing results produced by 
FBS-EVs. Once the 3T3-L1 fibroblasts reached confluence, cells were 
replenished with the fresh growth medium for 48 h before commencing the 
differentiation. At that point the first sample was collected. Subsequently, 
together with the adipogenic cocktail, all six experimental groups, one for each 
time point, were treated with 30 μg of ZL-, ZF-EVs or left untreated, as indicated 
in Figure 55. After 48 h, the first ´Differentiation ´experimental group was 
collected and stored at -800C, following the next round of treatment for the 
remaining groups. Once all experimental groups were collected, total RNA was 
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isolated and processed for the qPCR analysis of adipogenesis-related gene 
expression. Each sample was run in duplicate. Validation and normalization was 
done using various housekeeping genes, depending on the differentiation stage 
of the 3T3-L1 cells.  
The issue of housekeeping genes used at different stages of 3T3-L1 cell 
differentiation has been studied already and the research paper validating 
reference genes for qPCR gene expression analysis was published (Arsenijevic 
et al. 2012). Here, the recommended, most stable housekeeping genes were 
used, moreover the analysis was performed with each individual housekeeping 
gene to assure accuracy. The ATP synthase subunit beta, mitochondrial (ATP-
5b) and hypoxanthine-guanine phosphoribosyltransferase (HPRT) were used to 
normalize the clonal expansion phase sample group and the large ribosomal 
protein L13a (RPL), Non-POU-domain containing octamer binding protein 
(NoNo) and ß-actin (ACTB) the terminal differentiation phase experimental 
groups. Clonal expansion corresponds to the differentiation experimental groups 
and the remaining to the terminal differentiation. 
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Figure 55 Experimental design of the study of the effect of Zucker rat hepatocyte 
secreted EVs on differentiation of 3T3-L1 cells. Diagram representing the experimental 
designed to study the influence of Zucker rat hepatocyte secreted EVs on the progression of 
differentiation of 3T3-L1 cells into adipocytes. 3T3-L1 cells were differentiated following the 
standard protocol with minor modifications of the EV depleted medium being used. As 
indicated by upward dotted arrow, at each time point, cells were differentiated as usual or in 
the presence of 30 µg of ZL- or ZF-EVs. The protocol follows 12-day differentiation 
timeline with media change every 48h. At each time point samples were collected for 
subsequent qPCR analysis. The final samples were analyzed by flow cytometry for lipid 
accumulation by staining the cells with Bodipy.  
 
 
 
 
 
259 
 
Following the induction of differentiation, at the clonal expansion stage, gene 
expression analysis was performed and compared to the expression in 3T3-L1 
fibroblasts, which were used as a control (Figure 56). Then, the same panel of 
genes was analyzed at the terminal differentiation stage that begins after insulin 
addition and ends at day 12 (Figure 56). In this case, the level of gene 
expression in pre-adipocytes was used as control (Figure 57). We analysed the 
expressions of several representative genes of various classes such as 
differentiation related Pparg, adipocyte fatty acid binding protein (Ap2) and 
CCAAT/enhancer binding protein alpha (Cebpa) (Figure 56A). PPARγ is a 
master regulator of adipogenesis and has been shown to be crucial and sufficient 
for adipocyte development in vitro and in vivo (Sarjeant & Stephens 2012). AP2 
is a key mediator of intracellular transport and metabolism of fatty acids. Its 
expression during adipocyte differentiation is regulated through the actions of 
PPARγ and C/EBPalpha (Sun et al. 2003). Another set of genes was related with 
lipid metabolism such as fatty acid synthase (Fasn), adipose differentiation-
related protein (Plin2), perilipin-3 (Plin3), involved in lipid droplet formation (Nose 
et al. 2013). Furthermore, adiponectin gene (Adipoq), which promotes adipocyte 
differentiation, insulin sensitivity, and lipid accumulation was also induced in our 
panel. Moreover, the ability of adipocytes to respond to insulin and to express 
fatty acid binding protein genes, lipoprotein lipase and Glut4 is required during 
their differentiation into mature adipocytes (Yamamoto et al. 2002). Knowing that, 
the expression of Slc2a4 gene, encoding for Glut4 was also assessed in our 
study. Finally, the expression of known adipose-produced chemokine, CCL5 
(RANTES), which promotes the recruitment of macrophages to adipose tissue 
(Keophiphath et al. 2010) was also measured.  
The results indicate that no major changes were seen in the level of expression 
of Pparg and Ap2 in cells differentiated in the presence of EVs, as compared to 
the untreated sample at the clonal expansion stage. Upon differentiation, the 
expression of the Cebpa increased 8-fold, however, cells differentiated in the 
presence of EVs did not reach that level of expression. Nearly, a 2-fold decrease 
was observed in cells treated with ZL-EVs and 1.5 times in ZF treated cells. More 
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pronounced changes were seen in the expression of lipid-related genes (Figure 
56B). The expression of Fasn was increased in cells differentiated with ZF-EVs 
and in turn slightly decreased in cells treated with ZL-EVs. Moreover, the 
increase in the expression of Plin3 in ZF-EV treated adipocytes was observed 
with the same trend for the Slc2a4 gene, nearly 5-fold increase in ZF-EV treated 
cells. Differentiation strongly induced the expression of adiponectin, however 
treated cells, did not reach the same level of abundance of adiponectin mRNA as 
the untreated cells. The association of chronic, low grade inflammation and the 
secretion of inflammatory cytokines and chemokines with the adipose tissue in 
obesity has been well described with TNF and IL-6 being the first ones to be 
identified as a possible link (Matter & Handschin 2007). Since then many more 
have been identified, among them, CCL5 also known as RANTES, a T-cell 
expressed and secreted chemokine (Matter & Handschin 2007), which seems to 
be very strongly induced by ZL-EVs (Figure 56C and 56C).  
The same panel of genes, as in Figure 57, was assessed during the terminal 
differentiation stage of adipogenesis at four different time points. First, after the 
addition of insulin and later at day 6, day 8, and day 10 of differentiation with the 
addition of complete medium (Figure 55) The data was analyzed using pre-
adipocytes, just after the induction of differentiation as a control.  
With regards to genes involved in the differentiation process, we found that cells 
treated with ZF-EVs did not respond to insulin as the ZL-control or the untreated 
(Figure 57). The same trend was seen for Ap2 and Cebpa gene expression. At a 
subsequent stage with the first addition of complete medium (day 6), the 
response was recovered, with a notable increase in expression of all three 
genes, Pparg, Ap2. ZL-EV treated cells caused slightly higher induction of Ap2 
and Cebpa and ZF-EVs in Pparg. The increasing trend was also maintained in 
the following stage, at day 8, the elevated expression in EV-treated samples in 
the expression of all three genes, more in ZF-EVs treated cells. 
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Figure 56 Gene expression analysis in differentiating 3T3-L1 cells in the presence of 
Zucker rat hepatocyte secreted EVs. mRNA levels of genes encoding for (A) Peroxisome 
proliferator-activated receptor gamma, Fatty acid binding protein, CCAAT/enhancer-
binding protein alpha, respectively (B) Fatty acid synthase, Perilipin2, Perilipin3, 
Adiponectin, Glut4, respectively (C) RANTES, at the clonal expansion stage of the 
differentiation. Biological replicates = 1, technical replicate = 3.  
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Figure 57 Gene expression analysis in differentiating 3T3-L1 cells in the presence of 
Zucker rat hepatocyte secreted EVs. mRNA levels of genes encoding for (A) Peroxisome 
proliferator-activated receptor gamma, Fatty acid binding protein, CCAAT/enhancer-
binding protein alpha, respectively (B) Fatty acid synthase, Perilipin2, Perilipin3, 
Adiponectin, Glut4, respectively (C) RANTES, at the terminal stage of differentiation. 
Biological replicates = 1, technical replicate = 3.  
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At later stages of differentiation, when cells mostly accumulate lipids, the trend 
was reversed, as seen by the decline in expression of adipogenesis-related 
genes in cells differentiated with ZF-EVs. In the lipid-related gene group we 
found decreasing tendency in treated cells, upon the stimulation with insulin, for 
all genes analyzed. Remarkably, Adipoq and Plin2 expression was specifically 
reduced in ZF-EV treated cells. At day 6, the first day when growth medium 
without other factors was added to cells, the response in EV-treated cells was 
recovered with cells exposed to ZF-EVs exhibit lowered capacity to recover as 
compared to cells treated with ZL-EVs. Higher expression was only seen in 
Adipoq following exposure to ZF-EVs. Interestingly, between day 8 and day 10 of 
differentiation, the expression profiles reversed. Plin2 and Adipoq expression 
switches from being markedly increased at day 8 to being reduced at day 10, 
when compared to untreated as well as ZL-treated cells. The expression pattern 
of both genes followed the same trend throughout the remaining of the 
differentiation process. In the last two stages, Plin3 expression remained 
unchanged across all sample groups. 
The expression of Ccl5 was very specific and mainly associated with ZL-EV 
treated cells. The five-fold increase seen at day 8 recovered significantly during 
the final stage (day 10). A very slight increase was also associated to ZF-EV 
treated cells, again more visible at day 8, as with cells treated with ZL-EVs 
(Figure 57C). 
At day 12 of differentiation, when adipocytes were fully differentiated, cells were 
collected for lipid accumulation analysis by staining with Bodipy and subsequent 
quantification by flow cytometry. The analysis revealed that the presence of both, 
ZL and ZF-EV negatively influenced lipid accumulation in 3T3-L1 adipocytes 
(Figure 58A). Although not statistically significant, there was a decrease in lipid 
accumulation in adipocytes differentiated with ZL-EVs and even further when 
exposed to ZF-EVs (Figure 58B).  
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Figure 58 Decreased lipid accumulation following differentiation of the 3T3-L1 cells 
in the presence of Zucker rat hepatocyte EVs. 3T3-L1 cells were differentiated in the 
presence of EVs. On day 12, cells were collected and stained with Bodipy (10 µg/ml) and 
analyzed by flow cytometry. (A) Flow cytometry histograms. (B) Quantification of the 
median FITC-A fluorescence; n=1.  
 
In conclusion of this part, EVs seem to affect the differentiation of 3T3-L1 cells 
and depending on the differentiation stage, a response of different genes varies. 
At the clonal expansion stage, ZF-EVs specifically increased the expression in 
the Fasn and Slc2a4 genes. Moreover, ZF-EVs specifically decreased the 
expression of Adipoq, which could indicate a transfer of phenotype as we have 
previously shown that ZF-EVs carried decreased adiponectin. Finally, the 
induction of Ccl5 expression by ZL-EVs was very specific and was also seen at 
later stages.  
265 
 
6.3.2 The influence of acute and chronic exposure of hepatic-EVs on the 
gene expression profile of the 3T3-L1 adipocytes 
 
We next sought to investigate the acute and chronic effects of hepatocyte-
derived EVs on gene expression in recipient 3T3-L1 adipocytes. The 
experimental design is shown on Figure 59. Briefly, 3T3-L1 adipocytes were 
grown and differentiated in 12-multiwell plate. Mature adipocytes were either left 
untreated or treated with ZL and ZF-EVs (30 µg) for 24 h in EV-depleted 
medium. At that point a set of samples (acute) was collected and cell pellets kept 
at -800C, until needed. Then, another set of cells were given three subsequent 
treatments with Zucker rat hepatocyte-derived EVs, 10 µg, each time for the 24 h 
period. Three days later, the second set of samples was collected, and RNA 
isolated for subsequent qPCR analysis.  
Gene expression analysis of several selected genes of various classes was 
performed on acute (Figure 60) and chronically (Figure 61) treated adipocytes. 
The untreated cells were used as a control in the analysis. 
We determined the expression of Pparg, Rent, Fasn, Plin3, Tnf, COXIII and 
Adipoq (Figure 60). The results indicate that the genes mostly affected by acute 
treatment with ZF-EVs were those encoding for Pparg and Resistin proteins. As 
already mentioned, PPARγ is an essential regulator of adipogenesis, as no 
single factor has been identified that can drive adipogenesis in its absence. It is 
also important for the maintenance of the fully differentiated state both in vivo 
and in vitro (Lee & Ge 2014). Resistin, on the other hand, is a signalling molecule 
that is induced during adipogenesis and nearly exclusively secreted by white 
adipose tissue. With its discovery in 2002, many studies followed, which 
associated the elevated expression of Resistin with diet-induced obesity, 
confirmed in genetic models of obesity such as ob/ob and db/db mice. Moreover, 
purified Resistin was able to induce reduction in insulin stimulated glucose 
uptake in 3T3-L1 adipocytes (Steppan et al. 2002).  
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Figure 59 Experimental design of the study of the effect of Zucker rat hepatocyte 
secreted EVs on the gene expression in 3T3-L1 adipocytes. Diagram representing the 
experimental design to study the influence of Zucker rat hepatocyte secreted EVs on gene 
expression in 3T3-L1 adipocytes. 3T3-L1 cells were differentiated following standard 
protocol. On day 13, 3T3-L1 adipocytes were acutely treated with 30 µg of ZL- and ZF-EVs 
and in the chronic experimental group, cells were treated three times with 10 µg of ZL and 
ZF-EVs for 24 h each.  
 
Moreover, the expression of Fasn and Plin3, lipid-related genes were unaffected 
by exposure to Zucker-EVs. A very small increase was seen in the expression of 
genes encoding for Adiponectin and for the Cytochrome c oxidase subunit III 
(COXIII), following acute exposure to ZF-EVs. A more extensive panel of genes 
was screened in the chronic experimental group (Figure 61). First, when 
comparing the expression of the same genes in both experimental groups, acute 
and chronic.  
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Figure 60 Changes in the gene expression in 3T3-L1 adipocytes upon acute exposure 
on Zucker rat hepatocyte secreted EVs. qPCR analysis of gene expression in 3T3-L1 
adipocytes following acute exposure to ZL-and ZF-EVs, biological replicates n=3, technical 
replicates n=2; housekeeping gene used for normalization was ß-actin. Error bars = SD. 
Unpaired student t-test was performed to determine significant differences. 
 
The fold induction of expression increased in samples following the chronic 
treatment. Importantly, in both experimental settings, there was an increase in 
Pparg and Rent gene expression, following the treatment with ZF-EVs. 
Moreover, an increase in COXIII transcription following the acute treatment with 
ZF-EVs becomes significant after chronic exposure to those EVs.  
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Figure 61 Changes in the gene expression in 3T3-L1 adipocytes upon chronic 
exposure on Zucker rat hepatocyte secreted EVs qPCR analysis of gene expression in 
3T3-L1 adipocytes following chronic exposure to ZL-and ZF-EVs, biological replicates n=1, 
technical replicates n=2; housekeeping gene used for normalization was ß-actin. 
 
Interestingly, in terms of the respiratory functions there seem to be a ligth 
increase in the transcription of the Nrf1 gene encoding for the nuclear respiratory 
factor 1, which could indicate a transient enhancement in mitochondrial 
respiratory capacity in 3T3-L1 adipocytes. Interestingly, genes related with lipid 
metabolism such as Fasn was downregulated as opposed to Plin2 which was 
highly upregulated in 3T3-L1 adipocytes exposed to ZF-EVs.  
Overall, we observed that, EVs secreted by Zucker rat hepatocytes could modify 
gene expression in recipient 3T3-L1 adipocytes and, through that, to influence a 
broad spectrum of biological processes involved in their physiology. 
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6.3.3 The influence of hepatic-EVs on the adipokine secretion of the 3T3-L1 
adipocytes 
 
Based on our findings, described in the previous sections on modulation of gene 
expression by hepatic-EVs in 3T3-L1 adipocytes, we wanted to determine 
whether, treatment with EVs secreted by Zucker rat hepatocytes, in ZL and ZF 
models provoked changes in adipokine secretion in 3T3-L1 adipocytes by using 
the Proteome Profiler Mouse Adipokine Array Kit (Section.2.16.). Figure 62 
shows the design of the adipokine experiment. The array was used to screen 
supernatants from 3T3-L1 adipocytes previously exposed to Zucker hepatocyte-
derived EVs. Results of densitometry were normalized to the untreated sample 
and presented as a fold increase in a heatmap diagram with the gradient of 
colours ranging from downregulated red to upregulated green (Figure 62). 
Moreover, a percentage of standard deviation between duplicates in both groups 
was also calculated. A total of 28 out of 38 adipokines were detected in our 
supernatants and overall, the expression of several adipokines was found altered 
upon the treatment with EVs and interestingly, most of the changes were 
mediated by ZL-EVs (Figure 62).  
Exposure to ZL-EVs caused a very important increase in the secretion of several 
adipokines by 3T3-L1 adipocytes including RANTES (Ccl5), Il-6, Lipocalin2 and 
FetuinA. The up-regulation of RANTES by ZL-EVs in differentiating 3T3-L1 cells 
was previously shown by qPCR (Figure 55C and Figure 56C). The circulating 
levels of RANTES were shown to be increased in subjects with impaired glucose 
tolerance and type 2 diabetes (Nomura et al. 2000). Moreover, the release of 
RANTES is adipocyte size dependant, with larger fat cells releasing significantly 
more (Skurk et al. 2009). Over 8-fold increase in RANTES secretion was seen 
upon treatment with Zucker rat hepatocyte-derived EVs (Figure 63).  
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Figure 62 Experimental design of the adipokine array experiment. 3T3-L1 adipocytes 
were grown and differentiated in 12-well plate format. At day 13, cells were treated with 30 
µg of ZL- and ZF-EVs or left untreated for 12 h, in EV depleted medium. The treatment 
was then removed and replaced with fresh medium for another 12 h. The conditioned 
medium of adipocytes was assayed for the presence of 38 adipokines. 
 
The second most highly up-regulated adipokine by ZL-EVs, was IL-6, which 
increased concentration positively correlate with obesity and insulin resistance 
(Rotter et al. 2003). Moreover, FetuinA was also found highly up-regulated upon 
exposure to ZL EVs (Figure 63). This multifunctional protein, modulates a 
number of signalling pathways such as TGF-ß and insulin (Nangami et al. 2014).  
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Figure 63 Adipokine Array Heatmap. Changes observed in the secretion of a adipokines 
by 3T3-L1 adipocytes upon exposure to ZL- and ZF-EVs (30 µg/12h). SD (%) is 
shown/adipokine; biological replicate = 1, technical replicate = 2. 
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It has been shown to be involved in cell adhesion, one mechanism proposed 
being, a shuttle of histones in exosomes by FetuinA which then by interacting 
with cell surface heparin sulfate proteoglycans mediate cell adhesion. On the 
other hand, in adipose tissue FetuinA acts as chemoattractant for macrophage 
migration and polarizes adipose tissue M2 macrophages to the proinflammatory 
M1 subtype (Chatterjee et al. 2013).  
 
We found that the majority of adipokines tested were either unchanged or 
downregulated upon treatment with ZF-EVs. A marked decrease in the 
expression of anti-inflammatory cytokine IL-10 was observed. One of its anti-
inflammatory effects is antagonizing the action of TNF (Lumeng, Bodzin, et al. 
2007). Here, no change in TNF was observed. The decrease in circulating IL-10 
in serum of obese subjects has been associated with obesity (Esposito et al. 
2003). Moreover, the increased secretion of Lipocalin2 by 3T3-L1 adipocytes 
was caused by both ZL as well as ZF-EVs, the effect that seems to be 
associated to hepatic-EVs. None of those differences reached statistical 
significance, most likely due to the limited sample number. 
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6.3.4 The Influence of Zucker Rat hepatocyte-derived EVs on lipid 
metabolism of 3T3-L1 adipocytes 
 
Our previous results indicate that there was a slight increase in lipid content in 
the sample of ZF-EVs as compared to ZL-EVs. However, detailed lipidomic 
analysis would be needed to identify specific types of lipids and their proportion 
in ZL- and ZF-EVs. Lipid transport can be mediated by EVs, which carry 
bioactive lipids such as sphingomyelin, cholesterol, lysophosphatidylcholine, 
arachidonic acid and other fatty acids, prostaglandins, and leukotrienes among 
others, either in their membrane or in their lumen (Record et al. 2014).  
With that in mind, we wanted to investigate whether EVs, secreted by steatotic 
hepatocytes from Zucker fatty rat hepatocytes could modulate the lipid content in 
recipient 3T3-L1 adipocytes. The approach taken was to measure the amount of 
free glycerol (Section 2.13) released by 3T3-L1 adipocytes following the 
treatment with ZL and ZF-EVs (Figure 64A), as well as, upon the exposure to 
the conditioned medium coming from the previously EV-treated adipocytes 
(Figure 64B) and finally the number of triglycerides was measured directly in 
treated cells (Figure 64C).  
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Figure 64 Changes in the lipid content in 3T3-L1 adipocytes upon treatment with 
Zucker rat hepatocyte secreted EVs. (A) The amount of free glycerol was determined in 
supernatant of the 3T3-L1 adipocytes following the 24h treatment with 10 µg of ZL and ZF 
EVs; n = 3. (B) Conditioned medium of 3T3-L1 adipocytes treated with ZL and ZF-EVs 
from the previous experimental group; n= 3. (C) The lipase assay was used to measure the 
triglyceride content in lysates from 3T3-L1 adipocytes previously treated with ZL- and ZF-
EVs; n= 3. Error bars = SD. Unpaired student t-test was performed to determine significant 
differences 
 
Our results indicate that ZF-EVs could influence lipid metabolism of 3T3-L1 
adipocytes. On one hand, there was a significant decrease in free glycerol 
released by cells treated with ZF-EVs (Figure 64A). Interestingly, when 3T3-L1 
adipocytes were cultured in the presence of the conditioned medium of 3T3-L1 
adipocytes previously exposed to ZL- and ZF-EVs, an increasing tendency can 
be seen in treated cells (Figure 64B). The increase in absorbance at 540nm was 
directly proportional to the glycerol concentration in the sample and therefore to 
the triglyceride content. Moreover, when the triglyceride concentration was 
assessed in cells previously treated with EVs, an elevated concentration of free 
glycerol released was found (Figure 64C). 
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6.3.5 The influence of hepatic-EVs on the glycolytic function of the 3T3-L1 
adipocytes 
 
The proteomic analysis revealed that most represented proteins in ZF-EVs were 
those related with glycolysis and a pentose phosphate pathway (Table 10). We 
therefore wanted to find out whether they were able to modulate the 
bioenergetics of the 3T3-L1 adipocytes, and transfer their glycolytic phenotype 
onto the recipient cells. The experimental design, aimed to study the glycolytic 
functions in 3T3-L1 adipocytes exposed to ZL- or ZF-EVs (Figure 65). Briefly, 
3T3-L1 fibroblasts were grown and differentiated on a Seahorse XF24 V7 
microplates. At day 12 of differentiation, mature adipocytes were either left 
untreated or treated with 10 µg of ZL- or ZF-EVs for 24 h. The 24h-conditioned 
medium of EV-treated adipocytes was given to other adipocytes, and originally 
treated adipocytes received another dose of ZL- and ZF-EVs (Figure 65). 
Glycolytic function of the 3T3-L1 adipocytes in both settings was assessed using 
a Seahorse XF glycolysis stress test with various parameters being represented, 
such as the non-glycolytic acidification rate, glycolysis, glycolytic capacity and 
glycolytic reserve for the EVs treated cells (Figure 66A) and the conditioned 
medium treated cells (Figure 66B). Our results indicate that ZF-EVs may have 
an influence on metabolic responses in 3T3-L1 adipocytes as seen by a 
significantly increased rate of glycolysis in 3T3-L1 adipocytes treated with ZF-
EVs (Figure 66A). 
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Figure 65 Experimental design to study the influence of Zucker rat hepatocyte-EVs 
on glycolytic functions of the 3T3-L1 adipocytes. Seahorse XF metabolic flux analyzer 
was used to perform glycolysis stress test on adipocytes previously treated with two doses of 
ZL- and ZF-EVs (10 µg) and cells cultured with the conditioned medium of adipocytes 
previously treated with ZL- and ZF-EVs; n=3/condition. 
 
In the remaining glycolytic parameters, no changes were observed. Moreover, 
culturing 3T3-L1 adipocytes in the presence of conditioned medium of adipocytes 
previously treated with ZL- and ZF-EVs did not have a significant influence on 
glycolytic function of recipient cells (Figure 66B) which could indicate that the 
effect is specifically mediated by EVs. 
278 
 
 
Figure 66 Glycolytic changes in 3T3-L1 adipocytes upon treatment with Zucker rat 
hepatocyte-secreted EVs. (A) The effect of Zucker rat hepatocyte EVs; n=3 and (B) 
conditioned medium of adipocytes previously exposed to Zucker rat hepatocyte EVs on 
glycolytic functions of 3T3-L1 adipocytes, n=3. Glycolytic parameters such as non-glycolytic 
acidification, glycolysis, glycolytic capacity and glycolytic reserve was measured using 
Seahorse XF analyzer; error bars=SD p value=0.01- 0.05=*. Unpaired student t-test was 
performed to determine significant differences.  
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6.3.6 The influence of hepatic-EVs on insulin sensitivity of the 3T3-L1 
adipocytes 
 
Insulin resistance is one of the principal causes of metabolic perturbations 
associated with MetS. Therefore, we next decided to investigate the possible 
effect of Zucker rat hepatocyte-EVs on insulin sensitivity in 3T3-L1 adipocytes. 
For that, 3T3-L1 adipocytes were treated with ZL- and ZF-EVs, and WB analysis 
was carried out for insulin activated Akt(Ser473) and Erk1/2 protein 
phosphorylation (Figure 67A).  
 
 
Figure 67 Insulin sensitivity studies in 3T3-L1 adipocytes upon acute exposure to 
Zucker rat hepatocyte-derived EVs. (A) Representative WB for of 3T3-L1 adipocytes 
acutely exposed to Zucker rat hepatocyte derived-EVs (30 µg) for 24 h (B) Fold increase in 
Akt(Ser473) phosphorylation upon insulin stimulation (C) Fold increase in Erk1/2 
phosphorylation upon insulin stimulation; n=2/condition (D) Insulin stimulated glucose 
uptake in 3T3-L1 adipocytes upon treatment with ZL- and ZF-EVs; biological replicate=1, 
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technical replica=6; error bars=SD p values were denoted as follows: 0.01- 0.05=*, 0.01-
0.001=**. Unpaired student t-test was performed to determine significant differences. 
 
 
Results of densitometry were presented as a fold increase in phosphorylation 
upon induction with insulin. The quantification revealed that upon acute treatment 
with ZL-EVs, there was a significant increase in insulin stimulated 
phosphorylation of Akt(Ser473) and even further with ZF-EVs. Interestingly, the 
same result was obtained when insulin stimulated glucose uptake was performed 
in the 3T3-L1 adipocytes pre-treated with ZL and ZF-EVs (Figure 67D). 
Moreover, ZL-EVs caused enhanced phosphorylation of Erk1/2 protein whereas 
in ZF-EV treated cells, a decreasing trend was detected (Figure 67C). 
The increase in Akt(Ser473) phosphorylation upon acute treatment with EVs 
could be a transient response or a step before the resistance develops. We 
therefore repeated the experiment with three subsequent doses of EVs. Two 
independent experiments were carried out (4 biological samples/condition) and 
the representative WB is shown in Figure 68A. The quantifications of activated 
Akt(Ser473) is shown in Figure 68B and Figure 68C and are represented as a 
percentage of phosphorylated protein at basal state and upon insulin stimulation. 
Then, the fold change increase in phosphorylation upon insulin stimulation was 
calculated, and the average of the 4 samples plotted (Figure 68D). Although, not 
significant, results indicate that ZF-EVs cause a reduction in Akt(Ser473) 
phosphorylation in the recipient 3T3-L1 adipocytes. ZL-EVs on the other hand 
cause an increase in phosphorylation. The same trend was seen in the 
phosphorylation of Erk1/2 protein (Figure 68G). 
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Figure 68 Insulin sensitivity studies in 3T3-L1 adipocytes upon chronic exposure to 
Zucker rat hepatocyte-derived EVs. (A) Representative WB of 3T3-L1 adipocytes 
chronically exposed to Zucker rat hepatocyte derived-EVs (3X10 µg) for 24 h each time (B) 
Quantification of the Akt(Ser473) phosphorylation (%), experiment 1 (C) Quantification of 
the Akt(Ser473) phosphorylation (%), experiment 2 (D) Fold increase in Akt(Ser473) 
phosphorylation upon insulin stimulation (100 nm insulin; 5 min) (E) Quantification of the 
Erk1/2 phosphorylation (%), experiment 1 (F) Quantification of the Erk1/2 
phosphorylation (%), experiment 2 (G) Fold increase in Erk1/2 phosphorylation upon 
insulin stimulation; n=4; error bars=SD; ImageJ software was used for densitometry. 
 
 
To complement the study, we decided to examine the phosphorylation of the 
mechanistic target of rapamycin (mTOR) via its targets, the 4E-BP1 and 
ribosomal protein S6, in response to insulin, following the same study design as 
of acute and chronic exposure. Phosphorylation of the ribosomal protein S6 
(rpS6) was the first discovered to be post-translationally modified (Gressner & 
Wool 1974). 
RpS6 phosphorylation is commonly used as a readout of mechanistic target of 
rapamycin complex 1 (mTORC1) activity (Biever et al. 2015) and the abnormal 
induction of mTORC1 signalling has been observed in response to insulin 
resistance and associated with diabetes progression (Tsai et al. 2016). In 
addition, mTOR serves a central role in controlling and regulating vital processes 
such as metabolism, proliferation, growth and survival (Laplante & Sabatini 
2013). 
The representative WB figure is shown in Figure 69A. Bands were quantified, 
and the results represented as a fold increase in phosphorylation of 4E-BP1 and 
rpS6 proteins upon insulin stimulation (Figure 69B and Figure 69, respectively). 
Our results show that when the 3T3-L1 adipocytes were acutely exposed to ZL-
EVs, an increase in 4E-BP1 was observed, only a very small increase was seen 
in cells treated with ZF-EVs. However, the phosphorylation of the ribosomal 
protein S6 was significantly reduced when EVs were applied (Figure 69C).  
283 
 
 
 
Figure 69 Insulin sensitivity studies in 3T3-L1 adipocytes upon acute exposure to 
Zucker rat hepatocyte-derived EVs. Representative WB of 3T3-L1 adipocytes acutely 
exposed to Zucker rat hepatocyte derived-EVs (30 µg) for 24h (B) Fold increase in rpS6 
phosphorylation upon insulin stimulation (100nm insulin; 5min) (C) Fold increase in 4E-
BP1 phosphorylation upon insulin stimulation; n=2/condition; error bars=SD; ImageJ 
software was used for densitometry. Unpaired student t-test was performed to determine 
significant differences.  
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The experiment was repeated, this time culturing cells in the presence of three 
subsequent doses of Zucker rat hepatocyte-derived EVs, over a 72-h period, as 
previously. The representative WB figure is shown in Figure 70A with the 
quantification of two independent experiments, carrying 4 biological replicates, 
meaning 4 independent preparation of ZL- and ZF-EVs, was done for 4E-BP1 
and rpS6 proteins at basal and insulin induced states (Figure 70B and Figure 
70C) When the fold change was calculated, it was shown that cells exposed to 
EVs had reduced 4E-BP1 phosphorylation, with no difference between ZL- and 
ZF-treated cells (Figure 70D). More importantly, it was found that ZF-EV-treated 
adipocytes had significantly reduced phosphorylation of rpS6 (Figure 70G).  
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Figure 70 Insulin sensitivity studies in 3T3-L1 adipocytes upon chronic exposure to 
Zucker rat hepatocyte-derived EVs. (A) Representative WB of 3T3-L1 adipocytes 
chronically exposed to Zucker rat hepatocyte derived-EVs (3X10 µg) for 24h each time (B) 
Quantification of the 4E-BP1 phosphorylation (%), experiment 1 (C) Quantification of the 
4E-BP1 phosphorylation (%), experiment 2 (D) Fold increase in rpS6 phosphorylation upon 
insulin stimulation (100nm insulin; 5min) (E) Quantification of the Erk1/2 phosphorylation 
(%), experiment 1 (F) Quantification of the rpS6 phosphorylation (%), experiment 2 (G) 
Fold increase in Erk1/2 phosphorylation upon insulin stimulation; n=4; error bars=SD; p 
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values were denoted as follows: 0.01- 0.05=*, 0.01-0.001=**, ImageJ software was used for 
densitometry. Unpaired student t-test was performed to determine significant differences.  
 
 
6.4 Summary 
 
We conclude that hepatocyte-derived EVs can influence physiology and 
metabolism of the 3T3-L1 adipocytes on different levels.  
First, during the differentiation of 3T3-L1 cells into adipocytes, they influenced 
the expression of an array of genes, including master regulators of adipogenesis, 
PPARγ and C/EBPα. In terms of lipid metabolism, ZF-EVs, specifically increased 
the expression of genes encoding for the Fatty acid synthase, Perilipin3 and 
Glut4, upon induction of differentiation. Moreover, hepatic-EVs were able to 
decrease the expression of adiponectin gene, at the clonal expansion stage and 
interestingly, exclusively ZL-EVs induced RANTES expression. 
During the terminal differentiation stage of the 3T3-L1, cells differentiation in the 
presence of ZF-EVs did not respond to the addition of insulin media in the case 
of all assayed genes. Although the response was later recovered, at the final 
time point, it seems that ZF-EVs can negatively regulate the expression of all 
analysed genes and negatively influence the accumulation of lipids in 3T3-L1 
adipocytes. Hepatic-EVs also regulated gene expression in already mature 3T3-
L1 adipocytes, differentially upon acute and chronic exposure.  
In addition, hepatic-EVs modulated the secretion of adipokines in recipient 3T3-
L1 adipocytes. We observed that upon exposure to EVs, they show evidence of 
inflammatory phenotype with increased secretion of pro-inflammatory cytokines 
and decreased anti-inflammatory IL-10.  
Along these lines, ZF-EVs were able to transfer the glycolytic phenotype showed 
by the parental hepatocytes onto the 3T3-L1 adipocytes, as judged by the 
increased rate of glycolysis after treatment with EVs.  
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Lastly, hepatic-EVs modified the insulin sensitivity in 3T3-L1 adipocytes, 
differentially, depending on the length of the treatment. Our results indicate that 
upon acute treatment, hepatic-EVs caused the increase in insulin-stimulated 
Akt(Ser473) phosphorylation and glucose uptake, however significant reduction 
in the ribosomal S6 protein phosphorylation. Interestingly, while ZL-EVs caused 
a significant increase in Erk1/2 phosphorylation, on a contrary in a group treated 
with ZF-EVs there was a decreasing trend. In the chronic experimental group, 
ZF-EVs caused the reduction in Akt(Ser473) and Erk1/2 phosphorylation as well 
as significantly decreased the ribosomal S6 phosphorylation. Graphically 
represented on Figure 71.  
 
 
6.5 Discussion 
 
The study on Zucker rats has showed that while the substrate necessary to 
create and to sustain the enlarged adipose mass of the obese animal has more 
than a single site of origin, several lines of evidence suggest that the liver is the 
major site of synthesis for the substrate (Goldstein & Johnson 1980). Moreover, it 
has been reported that 80-90% of the substrate for adipose tissue in the obese 
Zucker rat is supplied by the liver (Godbole & York 1978). Elevated rates of 
hepatic lipogenesis have been found in Zucker obese rats when compared to 
their lean littermates as early as 44 days of age (Goldstein & Johnson 1980).  
Therefore, the last part of this doctoral thesis was dedicated to study the possible 
effects that EVs secreted by steatotic hepatocytes may exhibit on adipocytes.  
Decrease in abdominal subcutaneous preadipocyte differentiation capacity is 
associated with visceral obesity, adipocyte hypertrophy, and a dysmetabolic 
state (Lessard et al. 2014). Moreover, reduced generation of new adipocytes in 
the state of hypertrophy was correlated with insulin resistance (Arner et al. 2010). 
With that in mind, we hypothesized whether hepatic EVs were implicated in the 
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pathology of reduced adipogenic capacity. We used the multi-stepdifferentiation 
of 3T3-L1 cells into adipocytes, that can be tightly controlled by the presence of 
hormonal cocktail consisting of insulin, DEX and IBMX. The addition of these 
compounds allows controlling fundamental steps in the adipocytes differentiation 
process including the expression of adipocyte-specific genes and the 
accumulating triacylglycerol lipid droplets (Gregoire et al. 1998). The adipogenic 
differentiation involved a series of media replenishment every 48-h starting with 
the differentiation cocktail, then insulin containing media and three rounds or 
complete media replenishments. Therefore, the experimental design employed 
here was that at every point of replenishment, the media was supplemented with 
10 µg of ZL- or ZF-EVs or left untreated. At the molecular level, adipogenesis is 
regulated by a complex transcriptional cascade. In one study, which explored the 
effects of macrophage-conditioned medium on adipocytes, the researchers found 
that the critical time point for the inhibition was the first 2 days of the 8-day 
differentiation period, the period associated with the mitotic clonal expansion 
phase (Constant et al. 2008).  
We showed that during the clonal expansion stage, the presence of EVs did 
affect the expression of adipogenesis regulators, the Pparg, Ap2 and Cebpa. 
However, ZF-EVs specifically caused an increase in expression of the lipogenic 
enzyme, the fatty acid synthase, which was accompanied by the increase in the 
expression of adipocyte-related perilipin 3 protein. Elevated lipogenesis is a key 
determinant of excessive fat deposition in adipose tissue (Boizard et al. 1998). 
We have already shown that the pro-lipogenic profile of ZF-EVs may be 
transferable and the increase in lipogenic gene expression could be the step 
towards the induction of hypertrophic phenotype in 3T3-L1 adipocytes. We have 
also shown that by exposing adipocytes to ZF-EVs, we shifted the metabolic 
profile of these cells by causing the augment in the rate of glycolysis (Figure 
62A). Thus, the promotion of lipid synthesis at the early stages of adipogenesis 
elevated lipogenesis that is a characteristic of the obese state. Later, when solely 
insulin containing media was applied, ZF-EVs impaired the response of 
adipogenesis regulators Pparg, Ap2 and Cebpa, as well as, genes related with 
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lipid metabolism. This could indicate that cells in the presence of hepatic EVs 
were not able to respond to adipogenic effects of insulin. Alternatively, a lower 
population of differentiated adipocytes could be present in the culture. It could 
also be that the first increase in gene expression response was priming effect, 
which could also be related with a transient increase in DNA synthesis, which 
occurs after the addition of the differentiation cocktail (Reichert & Eick 1999). 
During the serum-based stage of 3T3-L1 differentiation, at day 6 and 8, the 
presence of EVs caused an increase in transcription of most genes tested. 
Importantly, when considering the last time point of the differentiation steps, ZF-
EVs exerted negative effects on the expression of adipogenesis regulators, lipid 
droplet associated perilipin 2, and adiponectin. Generally, adiponectin is present 
in plasma at very high concentration and is inversely associated with visceral fat 
accumulation. Overexpressing adiponectin in ob/ob mice has been shown to 
dramatically improve the metabolic and inflammatory phenotype of these mice 
with the restoration of insulin sensitivity, mediated by increased PPARγ and 
redistribution of lipids from ectopic deposits in peripheral organs to the 
subcutaneous adipose depots (Kim et al. 2007). Our results show that the 
reduced levels of adiponectin associated to ZF-EVs could resemble the state of 
reduced adiponectin in obesity, which would again indicate the transfer of 
specific aspects of cellular phenotype by ZF-EVs onto recipient cells. Additional 
experiment would be needed to reveal the exact mechanism, but it could be 
related with downregulation of specific signalling pathways, which we observed 
in 3T3-L1 adipocytes upon exposure to ZF-EVs. All together, these results show 
that at each stage of the differentiation process there are specific responses to 
the stimulus of hepatic-EVs. Our data suggest that the main process affected by 
hepatic-EVs during adipocyte differentiation was lipid accumulation. This could 
also be associated with less cells being differentiated in the presence of hepatic-
EVs. Furthermore, our preliminary results indicate that in already mature 3T3-L1 
adipocytes, ZF-EVs may promote lipolysis, which is also one of the 
characteristics of obese state.  
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According to current knowledge, in normal conditions adipocytes release 
biologically active molecules known as ‘adipokines’ and anti-inflammatory 
cytokines such as IL-10, IL-1R to maintain homeostasis and protect from 
development of obesity associated IR and inflammation (Caruso et al. 2010). The 
state of obesity causes significant deregulation in adipokine secretion and a shift 
towards the pro-inflammatory state. Our adipokine array experiment showed that 
hepatic-EVs were able to significantly modulate the secretion of adipokines in 
3T3-L1 adipocytes. Treatment with ZF-EVs decreased the expression of anti-
inflammatory IL-10 secretions, which is a change associated with obesity. 
Unexpectedly, ZL-EVs caused very significant induction in pro-inflammatory, IL-6 
and RANTES adipokine secretion in 3T3-L1 adipocytes, which was not the case 
for the ZF-EVs. Moreover, ZL-EVs specifically induced nearly 6-fold increase in 
FetuinA secretion by 3T3-L1 adipocytes. Moreover, we showed that the secretion 
of lipocalin2 by 3T3-L1 adipocytes was highly elevated by the exposure to 
hepatic-EVs, which has been shown to be strongly associated with obesity and 
was found elevated in 3T3-L1 adipocytes by IR promoting agents (Yan et al. 
2007). Overall, there were changes in secretion of nearly 30 adipokines, which 
indicate that hepatic-EVs may cause a shift in an overall metabolic phenotype of 
3T3-L1 cells seen in obese-adipose tissue.  
Lastly, we focused our efforts on studying the effects of hepatic-EVs on insulin 
sensitivity in 3T3-L1 adipocytes by assessment of Akt, Erk1/2, and components 
of mTOR pathway, rpS6, and 4E-BP1 phosphorylation, at basal state and upon 
insulin stimulation following exposure to ZL- and ZF-EVs. In addition, our 
experimental design included two-time points, the acute and chronic treatment 
with hepatic-EVs. We observed significant differences in response of 3T3-L1 
adipocytes between the two treatment groups. Our results indicate that acute (24 
h) exposure to hepatic-EVs cause transient increase in phosphorylation of 
Akt(Ser473) and Erk1/2 as well as in insulin-stimulated glucose uptake, which 
following chronic exposure (3x24 h) was attenuated by ZF-EVs. Furthermore, the 
phosphorylation of rpS6 was significantly reduced already at acute exposure by 
hepatic-EVs and specifically by ZF-EVs at a chronic time point. Dysregulation of 
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the mTORC1 pathway has been implicated in the obesity and its related 
metabolic complications (Catania et al. 2011). Overnutrition leads to persistent 
hyperactive mTORC1/S6K1 signalling which phosphorylates IRS1 at serine 
residues leading to reduction in insulin signalling (mTORC2/Akt). This decrease 
in insulin sensitivity results in metabolic imbalance (Yang & Ming 2012). Elevated 
levels of insulin, pro-inflammatory cytokines and nutrients most probably feed 
mTORC1 activity in obesity (Laplante & Sabatini 2013). In that regard, it has 
been postulated that the action of mTORC1 on insulin resistance in adipose 
tissue is via the S6K1-mediated inhibition of insulin signalling and may aggravate 
systemic insulin resistance by promoting FFA release by adipocytes, ectopic fat 
deposition, and lipotoxicity (Laplante & Sabatini 2013).  
In contrary, another study has shown that mTORC1 activation by insulin was 
attenuated in adipocytes from patient in obese, insulin-resistant state (Öst et al. 
2010). In addition, treatment with rapamycin was linked to inhibition of IRS1 and 
induction of insulin resistance phenotype (Paolo et al. 2006). Steatotic EVs seem 
to contribute to the induction of insulin resistance phenotype related with the 
development of MetS, however to reveal mechanism behind this effect, more 
experiments would have to be conducted. mTORC1 has been shown to play a 
key role in lipid storage by stimulating the synthesis of triglycerides in WAT and 
differentiation of preadipocytes into adipocytes through up-regulation of PPARγ 
(Yang & Ming 2012). In agreement with our results, ZF-EVs cause a decrease in 
phosphorylation of rpS6 in 3T3-L1 adipocytes, and during adipogenesis, they 
affect lipid accumulation in differentiating 3T3-L1 cells. These data together could 
indicate that this effect on lipid accumulation in differentiating adipocytes is 
mediated by reduction in rpS6. However, further experiments are needed to 
confirm this aspect. Although our results on functional effects of hepatic-EVs on 
the physiology of the 3T3-L1 adipocytes are still preliminary, they indicate that 
EVs secreted by hepatocytes may have a profound effect on the physiology of 
adipocytes in the context of MetS. We show that they may be contributing factor 
towards the development of insulin resistance in adipocytes. 
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Figure 71 Summary diagram of results described in chapter 4. Graphical representation 
of results regarding the effects of steatotic-EVs on insulin sensitivity, adipokine secretion 
and metabolism of the 3T3-L1 adipocytes.  
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7. Concluding discussion  
 
EVs have emerged as very important mediators in cell-to-cell communication, 
maintaining homeostasis but also propagating the development of different 
pathologies. They are under intense research in a wide range of areas from 
cancer to immunology, degenerative and infectious diseases, metabolic and 
inflammatory conditions among many others. They already serve as non-invasive 
biomarkers and have proven useful in regenerative therapies. It is therefore 
crucial to understand the mechanisms that govern their production and release, 
their selective packaging of different molecules and their interaction with the 
extracellular environment, under homeostatic conditions and during pathology.  
In this study we hypothesized, that the secretion and the content of 
extracellular vesicles, are affected by different manifestations of metabolic 
syndrome and that they influence adipocytes biology. To address these 
issues, we established and characterized in vitro cellular models resembling the 
metabolic syndrome conditions in different tissues. The 3T3-L1 adipocytes were 
exposed to three independent pathological states, namely hypoxia (1%), the 
macrophage-conditioned medium and the FFA mix to induce the conversion into 
lipid-overloaded enlarged adipocytes. Additionally, the Raw264.7 macrophages 
were activated with LPS to induce the M1 proinflammatory phenotype. Moreover, 
the hepatocellular steatosis was induced in three different hepatic cell lines, 
AML12, MLP29 and HepG2 with the mix of FFAs. Finally, primary steatotic 
hepatocytes were isolated from the Zucker fatty rat that constitutes a well-known 
genetic model of obesity. The culture conditions of all cellular models were 
carefully chosen for the subsequent isolation of EVs from the conditioned 
medium. In the last part, we focused on studying the possible influence of the 
proinflammatory macrophage derived-EVs and steatotic derived-EVs on 
adipocytes.  
The three most important tissues involved in fatty acid metabolism are the 
adipose tissue, skeletal muscle and liver, each of which has a triglyceride store, 
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which can be mobilized by hydrolysis when needed. Fatty acids from adipose 
tissue can be released into the circulation for delivery to other tissues and in liver 
they serve as a substrate for re-esterification within the endoplasmic reticulum 
(ER) to make triglycerides that will be secreted as VLDL. These processes are 
controlled by the action of insulin (Frayn et al. 2006). It is clear, that there is 
cooperation amongst the tissues, which is deregulated in MetS, and the notion 
that this cooperation is mediated by EVs has already been shown. Most of 
studies regarding the involvement of EVs in MetS, focused on the adipose tissue 
derived–EVs, and the effect on peripheral organs. However, hepatocytes are 
also known to release EVs, therefore the possibility that hepatocyte secreted-
EVs are taken up by adipocytes and modulate their physiology cannot be 
discarded.  
This study demonstrates that the profile of small EVs secreted by all our cellular 
models of MetS is highly affected in terms of the profile of proteins and the 
concentration of secreted-EVs. There is an overall enhanced secretion of EVs 
with very minor changes in the mean particle size. The lipid overload in 3T3-L1 
adipocytes caused increased secretion of vesicles containing exosomal markers 
such as Cd81, Aip1/Alix and Flotillin1 and the lysosomal-LIMPII. It is an 
interesting result considering that in all remaining models used, under the 
pathological conditions the expression of these protein markers is highly 
decreased. Moreover, we found Glut4 to be associated to adipocyte secreted-
EVs and importantly to be increased in hypoxic-EVs and those from adipocytes 
cultured in the presence of the macrophage-conditioned medium. Unexpectedly, 
we found very significant decrease in the secretion of EVs by LPS-activated 
macrophages, with all protein markers being downregulated. Interestingly, those 
expressed in basal macrophage-derived EVs are modified, showing at different 
molecular weights when compared to lysate controls. Furthermore, EVs isolated 
from our models of hepatocellular steatosis showed some striking differences. In 
steatotic AML12 derived-EVs there was a clear decrease in exosomal protein 
markers in treated cells, and the opposite effect was observed for the MLP29 
derived-EVs. Moreover, the MLP-EVs expressed overall more protein markers 
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Overall, we have seen increase in the secretion of EVs in those conditions. Our 
main model of hepatocyte-derived EVs to address the effect on adipocytes was 
the one isolated from ZL and ZF primary hepatocytes. Metabolic profiling of ZL 
and ZF primary hepatocytes has revealed a very significant decrease in all 
mitochondrial functions and increase in glycolytic capacity of steatotic 
hepatocytes. In terms of EVs, the differences were observed in all analyses that 
were carried out. ZF-EV preparations exhibit significantly higher protein content, 
and significantly increased concentration of particles. There is a decreasing 
tendency in most of EV-related protein markers except for HSPs and 
unexpectedly a COMT protein in ZF-EVs. Density gradient reveals the existence 
of different populations of EVs and proteomic analysis of these EVs has 
strengthen the findings as to the metabolic differences seen in cells. Most 
upregulated proteins in ZF-EVs were associated with glycolysis, pentose 
phosphate pathway and the fat metabolism. On the other hand, those 
downregulated were mostly mitochondrial. Thus, EV-observed changes reflected 
cellular metabolism. Related to that, we found adiponectin associated to 
hepatocytes-secreted EVs, and being highly downregulated in ZF-EVs, in 
agreement with the circulating low adiponectin reported in obese samples.  
Moreover, we isolated nucleic acids from Zucker EVs and found higher content 
of RNA in those EVs derived from ZF-hepatocytes. Active P450 2D1 was 
detected in Zucker hepatocytes-EVs, with lower activity in ZF-EVs. These results 
suggest that these EVs have the potential to significantly influence the 
extracellular environment. Then, we have progressed onto studying the possible 
effect of those EVs on adipocyte biology. We have seen that at the early stages 
of adipogenesis ZF-EVs were able to increase the expression of genes encoding 
for the fatty acid synthase, perilipin3 and glut4. In addition, at later stages they 
were able to modulate genes, which regulate the transcriptional cascade of 
adipogenesis, such as the Pparg, Ap2, Cebpa and Adipoq. This result was also 
observed when we analyzed the gene expression in adipocytes following chronic 
exposure ZF-EVs. Adipokine array on adipocytes treated with ZF-EVs revealed a 
drop in anti-inflammatory cytokine IL-10 secretion. Finally, they, very specifically, 
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influenced the phosphorylation of S6, the target of S6 kinase of the mTOR 
pathway.  
The formation of EVs and their secretion has received great attention in last 
decades, however, the mechanisms that govern specific packaging in normal 
and pathological conditions are still not well understood. In that regard, when we 
consider our cellular models of MetS consistently exhibit a significant decrease in 
the expression of exosomal markers, which means that pathological conditions, 
not only affect the number of EVs secreted but also their protein content. Our 
result also points towards the existence of different EV subtypes secreted by 
steatotic hepatocytes with nonclassical protein cargo. The alteration of 
environmental parameters results in changes in the EVs’ molecular signature 
(Giebel 2017). It could be a regulated stress response with HSPs strongly 
associated to EVs secreted by affected cells. More commonly proposed roles of 
EVs include the transport of signalling/regulatory molecules for intracellular 
communication and modulation of functions in recipient cells (H. Lee et al. 2016). 
Considering this, as already emphasized, here for the first time we have shown 
that hepatic-EVs may greatly influence the many aspects of adipocyte biology in 
the context of MetS. Our preliminary results indicate that EVs can transfer their 
phenotype onto a recipient cell. 
Importantly, we discovered that these EVs faithfully reflect the cell of origin, not 
only carrying cell-specific protein markers but also reflect the metabolic state of 
the parent cell. We have shown that EVs secreted by pro-inflammatory 
Raw264.7 macrophages activated with LPS carry Tnf associated, which could be 
mediating the effect that they exert over mitochondrial functions of the 3T3-L1 
adipocytes. Tnf caused mitochondrial dysfunction, decreased mitochondrial 
membrane potential and decreased reduction of ATP in 3T3-L1 adipocytes 
(Chen et al. 2010). We have shown that EVs released by steatotic hepatocytes 
reflect glycolytic phenotype of the parent cell with the reduction in mitochondrial 
proteins, which was the feature of our steatotic hepatocytes. It could be that 
under steatotic conditions, mitochondrial-mediated ROS formation or lipotoxicity 
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caused accumulation of toxic material that can then be secreted via EVs. 
Concerning this, it cannot be discarded that in these conditions, EVs could serve 
as an alternative disposal of unwanted or damaged cellular material.  
We have characterized our EVs in terms of the expression of classical EV 
markers, therefore in the future studies we would aim for the identification of 
specific marker associated to or differentially expressed in steatotic-EVs. 
Furthermore, our results would have to be validated in vivo, although it is not an 
easy task as serum contains a pool of circulating EVs released from more than 
one site of origin. Furthermore, to date, no single marker was identified which 
would allow clear discrimination between different subtypes of EVs as different 
vesicle types are enriched in parallel fractions (Giebel 2017).  
Our work on characterization of EVs secreted by steatotic hepatocytes is first of 
this kind and contributes to the basic knowledge on the nature of these EVs. 
Moreover, here for the first time, we show that hepatic-EVs may deeply affect the 
physiology of adipocytes. Our results validate, at least to some extent, the 
hypothesis that in fact, EVs are one of the means of cell-cell cross talk in tissues 
involved in the development and propagation of pathology of MetS.  
Future studies should consider (i) further characterization of miRNA content of 
EVs isolated from different models of metabolic syndrome to identify their 
possible dysregulation in pathology. Another vital issue would be (ii) performing 
lipidomic studies on EVs isolated from our models to determine whether the lipid 
overload phenotype of cells in obesity has got an impact on a lipid content of 
their secreted EVs. Moreover, essential would be to (iii) characterize the 
contribution of different subpopulations of EVs by inhibition of their release would 
be important to understand whether during pathological conditions any of the 
secretory pathways is affected or whether there exists a compensatory switch. In 
addition to that, in terms of functional studies, it would be important to identify the 
population which mostly contribute to the effects of 3T3-L1 adipocytes. Following 
on that idea, next step would be to (iv) identify the biological components of 
steatotic EVs which are responsible for effect on different aspects of the 3T3-L1 
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adipocyte biology Finally, (v) for further studies on the effect of EVs on the 
recipient cells, it would be important to do the dose-response curve to establish 
the working range of EVs necessary to produce maximal effect. 
 
Limitations and considerations 
Given the EV isolation procedure used in this study, this thesis is focused in the 
study of small EVs. Techniques normally used to purify EVs mainly involve 
differential ultracentrifugation, and hence, are not selective for any specific type 
of vesicles, thus our EV preparations can contain exosomes, small microvesicles 
and small apoptotic blebs. In addition, some non-vesicular material including 
lipoproteins and protein aggregates may also be isolated in the EV preparations. 
To control the amount of these non-vesicular material we have routinately 
performed WB for markers of intracellular organelles, and in the case of primary 
hepatocytes of lipoproteins. As judged by the WB analysis, the level of 
contamination by intracellular organelles and lipoproteins were low in our EV 
preparations.  
Primary hepatocytes are the gold-standard in vitro system to study hepatocyte 
biology, however it has several limitations. When hepatocyte are cultured in 
standard cell culture medium in a plastic container, the cells lose their gap 
junctions within 12-24 h and adapt to flattened shape (Na et al. 2014). It has 
been widely recognized that cultured hepatocytes are subject to a gradual loss of 
liver-specific functions, especially a decreased in some CYP expression. For 
example, CYP 2E1 and CYP 3A4 are diminished in few days in culture however 
the CYP 1A2 and CYP 2C9 are unaffected by isolation and culture (George et al. 
1997). Various culturing methods have been explored to maintain the liver-
specific characteristics of hepatocytes during prolonged culture. The addition of 
specific nutrients, hormones, and inducers to the culture medium (Block et al., 
1996; ’t Hoen et al., 2000; Sewer and Morgan, 1997; Vernia et al., 2001); and, 
the co-culturing of hepatocytes with other cell types (e.g., the hepatic Kupffer 
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cells) may be necessary for cofactor supply (Milosevic et al., 1999). In many 
studies they have used insulin as an additive to the culture media as it enhances 
initial cell attachment, especially important for cells seeded onto tissue culture 
plastic. Moreover, the common use of corticosteroids, such as, DEX are equally 
important as contributes to the preservation of hepatocyte morphology, survival 
and tissue-specific functions (e.g. albumin synthesis). Once isolated, 
hepatocytes can be maintained in monolayer culture for a maximum of 4 weeks 
(Brandon et al. 2003). To study cells keeping most of the hepatocyte functions, in 
our experiments we did not exceed 36 h in culture for primary rat hepatocytes.  
In vivo physiological conditions represent a complex, multi-organ interaction and 
therefore reproducing these settings in vitro can be challenging. Setting up the 
co-culture systems would be one possibility for improvement, such that in our 
experimental design, the culture of primary hepatocytes with conditioned medium 
of adipocytes could have been an option. We chose to use Zucker rat 
hepatocytes as a model of hepatic steatosis for further isolation of EVs having in 
mind the yield necessary for further experiments. The ob/ob or db/db mice 
models would be more suitable in terms of species mach, however the yield 
would probably be significantly less and would limit the possibility of performing 
all functional studies.  
The issue with normalization and loading control for WB when working with EVs 
is still unresolved. There is no marker yet known to be ubiquitously in all EVs, 
regardless the origin. In addition, the expression of EV-related markers in 
pathological conditions may be largely affected. Also, the choice of normalization 
technique depends a lot on downstream purpose. The number of EVs seems like 
a reasonable approach however, there is no consensus yet as to the 
physiological and pathological concentration of circulating EVs.  
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CONCLUSSIONS 
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8. Conclusions 
 
• Successful establishment of in vitro cellular models reflecting the 
conditions of MetS such as adipocyte hypertrophy, adipocytes in hypoxia, 
adipocytes exposed to the proinflammatory cytokines, hepatocellular steatosis 
and inflammation. 
• Our cell culture models were valid for isolation of EVs from the 
conditioned-medium by removal of the treatment containing medium, for 
subsequent production of EVs. 
• MetS-resembling conditions alter the expression of EV-related proteins. 
• Hypertrophy and hypoxia induce higher secretion of EVs in adipocytes.  
• Hypertrophic adipocytes secrete EVs with increased expression of Cd81, 
LimpII, and Flotillin1 proteins.   
• Adipocytes under hypoxic conditions secrete EVs that are able to inhibit 
insulin stimulated Akt(Ser473) phosphotylation and glucose uptake in 3T3-L1 
adipocytes. 
•  Macrophages after initial activation of LPS secrete fewer small EVs than 
unactivated macrophages.  
• EVs secreted by LPS-activated macrophages carry Tnf and has lower 
amount of EVs-related proteins. 
• EVs secreted by LPS-activated macrophages decrease mitochondrial 
function and alter insulin sensitivity on adipocytes. 
• EVs secreted by steatotic MLP29 cells exhibit significantly different EV-
phenotype than AML12-derived EVs, with a decrease in Cd81 and an increase in 
Aip1, Rab8, Hsp70, and Flotillin1. 
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• EVs secreted by steatotic hepatocytes secrete significantly more EVs than 
their lean counterpart, and carry a distint protein cargo with a severe reduction in 
exosomal markers. 
• EVs derived from hepatocytes carry adiponectin, and the abundance are 
lower in in ZF-EVs.  
• EVs derived from hepatocytes affect adipocytes differentiation, adipokines 
secretion and insulin sensitivity in adipocytes. 
 
General Conclusion: 
• The results presented in this thesis show that the composition of EVs is 
significantly altered in conditions of MetS and that they could play a very 
important role in the development and propagation of MetS associated 
pathologies. 
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Table 16 Down-regulated DEPs in ZF-EVs. 
Description Mapped ID Peptide 
count 
Unique 
peptide 
ANOVA 
(pvalue) 
Fold 
change 
Lysosome-associated 
membrane glycoprotein 1 
LAMP1_RAT 2 2 0.00216 21.1 
4F2 cell-surface antigen 
heavy chain 
4F2_RAT 2 2 0.000332 8.2 
Solute carrier organic 
anion transporter family 
member 1A4 
SO1A4_RAT 6 5 0.000751 7.8 
Serum albumin ALBU_RAT 10 9 0.004688 6.7 
Glutamate 
dehydrogenase 1, 
mitochondrial 
DHE3_RAT 17 16 0.000455 6.1 
Membrane-associated 
progesterone receptor 
component 1 
PGRC1_RAT 7 7 0.000282 5.9 
Integrin beta-1 ITB1_RAT 2 2 0.009592 5.8 
CD81 antigen CD81_RAT 4 4 0.010499 5.8 
Cytochrome P450 2C11 CP2CB_RAT 9 7 0.000135 5.7 
Mannose-binding 
protein C 
MBL2_RAT 3 3 0.001403 4.6 
Basigin BASI_RAT 4 4 0.000395 4.5 
Propionyl-CoA 
carboxylase beta chain, 
mitochondrial 
PCCB_RAT 3 3 0.010487 4.5 
UDP-
glucuronosyltransferase 
2B15 
UDB15_RAT 2 1 0.003722 4.5 
Retinol dehydrogenase 7 RDH7_RAT 14 7 0.000666 4.4 
Alpha-1-macroglobulin A1M_RAT 13 13 0.011078 4.2 
Aldehyde 
dehydrogenase, 
mitochondrial 
ALDH2_RAT 12 10 0.00631 4.1 
Cytochrome P450 2D4 CP2D4_RAT 7 1 0.000996 4.0 
Cytochrome b5 CYB5_RAT 4 4 0.003195 3.9 
Monocarboxylate 
transporter 1 
MOT1_RAT 2 2 0.000853 3.9 
UDP- UDB17_RAT 5 4 0.000309 3.7 
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glucuronosyltransferase 
2B17 
Isocitrate dehydrogenase 
[NADP], mitochondrial 
IDHP_RAT 5 4 0.009461 3.7 
Epoxide hydrolase 1 HYEP_RAT 15 14 0.005863 3.7 
Peroxisomal acyl-
coenzyme A oxidase 2 
ACOX2_RAT 6 4 0.032224 3.6 
Retinol dehydrogenase 2 RDH2_RAT 10 3 0.000416 3.6 
Ubiquitin-40S ribosomal 
protein S27a  
RS27A_RAT 2 2 0.000894 3.6 
Pyruvate carboxylase, 
mitochondrial 
PYC_RAT 10 10 0.001833 3.5 
Cytochrome P450 2D26 CP2DQ_RAT 21 14 0.001033 3.5 
Syndecan-4 SDC4_RAT 3 3 0.000117 3.4 
Hydroxymethylglutaryl-
CoA lyase, mitochondrial 
HMGCL_RAT 4 4 0.001007 3.4 
Angiopoietin-related 
protein 4 
ANGL4_RAT 6 6 0.003935 3.4 
Propionyl-CoA 
carboxylase alpha chain, 
mitochondrial 
PCCA_RAT 6 6 0.001953 3.4 
Protein disulfide-
isomerase A3 
PDIA3_RAT 19 19 5.38E-05 3.4 
Cytochrome P450 2C23 CP2CN_RAT 2 1 0.00802 3.4 
Sodium/potassium-
transporting ATPase 
subunit alpha-1 
AT1A1_RAT 7 7 0.000241 3.4 
Cytochrome P450 2D1 CP2D1_RAT 14 2 0.000934 3.3 
Methylcrotonoyl-CoA 
carboxylase subunit 
alpha, mitochondrial  
MCCA_RAT 3 3 0.012852 3.3 
Galectin-3-binding 
protein 
LG3BP_RAT 3 3 0.031651 3.2 
Coronin-1A  COR1A_RAT 3 3 0.024358 3.2 
Cytochrome P450 2D10 CP2DA_RAT 15 2 0.001969 3.2 
Selenium-binding 
protein 1 
SBP1_RAT 7 7 0.04765 3.2 
Eukaryotic translation 
initiation factor 3 subunit 
E 
EIF3E_RAT 3 3 0.009031 3.1 
17-beta-hydroxysteroid 
dehydrogenase type 6 
H17B6_RAT 2 1 0.001532 3.1 
Medium-chain specific 
acyl-CoA dehydrogenase, 
mitochondrial  
ACADM_RAT 4 4 0.013927 3.0 
Phenazine biosynthesis- PBLD_RAT 5 5 0.038428 2.9 
343 
 
like domain-containing 
protein  
Major vault protein MVP_RAT 18 18 0.002022 2.9 
Alanine--glyoxylate 
aminotransferase 2, 
mitochondrial  
AGT2_RAT 2 2 0.009529 2.9 
Plasminogen  PLMN_RAT 2 2 0.010958 2.9 
Isovaleryl-CoA 
dehydrogenase, 
mitochondrial 
IVD_RAT 2 1 0.002316 2.9 
Solute carrier family 2, 
facilitated glucose 
transporter member 2  
GTR2_RAT 3 3 0.000316 2.9 
Aconitate hydratase, 
mitochondrial  
ACON_RAT 10 10 0.036747 2.8 
Delta-1-pyrroline-5-
carboxylate 
dehydrogenase, 
mitochondrial  
AL4A1_RAT 3 3 0.030486 2.8 
Catalase  CATA_RAT 19 18 0.000515 2.7 
Carbamoyl-phosphate 
synthase [ammonia], 
mitochondrial  
CPSM_RAT 58 56 0.022821 2.7 
Phosphatidylinositide 
phosphatase SAC1  
SAC1_RAT 2 2 0.002129 2.7 
Sarcosine 
dehydrogenase, 
mitochondrial  
SARDH_RAT 11 10 0.029758 2.65 
3-ketoacyl-CoA thiolase, 
mitochondrial  
THIM_RAT 13 13 0.02138 2.61 
40S ribosomal protein 
S25  
RS25_RAT 2 2 0.032298 2.60 
60S ribosomal protein 
L27a  
RL27A_RAT 2 2 0.001893 2.57 
Sulfotransferase 1C1  ST1C1_RAT 4 4 0.016644 2.56 
Solute carrier family 22 
member 7  
S22A7_RAT 2 2 0.012442 2.55 
Choline dehydrogenase, 
mitochondrial  
CHDH_RAT 8 8 0.038216 2.55 
D-beta-hydroxybutyrate 
dehydrogenase, 
mitochondrial  
BDH_RAT 5 4 0.029277 2.54 
Protein disulfide-
isomerase A4  
PDIA4_RAT 4 4 0.001487 2.53 
Microsomal glutathione 
S-transferase 1  
MGST1_RAT 2 2 0.003286 2.52 
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Fibrinogen gamma chain  FIBG_RAT 13 13 0.047215 2.50 
Clusterin CLUS_RAT 15 14 0.023728 2.33 
Succinate dehydrogenase 
[ubiquinone] 
flavoprotein subunit, 
mitochondrial 
SDHA_RAT 4 4 0.017234 2.32 
Hydroxymethylglutaryl-
CoA synthase, 
mitochondrial 
HMCS2_RAT 15 13 0.026934 2.26 
Cytochrome P450 2C7 CP2C7_RAT 5 5 0.034547 2.26 
Programmed cell death 
6-interacting protein 
PDC6I_RAT 15 15 0.002796 2.26 
Secreted phosphoprotein 
24 
SPP24_RAT 3 3 0.044347 2.24 
Glycogen [starch] 
synthase, liver 
GYS2_RAT 5 5 0.000323 2.23 
Electron transfer 
flavoprotein-ubiquinone 
oxidoreductase, 
mitochondrial 
ETFD_RAT 6 6 0.020697 2.22 
NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 10, 
mitochondrial1 
NDUAA_RAT 3 3 0.045338 2.22 
Serum 
paraoxonase/arylesterase 
1 
PON1_RAT 4 4 0.00649 2.21 
Malate dehydrogenase, 
mitochondrial 
MDHM_RAT 7 7 0.012193 2.19 
Estrogen 
sulfotransferase, isoform 
1 
ST1E1_RAT 11 10 0.007945 2.19 
Peroxisomal trans-2-
enoyl-CoA reductase 
PECR_RAT 5 5 0.011374 2.13 
Methylmalonate-
semialdehyde 
dehydrogenase 
[acylating], 
mitochondrial 
MMSA_RAT 10 9 0.021764 2.12 
Tripeptidyl-peptidase 2 TPP2_RAT 10 8 0.000676 2.12 
60S ribosomal protein 
L15 
RL15_RAT 3 3 0.004057 2.08 
Transforming protein 
RhoA 
RHOA_RAT 2 2 0.000621 2.06 
40S ribosomal protein S8 RS8_RAT 5 5 0.006537 2.06 
26S protease regulatory PRS7_RAT 9 9 0.018345 2.06 
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subunit 7 
UDP-
glucuronosyltransferase 
2B21 
UD2B2_RAT 3 3 0.016515 2.04 
Serine/threonine-protein 
phosphatase PP1-alpha 
catalytic subunit 
PP1A_RAT 2 2 0.003579 2.03 
Serotransferrin TRFE_RAT 4 4 0.007944 2.03 
Guanine nucleotide-
binding protein subunit 
beta-2-like 1 
GBLP_RAT 9 8 0.019976 2.03 
78 kDa glucose-regulated 
protein 
GRP78_RAT 5 3 0.007385 2.03 
2-hydroxyacyl-CoA lyase 
1 
HACL1_RAT 2 2 0.006172 1.99 
Guanine nucleotide-
binding protein G(i) 
subunit alpha-2 
GNAI2_RAT 4 4 0.013582 1.94 
Fatty aldehyde 
dehydrogenase 
AL3A2_RAT 6 5 0.018048 1.91 
Calreticulin CALR_RAT 3 3 0.019479 1.90 
60S ribosomal protein 
L32 
RL32_RAT 2 1 0.034898 1.88 
60 kDa heat shock 
protein, mitochondrial 
CH60_RAT 6 6 0.005119 1.88 
Peroxisomal acyl-
coenzyme A oxidase 3 
ACOX3_RAT 2 2 0.002165 1.86 
60S ribosomal protein 
L18 
RL18_RAT 4 4 0.018596 1.85 
Ras-related protein Rap-
1b 
RAP1B_RAT 3 3 0.00527 1.78 
Annexin A6  ANXA6_RAT 9 9 0.037249 1.77 
Pituitary tumor-
transforming gene 1 
protein-interacting 
protein  
PTTG_RAT 2 2 0.012884 1.77 
Adenylyl cyclase-
associated protein 1  
CAP1_RAT 2 2 0.002424 1.7 
NAD kinase 2, 
mitochondrial  
NAKD2_RAT 5 4 0.040639 1.7 
Xaa-Pro aminopeptidase 
1  
XPP1_RAT 4 4 0.023784 1.7 
Endoplasmin  ENPL_RAT 12 11 0.027676 1.7 
UDP-glucose 6-
dehydrogenase  
UGDH_RAT 7 7 0.024328 1.7 
Cytoplasmic dynein 1 DYHC1_RAT 18 18 0.040524 1.6 
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heavy chain 1  
Methyltransferase-like 
protein 7B 
MET7B_RAT 2 2 0.010377 1.6 
Heat shock 70 kDa 
protein 1A 
HS71A_RAT 7 5 0.033711 1.6 
Ras-related protein Rab-
1A 
RAB1A_RAT 4 2 0.014829 1.6 
Peroxisomal 
multifunctional enzyme 
type 2 
DHB4_RAT 8 8 0.020389 1.6 
 
 
Table 17 Up-regulated DEPs in ZF-EVs. 
Description Mapped ID Peptid
e count 
Uniqu
e 
peptid
e 
ANOV
A 
(pvalue) 
Fold 
change 
Glucose-6-phosphate 1-
dehydrogenase G6PD_RAT 6 5 0.000605 7.2 
NADP-dependent malic 
enzyme MAOX_RAT 3 3 
2.09E-
05 6.6 
60S ribosomal protein L23 RL23_RAT 2 2 0.005227 5.1 
Alcohol sulfotransferase A ST2A2_RAT 7 5 0.003782 3.9 
ATP-citrate synthase ACLY_RAT 42 42 0.000618 3.6 
Retinal dehydrogenase 1 AL1A1_RAT 10 4 0.001163 3.5 
6-phosphogluconate 
dehydrogenase, 
decarboxylating 6PGD_RAT 16 16 
3.56E-
07 3.4 
Aldehyde dehydrogenase, 
cytosolic 1 AL1A7_RAT 10 4 0.018937 3.1 
Microtubule-associated 
protein RP/EB family 
member 2 
MARE2_RA
T 2 2 0.018809 3.0 
Glutathione S-transferase 
kappa 1 GSTK1_RAT 3 3 0.012802 2.8 
Glutathione S-transferase 
theta-1 GSTT1_RAT 4 4 0.038933 2.5 
Fatty acid synthase FAS_RAT 83 82 0.002199 2.5 
Long-chain-fatty-acid--CoA 
ligase 5 ACSL5_RAT 3 2 0.00896 2.5 
Cytochrome P450 2A1 CP2A1_RAT 4 4 0.013636 2.4 
Carboxymethylenebutenolidas
e homolog CMBL_RAT 3 3 0.011306 2.4 
Destrin DEST_RAT 2 2 0.012824 2.3 
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Tubulin alpha-1C chain TBA1C_RAT 17 3 0.009453 2.3 
Synaptic vesicle membrane 
protein VAT-1 homolog VAT1_RAT 5 5 0.008198 2.1 
60S ribosomal protein L9 RL9_RAT 2 2 0.037221 2.0 
Bifunctional purine 
biosynthesis protein PURH PUR9_RAT 2 2 0.011392 1.9 
Macrophage migration 
inhibitory factor MIF_RAT 2 2 0.000123 1.9 
Dihydropteridine reductase DHPR_RAT 7 7 0.040027 1.9 
Polyadenylate-binding protein 
1 PABP1_RAT 2 2 0.000186 1.86 
Transitional endoplasmic 
reticulum ATPase TERA_RAT 10 10 0.019298 1.81 
Aspartate--tRNA ligase, 
cytoplasmic SYDC_RAT 7 7 0.013114 1.7 
Elongation factor 1-alpha 1 EF1A1_RAT 7 7 0.006062 1.7 
GTP-binding protein SAR1b SAR1B_RAT 3 3 0.011995 1.7 
Phosphoglycerate kinase 1 PGK1_RAT 17 15 0.009191 1.7 
60 kDa lysophospholipase LPP60_RAT 3 3 0.045716 1.7 
Elongation factor 1-delta EF1D_RAT 4 4 0.040249 1.6 
Cytosolic 10-
formyltetrahydrofolate 
dehydrogenase AL1L1_RAT 39 37 0.006914 1.6 
Glucokinase regulatory 
protein GCKR_RAT 4 4 0.010341 1.6 
Acetyl-CoA carboxylase 1 
ACACA_RA
T 54 54 0.021909 1.5 
Phenylalanine-4-hydroxylase PH4H_RAT 7 7 0.049157 1.5 
40S ribosomal protein S4, X 
isoform RS4X_RAT 6 6 0.003988 15.5 
Glucose-6-phosphate 1-
dehydrogenase G6PD_RAT 6 5 0.000605 7.2 
NADP-dependent malic 
enzyme MAOX_RAT 3 3 
2.09E-
05 6.6 
60S ribosomal protein L23 RL23_RAT 2 2 0.005227 5.1 
Alcohol sulfotransferase A ST2A2_RAT 7 5 0.003782 3.9 
ATP-citrate synthase ACLY_RAT 42 42 0.000618 3.6 
Retinal dehydrogenase 1 AL1A1_RAT 10 4 0.001163 3.5 
6-phosphogluconate 
dehydrogenase, 
decarboxylating 6PGD_RAT 16 16 
3.56E-
07 3.4 
Aldehyde dehydrogenase, 
cytosolic 1 AL1A7_RAT 10 4 0.018937 3.1 
Microtubule-associated 
protein RP/EB family 
member 2 
MARE2_RA
T 2 2 0.018809 3.0 
348 
 
Glutathione S-transferase 
kappa 1 GSTK1_RAT 3 3 0.012802 2.8 
Glutathione S-transferase 
theta-1 GSTT1_RAT 4 4 0.038933 2.5 
Fatty acid synthase FAS_RAT 83 82 0.002199 2.5 
Long-chain-fatty-acid--CoA 
ligase 5 ACSL5_RAT 3 2 0.00896 2.5 
Cytochrome P450 2A1 CP2A1_RAT 4 4 0.013636 2.4 
Carboxymethylenebutenolidas
e homolog CMBL_RAT 3 3 0.011306 2.4 
Destrin DEST_RAT 2 2 0.012824 2.3 
Tubulin alpha-1C chain TBA1C_RAT 17 3 0.009453 2.3 
Synaptic vesicle membrane 
protein VAT-1 homolog VAT1_RAT 5 5 0.008198 2.1 
60S ribosomal protein L9 RL9_RAT 2 2 0.037221 2.0 
Bifunctional purine 
biosynthesis protein PURH PUR9_RAT 2 2 0.011392 1.9 
Macrophage migration 
inhibitory factor MIF_RAT 2 2 0.000123 7.2 
 
